<SEC-DOCUMENT>0001493152-25-004872.txt : 20250204
<SEC-HEADER>0001493152-25-004872.hdr.sgml : 20250204
<ACCEPTANCE-DATETIME>20250204164543
ACCESSION NUMBER:		0001493152-25-004872
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250204
DATE AS OF CHANGE:		20250204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Telomir Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001971532
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				872606031
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41952
		FILM NUMBER:		25589075

	BUSINESS ADDRESS:	
		STREET 1:		100 SE 2ND ST
		STREET 2:		SUITE 2000 #1009
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131
		BUSINESS PHONE:		786-396-6723

	MAIL ADDRESS:	
		STREET 1:		100 SE 2ND ST
		STREET 2:		SUITE 2000 #1009
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:TELO="http://telomirpharma.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_TELO_telomirpharma.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001971532 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001971532</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:IssuanceOfWarrantsOnRelatedPartyLineOfCredit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:AccruedOfferingExpense" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:DebtConversionToCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:AdvancesToAffiliates" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0576" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0578" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0673" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0691" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="xdx2ixbrl0707" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="xdx2ixbrl0709" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_custom_StockOptionsOneMember" id="xdx2ixbrl0744" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0760" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2023-12-31" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0791" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0809" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0841" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="telo-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-112023-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-11</xbrli:startDate>
        <xbrli:endDate>2023-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-302023-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-30</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-112023-12-11_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-11</xbrli:startDate>
        <xbrli:endDate>2023-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-132024-02-13_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-13</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-11_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MiralogxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-15_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-30</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-112023-12-11_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-11</xbrli:startDate>
        <xbrli:endDate>2023-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-24_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-092024-12-09_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-09</xbrli:startDate>
        <xbrli:endDate>2024-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-09_custom_StarwoodTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TampaFloridaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">TELO:TampaFloridaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_custom_BayShoreTrustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TELO:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember11697890">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnderwriterWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember11698062">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BayShoreTrustWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:TwoThousandTwentyThreePrivatePlacementWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnderwriterWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">TELO:StockOptionsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StockOptionsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">TELO:StockOptionsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001971532</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000586" toRefs="Footnote000621"/>
  <ix:relationship fromRefs="Fact000592" toRefs="Footnote000621"/>
  <ix:relationship fromRefs="Fact000610" toRefs="Footnote000625"/>
  <ix:relationship fromRefs="Fact000618" toRefs="Footnote000625"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Form
<span id="xdx_906_edei--DocumentType_c20240101__20241231_z8Wwdcgmmqj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentAnnualReport_c20240101__20241231_zNv4xoLDsXoa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20240101__20241231_zxO1HG1e9pKe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20240101__20241231_z8VavaEdlD0a"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_907_edei--DocumentFiscalYearFocus_c20240101__20241231_zpG5SMq2SPIf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20240101__20241231_zKQzaYbsMuz7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from__________ to</b> _________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number <span id="xdx_903_edei--EntityFileNumber_c20240101__20241231_zoEUo9bRx793"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:EntityFileNumber">001-31361</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20240101__20241231_zRBVYMOcnPN5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityRegistrantName">Telomir
Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zaQqTeVOHhP4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Florida</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20240101__20241231_zhnVyFv2cCQc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">87-2606031</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incorporation
    or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20240101__20241231_zVAxCY47Bhb1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityAddressAddressLine1">100
    SE 2<sup>nd</sup> St</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_907_edei--EntityAddressAddressLine2_c20240101__20241231_zA4tsNnL5hFg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine2">Suite
    200 #1009</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20240101__20241231_zWn0uYtdcm87"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Miami</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_904_edei--EntityAddressStateOrProvince_c20240101__20241231_zvRgayj6SOD4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000024" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20240101__20241231_zoFmJZJTGMn9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">33131</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number: <span id="xdx_900_edei--CityAreaCode_c20240101__20241231_zqDVTOOQ72Rd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:CityAreaCode">786</ix:nonNumeric></span>-<span id="xdx_905_edei--LocalPhoneNumber_c20240101__20241231_zwkEecTk22Ol"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:LocalPhoneNumber">396-6723</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s) </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--Security12bTitle_c20240101__20241231_zduv55M4GHq9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:Security12bTitle">Common
    stock, no par value</ix:nonNumeric></span> </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20240101__20241231_z3hSdDZUyBr6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:TradingSymbol">TELO</ix:nonNumeric></span>
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_908_edei--SecurityExchangeName_c20240101__20241231_zLTylox0zPO4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90B_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zKheGo7DIAZd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90C_edei--EntityVoluntaryFilers_c20240101__20241231_zPdWfL9Dmb4a"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_901_edei--EntityCurrentReportingStatus_c20240101__20241231_zssiR6Ohd965"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)
<span id="xdx_901_edei--EntityInteractiveDataCurrent_c20240101__20241231_zbgVgzz01UD4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting
company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221;
in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20241231_zYrBsh0xWbub"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20240101__20241231_zyLYqbkK0PZk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20240101__20241231_zBbJ35sYM4k8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_901_edei--EntityExTransitionPeriod_c20240101__20241231_z2kWxsuAU4d4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20240101__20241231_ze1YyNj4RQjb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_906_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zyBxf1tZkVe9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90F_edei--EntityShellCompany_dbF_c20240101__20241231_zRI5mGHJwK1c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate market value of the voting and non-voting common equity held
by non-affiliates as of June 30, 2024, was $<span id="xdx_906_edei--EntityPublicFloat_iI_pn5n6_c20240630_zrQVIqlmbMt2"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">113.3</ix:nonFraction></span> million based on the closing sale price of the company&#8217;s common stock on
such date of $4.81 per share, as reported by the NASDAQ Capital Market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 4, 2025, there were <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250204_zWFMp4DaVevk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-02-04" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></span> shares of company common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual
Report on Form 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended December 31, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
    OF CONTENTS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>Page</b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Cautionary Note on Forward-Looking Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Description of Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Description of Property</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Mine Safety Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Equity and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ZM_003">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ZM_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#S_03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we have indicated otherwise, or the context otherwise requires, references in this Report to &#8220;TELO,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; or similar terms refer to Telomir Pharmaceuticals, Inc., a Florida corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
time to time, we may use our website, our Facebook page at https://www.facebook.com/people/Telomir-Pharmaceuticals-Inc/100087267737318/#,
our Twitter at https://x.com/TelomirPharma, and on our LinkedIn account at <span style="text-decoration: underline">https://www.linkedin.com/company/telomir-pharmaceuticals-inc/posts/?feedView=all
</span>to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors
section of our website, available at <b>www.telomirpharma.com</b>. Investors are encouraged to review the Investors section of our website
because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and
can be accessed through our website, our Facebook page, our Twitter posts and our LinkedIn posts are not incorporated into, and does
not form a part of, this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements <span style="background-color: white">(as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act) that
reflect our current expectations and views of future events</span>. In some cases, you can identify forward-looking statements by terms
such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221;
&#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221; or the negative of these terms or other
similar expressions. In particular, statements about the markets in which we operate, including expectations regarding our studies, growth
of our various markets, and our expectations, beliefs, plans, strategies, objectives, prospects, assumptions, or future events or performance
contained in this Annual Report under the headings &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; and &#8220;Business&#8221; are forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed
in this Annual Report under the headings &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and &#8220;Business,&#8221; may cause our actual results, performance, or achievements to differ materially
from any future results, performance or achievements expressed or implied by these forward-looking statements, or could affect our share
price. Important factors that could cause actual results or events to differ materially and adversely from those expressed in forward-looking
statements include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully commercialize and market our product candidates, if approved by the FDA; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market size, opportunity, and growth potential for our product candidates, if approved by the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding for our operations and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of anticipated regulatory filings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future expenses, capital requirements and need for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance product candidates into, and successfully complete, clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and enroll suitable patients in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of our product candidates, if approved by the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, product candidates, and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the
    future impact of such events on our business operations and funding requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks and factors listed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the risks and uncertainties set forth in this Annual Report, you are cautioned not to place undue reliance on such forward-looking statements.
The forward-looking statements contained in this Annual Report are not guarantees of future performance and our actual results of operations,
financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking
statements contained in this Annual Report. In addition, even if our results of operations, financial condition and liquidity, and events
in the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report, they may not
be predictive of results or developments in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement that we make in this Annual Report speaks only as of the date of such statement. Except as required by federal
securities laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1. Description of Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Telomir-1 is a novel oral small molecule metal
ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease
progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age-related conditions,
including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson&#8217;s disease (a genetic disorder leading to
toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Oxidative stress also
plays a critical role in the propagation and severity of viral infections like bird flu, where the virus triggers an imbalance between increased production of reactive oxygen species (ROS) and reduced antioxidant
host responses that leads to increased redox stress, a process which ultimately excessive weakens
immune defenses, increases inflammation, and enables enhanced viral replication. By reversing oxidative stress, Telomir-1 may help
strengthen immune resilience and reduce disease severity, offering broad therapeutic potential across both age-related and
infectious diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomeres
are repetitive DNA sequences at the end of chromosomes that protect the chromosomes from becoming frayed or tangled. Each time a cell
divides, the telomeres become slightly shorter, and eventually they become so short that the cell can no longer divide, with the result
being that the cell dies. Effectively, telomeres protect the ends of our chromosomes by forming a cap, much like the plastic tip on shoelaces,
thereby allowing the chromosome to be replaced properly during cell division. If demonstrated by future clinical trials and approved
by the U.S. Food and Drug Administration, or FDA, we believe Telomir-1 may protect variable cells by elongating and stimulating the telomeres
to sustain self-renewal and longevity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our preclinical studies, we have
gathered experimental evidence suggesting that Telomir-1 may act as a regulator of essential metal ions such as iron, zinc, and copper.
While these trace elements are critical for various physiological functions, imbalances&#8212;whether due to excess or deficiency&#8212;can
drive oxidative stress, leading to cellular damage, telomere shortening, and accelerated aging. This oxidative burden is also linked to
age-related conditions and certain cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Telomir-1 has the potential to protect cells in situ by mitigating
metal overload, particularly of iron and copper, which are known to accelerate oxidative stress and contribute to telomere attrition.
By modulating ion levels and reducing oxidative damage, Telomir-1 may help preserve telomere integrity, restore cellular homeostasis,
and enhance overall cell resilience, potentially slowing down age-related degeneration. Additionally, by reversing oxidative stress, Telomir-1
may help mitigate the severity of viral infections such as bird flu by strengthening cellular defense mechanisms and improving immune
system function, potentially reducing disease progression and severity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
focus is on addressing the effects of iron and copper overload while emphasizing the protective role of zinc. Excess iron can cause serious
health problems, such as liver fibrosis, liver failure, heart issues, and endocrine dysfunction. It is also linked to type 2 diabetes
mellitus (T2DM), as it disrupts insulin secretion, increases insulin resistance, and affects glucose production in the liver. In the
retina, iron buildup leads to oxidative stress and damage, contributing to Age-related Macular Degeneration (AMD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copper,
while essential for many physiological processes, becomes harmful when present in excess. High levels of copper increase oxidative stress,
damage retinal cells, and disrupt mitochondrial energy production, which can result in cell death and tissue degeneration. Copper overload
is particularly significant in Wilson&#8217;s disease, a rare genetic disorder that causes toxic copper accumulation in vital organs
like the liver and brain, leading to severe health complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, zinc plays a protective role by reducing oxidative stress, regulating iron and copper levels, and restoring balance in cases
of imbalance or deficiency. This highlights zinc&#8217;s critical role in maintaining physiological health and equilibrium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to investigate the molecular mechanisms of action of Telomir-1 through various biochemical methods. Additionally, we utilize
a range of animal models to evaluate the drug&#8217;s therapeutic potential and activity. As our research advances and our understanding
deepens, we may consider exploring alternative indications or adjusting our focus based on emerging insights or evolving circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
is currently undergoing preclinical investigation, with the goal of submitting an Investigational New Drug (IND) application and an Investigational
New Animal Drug (INAD) application to the FDA. If accepted, these submissions would enable progression to human and animal clinical trials.
Our research focuses on Telomir-1&#8217;s potential to interrupt, regulate, and prevent inflammatory pathways and enzymatic intracellular
processes responsible for cellular metal imbalances. Preliminary studies suggest that Telomir-1 may achieve these outcomes by selectively
binding to and exchanging between metal ions in a form- and dose-dependent manner, slowing enzyme reactivity, and preserving cellular
functions. If clinical trials demonstrate its efficacy and it gains FDA and other regulatory approvals, we believe Telomir-1 could serve
as a non-toxic, orally administered ion-overload regulator with the potential to balance enzyme and pathway overactivity caused by excessive
metal reactivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have completed multiple preclinical studies on Telomir-1, including those demonstrating that Telomir-1 is non-mutagenic and
possesses strong biological and metal-binding properties (Graphic 1). Using advanced &#8220;in silico modeling,&#8221; driven by artificial
intelligence to predict a compound&#8217;s therapeutic potential, chemical and biological activity, and toxicity, we continue to uncover
evidence supporting Telomir-1&#8217;s potential to address metal-overload conditions. Additionally, recent independent in vitro studies
have confirmed that Telomir-1 exhibits strong binding affinities for copper and iron, with reduced binding affinity for zinc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_001.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Graphic
1: Telomir-1 is capable binding to several metal ions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
collaborate with third-party organizations to conduct research and advance development efforts. One such partner, InSilico Trials, utilizes
in silico digital simulations to support drug development through computational modeling. These techniques allow us to efficiently predict
the safety and efficacy of potential compounds, reducing the need for extensive clinical trials. Additionally, we work with Recipharm
and Smart Assays to assess Telomir-1&#8217;s binding properties and investigate ion competition and exchange under varying conditions,
further refining its therapeutic potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
example of these findings is illustrated in the Graphic 2 below, created in collaboration with Smart Assays Biotechnologies Ltd. The
figure depicts the concentration of free iron (Fe&#178;&#8314;) in the presence of Telomir-1 (T1) and various ions. When Telomir-1
is introduced, the concentration of free iron decreases (indicated by the shift from the blue point to the orange point). This is
direct evidence for the binding of iron to T1, reducing its free ion concertation in the solution. However, the addition of
copper (Cu&#178;&#8314;) at varying concentrations leads to an exchange between bound iron and copper, resulting in the release of
previously bound iron and restoration of free iron levels in solution. This is evidenced by an increase in free iron concentration,
corresponding to the amount of copper added. In contrast, zinc does not induce an exchange effect on the binding of iron to
Telomir-1, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">indicating a lower affinity of Zinc to
Telomir-1.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_002.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Graphic
2: Ionic exchange between iron and copper or zinc</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wilson&#8217;s
disease </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilson&#8217;s
disease is a rare genetic disorder affecting approximately 1 in 30,000 individuals worldwide. It is caused by mutations in the ATP7B
gene, which disrupt the body&#8217;s ability to regulate copper metabolism. This results in toxic copper accumulation, particularly in
the liver and brain, leading to severe complications such as liver failure, neurological damage, and psychiatric disorders. Without treatment,
Wilson&#8217;s disease is fatal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
treatments, including chelating agents (e.g., penicillamine and trientine) and zinc therapy, focus on reducing copper levels but have
notable limitations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chelating
                                            agents</b> can cause significant side effects, such as kidney damage, bone marrow suppression,
                                            and gastrointestinal issues, and require lifelong adherence, which can be burdensome for
                                            patients.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Zinc
                                            therapy</b> reduces copper absorption in the gut but may lead to side effects such as anemia,
                                            gastrointestinal discomfort, and diminished effectiveness over time.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
challenges highlight the urgent need for novel therapies that address the root cause of Wilson&#8217;s disease while minimizing adverse
effects. Telomir-1, with its targeted copper-binding properties, has the potential to provide a safer, more effective treatment by directly
addressing the underlying mechanisms of the disease. Furthermore, Wilson&#8217;s disease qualifies as a candidate for orphan drug designation
due to its rarity and life-threatening nature, offering opportunities for accelerated development and additional regulatory and financial
incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are actively investigating Telomir-1&#8217;s potential in treating Wilson&#8217;s disease by studying its effects on copper toxicity
through in vitro experiments and a mouse model of the disease. These studies are currently ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
2 Diabetic (NIDDM)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
collaboration with the India-based research organization Pentagrit, in 2024 Telomir conducted preclinical studies evaluating two
forms of Telomir-1, administered orally at three different doses, in zebrafish models of Type 2 diabetes mellitus induced by a
high-calorie diet. The study assessed key metabolic indicators, including fasting glucose levels, Oral Glucose Tolerance Test (OGTT)
results, insulin concentrations, and HOMA-IR. The findings revealed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reversal
    of Hyperglycemia and Insulin Resistance:</b> Telomir-1 demonstrated dose-dependent efficacy in normalizing blood glucose and reducing
    insulin levels, restoring glucose homeostasis.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significantly
    Reduced HOMA-IR Values:</b> Telomir-1 showed a substantial improvement in insulin sensitivity to near pre-diabetes values, underscoring
    its potential to mitigate insulin resistance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enhanced
    Glucose Clearance:</b> Significant improvements in OGTT results highlighted Telomir-1&#8217;s impact on glucose metabolism.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increased
    Survival Rates:</b> Treated models exhibited improved survival compared to controls, showcasing Telomir-1&#8217;s comprehensive therapeutic
    potential.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
Novel Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
introduces a novel mechanism of action by addressing the cellular role of iron metabolism in chronic diseases such as Type 2 diabetes.
Excess iron contributes to oxidative stress, beta-cell damage, and insulin resistance. Telomir-1 is designed to normalize iron homeostasis,
reducing oxidative stress and enhancing insulin sensitivity. This differentiates it from current diabetes drugs that primarily treat
symptoms without targeting the underlying causes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study demonstrated significant reductions in fasting plasma glucose to basal levels, improvements in glucose tolerance, and a reversal
of insulin resistance to near pre-diabetic levels. These results were accompanied by improved HOMA-IR values, a standard measure of insulin
sensitivity and resistance, and increased survival rates in treated models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Global
Impact of Type 2 Diabetes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the International Diabetes Federation, over 800 million adults worldwide are affected by Type 2 diabetes (both diagnosed and undiagnosed),
with annual healthcare costs exceeding $966 billion as of 2021. Existing treatments primarily manage blood glucose and symptoms but fail
to address the root causes of the disease. These therapies are often associated with significant limitations, including minimal impact
on insulin resistance, gastrointestinal issues, risk of hypoglycemia, cardiovascular risks, and weight gain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
findings from this zebrafish diabetes model suggest that Telomir-1 could offer a transformative approach to managing Type 2 diabetes.
By targeting the underlying mechanisms of insulin resistance and oxidative stress through iron metabolism normalization, Telomir-1 represents
a potential breakthrough in diabetes treatment. A key indicator of its success was the significant reduction in HOMA-IR values, highlighting
its ability to improve insulin sensitivity and glucose regulation. The reversal of insulin resistance to near pre-diabetic levels underscores
Telomir-1&#8217;s potential as a groundbreaking therapy (Graphic).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_03.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Graphic
3: Effects of two forms of Telomir-1 on HOMA-IR, a measure of insulin resistance in Zebrafish</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating the potential in NIDDM by studying the effect of Telomir-1 on several metabolic parameters in a rat model of
NIDDM. These studies are ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age
reversal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have carried out a preclinical study, conducted in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic-based
assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a well-established model for aging studies. The microfluidic
platform allowed precise, automated tracking of lifespan, health span, and age-related mobility decline in real-time, enabling the research
team to accurately measure the effects of Telomir-1 on these critical metrics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
forms of Telomir-1 were administered in two concentrations, allowing the study to examine dose-dependent responses in treated subjects.
The study found that Telomir-1 significantly enhanced lifespan and health span parameters in aged microorganism populations. Key findings
included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enhanced
    Mobility in Older Organisms</b>: Subjects treated with Telomir-1 showed improved motility, particularly in later stages of life,
    compared to untreated controls. This enhanced movement in advanced age suggests a slowing of the aging process, as mobility is a
    key indicator of biological health.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reduced
    Biological Aging</b>: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1.
    This significant finding points to Telomir-1&#8217;s potential to slow down, and in certain aspects, reverse biological aging, making
    it a promising candidate for longevity treatments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increased
    Lifespan</b>: Telomir-1 was associated with a statistically significant increase in lifespan among treated populations. This further
    supports Telomir-1&#8217;s role in promoting longevity</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Graphic
4: Effect of Telomir-1 on c.elegans life span</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Graphic
5: Effect of two forms of Telomir-1 on several motility parameters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Progeria
Study: Telomir-1 Shows Promising Age-Reversal Effects</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recently completed a study evaluating the effects of Telomir-1 in a nematode model of Progeria (Caenorhabditis elegans). The study
focused on nematodes with a mutation in the wrn-1 gene, the equivalent of the human WRN gene, which is implicated in Werner Syndrome,
a form of Progeria. In C. elegans, wrn-1 depletion is associated with a significantly reduced mean and median lifespan compared to normal
(wild-type) organisms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study demonstrated significant age-reversal effects in <i>wrn-1</i>-mutated nematodes treated with Telomir-1. Treatment effectively restored
longevity levels to those comparable to wild-type organisms. Additional benefits included an extended healthy lifespan and normalization
of physiological parameters such as movement velocity and tail amplitude.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
studies in a Progeria human cell line are planned in collaboration with Smart Assays to build on these promising findings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oxidative
Stress Study: Telomir-1 Shows potential to Fully Reverse Oxidative Stress and Provide Robust Cellular Protection</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxidative
stress is a key driver of aging and disease progression, contributing to conditions such as Alzheimer&#8217;s, Age-related Macular Degeneration
(AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the severity of viral infections, including avian
influenza (bird flu), by increasing inflammation, cellular damage, and impairing immune responses. Addressing oxidative stress is essential
for mitigating these effects and improving patient outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals recently conducted preclinical studies in collaboration with Smart Assays Biotechnologies Ltd. to evaluate Telomir-1&#8217;s
ability to combat copper-induced oxidative stress. The study, performed in human cell lines, demonstrated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reversal of Oxidative Stress</b> &#8211; Telomir-1 fully
normalized Reactive Oxygen Species (ROS) levels, effectively reversing oxidative damage.</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#9679;</td>
  <td style="text-align: justify"><b>Cellular Protection</b> &#8211; Telomir-1 provided strong protection against copper-induced toxicity
  while maintaining cellular integrity.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#9679;</td>
  <td style="text-align: justify"><b>Regulatory Mechanism</b> &#8211; Telomir-1 demonstrated effects at doses significantly lower than
  copper levels, indicating a unique regulatory mechanism beyond copper ion chelation.</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
findings suggest Telomir-1&#8217;s potential to preserve cellular integrity, combat oxidative damage, and regulate metal ion balance&#8212;critical
factors in aging-related diseases and viral infections. This breakthrough supports further clinical development to assess its full potential
in disease intervention.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_007.jpg" alt="" style="height: 313px; width: 516px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Graphic 6: Effect of Telomir-1 on Oxidative Stress</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_008.jpg" alt="" style="height: 246px; width: 521px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Graphic 7: Effect of Telomir-1 on Copper Toxicity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expanding
Telomir-1&#8217;s Therapeutic Potential</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
on these results, Telomir is planning and advancing studies to expand the therapeutic potential of Telomir-1. Key ongoing initiatives
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wilson&#8217;s
    Disease Study:</b> Investigating Telomir-1&#8217;s effects on copper regulation in preclinical models.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
    2 Diabetes Studies:</b> Following success in zebrafish studies, ongoing research in rat models aims to confirm Telomir-1&#8217;s
    efficacy in reversing key metabolic abnormalities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age-related
    Macular Degeneration:</b> Assessing Telomir-1&#8217;s impact on retinal degeneration and Drusen formation caused by metal accumulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Progeria:
    </b>Examining Telomir-1&#8217;s impact on accelerated aging and telomere function.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cancer
    Research:</b> Exploring anti-cancer applications using xenograft studies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alzheimer&#8217;s
    Disease:</b> Investigating Telomir-1 for its potential to address cognitive decline and neurodegeneration. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metal
    Toxicity:</b> Examining Telomir-1&#8217;s capacity to reduce harmful metal accumulation and associated cellular damage.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DNA
    Methylation Analysis:</b> Studying Telomir-1&#8217;s role in modulating DNA methylation to restore healthy gene expression patterns
    linked to aging and disease</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Viral Infections:</b> Investigating Telomir-1&#8217;s
    effects on viral pathogenesis, including its potential to mitigate oxidative stress and immune dysfunction in infections such as
    avian influenza (bird flu).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
Plans and Milestones</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
has demonstrated significant potential in reversing age-related and metabolic conditions while targeting underlying disease mechanisms.
As the company continues to refine the molecular understanding of Telomir-1, efforts are underway to identify the most impactful indication
for its initial IND application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is optimizing manufacturing processes to produce GMP-grade Telomir-1 for IND-enabling studies and future clinical trials. Safety
studies are scheduled for Q2 2025, with IND submission targeted for Q4 2025 and first-in-human trials anticipated in early 2026. Concurrently,
the company aims to secure an INAD to enable veterinary applications, highlighting Telomir-1&#8217;s dual potential for both human and
animal health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
these initiatives, Telomir is committed to revolutionizing treatments for age-related and chronic diseases by addressing their root causes
and paving the way for transformative healthcare solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Potential</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market potential for Telomir-1 is substantial, given its focus on addressing the root causes of age-related diseases and promoting longevity.
Chronic diseases such as diabetes, cancer, Alzheimer&#8217;s, and cardiovascular disorders, which are closely tied to aging, account
for over 75% of healthcare spending in the United States, exceeding $4 trillion annually, according to the CDC. As the global population
ages, the demand for innovative therapies targeting the underlying mechanisms of these conditions is expected to grow significantly.
Furthermore, Verified Market Research reports that the anti-aging drug market was valued at approximately $91.05 billion in 2024 and
is projected to reach $160.24 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.32%. With its novel mechanism of
action that regulates cellular metal imbalances and reduces oxidative stress, Telomir-1 is uniquely positioned to capitalize on these
expanding markets, offering transformative potential to enhance health span, slow disease progression, and redefine longevity treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Clinical
IND-Enabling Studies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
outlined in the table below, we have successfully completed several IND-enabling studies for Telomir-1, demonstrating its non-toxic profile.
In collaboration with Frontage Laboratories, our research has also established the metabolism and maximum tolerated dose (MTD) of Telomir-1,
providing critical data to support its development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; background-color: white; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
    of Study</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 16%; background-color: white; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Species</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24%; background-color: white; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 34%; background-color: white; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolite
    Identification</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
    mouse, SD-rat, Beagle dog, Cynomolgus monkey and human</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    determine the metabolic pathways of Telomir-1 across species</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
    showed little/no metabolism by CYP enzymes.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
    Reaction Phenotyping Using Liver S9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mouse,
    rat, monkey and human liver</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    of the Enzymes Involved in the Metabolism of Telomir-1 Using Hepatic S9 Fraction</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    compound does not appear to be a substrate of cytochrome P450 enzymes. There was little/no metabolism of Telomir-1 in dog S9, consistent
    with the fact that the dog lacks aldehyde oxidase activity.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) reaction phenotyping</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of Telomir-1 to be a victim of drug-drug interactions</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
    was extensively metabolized in mouse, rat, monkey, dog, and human hepatocytes.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytochrome
    P450 (CYP) inhibition</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate the potential of Telomir-1 to cause drug-drug interactions as a perpetrator</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir-1
    (up to 100 &#181;M) did not inhibit any of the tested CYP enzymes.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
    protein binding</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CD-1
    mouse, SD rat, Beagle dog, Cynomolgus monkey and human</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    know the unbound fraction of Telomir-1 in plasma</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
    highly protein bound</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Rats</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sprague
    Dawley Rats</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of Telomir-1 and to estimate the MTD of Telomir-1 following</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    MTD following 7 days of repeated administration of Telomir-1 at dose levels of 50, 200, and 750 mg/kg/day in rats was determined
    to be &#8805; 750 mg/kg/day</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Dogs</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beagle
    Dogs</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate and characterize the toxicokinetic and toxicity of Telomir-1 and to estimate the MTD of Telomir-1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    were no treatment-related clinical observations, body weights, clinical pathology and anatomic gross pathology findings up to 7.5
    mg/kg/day.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SafetyScreen44
    <sup>TM</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    evaluate, in Enzyme, and Radioligand Binding assays, the activity of Telomir-1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    significant results noted</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
preclinical studies referenced in this Annual Report were conducted in collaboration with third-party organizations, including
Frontage Laboratories, InSilico Trials, Pharmaseed Ltd, Smart Assay Biotechnologies Ltd., Recipharm, Naji Biosciences, and Pantagrit. These partners
played a key role in supporting the execution and analysis of the research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Clinical Development Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completing toxicology studies and preclinical proof-of-concept studies, we plan to submit an Investigational New Drug (IND) application
to the FDA for Telomir-1. While the specific indication is still being evaluated, we intend to explore additional indications with FDA
guidance as the development program evolves. Our first IND submission for Telomir-1 is targeted for the fourth quarter of 2025. If approved
by the FDA, we plan to initiate a Phase I double-blind, randomized, placebo-controlled trial approximately 30 days post-submission. This
trial will assess the safety, tolerability, and pharmacokinetics of Telomir-1 in 40&#8211;60 healthy adult male and female participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
progress of our clinical development program will depend on FDA acceptance of our IND submissions. As discussions with the FDA progress,
we may adjust timelines for filings and associated clinical trials when necessary. It is important to acknowledge that conducting clinical
trials is inherently uncertain, and there can be no assurance that our clinical development activities will proceed according to the
planned timelines outlined above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Manufacture
of Product for Clinical Development Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthem
Biosciences, a leading contract development and manufacturing organization, initially developed the large-scale synthesis protocol for
Telomir-1, enabling the production of material required for preclinical studies. The manufacturing and synthesis processes have since
been successfully transferred to Recipharm, a globally recognized CDMO known for its expertise in advanced chemistry, operational excellence,
and commitment to delivering high-quality manufacturing solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Market
Opportunity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-size: 10pt">Telomir-1
is under investigation for its therapeutic potential across multiple areas, including Progeria, Type 2 Diabetes, Wilson&#8217;s
disease, Age-related Macular Degeneration (AMD), Alzheimer&#8217;s disease, cancer, and other age-related conditions. Additionally,
Telomir-1 is being explored for its potential in mitigating the severity of viral infections such as avian influenza (bird flu) by
addressing oxidative stress and immune dysfunction. These indications are being carefully evaluated to identify the most impactful
opportunities for clinical development and market entry</span><span style="font-size: 12pt">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market potential for these conditions is substantial across the United States, Canada, and Mexico. The Type 2 Diabetes market in the
U.S. alone was valued at approximately $30.47 billion in 2022, according to Fortune Business Insights, driven by rising prevalence and demand
for advanced therapies. The global AMD market is projected to reach $18 billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030.
Alzheimer&#8217;s disease, one of the most pressing age-related conditions, is projected to grow significantly, with the global market
expected to reach $13 billion by 2031, according to Allied Market Research, fueled by increasing diagnoses and advancements in treatments
targeting cognitive decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S oncology market,
covering a broad range of cancers, was valued at $74.1 billion in 2023, and is projected to reach $180.12 billion by 2033, growing at
a CAGR of 9.2% from 2024 to 2033, as per Precedence Research. Meanwhile, the anti-aging and age-reversal market was valued at $91.05
billion in 2024 globally and is projected to grow to $160.24 billion globally by 2031, with a CAGR of 7.32%, according to Verified Market
Research.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: normal">Rare
diseases such as Progeria and Wilson&#8217;s disease, despite having smaller patient populations, represent highly lucrative
opportunities due to significant unmet medical needs and strong pricing potential. For instance, the annual treatment cost for
Progeria exceeds $1 million, based on the price of Zokinvy (lonafarnib), the FDA-approved drug for the condition. Similarly,
treatments for Wilson&#8217;s disease, like Syprine (trientine hydrochloride), can cost approximately $300,000 per
year</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global antiviral drugs market is experiencing
significant growth, driven by the increasing prevalence of viral infections and advancements in treatment options. In 2022, the market
was valued at approximately $49.8 billion and is projected to reach around $71.1 billion by 2032, reflecting a compound annual growth
rate (CAGR) of 3.73% during this period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically focusing on avian influenza (bird
flu), the treatment market was estimated at $22.06 billion in 2023 and is expected to grow at a CAGR of 8.18%, reaching approximately
$38.27 billion by 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These figures highlight the substantial market opportunity for innovative
treatments addressing chronic, age-related, and viral diseases. With increasing demand for therapies targeting oxidative stress, cellular
degeneration, and immune resilience, Telomir-1 is well-positioned to address these critical unmet medical needs. Its broad therapeutic
potential, spanning rare diseases, metabolic disorders, neurodegeneration, and viral infections, represents a significant market opportunity
across North America and beyond, reinforcing its potential as a transformative solution in modern medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
license the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), an intellectual
property development and holding company. &#160;MIRALOGX has filed a Patent Cooperation Treaty (PCT) application, PCT/US2023/073106 on
August 29, 2023. The application designated the U.S. and will enter U.S. national phase. The application, if granted and subject to payment
of patent maintenance fees, would offer protection extending through at least August 29, 2043 in the U.S. The patent rights for Telomir-1
outside of the United States are not included in our current patent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license from MIRALOGX is set forth in an Amended and Restated Exclusive License Agreement, dated August 11, 2023, between us and MIRALOGX,
pursuant to which we obtained the exclusive perpetual right and license under the above-described patent rights to make, have made, use,
and sell &#8220;Licensed Products&#8221; in the U.S. for human uses and pre-clinical studies and activities of any kind conducted in
furtherance of obtaining regulatory approval or commercialization for human uses (the &#8220;Initial MIRALOGX License Agreement&#8221;).
On November 10, 2023, we and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant to which
the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals, in
addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and
commercialization of veterinary, in addition to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License
Agreement, the &#8220;MIRALOGX License Agreement&#8221;). &#8220;Licensed Product&#8221; is defined in the agreement as a drug product
containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl) pyridine or a pharmaceutically acceptable salt, ester, or solvate
thereof. We also have the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement provides
for the payment to MIRALOGX of an 8% royalty (payable quarterly) on our net sales of Licensed Products by us or our sublicensees and
on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in the license agreement. Further,
no payments have been made to date under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions impose substantial and burdensome requirements upon companies
involved in the clinical development, manufacture, marketing, and distribution of drugs. These agencies and other federal, state, and
local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness,
labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling
and export and import of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&#8217;s refusal to approve pending New Drug Applications (NDAs), withdrawal of an approval, imposition
of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required
by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice
    (&#8220;GLP&#8221;) regulations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board (&#8220;IRB&#8221;), at each clinical site before each trial may be initiated;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCP&#8221;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    that the API and finished product are manufactured under cGMP conditions and meet all applicable standards of identity, strength,
    quality, and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity,
    strength, quality, and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing
    or sale of the drug in the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)
    or to conduct a post-approval study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-clinical
studies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any drug or biological product candidate in humans, the product candidate must undergo rigorous pre-clinical testing. The pre-clinical
developmental stage generally involves laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate
toxicity in animals, to assess the potential for adverse events (&#8220;AEs&#8221;) and, in some cases, to establish a rationale for
therapeutic use. The conduct of pre-clinical studies is subject to federal regulations and requirements, including GLP regulations for
safety/toxicology studies. An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information,
analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from the FDA to ship an investigation product and then administer it to humans and must be allowed
to proceed by the FDA before human clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive
AEs and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the
FDA, unless the FDA raises concerns or questions before that time related to one or more proposed clinical trials and places the trial
on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance with
GCPs, which include the requirement that all research patients provide their informed consent for their participation in any clinical
trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries. Information about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov
website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects
of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years
after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress
of development programs. Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow
up. In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of an NDA or a Biologics
License Application (&#8220;BLA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if significant
adverse events (&#8220;SAEs&#8221;) occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may
impose other sanctions on various grounds, including a finding that the research patients are being exposed to an unacceptable health
risk. Similarly, an IRB can refuse, suspend, or terminate approval of a clinical trial at its institution if the clinical trial is not
being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional pre-clinical studies and must also develop additional information about the
physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency,
and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Marketing
Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Assuming
successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed
information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, are submitted
to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of
an NDA is subject to a substantial application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
review process typically takes twelve months from the date the NDA is submitted to the FDA. The FDA conducts a preliminary review of
all NDAs within the first 60 days after submission to determine whether they are sufficiently complete to permit substantive review before
accepting them for &#8220;filing.&#8221; The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information and may be subject to an additional application user fee. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins
an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether
the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued
safety, quality and purity. Under the current guidelines in effect in the Prescription Drug User Fee Act (PDUFA), the FDA has a goal
to review and act on the submission within ten months from the completion of the preliminary review of a standard NDA for a new molecular
entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include
medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution
methods, patient registries, or other risk minimization tools.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
FDA may refer to an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to <span style="background-color: white">ensure</span> the consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may
inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">After
evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding
the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter.
A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of
the NDA and may require additional clinical trials or pre-clinical studies in order for FDA to reconsider the application. Even with
submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-approval
requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing annual user fee requirements for any
marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employees
and Human Capital Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February <span>4th,</span> 2025, we had 5 part-time employees &#160;None of our employees is represented by a labor union or are covered
by a collective bargaining agreement. We consider our relationship with our employees to be satisfactory. In addition, we utilize the
services of contractors and part-time outside consultants to support our organization&#8217;s needs. We expect to continue to build our
team to ensure we can effectively execute our development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><i></i> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
Proceedings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse
to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries. No director or executive officer
has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against
it during the past ten years. No current director or executive officer has been convicted of a criminal offense or is the subject of
a pending criminal proceeding during the past ten years. No current director or executive officer has been the subject of any order,
judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any
type of business, securities or banking activities during the past ten years. No current director or officer has been found by a court
to have violated a federal or state securities or commodities law during the past ten years. From time to time, we may be named in claims
arising in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the
future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial
resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporation
Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were organized as a Florida corporation in August 2021 for the purpose of pursuing the development and commercialization of Telomir-1
in the United States in human applications. We were originally incorporated under the name &#8220;Metallo Therapies Inc.&#8221; and changed
our name to &#8220;Telomir Pharmaceuticals, Inc.&#8221; in October 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is a virtual office and is located at 100 SE 2<sup>nd</sup> St., Suite 2000 #1009 Miami, Florida 33131. Our
telephone number is (786) 396-6723.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is www.telomirpharma.com. The information contained on, or that can be accessed through, our website is deemed not to
be incorporated in this Annual Report or to be part of this Annual Report. You should not consider the information contained on our website
to be part of this Annual Report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
in shares of our common stock is very speculative and involves a high degree of risk.</i></b><i> You should carefully consider the risks
and uncertainties described below, the section of this Annual Report entitled &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this Annual Report. The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or
that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our
business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and
you could lose part or all of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties that you should consider before investing in our company. You should carefully
consider all of the risks described more fully in the section titled &#8220;Risk Factors&#8221; in this Annual Report on page 19,
before deciding to invest in our common stock. If any of these risks actually occurs, our business, financial condition and results of
operations would likely be materially adversely affected. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
factors that could cause actual results or events to differ materially, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
depend on rights to Telomir-1 that are or will be licensed to us.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>If
third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual
property, our operating profits could be adversely affected.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been
granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Operations and Financial Condition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are an early development-stage company with no revenues and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>our financial condition raises substantial
doubt as to our ability to continue as a going concern</i></span>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Because
we have a limited operating history, you may not be able to accurately evaluate our operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>We
will need to raise additional financing for the continuation of our operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Our
operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues
and succeed overall.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have yet to achieve a profit and will not achieve a profit in the near future, if at all.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Certain
of our executive officers are not be employed by us on a full-time basis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conflicts
of interest may arise between us and MIRALOGX.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business and Our Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
future success will largely depend on the success of Telomir-1 and any future product candidates, which development will require significant
capital resources and years of clinical development effort.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement
capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
expect to face intense competition, often from companies with greater resources and experience than we have.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
have significant and increasing liquidity needs and may require additional funding.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Development and Regulatory Approval of Our Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
regulatory approval processes with the FDA are lengthy and inherently unpredictable.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>There
is a high rate of failure for drug candidates proceeding through clinical trials.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance Upon Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to the Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Because
of the speculative nature of an investment in our company, you may lose your entire investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain
of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on rights to Telomir-1 that are or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any
loss of our rights to it could prevent us from selling our product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
our present and future pipeline of treatments, Telomir-1 is in-licensed from another company. We do not currently own any intellectual
property rights, including the patent application that underlies this license. Our rights to use Telomir-1 is subject to the negotiation
of, continuation of and compliance with the terms of this license. Thus, the non-provisional patent application is not written by us
or our attorneys, and we did not have control over the drafting and prosecution. The patent owner and our licensor might not have given
the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owner of the
patent application and had control over the drafting. We cannot be certain that drafting of the licensed patent application, or patent
prosecution, by the licensor have been or will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents and other intellectual property rights. This absence of control over the drafting, prosecution of patent and
applications, along with non-compliance with royalty payments and confidentiality breaches are just some of the ways that may result
in the Company&#8217;s&#8217; loss of the license and inability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
additional research and development activity, pre-clinical testing, and/or clinical testing Telomir-1 is required before we will have
a chance to achieve a viable product for licensing or commercialization. Our business currently depends entirely on the successful development,
regulatory approval, and licensing or commercialization of our product candidate, which may never occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
of our licensed patent application or defense of any claims asserting invalidity of these patents is often subject to the control or
cooperation of our licensor. Legal action could be initiated against the owners of the intellectual property that we license and an adverse
outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license
intellectual property that we may need to operate our business. In addition, such licensor may resolve such litigation in a way that
benefits it but adversely affects our ability to have freedom to operate to develop and commercialize Telomir-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. We may rely upon a combination of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality
agreements to protect the intellectual property of our product candidates. The strengths of patents in the pharmaceutical field involve
complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our
products and technology. However, patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and
enforce. Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to look to
patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection
may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting,
defending, or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other
proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may not develop additional
proprietary products that are patentable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical products are complex and uncertain. Although we have sought and expect to continue to seek patent
protection for our product candidates, their methods of use, and methods of manufacture, any, or all of them may not be subject to effective
patent protection. If any of our products are approved and marketed for an indication for which we do not have an issued patent, our
ability to use our patents to prevent a competitor from commercializing a non-branded version of our commercial products for that non-patented
indication could be significantly impaired or even eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of information related to our product candidates by us, or others may prevent us from obtaining or enforcing patents relating to these
products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design
around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail
to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product to compete
with our product candidates. We may also face competition from companies who develop a substantially similar product to one of our product
candidates that is not covered by any of our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not own the rights to the intellectual property and technology that will be used to commercially develop our initial product candidate,
Telomir-1. MIRALOGX, which is a separate intellectual property development company owned by a trust established by the Company&#8217;s
founder, holds the patent rights to Telomir-1, which are currently comprised of a pending non-provisional patent application. Pending
the issuance of the non-provisional patent application, we will have an exclusive, license from MIRALOGX to develop and commercialize
Telomir-1 in the U.S. for human and non-human applications. The term of the license will continue through the date of the expiration
of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic partnership/sublicensing agreement
covering the licensed products. The licensed patent rights are expected to extend through 2043. We expect additional patent terms may
be awarded, including additional patent terms based on the time for regulatory review of drug products. There are no up-front, execution,
or milestone payments required under the license agreement. Further, no payments have been made to date under the agreement. We are also
required to pay an 8% royalty on net sales or revenue in exchange for an exclusive, worldwide license to patent rights, and we may bring
suit in our own name to enforce our patent rights under the license agreement. In the event we are unable to enforce our rights under
the agreement or are unable to detect unauthorized use of our intellectual property, we may lose the benefit of the licensed rights used
to commercially develop Telomir-1. MIRALOGX will control the prosecution of the patent applications for Telomir-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual
property, our operating profits could be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights,
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time consuming to defend and divert management&#8217;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that our product candidates, or our commercialization thereof, does not and will not infringe any third party&#8217;s intellectual
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been
granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been granted a license to the right to develop Telomir-1 in the United States but not in countries outside the United States, as
MIRALOGX has retained all rights outside the United States and may license such rights to other parties. Accordingly, MIRALOGX potentially
could develop a competing product for such jurisdictions outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Operations and Financial Condition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an early development-stage company with no revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
very early development-stage enterprise that is focused on the development of a pre-clinical pharmaceutical product, we have generated
no revenue and have an accumulated deficit of $30.6 million and $14.1 million as of December 31, 2024 and December 31, 2023, respectively.
There can be no assurance that sufficient funds required to pursue our development program will be generated from operations or that
funds will be available from external sources, such as debt or equity financings or other potential sources. The lack of additional capital
resulting from the inability to generate cash flow from operations, or to raise capital from external sources would force us to substantially
curtail or cease operations and would, therefore, have a material adverse effect on business. Furthermore, there can be no assurance
that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect
on our existing stockholders. It is for these reasons substantial doubt about our ability to continue as a going concern exists and an
explanatory paragraph relating to our ability to continue as a going concern can be found within the report of our independent registered
public accounting firm on our audited financial statements for the fiscal year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to overcome the circumstances that impact our ability to remain a going concern in the future through the growth of revenues with
interim cash flow deficiencies being addressed through additional equity and debt financing. We anticipate raising additional funds through
public or private financing, strategic relationships, or other arrangements in the near future to support our business operations; however,
we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing
will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue operations.
Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing
in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and
stock price and require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy
proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing,
if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require
that we relinquish valuable rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we have a limited operating history, you may not be able to accurately evaluate our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had limited operations to date. Therefore, we have a limited operating history upon which to evaluate the merits of investing in
our company. Our stockholders should be aware of the difficulties normally encountered by new companies and the high rate of failure
of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and
delays encountered in connection with the operations that we plan to undertake. These potential problems include, but are not limited
to, unanticipated problems relating to the ability to generate sufficient cash flow to operate our business, and additional costs and
expenses that may exceed current estimates. We expect to continue to incur significant losses into the foreseeable future. We recognize
that if the effectiveness of our business plan is not forthcoming, we will not be able to continue business operations. There is no history
upon which to base any assumption as to the likelihood that we will prove successful, and it is doubtful that we will generate any operating
revenues or ever achieve profitable operations. If we are unsuccessful in addressing these risks, our business will most likely fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>We
will need to raise additional financing for the continuation of our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have generated no revenues and currently operate at a loss, we are completely dependent on the continued availability of financing
in order to continue our business operations. There can be no assurance that financing sufficient to enable us to continue our operations
will be available to us in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need additional funds to complete further development of our business plan to achieve a sustainable level where ongoing operations
can be funded out of revenues. We expect that adequate resources are available to fund our operations and initial clinical development
programs midway through the first quarter of 2026. We will require further funding to fully implement our business plan
to its fullest potential and achieve our growth plans. There is no assurance that any additional financing will be available or if available,
on terms that will be acceptable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to continue
as a going concern and the failure of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Our
operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues
and succeed overall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations may fluctuate as a result of a number of factors, some of which are beyond our control including but not limited
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic conditions in the geographies and industries where we sell our services and conduct operations; legislative policies where
    we sell our services and conduct operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    budgetary constraints of our customers; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our strategic growth initiatives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with the launching or integration of new or acquired businesses; timing of new product introductions by us, our suppliers
    and our competitors; product and service mix, availability, utilization and pricing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    mix, by state and country, of our revenues, personnel, and assets; movements in interest rates or tax rates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in, and application of, accounting rules; changes in the regulations applicable to us; and litigation matters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, we may not succeed in our business, and we could go out of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have yet to achieve a profit and will not achieve a profit in the near future, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet produced any revenues or profit and will not in the near future, if at all. We cannot be certain that we will be able to
realize sufficient revenue to achieve profitability. Further, many of our competitors have a significantly larger industry presence and
revenue stream but have yet to achieve profitability. Our ability to continue as a going concern in the future is dependent upon raising
capital from financing transactions, increasing revenue and keeping operating expenses below our revenue levels in order to achieve positive
cash flows, none of which can be assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Certain
of our executive officers are not employed by us on a full-time basis.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
Aminov, our Chief Executive Officer and Chairman of our board of directors, is not employed by our company on a full-time basis. As intended
to be provided in his employment agreement with our company, he works on a part-time and as-needed basis. Because he does not work full
time for our company, instances may occur where he may not be immediately available to provide solutions to problems or address concerns
that arise in the course of us conducting our business and thus adversely affect our business. In addition, he can become subject to
conflicts of interest because he devotes part of his working time to other business endeavors and may have responsibilities to other
entities. Although Mr. Aminov is aware of his duties and accountability to our company and to applicable laws and policies relating to
corporate opportunity and conflicts of interest, such conflicts of interest may include deciding how much time to devote to our affairs,
as well as what business opportunities should be presented to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
Yanez, our Chief Financial Officer, is not employed by our company on a full-time basis. As intended to be provided in her employment
agreement with our company, she works on a part-time and as-needed basis. Because she does not work full time for our company, instances
may occur where she may not be immediately available to provide solutions to problems or address concerns that arise in the course of
us conducting our business and thus adversely affect our business. In addition, she can become subject to conflicts of interest because
she devotes part of her working time to other business endeavors and may have responsibilities to other entities. Although Mrs. Yanez
is aware of her duties and accountability to our company and to applicable laws and policies relating to corporate opportunity and conflicts
of interest, such conflicts of interest may include deciding how much time to devote to our affairs, as well as what business opportunities
should be presented to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conflicts
of interest may arise between us and MIRALOGX.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIRALOGX
has a non-provisional patent application to the rights to Telomir-1. MIRALOGX is a separate intellectual property development company
owned by the Bay Shore Trust, which is an irrevocable trust established by our founder, Jonnie R. Williams, Sr., and in which Brian McNulty
is the trustee. The Bay Shore Trust is also our largest stockholder. We have an exclusive license from MIRALOGX to develop and commercialize
Telomir-1 in the U.S. for human and non-human applications. Although the interests of MIRALOGX are 100% owned by the Bay Shore Trust,
and Mr. Williams is not an officer or director of MIRALOGX and Mr. Williams does not have voting or dispositive power over the shares
of our company held by Bay Shore Trust, our relationship with the Bay Shore Trust, Mr. Williams may create, or may create the appearance
of, conflicts of interest when we are faced with decisions that could have different implications for MIRALOGX than the decisions have
for us. Furthermore, in light of the license agreement that we have with MIRALOGX, if a dispute were to arise between MIRALOGX and us
relating to our past or future relationship with MIRALOGX or with respect to intellectual property matters, these potential conflicts
of interest may make it more difficult for us to favorably resolve such disputes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business and Our Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success will largely depend on the success of Telomir-1 and any future product candidates, which development will require significant
capital resources and years of clinical development effort.</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no drug products on the market, and all of our drug development projects are in a pre-clinical stage of development. Our
business depends almost entirely on the successful pre-clinical and clinical development, FDA regulatory approval, and commercialization
of our product candidates, principally Telomir-1. Our stockholders need to be aware that substantial additional investments including
pre-clinical and clinical development and FDA regulatory submission and approval efforts will be required before we are permitted to
undertake clinical studies and market and commercialize our product candidates, if ever. It may be several years before we can commence
clinical trials, if ever. Any clinical trial will be subject to extensive and rigorous review and regulation by numerous government authorities
in the United States and other jurisdictions where we intend, if approved, to market our product candidates. Before obtaining regulatory
approvals for any of our product candidates, we must demonstrate through pre-clinical testing and clinical trials that the product candidate
is safe and effective for its specific application. This process can take many years and may include post- marketing studies and surveillance,
which would require the expenditure of substantial resources. Of the large number of drugs in development for approval in the United
States (and the rest of the world), only a small percentage will successfully complete the FDA regulatory approval financing to fund
our planned research, development, and clinical programs, we cannot assure you that any of our product candidates will be successfully
developed or commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to formulate or scale up any or all of our product candidates. There is no guarantee that any of the product candidates
will be or are able to be manufactured or produced in a manner to meet the FDA&#8217;s criteria for product stability, content uniformity
and all other criteria necessary for product approval in the United States and other markets. Any of our product candidates may fail
to achieve their specified endpoints in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
product candidates may not be approved even if they achieve their specified endpoints in clinical trials. The FDA may disagree with our
trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed
and commented on the design for our clinical trials. The FDA may also approve a drug for fewer or more limited indications than we request
or may grant approval contingent on the performance of costly post-approval clinical trials (i.e., Phase IV trials). In addition, the
FDA may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to expand our pipeline and obtain regulatory approval for our product candidates within the timelines we anticipate, we
will not be able to execute our business strategy effectively and our ability to substantially grow our revenues will be limited, which
would have a material adverse impact on our long-term business, results of operations, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to progress our plan will depend on our ability to clinically develop, gain regulatory approval for and ultimately commercialize
our product candidates. Our ability to successfully commercialize our product candidates will depend on, among other things, our ability
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    pre-clinical and other nonclinical studies and clinical trials in a manner that allows us to progress our studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receive
    IND acceptance and regulatory approvals from the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">produce,
    through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently
    large quantities of product candidates to permit successful commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    reimbursement from payers such as government health care programs and insurance companies and achieve commercially attractive levels
    of pricing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure
    acceptance of our product candidates from physicians, health care payers, patients, and the medical community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    positive publicity surrounding our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our spending as costs and expenses increase due to clinical trials and commercialization; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    and enforce sufficient intellectual property for our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure or delay with respect to any of the factors above could have a material adverse effect on our business, results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
positive results from future pre-clinical testing of our product candidates and potential future clinical trials may not necessarily
be predictive of the results from Phase I, Phase II or Phase III clinical trials. In addition, our interpretation of results derived
from clinical data or our conclusions based on our pre-clinical data may prove inaccurate. Frequently, pharmaceutical and biotechnology
companies have suffered significant setbacks in clinical trials after achieving positive results in pre-clinical testing and early phase
clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks may be caused by the fact that pre-clinical
and clinical data can be susceptible to varying interpretations and analyses. Furthermore, certain product candidates may perform satisfactorily
in pre-clinical studies and clinical trials but nonetheless fail to obtain FDA approval or appropriate approvals by the appropriate regulatory
authorities in other countries. If we fail to produce positive results in our clinical trials for our product candidates, the development
timeline and regulatory approval and commercialization prospects for them and as a result our business and financial prospects, would
be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement
capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenues ultimately depends on our ability to sell our approved products and secure adequate third-party reimbursement.
We currently have limited experience in marketing and selling our products. We currently do not have any products approved for sale in
the United States or in any other country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates will not happen for the foreseeable future and will depend on a number of factors beyond
our control, including the willingness of physicians to prescribe our products to patients, payers&#8217; willingness and ability to
pay for the drugs, the level of pricing achieved, patients&#8217; response to our drugs and the ability of our marketing partners to
generate sales. There can be no guarantee that we will be able to establish or maintain the personnel, systems, arrangements and capabilities
necessary to successfully commercialize Telomir-1 or any product candidate approved by the FDA in the future. If we fail to establish
or maintain successful marketing, sales and reimbursement capabilities or fail to enter into successful marketing arrangements with third
parties, our product revenues may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing
our growth and executing our growth strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management and personnel, systems, and facilities currently in place may not be adequate to support our business plan and future growth.
As a result, we may need to further expand certain areas of our organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
need to effectively manage our operations, growth and various projects requires that we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain enough talented employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our clinical trials effectively;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our external manufacturing operations with contract research organizations effectively and in a cost-effective manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    our development efforts effectively while carrying out our contractual obligations to contractors and other third parties; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may utilize the services of part-time outside consultants and contractors to perform several tasks for us, including tasks
related to compliance programs, clinical trial management, regulatory affairs, formulation development and other drug development functions.
Our growth strategy may entail expanding our use of consultants and contractors to implement these and other tasks going forward. If
we are not able to effectively expand our organization by hiring new employees and expanding our use of consultants and contractors,
we may be unable to successfully implement the tasks necessary to effectively execute on our planned research, development, manufacturing,
and commercialization activities and, accordingly, may not achieve our research, development and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to face intense competition, often from companies with greater resources and experience than we have.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs and medicines is highly competitive. We compete with a variety of multinational pharmaceutical
companies and specialized biotechnology companies, as well as products and processes being developed by universities and other research
institutions. Many of our competitors have developed, are developing, or will develop drugs and processes which may be competitive with
our drug candidates. Competitive products include those that have already been approved by medicines regulators and accepted by the medical
community and any new products that may enter the market. For some of our drug development programs / areas of interest, other treatment
options or products are currently available, under development, and may become commercially available in the future. If any of our product
candidates are approved for the diseases and conditions we are currently pursuing, they may compete with a range of medicines or therapeutic
treatments that are either in development, will be developed in the future or currently marketed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
companies may have a competitive advantage over us due to their size and experiences, financial resources, and institutional networks.
Many of our competitors may have significantly greater financial, technical, and human resources than we do. Due to these factors, our
competitors may have an advantage in marketing their approved drugs and may obtain regulatory approval of their drug candidates before
we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop drugs or
medicines that are safer, more effective, more widely used and less expensive than ours. These advantages could materially impact our
ability to develop and, if approved, commercialize our product candidates successfully. Furthermore, some of these competitors may make
acquisitions or establish collaborative relationships among themselves or with third parties to increase their ability to rapidly gain
market share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities are conducted through outside contractors and manufacturers. Loss of our contracted manufacturing
facilities, stored inventory or laboratory facilities through fire, theft or other causes, or loss of our raw material, could have an
adverse effect on our ability to continue product development activities and to conduct our business. Failure to supply our partners
with commercial product may lead to adverse consequences, including the right of partners to take over responsibility for product supply.
We currently do not have insurance coverage to compensate us for such business interruptions. Our contract manufacturers and suppliers
provide that in their separate operations; however, such coverage may prove insufficient to fully compensate us for the damage to our
business resulting from any significant property or casualty loss to those facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have significant and increasing liquidity needs and may require additional funding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations have consumed substantial amounts of cash since inception. For the year ended December 31, 2024, we reported a net operating
cash outflow of $5.1 million and a net cash inflow from financing activities of $6.3 million. For the year ended December 31, 2023, we
reported a net operating cash outflow of $3.9 million and a net cash inflow from financing activities of $3.9 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development, and general and administrative expenses, and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new research and development initiatives and continued product commercialization efforts.
We may need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications and to fund commercialization of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of FDA approval, if any, and approvals in international markets of our product candidates, if at all; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and amount of revenue from sales of our products, or revenue from grants or other sources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    rate of progress and cost of our clinical trials and other product development programs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of establishing or outsourcing sales, marketing, and distribution capabilities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    and timing of completion of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply
    arrangements for our product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product
    candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel,
    facilities, and equipment requirements; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect to fund our future capital requirements from several sources including existing cash balances, future cash flows from operations
and the proceeds from equity offerings, we cannot assure you that any of these funding sources will be available to us on favorable terms,
or at all. Further, even if we can raise funds from all of the above sources, the amounts raised may not be sufficient to meet our future
capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
results may vary significantly in future periods.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expenses and operating results have fluctuated in the past and our revenues, expenses, and operating results are likely to fluctuate
significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    sales of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    achievement of product development objectives and milestones;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial enrollment and expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    and development expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and nature of contract manufacturing and contract research payments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter. Because of these factors, our financial results
in one or more future quarters may fail to meet the expectations of securities analysts or our stockholders, which could cause our share
price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend upon our key personnel and our ability to attract and retain employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future growth and success depend on our ability to recruit, retain, manage, and motivate our employees. The inability to hire or retain
experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Due
to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific,
technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to continue to attract and retain the qualified personnel necessary for the development of our business
or to recruit suitable replacement personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers, and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we will collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our customers, suppliers and business partners, and personally
identifiable information of our customers, clinical trial subjects and employees, and patients, on our networks, and with our third-party
cloud service providers. The secure processing, maintenance and transmission of this information is critical to our operations. Despite
our security measures, our information technology and infrastructure, and that of our third parties, may be vulnerable to attacks by
hackers or breached due to employee error, malfeasance, or other disruptions. Any breach could compromise our networks and the information
stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure or other loss of information could result
in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disrupt
our operations, damage our reputation, and cause a loss of confidence in our products and our ability to conduct clinical trials, which
could adversely affect our business and reputation and lead to delays in gaining regulatory approvals for Telomir-1 or other product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is increasingly dependent on critical, complex, and interdependent information technology (&#8220;IT&#8221;) systems, including
internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external
communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion,
and computer viruses, which may result in the impairment of our ability to operate our business effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our
planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems,
including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures,
additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced
systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could
harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity
improvements to a level that outweighs the costs of implementation, or at all. In addition, our systems and the systems of our third-party
providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons
or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual
property, could lead to the public exposure of personal information (including personally identifiable information or individually identifiable
health information) of our employees, clinical trial patients, customers, business partners, and others, could lead to potential identity
theft, or could lead to reputational harm. Data security breaches could also result in loss of clinical trial data or damage to the integrity
of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure
of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly
evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business,
could result in enforcement actions by U.S. states, the U.S. federal government or foreign governments, liability or sanctions under
data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties,
other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to
our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which
could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity
threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing
critical information or expose us to liability, which could adversely affect our business and our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we, our vendors, and our third-party cloud service providers may collect and store sensitive data,
including legally protected patient health information, credit card information, personally identifiable information about our employees
and patients, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing
cloud-based and on-site systems. These applications and data encompass a wide variety of business-critical information including research
and development information, commercial information and business and financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches, or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. We have measures in place that are designed to prevent, and if necessary to detect and respond to
such security incidents, breaches of privacy, and security mandates. However, in the future, any such access, disclosure or other loss
of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such
as HIPAA in the United States and the General Data Protection Regulation in the European Union, or GDPR, government enforcement actions
and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process
samples, provide test results, share and monitor safety data, bill payers or patients, provide customer support services, conduct research
and development activities, process and prepare company financial information, manage various general and administrative aspects of our
business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Geopolitical
events and global economic conditions, such as the Israel-Hamas war may impact the third parties that we engage to supply materials or
manufacture any products for our preclinical tests and clinical trials, which increases the risk of potential delay of development efforts,
as applicable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the third parties that we engage to supply any materials or manufacture any products for our preclinical tests and clinical trials should
cease to continue to do so for any reason, including due to the effects of global economic conditions, including the Hamas-Israel war,
we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers,
as applicable, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able
to obtain adequate supplies of our product, or the substances used to manufacture them, it will be more difficult for us to develop our
product and compete effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, and product candidates
and could delay our clinical trials and development programs as well as affect our marketing and commercialization efforts. In addition,
such dependence may increase our costs and expenses, and may otherwise harm our operations and financial condition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Development and Regulatory Approval of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results
of clinical trials are open to differing interpretations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are expensive, time consuming and difficult to design and implement. Regulatory agencies may analyze or interpret the results
differently than us. Even if the results of our clinical trials are favorable, the clinical trials for a number of our product candidates
are expected to continue for several years and may take significantly longer to complete. In addition, we, the FDA, or other regulatory
authorities, including state and local authorities, or an Institutional Review Board, or IRB, with respect to a trial at its institution,
may suspend, delay or terminate our clinical trials at any time, require us to conduct additional clinical trials, require a particular
clinical trial to continue for a longer duration than originally planned, require a change to our development plans such that we conduct
clinical trials for a product candidate in a different order, e.g., in a step-wise fashion rather than running two trials of the same
product candidate in parallel. The suspension, delay or termination could be for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any product candidate during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
    insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product formulation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorization to commence a trial, including &#8220;clinical holds&#8221; or delays requiring suspension
    or termination of a trial by a regulatory agency, such as the FDA, before or after a trial is commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature, or timing of studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing pre-clinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our contract research organizations, or CROs, or other third-party contractors to comply with all contractual requirements or
    to perform their services in a timely or acceptable manner;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials or the handling, storage, security, and recordkeeping;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could have a material adverse effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by U.S. federal and state governments in each of the markets where we have product candidates progressing
through the approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must also adhere to all regulatory requirements including FDA&#8217;s Good Laboratory Practice, Good Clinical Practice, and current Good
Manufacturing Practices requirements (&#8220;cGMP&#8221;) pharmacovigilance requirements, advertising, and promotion restrictions, reporting
and recordkeeping requirements. If we or our suppliers fail to comply with applicable regulations, including FDA pre-or post-approval
cGMP requirements, then FDA could sanction us. Even if a drug is FDA-approved, regulatory authorities may impose significant restrictions
on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials. Telomir-1,
and any of our product candidates that may be approved in the U.S. in the future, will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, distribution, import, export, advertising, promotion, sampling, recordkeeping and submission
of safety and other post-market information, including both federal and state requirements in the U.S. In addition, manufacturers and
manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing
procedures conform to GMP. As such, we, and our contract manufacturers (in the event contract manufacturers are appointed in the future)
are subject to continual review and periodic inspections to assess compliance with GMP. Accordingly, we and others with whom we work
must continue to spend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, quality control
and quality assurance. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and
to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s
approved label.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    untitled or warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to enjoin our activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter into a Corporate Integrity Agreement or closing our contract manufacturers&#8217;
    facilities, if any; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
our ability to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval
is withdrawn, the value of our business and our operating results may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&#8217;s attention from the operation of our business and damage our reputation. We expend significant resources
on compliance efforts and such expenses are unpredictable and might adversely affect our results. Changing laws, regulations and standards
might also create uncertainty, higher expenses and increase insurance costs. As a result, we intend to invest all reasonably necessary
resources to comply with evolving standards, and this investment might result in increased management and administrative expenses and
a diversion of management time and attention from revenue-generating activities to compliance activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes with the FDA are lengthy and inherently unpredictable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our drug candidates as medicines in the United States or other countries until we receive approval of a New
Drug Application (&#8220;NDA&#8221;) from the FDA or in any foreign countries until we receive the approval from the regulatory authorities
of such countries. Prior to submitting an NDA to the FDA for approval of our drug candidates we will need to have completed our pre-clinical
studies and clinical trials and demonstrate that our products meet all applicable standards of identity, strength, quality, and purity
throughout their expiration date. Successfully completing any clinical program and obtaining approval of an NDA is a complex, lengthy,
expensive, and uncertain process, and the FDA (or other country medicines regulatory body) may delay, limit, or deny approval of product
candidates for many reasons, including, among others, because:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials that may not meet the level of statistical or clinical significance required by the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with the FDA with respect to the number, design, size, conduct or implementation of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA to conduct additional clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disapproval
    by the FDA of certain formulations, labeling or specifications of product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that the data from pre-clinical studies and clinical trials are insufficient;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">findings
    by the FDA that our API or finished products do not meet all applicable standards of identity, strength, quality, and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the interpretation of data from pre-clinical studies and clinical trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change their approval policies or adopt new regulations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors, many of which are beyond our control, could increase development time and / or costs or jeopardize our ability to obtain
regulatory approval for our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a high rate of failure for drug candidates proceeding through clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, FDA may disagree with our
interpretation of the data. In the event that we obtain negative results from clinical trials for product candidates or other problems
related to potential chemistry, manufacturing and control issues or other hurdles occur and our product candidates are not approved,
we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability to execute on our current
business plan may be materially impaired, our reputation in the industry and in the investment community might be significantly damaged
and the price of our common stock could decrease significantly. In addition, our inability to properly design, commence and complete
clinical trials may negatively impact the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are found in violation of federal or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty and/or be suspended
from participation in federal or state health care programs, which may adversely affect our business, financial condition, and results
of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti-kickback
laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect
us particularly upon successful commercialization of our products in the U.S. The Medicare and Medicaid Patient Protection Act of 1987,
or federal Anti-Kickback Statute, makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its
behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business,
including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care program,
such as Medicare or Medicaid. Under federal law, some arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback
Statute. Although we seek to structure our business arrangements in compliance with all applicable requirements, it is often difficult
to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged
under the federal Anti-Kickback Statute and Federal False Claims Act. Violations of fraud and abuse laws may be punishable by criminal
and/or civil sanctions, including fines and/or exclusion or suspension from federal and state health care programs such as Medicare and
Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions
on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have adopted laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care
services reimbursed by any source, not just governmental payers. There are ambiguities as to what is required to comply with these state
requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement
authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these
laws. While we believe we have structured our business arrangements to comply with these laws, it is possible that the government could
allege violations of, or convict us of violating, these laws. If we are found in violation of one of these laws, we could be required
to pay a penalty and could be suspended or excluded from participation in federal or state health care programs, and our business, results
of operations and financial condition may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates,
limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already
marketed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates prior to or after any approval for commercial sale, cause serious or unexpected side effects, or are associated
with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in
    connection with approval or post-approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require us
    to recall any product that is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our product candidates that are being developed
    for pediatric indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants
or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully
commercialized. Following receipt of approval for commercial sale of a product we may voluntarily withdraw or recall that product from
the market if at any time we believe that its use, or a person&#8217;s exposure to it, may cause adverse health consequences or death.
To date we have not withdrawn, recalled, or taken any other action, voluntary or mandatory, to remove an approved product from the market.
In addition, regulatory agencies, IRBs, or data safety monitoring boards may at any time recommend the temporary or permanent discontinuation
of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are
not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants.
Although we have never been asked by a regulatory agency, IRB, or data safety monitoring board to discontinue a clinical trial temporarily
or permanently, if we elect or are forced to suspend or terminate a clinical trial of any of our product candidates, the commercial prospects
for that product will be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore,
any of these events may result in labeling statements such as warnings or contraindications. In addition, such events or labeling could
prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the
costs of commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products
either by us or by our collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance Upon Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates. If these third parties
do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be
able to obtain marketing approval for or commercialize our product candidates, and our business could be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third parties to conduct our clinical trials and preclinical and nonclinical studies. Specifically, we rely on, and
intend to continue to rely on, medical institutions, clinical investigators, contract research organizations, or CROs, and consultants
to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.
These CROs, investigators and other third parties play a significant role in the conduct and timing of these studies or trials and the
subsequent collection and analysis of data. Though we expect to carefully manage our relationships with our CROs, investigators and other
third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and prospects. Further, while we have and will have agreements
governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are
responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory
and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our regulatory
responsibilities. In addition, we and our CROs are required to comply with GLP and GCP requirements, as applicable, which are regulations
and guidelines enforced by the FDA and comparable foreign regulatory authorities related to the conduct of nonclinical studies and clinical
trials, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and
trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP or GCP or other requirements, the collected nonclinical
data or the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities
may require us to perform additional nonclinical studies or clinical trials before approving our marketing applications, if ever. Furthermore,
our clinical trials must be conducted with materials manufactured in accordance with cGMP regulations. Failure to comply with these regulations
may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that our CROs, investigators or other third parties will be unable to devote adequate time and resources to such trials or
studies or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols
or meet regulatory requirements, or otherwise perform in a substandard manner, our clinical trials may be extended, delayed or terminated.
In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other development activities that could harm our competitive position.
In addition, principal investigators for our clinical trials are expected to serve as scientific advisors or consultants to us from time
to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical
trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection
could prevent us from receiving regulatory approval for, or commercializing, Telomir-1 and any future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs have the right to terminate their agreements with us in the event of an uncured material breach and under other specified circumstances.
If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third
parties on commercially reasonable terms, in a timely manner or at all. Switching or adding CROs, investigators and other third parties
involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a
new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.
Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance
that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact
on our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently rely on a third party for the manufacture of Telomir-1 for clinical development and expect to continue to rely on third parties
for the foreseeable future. This reliance on third parties increases the risk that supplies of our product may not be manufactured in
accordance with specifications or that we will not have sufficient quantities of Telomir-1 or such quantities at an acceptable cost,
which could delay, prevent or impair our development or potential commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities.
We rely on a third party and expect to continue to rely on third parties for the manufacture of Telomir-1 and related raw materials
for clinical development, as well as for commercial manufacture if Telomir-1 receives marketing approval. There is a risk that supplies
of our product for use in pre-clinical or clinical testing will not be manufactured in accordance with our specifications, which could
render our trial data useless or lead to the creation of compounds which are novel and for which we do not have intellectual property
protection. Based on the terms of our contracts with our manufacturers, we may have no recourse against them in the case of such errors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the facilities used by third-party manufacturers to manufacture Telomir-1 must be approved by the FDA and any comparable foreign regulatory
authority pursuant to inspections that will be conducted after we submit an NDA to the FDA or make any comparable submission to a foreign
regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for
compliance with cGMP requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material
that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority,
they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture
of Telomir-1 or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would
significantly impact our ability to develop, obtain regulatory approval for or market Telomir-1, if approved. Our failure, or the failure
of our third-party manufacturers, to comply with applicable regulations also could result in sanctions being imposed on us, including
clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of Telomir-1
or other future products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies
of our products and our financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms, in a timely manner and
in compliance with cGMP or other regulatory requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or complete clinical trials of Telomir-1 or any future product candidates in a timely manner;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving marketing approvals, for Telomir-1 or any future product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease development or to recall batches of Telomir-1 or any future product candidates; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize Telomir-1 or any future product candidates, an inability to meet commercial demands
    for Telomir-1 or any future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we do not have any long-term commitments or supply agreements with any third-party manufacturers. We may be unable to establish
any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to
timely obtain sufficient quantities of Telomir-1 or such quantities at an acceptable cost. Even if we are able to establish agreements
with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of the manufacturing agreement by the third party;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product candidates according to our specifications;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to obtain adequate raw materials and other materials required for manufacturing;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product according to our schedule or at all;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to successfully scale up manufacturing capacity, if required;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our proprietary information, including any potential trade secrets and know-how; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval or jeopardize
our ability to commence or continue commercialization of Telomir-1 or any future product candidates, and any related remedial measures
may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source
for all required raw materials used in the manufacture of our product candidates. If our existing or future third-party manufacturers
cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or
at all. Without additional suppliers of required raw materials, we may also be unable to meet the commercial needs of a commercial launch
of any future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our current and anticipated future dependence upon others for the manufacture of Telomir-1 and any future product candidates
may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely
and competitive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely on third parties to conduct our pre-clinical trials and those third parties may not perform satisfactorily, including
failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements or our pre-clinical protocols.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on Contract Research Organizations (&#8220;CROs&#8221;) to conduct our pre-clinical trials, as we currently do not plan
to independently conduct pre-clinical trials of any of our product candidates. Our agreements with these CROs, and other third parties
might terminate for a variety of reasons, including a failure to perform by the third parties to such agreements. If we were ever to
need to enter into alternative arrangements or if we were to need to change a CRO for an ongoing pre-clinical trial, we might experience
delays in our pre-clinical development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have existing, and will likely continue to seek additional collaboration arrangements with pharmaceutical or biotechnology companies
for the manufacturing, testing, development or commercialization of our product candidates. We may, with respect to our product candidates,
enter into new arrangements on a selective basis depending on the merits of retaining commercialization rights for ourselves as compared
to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for each product candidate,
both in the U.S. and internationally. To the extent that we decide to enter into collaboration agreements, we will face significant competition
in seeking appropriate collaborators and the terms of any collaboration or other arrangements that we may establish may not be favorable
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
existing or future collaboration entered into may not allow us to achieve our goals for such collaboration on a timely basis or at all.
Our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant
discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a
collaboration arrangement regarding development, intellectual property, regulatory or commercialization matters can lead to delays in
the development process or commercialization of the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Any such
termination or expiration could harm our business reputation and may adversely affect us financially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on a limited number of suppliers for the materials and components required to manufacture our product candidates. As a result,
we may not be able to obtain sufficient quantities of critical materials and components in the future. A delay or interruption by our
suppliers may also harm our business, results of operations and financial condition. In addition, the lead time needed to establish a
relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new
supplier. The time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional
costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our dependence
on single-source suppliers exposes us to numerous risks, including the following: our suppliers may cease or reduce production or deliveries,
raise prices or renegotiate terms; our suppliers may become insolvent or cease trading; we may be unable to locate a suitable replacement
supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our
customers and cause them to turn to our competitors for future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to the Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline,
even if our business is doing well.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of substantial amounts of our common stock in the public market after our IPO, or the perception that these sales may occur, could materially
and adversely affect the price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. Those shares of common stock sold in our IPO will be freely tradable, without restriction, in the public market, except for
any shares sold to our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the date of the IPO, when 1,000,000 shares of common stock became publicly tradable, approximately 23,891,902 additional shares of common
stock were subject to &#8220;lock-up&#8221; agreements entered into in connection with the IPO, are or will become eligible to be sold
in the public market by existing stockholders by February 9, 2025 as a result of Rule 144 of the Securities Act, subject to volume and
other limitations imposed under the federal securities laws. Furthermore, additional shares of our common stock may be publicly tradable
as a result of exercises of stock options and restricted stock units (RSUs) under the 2023 Omnibus Incentive Plan. Sales of substantial
amounts of our common stock in the public market after the completion of the IPO, or the perception that such sales could occur, could
adversely affect the market price of our common stock and could materially impair our ability to raise capital through offerings of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
of the speculative nature of an investment in our company, you may lose your entire investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities carries a high degree of risk and should be considered as a speculative investment. We have a very limited
operating history, are in the pre-clinical stage of development of our product candidate, have never generated revenues, have not paid
dividends, and are unlikely to pay dividends in the immediate or near future. The likelihood of our being able to achieve our goals and
run our business must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered
in connection with the establishment of early-stage biotechnology companies. An investment in our securities may result in the loss of
the entirety of such investment. Only stockholders and potential stockholders who are experienced in high-risk investments and who can
afford to lose their entire investment should consider an investment in our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
founding stockholders, which include five trusts for the benefit of the family of our founder Johnnie R. Williams, Sr., as well as MIRALOGX,
collectively own in excess of 70% of our issued and outstanding common stock. Brian McNulty acts as the trustee for such trusts. Our
officers and directors also own shares of our common stock. Therefore, these entities and individuals could influence the outcome of
matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur as a result
of our utilization of a universal shelf registration statement or otherwise could depress the market price of our common stock and impair
our ability to raise capital through the sale of additional equity securities. Notably, a large number of shares of our common stock
held by founding stockholders of our company have been registered for public resale and could be sold on the public market, depressing
our stock price. Moreover, we cannot in general predict the effect that future sales of our common stock or the market perception that
we are permitted to sell a significant number of our securities would have on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract
and retain executive management and qualified board members.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a reporting issuer, we are subject to the reporting requirements of applicable securities legislation of the jurisdiction in which it
is a reporting issuer, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these
rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or
costly and increase demand on its systems and resources. Applicable securities laws will require us to, among other things, file certain
annual and quarterly reports with respect to its business and results of operations. In addition, applicable securities laws require
us to, among other things, maintain effective disclosure controls and procedures and internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to maintain and, if required, improve its disclosure controls and procedures and internal control over financial reporting to meet
this standard, significant resources and management oversight are required. Specifically, due to the increasing complexity of its transactions,
it is anticipated that we will improve our disclosure controls and procedures and internal control over financial reporting primarily
through the continued development and implementation of formal policies, improved processes and documentation procedures, as well as
the continued sourcing of additional finance resources. As a result, management&#8217;s attention may be diverted from other business
concerns, which could harm our business and results of operations. To comply with these requirements, we may need to hire more employees
in the future or engage outside consultants, which will increase costs and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to
continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general
and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing
bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us,
which could adversely affect our business and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company subject to these rules and regulations, we may find it more expensive for it to obtain director and officer liability
insurance, and it may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could
also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on its Audit
Committee and Compensation Committee, and qualified executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of disclosure of information in filings required of a public company, our business and financial condition will become more
visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in its favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm its business
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and any decision on our part to comply only with certain reduced reporting and disclosure
requirements applicable to emerging growth companies could make shares of our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act. For as long as we continue to be an emerging
growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies
that are not emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting
firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth
company until the fifth anniversary of the fiscal year end date following the completion of our initial public offering, however, our
status would change more quickly if we have more than US$1.235 billion in annual revenue, if the market value of our shares of common
stock held by non-affiliates equals or exceeds US$700 million as of June 30 of any year, or we issue more than US$1.0 billion of non-convertible
debt over a three-year period before the end of that period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
could find our shares less attractive if we choose to rely on these exemptions. If some investors find shares less attractive as a result
of any choice to reduce future disclosure, there may be a less active trading market for our shares and our share price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as we are an &#8220;emerging growth company&#8221;, our independent registered public accounting firm will not be required to
attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an &#8220;emerging
growth company&#8221; until the fifth anniversary of the fiscal year end date following our initial public offering, which became effective
on February 9, 2024. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s
assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require
us to incur the expense of remediation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify material weaknesses in our internal control over financial reporting, or if we are unable to comply with the requirements
of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered
public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when
required, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities
could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed,
the SEC, or other regulatory authorities, which could require additional financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and, even if we no longer qualify as an emerging growth company, we may still be subject
to reduced reporting requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30<sup>th</sup>; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make the comparison of our financial statements with other public companies difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading
market for our shares and make obtaining future debt or equity financing more difficult for the Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &#8220;TELO&#8221;. However, there is no assurance that we will
be able to continue to maintain our compliance with the Nasdaq continued listing requirements. If we fail to do so, our securities may
be de-listed and cease trading on Nasdaq. As a result, selling our securities could be more difficult because smaller quantities of shares
or warrants would likely be bought and sold, transactions could be delayed, and security analysts&#8217; coverage of us may be reduced.
In addition, in the event our securities are delisted, broker-dealers would face certain regulatory requirements which may discourage
them from effecting transactions in the securities and further limit the liquidity of the securities. These factors could result in lower
prices and larger spreads in the bid and ask prices for the securities. Such delisting from Nasdaq and continued or further declines
in the share price of the securities could also greatly impair our ability to raise additional necessary capital through equity or debt
financing and could significantly increase the ownership dilution to shareholders caused by our issuing equity in financing or other
transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our shares were to be delisted from Nasdaq, they may become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delisting
from Nasdaq may cause the securities of the Company to become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. The SEC generally
defines a penny stock as an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00
per share, and that is not listed on a national securities exchange, such as Nasdaq subject to certain exemptions. Therefore, if shares
of our common stock were to be delisted from Nasdaq, the securities of the Company could become subject to the SEC&#8217;s &#8220;penny
stock&#8221; rules. These rules require, among other things, that any broker engaging in a purchase or sale of our securities provide
its customers with: (i) a risk disclosure document, (ii) disclosure of market quotations, if any, (iii) disclosure of the compensation
of the broker and its salespersons in the transaction, and (iv) monthly account statements showing the market values of our securities
held in the customer&#8217;s accounts. A broker would be required to provide the bid and offer quotations and compensation information
before effecting the transaction. This information must be contained in the customer&#8217;s confirmation. Generally, brokers are less
willing to affect transactions in penny stocks due to these additional delivery requirements. These requirements may make it more difficult
for shareholders to purchase or sell the shares of our common stock. Since the broker, not us, prepares this information, we would not
be able to assure that such information is accurate, complete or current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Some
provisions of Florida law and our amended and restated articles of incorporation and amended and restated bylaws may have anti-takeover
effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our shareholders and may
prevent attempts by our shareholders to replace or remove our current management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
status as a Florida corporation and the anti-takeover provisions of the Florida Business Corporation Act, which we sometimes refer to
as the FBCA, may discourage, delay or prevent a change in control even if a change in control would be beneficial to our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control share acquisition statute, Section 607.0902 of the FBCA, generally provides that in the event a person acquires voting shares
of the company in excess of 20% of the voting power of all of our issued and outstanding shares, such acquired shares will not have any
voting rights unless such rights are restored by the holders of a majority of the votes of each class or series entitled to vote separately,
excluding shares held by the person acquiring the control shares or any of our officers or employees who are also directors of the company.
Certain acquisitions of shares are exempt from these rules, such as shares acquired pursuant to the laws of intestate succession or pursuant
to a gift or testamentary transfer, pursuant to a merger or share exchange effected in compliance with the FBCA if we are a party to
the agreement, or pursuant to an acquisition of our shares if the acquisition has been approved by our board of directors before the
acquisition. The control share acquisition statute generally applies to any &#8220;issuing public corporation,&#8221; which means a Florida
corporation which has:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    hundred or more shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
    principal place of business, its principal office, or substantial assets within Florida; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    (i) more than 10% of its shareholders are resident in Florida; (ii) more than 10% of its shares are owned by residents of Florida;
    or (iii) one thousand shareholders are resident in Florida.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
affiliated transaction (or so-called &#8220;business combination&#8221;) statute, Section 607.0901 of the FBCA, provides that we may
not engage in certain mergers, consolidations, sales of assets, issuances of stock, reclassifications, recapitalizations, and other affiliated
transactions with any &#8220;interested shareholder&#8221; for a period of three years following the time that such shareholder became
an interested shareholder, unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to the time that such shareholder became an interested shareholder, our board of directors approved either the affiliated transaction
    or the transaction which resulted in the shareholder becoming an interested shareholder; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&#8220;interested shareholder&#8221; is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the control share acquisition statute and the affiliated transactions statute may have the effect of discouraging or preventing certain
change of control or takeover transactions involving us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our amended and restated articles of incorporation and amended and restated bylaws contain provisions that may make it more
difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our shareholders, including
transactions in which shareholders might otherwise receive a premium for their shares. These provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nothing
    in our amended and restated articles of incorporation precludes future issuances without shareholder approval of the authorized but
    unissued shares of our common stock;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice procedures apply for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting
    of shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    special meeting of shareholders can only be called by our chairman of the board of directors, our chief executive officer, our president
    (in the absence of a chief executive officer), a majority of our board of directors or the holders of 10% or more of all of our votes
    entitled to be cast on any issue proposed to be considered at the special meeting of shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    provision in our amended and restated articles of incorporation or amended and restated bylaws provides for cumulative voting, which
    limits the ability of minority shareholders to elect director candidates; directors will only be able to be removed for cause;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    amended and restated articles of incorporation authorizes undesignated preferred stock, the terms of which may be established and
    shares of which may be issued, without the approval of the holders of our capital stock; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    litigation against us can only be brought in Florida.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also
discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us
to take corporate actions other than those you desire. See &#8220;Description of Capital Stock.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
amended and restated bylaws designates the state courts located within the state of Florida as the exclusive forum for substantially
all disputes between us and our shareholders and the federal district courts as the exclusive forum for Securities Act claims, which
could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty
owed by any of our current or former directors, officers or other employees to us or our shareholders, (iii) any action arising pursuant
to any provision of the FBCA, our amended and restated articles of incorporation or our amended and restated bylaws, or (iv) any other
action asserting a claim that is governed by the internal affairs doctrine shall be a state court located within the state of Florida
(or, if a state court located within the state of Florida does not have jurisdiction, the federal district court for the Middle District
of Florida); provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by
the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Our amended and restated bylaws also provide
that, unless we consent in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive
forum for the resolution of any claims arising under the Securities Act. Under the Securities Act, federal and state courts have concurrent
jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and our stockholders cannot waive
compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether
a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
becoming a shareholder in our company, you will be deemed to have notice of and have consented to the provisions of our amended and restated
bylaws related to choice of forum. The choice of forum provisions in our amended and restated bylaws may limit our shareholders&#8217;
ability to obtain a favorable judicial forum for disputes with us. Additionally, the enforceability of choice of forum provisions in
other companies&#8217; governing documents has been challenged in legal proceedings, and it is possible that, in connection with any
applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated bylaws
to be inapplicable or unenforceable in such action. If so, we may incur additional costs associated with resolving such action in other
jurisdictions, which could harm our business, results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities
or industry analysts may not regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our securities could be influenced by research and reports that industry and/or securities analysts may publish us,
our business, the market or our competitors. We do not have any control over these analysts and cannot be assured that such analysts
will cover us or provide favorable coverage. If any of the analysts who may cover our business change their recommendation regarding
our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would
likely decline. If any analysts who may cover our business were to cease coverage or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which in turn could cause the price of our securities or trading volumes to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will likely conduct further offerings of our equity securities in the future, in which case your proportionate interest may become diluted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely be required to conduct equity offerings in the future to finance our current projects or to finance subsequent projects that
we decide to undertake. If our common stock shares are issued in return for additional funds, the price per share could be lower than
that paid by our current shareholders. We anticipate continuing to rely on equity sales of our common stock shares in order to fund our
business operations. If we issue additional common stock shares or securities convertible into shares of our common stock, your percentage
interest in us could become diluted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise
adversely affect holders of our common stock, which could depress the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue one or more series of preferred stock. Our board of directors will have the authority
to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting
any series and the designation of such series, without any further vote or action by our shareholders. Our preferred stock could be issued
with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock
may delay or prevent a change in control of us, discouraging bids for our common stock at a premium to the market price, and materially
adversely affect the market price and the voting and other rights of the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have never declared or paid any cash dividends or distributions on our capital stock. We do not anticipate paying any cash dividends
on our common stock in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings,
if any, to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our common stock
in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
declaration, payment and amount of any future dividends will be made at the discretion of the board of directors, and will depend upon,
among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other
factors as the board of directors considers relevant. There is no assurance that future dividends will be paid, and, if dividends are
paid, there is no assurance with respect to the amount of any such dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_988_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-JAC_z5W88Q4ran8h" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000047-01" escape="true" id="Fact000047" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
1C. Cybersecurity.</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C01_gBFCRMPFAIAMT-JAC_zSLkgmWTNG61"><ix:continuation continuedAt="ConU000047-02" id="ConU000047-01">We
recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is
defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud,
extortion, harm to employees and violation of data privacy or security laws.</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gBFCRMPFAIAMT-JAC_zpHDwzGNC2tk"><ix:continuation continuedAt="ConU000047-03" id="ConU000047-02"><span id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zqebkt8Y6Xvi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000048" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">Identifying
and assessing cybersecurity risk is integrated into our overall risk management systems and processes.</ix:nonNumeric></span> <span id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zXUoPgJAApkl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000049" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Cybersecurity risks related to
our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including
third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity
incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable
data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement
appropriate changes.</ix:nonNumeric></span></ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C08_gBFCRMPFAIAMT-JAC_zGsxBEGjEGx9"><ix:continuation id="ConU000047-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zdsPmK3jxePe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000050" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">Our
risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from
third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.</ix:nonNumeric></span> <span id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zL3oPVtJjeWa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000051" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">Cybersecurity
risks are evaluated when determining the selection and oversight of applicable third-party service providers and potential fourth-party
risks when handling and/or processing our employee, business or customer data.</ix:nonNumeric></span></span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
2. Description of Property.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease
began in November 2022 and expired in April 2024. The lease was not renewed. The Company moved all corporate related activities in April
2024 to a shared office space in Tampa, Florida referenced footnote 5. In September 2024, the Company decided to no longer utilize the
shared space and moved to a virtual office model and does not have a physical office space as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.55pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZM_001"></span><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &#8220;TELO&#8221; and began trading February 9, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February <span>4th, 2025</span>, we had approximately 108 holders of record of our common stock. No cash dividends have been paid on the common
stock to date. A significant number of shares of our common stock are held in either nominee
name or street name brokerage accounts, and consequently, we are unable to determine the total number of beneficial owners of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have not paid any cash dividends
on our common stock to date and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to
retain earnings, if any, for the future operation and expansion of our business. Any determination to pay cash dividends in the future
will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition,
contractual restrictions, restrictions imposed by applicable laws and other factors that our board of directors may deem relevant</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unregistered
Sales of Equity Securities and Use of Proceeds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have previously disclosed all
sales of securities without registration under the Securities Act of 1933, as amended.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuer
Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZM_003"></span><b>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition. You should read the following discussion and analysis of our results of operations
and financial condition together with our financial statements and related notes and other information included elsewhere in this Annual
Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;
included elsewhere in this Annual Report. Additionally, our historical results are not necessarily indicative of the results that may
be expected for any period in the future.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical-stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development
of&#160;Telomir-1, a novel small molecule metal ion regulator, designed to lengthen the DNA&#8217;s protective telomere caps, which are
crucial in the aging process. The Company&#8217;s goal is to explore the potential of Telomir-1 starting with ongoing research in animals
and then in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had net losses of $16.5 million and $13.1 million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 11, 2023, we completed a reverse stock split of our outstanding common stock upon the filing of our Second Amended and Restated
Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse
stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number.
The shares issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants, have been adjusted to reflect
the reverse stock split. Unless otherwise noted, the share and per share information in this Annual Report reflects the reverse stock
split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracted
    research and manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    arrangements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    expenses incurred to advance the Company&#8217;s research and development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses have historically been the cost associated with our initial investment in pre-clinical research and development activities.
We expect research and development expenses to increase in the future as we advance Telomir-1 into and through clinical trials and
pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract
manufacturing. In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which
may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely
development and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be
affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we
are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue
from the commercialization and sale of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of administrative functions, as well as fees paid for legal consulting fees and facilities costs
not otherwise included in research and development expenses. Legal costs include general corporate legal fees and license costs. We expect
to incur additional expenses as a result of becoming a public company, including expenses related to compliance with the rules and regulations
of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations for years ended December 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General and
    administrative expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,636,333</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600,192</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Related party travel costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">370,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,767,550</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,235,341</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,574,306</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,242,174</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,942,048</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,338,542</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,643,049</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    on extinguishment of debt</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,486,767</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to common stockholders</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,532,716</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,071,864</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses.</i></b> We incurred general and administrative expenses of $9.6 million and $0.6 million during the years
ended December 31, 2024 and 2023, respectively. General and administrative expenses consisted of stock compensation expense of $6.7 million for new options granted in 2024,
payroll expense of $1.2 million which increased compared to 2023 due to more employees after
the IPO, accounting and legal expenses of $0.6 million relating to the IPO in 2024, and office and rent expenses of $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Travel Costs. </i></b>We incurred $0.4 million and $1.8 million in related party travel costs during the years ended December 31,
2024 and December 31, 2023 respectively. Related party travel costs consisted of a shared lease and use of an airplane with an entity
under common control. The related party travel costs are due to CRO and vendor site visits, plus IPO related efforts for the year ended
December 31, 2023. We ceased using the airplane after March 2024 and our obligations related to this lease terminated shortly thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses. </i></b>We incurred research and development expenses of $2.2 million and $1.6 million during the years ended
December 31, 2024 and 2023, respectively. The increase in research and development expenses during 2024 compared to 2023 is due to the
expansion of pre-clinical programs during 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
components of research and development expenses during 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">R&amp;D
    Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expense
    </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif">Toxicology</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif">$<span style="font-size: 10pt">1.5
                                            million</span></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-clinical research</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$<span style="font-size: 10pt">0.3
                                            million</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D consultants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">$<span style="font-size: 10pt">0.4
                                            million</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
expense.</i></b> We incurred $4.4 million in interest expense during the year ended December 31, 2024 in contrast to incurring none
for the year ended December 31, 2023. Interest expense during 2024 was composed of debt issuance costs related to a line of credit
financing that expired upon the completion of the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loss
on extinguishment of debt. </i></b>Pursuant to a conversion agreement, the following related party debt was converted to common stock
(after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) on November 30, 2023: The Bay Shore Line
of Credit &#8211; see note 4, balance of $1.4 million into 674,637 shares of our common stock and the MIRALOGX balance of $1.7 million.
into 837,841 shares of our common stock. The conversion of the Bay Shore Line of Credit and MIRALOGX balances resulted in a loss on the
debt conversion of $7,486,767 for the year ended December 31, 2023. No conversions occurred in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception in August 2021, we have financed our operations primarily through proceeds from our initial public offering that occurred
in February of 2024, an unsecured line of credit with the Bay Shore Trust, our majority shareholder, through a $1.0 million private placement
of shares of our Common Stock that occurred during the first quarter 2023 at $3.73 per share (after giving effect to our 1-for-2.05 reverse
stock split that occurred on December 11, 2023), and through a $1.0 million stock purchase agreement of our Common Stock with Starwood
Trust that occurred in the fourth quarter of 2024. We intend to finance our clinical development programs and working capital needs from
existing cash and potential new sources of debt and equity financing. Further, we plan to conduct a raise of capital in the near future
to assist in financing working capital needs.<i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024 we entered into an unsecured Promissory Note and Loan Agreement with the Starwood Trust, a separate trust which was
established by our founder for the benefit of his family. Under this Promissory Note and Loan Agreement (the &#8220;Starwood Note&#8221;),
we have the right to borrow up to an aggregate of $5 million from the Starwood Trust at any time up until the second anniversary of the
note. Our right to borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations,
or prospects. The Starwood Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance
of the note and provides for prepayment at any time without penalty. The Starwood Note accrues interest at a rate equal of 7% per annum,
simple interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on December 9, 2024, Starwood Trust entered into a stock purchase agreement with the Company to purchase 142,857 shares of unregistered
common stock at $7 a share for a total of $1.0 million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan Agreement (the
&#8220;Bay Shore Note&#8221;), we have the right to borrow up to an aggregate of $5 million from the Bay Shore Trust at any time up to
the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our IPO. Our right to borrow funds
under the Bay Shore Note is subject to the absence of a material adverse change in its assets, operations, or prospects. The Bay Share
Note, together with accrued interest, will become due and payable on the second anniversary of the issuance of the note, provided that
it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at a rate equal to 7% per annum, simple interest,
during the first year that the note is outstanding and 10% per annum, simple interest, thereafter. The Bay Shore Note is unsecured. As
of November 30, 2023, the total amount outstanding under the Bay Shore Note was $1.4 million. The total amount outstanding was converted
into 674,637 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per share (after giving effect to our 1-for-2.05
reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement. As of February 9, 2024, the agreement has
been terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX, an intellectual property development and holding company owned by Bay Shore Trust, and The Starwood Trust,
a separate trust established by our founder, have advanced funds on behalf of Bay Shore Trust to our company in order to fund operating
activities. The total amount advanced and outstanding as of November 30, 2023, was $1.7 million. These advances were converted into 837,841
shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per share (after giving effect to our 1-for-2.05 reverse
stock split that occurred on December 11, 2023) pursuant to a conversion agreement. The total amount advanced and outstanding as of December
31, 2024 was $0.06 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until
such time that we can generate significant revenue and profit. We had negative cash flow from operations of approximately $5.1 million
for the year ended December 31, 2024 and an accumulated deficit of approximately $30.6 million as of December 31, 2024. As of December
31, 2024 we had cash and cash equivalents of approximately $1.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently expect that our cash and cash equivalents will be sufficient to fund our operations, development plans, and capital expenditures
midway through the second quarter of 2025. As such, there is substantial doubt about the Company&#8217;s ability to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have any material non-cancellable contractual obligations as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our cash flows for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by (used in):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,070,428</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,859,796</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,335,328</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,859,608</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net change in cash</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,264,900</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Used in Operating Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, operating activities used $5.1 million of cash, primarily due to a net loss of $16.5 million, offset
by a $0.11 million change in accounts payable, accrued and prepaid expenses, $4.4 million in amortization of debt issuance costs and
$6.9 million of stock compensation expense. Accounts payable was composed of research and development payables, and accounting and legal
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, operating activities used $3.9 million of cash, primarily due to a net loss of $13.1 million, a $0.10
million net increase in accounts payable, accrued expenses and prepaid expenses, offset by $1.6 million in amortization of debt issuance
costs and $7.5 million of a loss on the conversion of debt to common stock. Accounts payable was composed of research and development
payables, rent and legal expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Cash Provided by Financing Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, financing activities provided $6.3 million of cash, resulting primarily from $6.8 million from the
sale of common stock and offset by $0.5 million in repayments to a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, financing activities provided $3.9 million of cash, resulting from $1.7 million in net borrowings from
a related party, $1.5 million in net borrowings under a related party line of credit, $1.0 million from the sale of common stock and
offset by a $0.3 million in deferred offering cost and $0.05 million in repayments to a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until
we successfully complete pre-clinical and clinical development of, receive regulatory approval for, and commercialize a program and we
do not know when, or if at all, that will occur. We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we advance the pre-clinical activities and studies and initiate clinical trials. In addition, if we obtain regulatory
approval for any programs, we expect to incur significant expenses related to product sales, marketing, and distribution to the extent
that such sales, marketing and distribution are not the responsibility of potential collaborators. The timing and amount of our operating
expenditure will depend largely on the factors set out above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
funding requirements and timing and amount of our operating expenditure will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress in the development of our Telomir-1 program and other development programs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of pre-clinical studies and clinical trials for any other current and future programs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of programs and technologies that we develop or may in-license&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our
    programs for which we receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and
    the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
    and defending any intellectual property-related claims&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs we incur in maintaining business operations&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of hiring additional clinical, quality control, manufacturing and other scientific personnel&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs adding operational, financial and management information systems and personnel&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sales of our programs for which we receive marketing approval&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration
    arrangements for programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential programs, product candidates, conducting pre-clinical studies and clinical trials is a time consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our programs, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need
to obtain substantial additional funds to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued and Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued and adopted accounting pronouncements that may potentially impact our financial position and results of
operations is disclosed in Note 1 to our financial statements appearing at the end of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under Generally Accepted
Accounting Principles (GAAP) and SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Critical Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company. Patent-related costs,
including registration costs, documentation costs and other legal fees associated with the application, are expensed in the period in
which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of FASB ASC 718, &#8220;<i>Compensation - Stock Compensation</i>&#8221;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Emerging
Growth Company Election</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act and have elected to take advantage of the
benefits of the extended transition period for new or revised financial accounting standards. We expect to continue to take advantage
of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to
the extent permitted by such standards. We expect to use this extended transition period for complying with new or revised accounting
standards that have different effective dates for public and non-public companies until the earlier of the date we (i) are no longer
an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
This may make it difficult or impossible to compare our financial results with the financial results of another public company that is
either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition
period exemptions because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions
set forth in the JOBS Act and compliance with applicable laws, if, as an emerging growth company, we rely on such exemptions, we are
not required to, among other things: (a) provide an auditor&#8217;s attestation report on our system of internal control over financial
reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002; (b) provide all of the compensation disclosures that may be required
of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; (c) comply with
any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement
to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis);
and (d) disclose certain executive compensation-related items such as the correlation between executive compensation and performance
and comparisons of the Chief Executive Officer&#8217;s compensation to median employee compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2027, (b) the last date of our fiscal
year in which we had total annual gross revenue of at least $1.07 billion, (c) the date on which we are deemed to be a &#8220;large accelerated
filer&#8221; under the rules of the SEC or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities
during the previous three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZM_005"></span><b>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting companies are not required to provide the information required by this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Financial Statements and Notes thereto and the reports of Salberg &amp; Company P.A for year ended December 31, 2024 and Chery
Bekaert for the year ended December 31, 2023, our independent registered public accounting firms, for the respective years ended
listed above, are set forth on pages F-1 through F-16 of this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 54; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZM_008"></span>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer)
(the &#8220;Certifying Officers&#8221;), has evaluated the effectiveness of our disclosure controls and procedures (as defined in&#160;Rules
13a-15(e) or&#160;15d-15(e) under the&#160;Exchange Act) as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221;
as defined in&#160;Rules 13a-15(e) and&#160;15d-15(e) under the&#160;Exchange Act, means controls and other procedures of a company that
are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the&#160;Exchange
Act&#160;is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
by a company in the reports that it files or submits under the&#160;Exchange Act&#160;is accumulated and communicated to the company&#8217;s
management, including its principal executive and principal accounting officers, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its
judgment in evaluating the cost-benefit relationship of possible controls and procedures. The Certifying Officers have concluded, based
on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective
to provide reasonable assurance that the objectives of our disclosure control system were met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Management of the
Company is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Section 13a-15(f)
of the&#160;Securities Exchange Act of 1934, as amended). Internal control over financial reporting is a process designed by, or under
the supervision of, the Company&#8217;s principal financial officer to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of the Company&#8217;s financial statements for external reporting purposes in conformity with U.S. generally
accepted accounting principles and include those policies and procedures that (i) pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and
directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements. During 2024, we designed
and implemented new and enhanced controls to strengthen our internal controls over financial reporting, including hiring additional experienced
accounting personnel, among other enhancements. Management believes these enhancements were sufficient to remediate previously identified
material weaknesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, management
conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the framework established
in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission. Based
on the criteria established by COSO management concluded that the Company&#8217;s internal control over financial reporting was effective
as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This Report does not include
an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal control over financial reporting
as smaller reporting companies are not required to include such report and emerging growth companies (&#8220;EGC&#8217;s&#8221;) are exempt
from this requirement entirely until they are no longer an&#160;EGC. Management&#8217;s report is not subject to attestation by the Company&#8217;s
independent registered public accounting firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no additional changes in our internal control over financial reporting (as defined in Rule
13(a)-15(f) of the Exchange Act) that occurred during the period covered by this annual report that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZM_009"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--NoInsiderTradingFlag_dbT_c20240101__20241231_zaMoW16FZnxl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" title="No insider trading flag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000053" name="TELO:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZM_010"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZM_011"></span><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZM_012"></span>Item
10. Directors, Executive Officers and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers and their ages as of the date of this Report are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
    Yanez, MBA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Treasurer, and Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Pratt Whalen, CPA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Paul Del Giudice, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    Eagle, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    MacPherson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief biography of each of our current executive officers and directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Erez
Aminov</i></b> has served as our Chief Executive Officer and Chairman since August 2024. Mr. Aminov is an experienced biotechnology consultant
and is also the Chief Executive Officer of MIRA Pharmaceuticals Inc. (&#8220;MIRA&#8221;). Mr. Aminov&#8217;s experience in the biotech
consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021.&#160; Locate Venture is a strategy and investment
consulting firm focused on advancing and supporting early-stage biotech startups. Prior to founding Locate Venture Corp., from February
2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products.
In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company&#8217;s operations, while also spearheading
new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov&#8217;s more than two decades of experience
includes experience with the biotech industry&#8217;s particular challenges, including creating strategic alliances and guiding startups
toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York. We believe that Mr. Aminov is
qualified to serve as one of our directors based on his finance and investment experience, particularly with early stage life sciences
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Michelle
Yanez, MBA</i></b> has served as our Chief Financial Officer since June 2024, and also currently serves as the Chief Financial Officer
of MIRA Pharmaceuticals. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech,
pharmaceutical, and life science companies. Ms. Yanez&#8217; experience includes a broad range of responsibilities in a highly complex
and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit and
finance committees. From May 2002 until its acquisition in April 2022, Ms. Yanez held various leadership positions at BioDelivery Sciences
International, Inc. (Nasdaq: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings
and managed finance documents and filings for the tender offer, leading to the acquisition of BioDelivery Sciences in April 2022. Ms.
Yanez also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development
company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Ms. Yanez is also
Co-Founder and Chief Financial Officer of Santander Pharma Consulting, a privately held life sciences consulting firm that provides business
development and commercial strategy services to pharmaceutical, medical devices, and life science companies offering guidance throughout
all stages of commercial development, from inception to product launch, since February 2024. Ms. Yanez earned her B.A. in Business Management
from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business,&#160;<i>Cum
Laude</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Matthew
Pratt Whalen, CPA</i></b>, is a Certified Public Accountant with over two decades of experience in public accounting and corporate
finance. Mr. Whalen currently serves as the Chief Financial Officer of Power Digital Marketing Inc., an industry leading digital marketing
agency, where he has driven significant revenue growth and led key financial transactions. Specifically, Mr. Whalen oversees the finance
team, manages tax and audit relationships, and handles treasury management. Prior to joining Power Digital, from 2010 to May 2021, Mr.
Whalen was the Chief Financial Officer of MRC Smart Technology Solutions, a subsidiary of Xerox Corporation where he played a pivotal
role in growing the company&#8217;s revenue and managed diverse teams across multiple departments. Mr. Whalen holds a B.A. in Accounting
from the University of San Diego and is a Certified Public Accountant in California. Mr. Whalen has also served on the Finance Committee
of United Way San Diego. We believe that Mr. Whalen is qualified to serve as one of our directors based on his extensive experience in
finance and as a Certified Public Accountant. Mr. Whalen has also served as a director of MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;Dr.
Matthew Paul Del Giudice</i></b> joined our company as a director in March 2024. Dr. Del Giudice has practiced as a radiologist since
2014. He currently serves as a general overnight emergency radiologist at the Cleveland Clinic and as a real estate investor with Comfort
Living, LLC. Prior to joining the Cleveland Clinic, from March 2021 to May 2022, Dr. Del Giudice was a general radiologist with Radiology
and Imaging Specialists in Lakeland, Florida. From July 2015 to February 2021, Dr. Del Giudice was a radiologist with Radiology Partners
Phoenix, and from July 2014 to June 2015, he practiced as a musculoskeletal radiologist at the University of Arizona Health Sciences
Center &#8211; Tucson. Dr. Del Giudice received his B.S. from the University of Illinois at Urbana-Champaign, his M.D. from Loyola University
Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology
fellowship at the University of Arizona Health Sciences Center &#8211; Tucson. Dr. Del Giudice is licensed to practice medicine in Florida
and Ohio. Dr. Del Giudice also serves as a director of MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Craig
Eagle, MD </i></b>joined our company as a director in November 2022. He has also served as a director of MyMD since April 16, 2021. Dr.
Eagle is currently the Chief Medical Officer of Guardant Health, Inc. since 2021. Previously, Dr. Eagle was Vice President of Oncology
for Genentech, where he oversaw the medical programs across Genentech&#8217;s oncology portfolio. Prior to his current role, Dr. Eagle
worked in several positions at Pfizer from 2009 to 2019, including as the oncology business lead in the United Kingdom and Canada, the
global lead for Oncology Strategic Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global
Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant
business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw
extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer&#8217;s oncology portfolio, health
outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and
the European Organization for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including
celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently serves as a member of the board of directors and chair
of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company. Dr. Eagle attended Medical School
at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in
Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his
training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets
before moving into the pharmaceutical industry. Dr. Eagle&#8217;s qualifications to sit on our board of directors include his long and
successful career in the international pharmaceutical industry, his senior executive experience in areas such as business growth, strategic
alliances and mergers and acquisition transactions, his experience as a member of both public and private company boards in the healthcare
and life science industries, and his wealth of oncology<b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Edward
MacPherson</i></b> joined our company as a director in March 2024. Mr. MacPherson currently serves as Chief Growth Officer for Power
Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO
and Head of Growth for Endrock Growth &amp; Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth
&amp; Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020),
curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December
2012 to March 2016). Mr. MacPherson holds a BA in Economics from Gettysburg College. Mr. MacPherson also serves as a director of MIRA
Pharmaceuticals, Inc. (Nasdaq:MIRA)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Advisor </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Itzchak Angel, </i></b>has served as our Chief Scientific Advisor to the Company since August, 2024. Since 2005, Dr. Angel has been the President and CEO
of Angel Pharmaceuticals Consulting &amp; Technologies where he assists pharmaceutical and biotechnology companies, individuals, medical
staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development.
In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of
clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors,
and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development
process&#8211;from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business
development, and organizational planning. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France)
where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine).
Some of Dr. Angel&#8217;s previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa,
Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot,
Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer&#8217;s&#8217;
Disease, Parkinson&#8217;s disease, metabolic disorders, psoriasis, and various cancer. He received a B.Sc. degree from Tel-Aviv University
in 1979 and earned his M.Sc degree from Tel-Aviv University in 1980, both in biology. He further studied at the Hamburg University, Germany,
obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda,
Maryland, where he pursued his research in Neurobiology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Composition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of our board of directors, which currently consists of seven members. The number
of directors is determined by our board of directors, subject to the terms of our amended and restated articles of incorporation and
bylaws Our board of directors will continue to consist of seven members, and our directors will be elected for one-year terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment, and affiliations, our board of directors has determined that Matthew Pratt Whalen, Dr. Matthew Paul
Del Giudice, Dr. Craig Eagle and Edward MacPherson, do not have any relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and are independent directors under the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including
the transactions described in the section of this Annual Report titled &#8220;Certain Relationships and Related Party Transactions.&#8221;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The
functions of these committees are described below. Members will serve on these committees until their resignation or until otherwise
determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from
time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee was established upon the effectiveness of our initial public offering on February 9, 2024 and consist of Matthew Pratt
Whalen, Edward MacPherson, and Dr. Matt Del Giudice, with Matthew Whalen serving as the chair of the audit committee. Mr. Whalen succeeded
Michael Jerman as Chair of the Audit Committee following Mr. Jerman&#8217;s resignation on November 18, 2024. Each member meets the requirements
for independence under the listing standards of Nasdaq and SEC rules and regulations, including Rule 10A-3(b)(1) under the Exchange Act.
Each member of our audit committee meets the financial literacy requirements of the listing standards of Nasdaq. In addition, our board
of directors has determined that Mr. Whalen is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee&#8217;s main purpose is to oversee our corporate accounting and financial reporting process. Our audit committee will
be responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
    to ensure the independence and performance of the independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent registered public accounting firm, our interim and year-end results of operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our policies on risk assessment and risk management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    related party transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public
    accounting firm; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
    our board of directors in monitoring the performance of our internal audit function.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards
of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee was initially established upon the effectiveness of our initial public offering on February 9, 2024. As of December
2024, the Compensation Committee consists of Dr. Matthew P. Del Giudice (Chair), and Mr. Edward MacPherson. Dr. Matthew P. Del Giudice
succeeded Talhia Tuck as Chair of the Compensation Committee following her resignation, along with Bradley Kroenig, from the Board of
Directors in August 2024.&#160;Each member of the committee meets the requirements for independence under the listing standards of Nasdaq
and SEC rules and regulations. Each member is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange
Act, or Rule 16b-3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
arriving at these determinations, our board of directors examined all factors relevant to determining whether any compensation committee
member had a relationship to us that is material to that member&#8217;s ability to be independent from management in connection with
carrying out such member&#8217;s duties as a compensation committee member.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee&#8217;s main purpose is to review and recommend policies relating to compensation and benefits of our officers
and employees. Our compensation committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving, and determining, or making recommendations to our board of directors regarding, the compensation and compensation arrangements
    of our executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity compensation plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving, or making recommendations to our board of directors regarding, incentive compensation and equity compensation plans;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general policies relating to compensation and benefits of our employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will operate under a written charter that satisfies the applicable rules and regulations of the SEC and the listing
standards of Nasdaq, a copy of which will be available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee was established upon the effectiveness of our initial public offering on February 9, 2024
and consists of Dr. Matthew P. Del Giudice and Dr. Craig Eagle, with Matthew P. Del Giudice serving as the chair of the nominating and
corporate governance committee. Each member of the committee meets the requirements for independence under the listing standards of Nasdaq
and SEC rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will be responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    evaluating, and selecting, or making recommendations to our board of directors regarding nominees for election to our board of directors
    and its committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and overseeing the annual evaluation of our board of directors and of its committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
    and making recommendations to our board of directors regarding the composition of our board of directors and its committees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our corporate governance practices; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to our board of directors regarding corporate governance guidelines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee will operate under a written charter that satisfies the applicable listing standards of
Nasdaq, a copy of which will be available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee Interlocks and Insider Participation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of our compensation committee is a current or former executive officer or employee of our company. None of our executive
officers serves as a member of the compensation committee of any entity that has one or more executive officers serving on our compensation
committee.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors administers
this oversight function directly through our board of directors as a whole, and through various standing committees of our board of directors
that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure, including risks associated with cybersecurity and data protection, and our audit committee has
the responsibility to consider our major financial risk exposures and the steps our management has taken to monitor and control these
exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee
will review legal, regulatory, and compliance matters that could have a significant impact on our financial statements. Our nominating
and corporate governance committee will monitor the effectiveness of our corporate governance practices, including whether they are successful
in preventing illegal or improper liability-creating conduct. Our compensation committee will assess and monitor whether any of our compensation
policies and programs has the potential to encourage excessive risk taking. While each committee is responsible for evaluating certain
risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee reports
about such risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors have adopted a code of business conduct and ethics applicable to all of our directors, officers (including our principal
executive officer, principal financial officer, and principal accounting officer) and all global employees in accordance with applicable
federal securities laws and corporate governance rules of the Nasdaq Capital Market. Our code of business conduct and ethics will be
available on our website. Any amendments to the code of business conduct and ethics, or waivers of its requirements, will, if required,
be disclosed on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance Guidelines</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted corporate governance guidelines, a copy of which will be available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not provide any cash compensation to any of our directors during the year ended December 31, 2024, in their capacity as directors.
However, on August 27, 2024, each non-employee director was granted an option to purchase 25,000 shares of our common stock under the
2023 Omnibus Plan, with an exercise price of $5.02. Each such option contained vesting terms in which half the options immediately vested
and the remaining half vested in six months. The options have a 10-year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses the material components of the executive compensation program for the following persons: (i) all persons serving as
our principal executive officers during 2024 and (ii) the most highly compensated of our other executive officers who received compensation
during 2024 of at least $100,000 and who were executive officers on December 31, 2024. We refer to these persons as our &#8220;named
executive officers&#8221; and their positions are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the compensation paid by us during the 2024 and 2023 fiscal years to our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name
    and principal position</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Salary</span></p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">($)</span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Bonus</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Stock</span></p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Awards</span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards<br/>
                                            (3)</b></span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">All
                                            Other</span></p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Total</span></p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">($)</span></p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
                                            Aminov,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,139</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,513,332</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,504</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(5)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,629,975</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and CEO <sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
                                 Yanez,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">74,479</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">782,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,930</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">865,410</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO, Treasurer, and Secretary <sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Christopher Chapman, <br/></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">154,075</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,763</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,838</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">former Chairman and CEO</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nathen Fuentes, <br/></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">224,913</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,971</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">226,883</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">former CFO, Treasurer, and Secretary</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Mr. Aminov was appointed Chaiman and Chief Executive Officer on August 8, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Ms. Yanez was appointed Chief Financial Officer, Treasurer, and Secretary on June 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards
Board Account Standards Codification&#160;Topic 718, Stock Compensation, as modified or supplemented, or FASB&#160;ASC Topic 718. The
assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 6 to our
Financial Statements for the year ended December 31, 2024 included in this Report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Amounts represent health insurance premiums paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(5) Amounts represent health insurance premiums paid,
car payments, car insurance payments, and club memberships costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Compensation Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a more detailed summary of the elements of our current executive compensation program as it relates to our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Erez
Aminov</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Effective
August 12, 2024, we entered into an employment agreement with Mr. Aminov, pursuant to which Mr. Aminov will serve as our Chief Executive
Officer and Chairman of our Board. Under his employment agreement, Mr. Aminov has agreed to devote reasonable business time and effort
to the business and affairs of the Company. Mr. Aminov&#8217;s employment agreement provides that his employment will be on an at-will
basis and can be terminated by either Mr. Aminov or our company at any time and for any reason. Under the agreement, Mr. Aminov will
receive a base salary of $0.275 million per year. In the event that Mr. Aminov&#8217;s employment is terminated by our company without
&#8220;Cause&#8221; or is terminated by Mr. Aminov for &#8220;Good Reason&#8221;, Mr. Aminov will be entitled to (1) be paid an amount
equal to Mr. Aminov&#8217;s annual base salary, which payment shall be made seventy-five percent (75%) in a lump sum within thirty (30)
days following the effective date of the general release of claims (following any revocation period) and twenty-five percent (25%) as
salary continuation payments in substantially equal installments over the six (6) months following the release effective date in accordance
with our customary payroll practices commencing on the first payroll date following the release effective date, and (2) receive twelve
(12) months&#8217; accelerated vesting of any stock options that are outstanding and unvested as of such termination, such that any outstanding
and unvested stock options that would have vested during the twelve- (12) month period following the termination date had Mr. Aminov
remained employed in good standing shall become immediately vested and exercisable for a period of three (3) months post-termination
(subject to Mr. Aminov executing and delivering a customary general release in favor of the company). &#8220;Cause&#8221; is defined
in the agreement to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. &#8220;Good
Reason&#8221; is defined to include a material adverse change in Mr. Aminov&#8217;s compensation or duties and level of responsibility.
The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Aminov is subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Michelle
Yanez, MBA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2024, we entered into an employment agreement with Ms. Yanez, pursuant to which Ms. Yanez will serve as our Chief Financial
Officer. Under her employment agreement, Ms. Yanez has agreed to devote reasonable business time and effort to the business and affairs
of the Company. Ms. Yanez&#8217; employment agreement provides that here employment can be terminated by either Ms. Yanez or our company
at any time and for any reason, upon no less than thirty (30) days&#8217; notice. Under the agreement, Ms. Yanez will receive a base
salary of $0.137 million per year. <span style="background-color: white">In the event that her employment is terminated by our company
without &#8220;Cause&#8221; or is terminated by Ms. Yanez for &#8220;Good Reason&#8221;, Ms. Yanez will be entitled to severance compensation
in the form of salary continuation for a period of three months (subject to Ms. Yanez executing and delivering a customary general release
in favor of the company). &#8220;Cause&#8221; is defined in the agreement to include dishonesty, misappropriation, willful misconduct,
breach of the agreement, and other customary matters. &#8220;Good Reason&#8221; is defined to include a material adverse change in Ms.
Yanez&#8217;s compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality and
invention-assignment covenants to which Ms. Yanez is subject. </span>The employment agreement also contains customary confidentiality
and invention-assignment covenants to which Ms. Yanez is subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Christopher
Chapman, MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2024, the Company was made aware of the passing of its Chairman and Chief Executive Officer, Dr. Christopher Chapman. There were no clauses in his employment agreement that had an effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nathen
Fuentes, CPA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2024, we entered into a Confidential Separation and Mutual General Release Agreement (the &#8220;Separation Agreement&#8221;)
with Nathen Fuentes whereby we mutually agreed that Mr. Fuentes&#8217; employment as our Chief Financial Officer ended as of June 18,
2024. Provided that Mr. Fuentes did not revoke the acceptance of the Separation Agreement and complied with the terms therein, we would
pay Mr. Fuentes from the date thereof an aggregate of $62,500 in equal installments over three months in accordance with our regular
payroll schedule. The amount was paid in accordance with the agreements and no amounts are still outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 62; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Grants
of Plan-Based Awards in 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Estimated
    Future Payouts Under Non-Equity Incentive Plan Awards</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Estimated
    Future Payouts Under Equity Incentive <br/>
    Plan Awards</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>All Other
    Stock Awards: Number of Shares of Stocks</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>All Other
    Option Awards: Number of Securities Underlying&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Exercise or
    Base Price of Option</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Closing stock
    price on Award</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Grant Date
    Fair Value of Stock and Option&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Grant</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Threshold</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Target</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Maximum</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Threshold</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Target</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Maximum</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">or
    Units</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Options</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Name</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Date<sup>(1)</sup></b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>($)</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>($)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>($)</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(#)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(#)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(#)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(#)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(#)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>($/Sh)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>($/Sh)</b></span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Erez Aminov, CEO</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8/27/2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,960,170</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5.02</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5.26</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,513,332</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Michelle Yanez, CFO</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8/27/2024</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5.02</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5.26</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">782,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Christopher Chapman, former
    CEO</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Nathen Fuentes, former CFO</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The &#8220;Grant Date&#8221; represents the date on which the Compensation Committee of the Board took action to grant the applicable
award</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest 50% at grant
date, and 50% six months from grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)The
stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest ratably in fourths
every six months beginning February 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
The Compensation Committee granted these stock awards using the closing price on 8/26/2024 of $5.02 as the basis for the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Retirement
Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently maintain any retirement plans for our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes outstanding unexercised options held by each of the named executive officers, as of December 31, 2024</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options (#) Exercisable</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options (#) Unexercisable</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity
    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options <br/>
(#)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Exercise Prices ($)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration Date</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares or Units of Stock That Have Not Vested (#)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Market
    Value of Shares or Units of Stock That Have Not Vested ($)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity
    Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested<br/>
 (#)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity
    Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not vested <br/>
(#)</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Erez Aminov</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">980,085</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">980,085</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/27/34</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right">&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 4%; text-align: right">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Michelle Yanez</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/27/34</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Christopher Chapman</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Nathen Fuentes</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
Exercises and Stock Vested</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
stock options were exercised by our executive officers during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Omnibus Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted, and our stockholders have approved, the Telomir Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (the
&#8220;2023 Omnibus Plan&#8221;) which became effective upon the completion of our initial public offering on February 9, 2024. The 2023
Omnibus Plan will authorize the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to
our employees and any of our parent and subsidiary corporations&#8217; employees, and the grant of non-statutory stock options, restricted
stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees, directors, and consultants
and any of our future subsidiary corporations&#8217; employees and consultants. The following is a summary of certain terms and conditions
of the 2023 Omnibus Plan. This summary is qualified in its entirety by reference to the 2023 Omnibus Plan attached as an exhibit to the
registration statement of which this Annual Report forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan is administered by our board of directors or our compensation committee, or any other committee or subcommittee or
one or more of our officers to whom authority has been delegated (collectively, the &#8220;Administrator&#8221;). The Administrator has
the authority to interpret the 2023 Omnibus Plan and award agreements entered into with respect to the 2023 Omnibus Plan; to make, change
and rescind rules and regulations relating to the 2023 Omnibus Plan; to make changes to, or reconcile any inconsistency in, the 2023
Omnibus Plan or any award agreement covering an award; and to take any other actions needed to administer the 2023 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eligibility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may designate any of the following as a participant under the 2023 Omnibus Plan: any officer or employee, or individuals
engaged to become an officer or employee, of our company or our affiliates; and consultants of our company or our affiliates, and our
directors, including our non-employee directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Types
of Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan permits the Administrator to grant stock options, stock appreciation rights (&#8220;SARs&#8221;), performance shares,
performance units, shares of common stock, restricted stock, restricted stock units (&#8220;RSUs&#8221;), cash incentive awards, dividend
equivalent units, or any other type of award permitted under the 2023 Omnibus Plan. The Administrator may grant any type of award to
any participant it selects, but only our employees or our subsidiaries&#8217; employees may receive grants of incentive stock options
within the meaning of Section 422 of the Internal Revenue Code. Awards may be granted alone or in addition to, in tandem with, or (subject
to the repricing prohibition described below) in substitution for any other award (or any other award granted under another plan of our
company or any affiliate, including the plan of an acquired entity).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Reserved Under the 2023 Omnibus Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan will provide that 6,500,000 shares of our common stock are reserved for issuance under the 2023 Omnibus Plan, all of
which may be issued pursuant to the exercise of incentive stock options. The number of shares available for issuance under our 2023 Omnibus
Plan will also include an annual increase on the first day of each fiscal year after the completion of the initial public offering on
February 9, 2024 equal to 1.0% of the outstanding shares of all class of our common stock as of the last day of the immediately preceding
fiscal year or such other amount as our board of directors may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares reserved for issuance under the 2023 Omnibus Plan will be reduced on the date of the grant of any award by the maximum
number of shares, if any, with respect to which such award is granted. However, an award that may be settled solely in cash will not
deplete the 2023 Omnibus Plan&#8217;s share reserve at the time the award is granted. If (a) an award expires, is canceled, or terminates
without issuance of shares or is settled in cash, (b) the Administrator determines that the shares granted under an award will not be
issuable because the conditions for issuance will not be satisfied, (c) shares are forfeited under an award, (d) shares are issued under
any award and we reacquire them pursuant to our reserved rights upon the issuance of the shares, (e) shares are tendered or withheld
in payment of the exercise price of an option or as a result of the net settlement of outstanding stock appreciation rights or (f) shares
are tendered or withheld to satisfy federal, state or local tax withholding obligations, then those shares are added back to the reserve
and may again be used for new awards under the 2023 Omnibus Plan. However, shares added back to the reserve pursuant to clauses (d),
(e) or (f) in the preceding sentence may not be issued pursuant to incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant stock options and determine all terms and conditions of each stock option, which include the number of stock
options granted, whether a stock option is to be an incentive stock option or non-qualified stock option, and the grant date for the
stock option. However, the exercise price per share of common stock may never be less than the fair market value of a share of common
stock on the date of grant and the expiration date may not be later than 10 years after the date of grant. Stock options will be exercisable
and vest at such times and be subject to such restrictions and conditions as are determined by the Administrator, including with respect
to the manner of payment of the exercise price of such stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Appreciation Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant SARs, which represent the right of a participant to receive cash in an amount or common stock with a fair market
value, equal to the appreciation of the fair market value of a share of common stock during a specified period of time. The 2023 Omnibus
Plan provides that the Administrator will determine all terms and conditions of each SAR, including, among other things: (a) whether
the SAR is granted independently of a stock option or relates to a stock option, (b) the grant price, which may never be less than the
fair market value of our common stock as determined on the date of grant, (c) a term that must be no later than 10 years after the date
of grant, and (d) whether the SAR will settle in cash, common stock or a combination of the two.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
and Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant awards of shares of common stock, restricted stock, RSUs, performance shares or performance units.
Restricted stock means shares of common stock that are subject to a risk of forfeiture or restrictions on transfer, which may lapse
upon the achievement or partial achievement of performance goals (as described below) or upon the completion of a period of service.
An RSU grants the participant the right to receive cash or shares of common stock, the value of which is equal to the fair market
value of one share of common stock, to the extent performance goals are achieved or upon the completion of a period of service.
Performance shares give the participant the right to receive shares of common stock to the extent performance goals are achieved.
Performance units give the participant the right to receive cash or shares of common stock which is valued in relation to a unit
that has a designated dollar value or the value of which is equal to the fair market value of one or more shares of common stock, to
the extent performance goals are achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator will determine all terms and conditions of the awards including (a) whether performance goals must be achieved for the
participant to realize any portion of the benefit provided under the award, (b) the length of the vesting or performance period and,
if different, the date that payment of the benefit will be made, (c) with respect to performance units, whether to measure the value
of each unit in relation to a designated dollar value or the fair market value of one or more shares of common stock, and (d) with respect
to performance shares, performance units, and RSUs, whether the awards will settle in cash, in shares of common stock (including restricted
stock), or in a combination of the two.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Incentive Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant cash incentive awards. An incentive award is the right to receive a cash payment to the extent one or more performance
goals are achieved. The Administrator will determine all terms and conditions of a cash incentive award, including, but not limited to,
the performance goals (described below), the performance period, the potential amount payable, and the timing of payment. While the 2023
Omnibus Plan permits cash incentive awards to be granted under the 2023 Omnibus Plan, we may also make cash incentive awards outside
of the 2023 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
Goals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the 2023 Omnibus Plan, the Administrator may establish objective or subjective performance goals which may apply to any performance
award. Such performance goals may include, but are not limited to, one or more of the following measures with respect to our company
or any one or more of our subsidiaries, affiliates, or other business units: net sales; cost of sales; gross income; gross revenue; revenue;
operating income; earnings before taxes; earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization;
earnings before interest, taxes, depreciation, amortization and exception items; income from continuing operations; net income; earnings
per share; diluted earnings per share; total stockholder return; fair market value of a share of common stock; cash flow; net cash provided
by operating activities; net cash provided by operating activities less net cash used in investing activities; ratio of debt to debt
plus equity; return on stockholder equity; return on invested capital; return on average total capital employed; return on net capital
employed; return on assets; return on net assets employed before interest and taxes; operating working capital; average accounts receivable
(calculated by taking the average of accounts receivable at the end of each month); average inventories (calculated by taking the average
of inventories at the end of each month); economic value added; succession planning; manufacturing return on assets; manufacturing margin;
and customer satisfaction. Performance goals may also relate to a participant&#8217;s individual performance. The Administrator reserves
the right to adjust any performance goals or modify the manner of measuring or evaluating a performance goal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Equivalent Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant dividend equivalent units. A dividend equivalent unit gives the participant the right to receive a payment, in
cash or shares of common stock, equal to the cash dividends or other distributions that we pay with respect to a share of common stock.
We determine all terms and conditions of a dividend equivalent unit award, except that dividend equivalent units may not be granted in
connection with a stock option or SAR, and dividend equivalent unit awards granted in connection with another award cannot provide for
payment until the date such award vests or is earned, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Stock-Based Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may grant to any participant shares of unrestricted stock as a replacement for other compensation to which such participant
is entitled, such as in payment of director fees, in lieu of cash compensation, in exchange for cancellation of a compensation right
or as a bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transferability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
are not transferable, including to any financial institution, other than by will or the laws of descent and distribution, unless the
Administrator allows a participant to (a) designate in writing a beneficiary to exercise the award or receive payment under the award
after the participant&#8217;s death, (b) transfer an award to a former spouse as required by a domestic relations order incident to a
divorce, or (c) transfer an award without receiving any consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adjustments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(a) we are involved in a merger or other transaction in which our shares of common stock are changed or exchanged; (b) we subdivide or
combine shares of common stock or declare a dividend payable in shares of common stock, other securities, or other property (other than
stock purchase rights issued pursuant to a stockholder rights agreement); (c) we effect a cash dividend that exceeds 10% of the fair
market value of a share of common stock or any other dividend or distribution in the form of cash or a repurchase of shares of common
stock that our board of directors determines is special or extraordinary, or that is in connection with a recapitalization or reorganization;
or (d) any other event occurs that in the Administrator&#8217;s judgment requires an adjustment to prevent dilution or enlargement of
the benefits intended to be made available under the 2023 Omnibus Plan, then the Administrator will, in a manner it deems equitable,
adjust any or all of (1) the number and type of shares subject to the 2023 Omnibus Plan and which may, after the event, be made the subject
of awards; (2) the number and type of shares of common stock subject to outstanding awards; (3) the grant, purchase, or exercise price
with respect to any award; and (4) the performance goals of an award. In any such case, the Administrator may also provide for a cash
payment to the holder of an outstanding award in exchange for the cancellation of all or a portion of the award, subject to the terms
of the 2023 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance
or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise
reserved or available under the 2023 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
of Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a change of control (as defined in the 2023 Omnibus Plan), the successor or surviving corporation may agree to assume some or all outstanding
awards or replace them with the same type of award with similar terms and conditions, without the consent of any participant, subject
to the following requirements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number and class
    of securities that would have been issuable to a participant upon the consummation of such change of control had the award been exercised,
    vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions of the
    award may be made.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the securities to which the awards relate after the change of control are not listed and traded on a national securities exchange,
    then (a) each participant must be provided the option to elect to receive, in lieu of the issuance of such securities, cash in an
    amount equal to the fair value of the securities that would have otherwise been issued, and (b) no reduction may be taken to reflect
    a discount for lack of marketability, minority, or any similar consideration, for purposes of determining the fair value of such
    securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a participant is terminated from employment without cause, or due to death or disability, or the participant resigns employment for
    good reason (as defined in any award or other agreement between the participant and our company or an affiliate) within two years
    following the change of control, then upon such termination, all of the participant&#8217;s awards in effect on the date of such
    termination will vest in full or be deemed earned in full.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the purchaser, successor, or surviving entity does not assume the awards or issue replacement awards, then immediately prior to the change
of control date, unless the Administrator otherwise determines:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    stock option or SAR then held by a participant will become immediately and fully vested, and all stock options and SARs will be cancelled
    on the change of control date in exchange for a cash payment equal to the excess of the change of control price of the shares of
    common stock over the purchase or grant price of such shares under the award.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    restricted stock and RSUs (that are not performance awards) will vest in full.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    performance shares, performance units and cash incentive awards for which the performance period has expired will be paid based on
    actual performance, and all such awards for which the performance period has not expired will be cancelled in exchange for a cash
    payment equal to the amount that would have been due under such awards, valued assuming achievement of target performance goals at
    the time of the change of control, prorated based on the number of full months elapsed in the performance period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    unvested dividend equivalent units will vest (to the same extent as the award granted in tandem with such units) and be paid.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other unvested awards will vest and any amounts payable will be paid in cash.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Term
of Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated by our board of directors, the 2023 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10<sup>th</sup>) anniversary of its effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
and Amendment of Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2023 Omnibus Plan at any time, subject
to the following limitations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    board of directors must approve any amendment to the 2023 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan, which may include an amendment to materially increase the number of shares reserved
    under the 2023 Omnibus Plan, if we determine that such approval is required by Section 16 of the Exchange Act, the Code, the listing
    requirements of any principal securities exchange or market on which the shares are then traded, or any other applicable law; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    must approve any amendment to the 2023 Omnibus Plan that would diminish the protections afforded by the participant award limits
    or repricing and backdating prohibitions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment,
Modification, Cancellation and Disgorgement of Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: 11.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the requirements of the 2023 Omnibus Plan, the Administrator may modify or amend any award or waive any restrictions or conditions
applicable to any award or the exercise of the award, or amend, modify, or cancel any terms and conditions applicable to any award, in
each case, by mutual agreement of the Administrator and the participant or any other person that may have an interest in the award, so
long as any such action does not increase the number of shares of common stock issuable under the 2023 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not need to obtain participant (or other interested party) consent for any such action (a) that is permitted pursuant to the adjustment
provisions of the 2023 Omnibus Plan; (b) to the extent we deem the action necessary to comply with any applicable law or the listing
requirements of any principal securities exchange or market on which our common stock is then traded; (c) to the extent we deem the action
is necessary to preserve favorable accounting or tax treatment of any award for us; or (d) to the extent we determine that such action
does not materially and adversely affect the value of an award or that such action is in the best interest of the affected participant
or any other person as may then have an interest in the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator can cause a participant to forfeit any award, and require the participant to disgorge any gains attributable to the award,
if the participant engages in any action constituting, as determined by the Administrator in its discretion, cause for termination, or
a breach of a material company policy, any award agreement or any other agreement between the participant and us or one of our affiliates
concerning noncompetition, nonsolicitation, confidentiality, trade secrets, intellectual property, nondisparagement or similar obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
awards granted under the 2023 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to any
recoupment under our Compensation Recovery Policy (as described below), or any recoupment or similar requirement otherwise made applicable
by law, regulation or listing standards to us or that may be provided for in any cash or equity award granted by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Recovery Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2023, our Board of Directors adopted a policy (commonly known as a &#8220;clawback&#8221; policy) which provides for the recovery
of erroneously awarded incentive compensation to certain of our officers in the event that we are required to prepare an accounting restatement
due to material noncompliance by us with any financial reporting requirements under the federal securities laws. This policy is designed
to comply with Section 10D of the Securities Exchange Act of 1934, as amended, related rules and the listing standards of the Nasdaq
Stock Market or any other securities exchange on which our shares are listed in the future. The policy is administered by our Board of
Directors or, if so designated by the Board of Directors, the Compensation Committee. Any determinations made by the Board shall be final
and binding on all affected individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
individuals covered by this policy (the &#8220;Covered Officers&#8221;) are any current or former employee who is or was identified as
our president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller),
any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other
officer who performs a significant policy-making function, or any other person (including any executive officer of our subsidiaries or
affiliates) who performs similar significant policy-making functions for us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy covers our recoupment of &#8220;Incentive-Based Compensation&#8221; (as defined in the policy) received by a person after beginning
service as a Covered Executive and who served as a Covered Officer at any time during the performance period for that Incentive Compensation.
In the event we are required to prepare an accounting restatement, the policy requires us to recover, reasonably promptly, any erroneously
awarded Incentive-Based Compensation (as determined by our Board of Directors or Compensation Committee) received by any Covered Officer
during the three completed fiscal years immediately preceding the date on which we are required to prepare such accounting restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing description of our Compensation Recovery Policy does not purport to be complete and is qualified in its entirety by the terms
and conditions of such policy, a copy of which is filed as an exhibit to this Report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_014"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this Report, the ownership of our securities by: (i) each of our directors, (ii) all persons
who, to our knowledge, are the beneficial owners of more than 5% of the outstanding shares of common stock, (iii) each of the executive
officers, and (iv) all of our directors and executive officers, as a group. Each person named in this table has sole investment power
and sole voting power with respect to the shares of common stock set forth opposite such person&#8217;s name, except as otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name of beneficial
    owner</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount
    and Nature of Beneficial Ownership</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percentage
    of Class as of February 4, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors and Executive
    Officers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Erez Aminov</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,009,685</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.28</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Michelle Yanez</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,391</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Matthew Whalen</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">*<span style="font-family: Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Matthew Del Giudice</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Edward MacPherson</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Craig Eagle</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">487,805</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All current directors and
    officers as a group (6 persons)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,559,381</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">5% Stockholders</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian McNulty<sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,949,152</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">*Represents beneficial ownership of less than
    1%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-indent: 23.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 5,406,431 shares held by the Bay Shore Trust, (ii) 1,853,659 shares held by the Celeste J. Williams Lifetime QTIP Trust, (iii)
    24,391 shares held directly by Mr. McNulty, (iv) 1,325,646 shared held by Miralogx LLC in which Bay Shore Trust is the beneficial
    owner and (v) 2,339,025 shares issuable pursuant to a warrant held by the Bay Shore Trust that is immediately exercisable. As trustee
    for both the Bay Shore Trust and Celeste J. Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power over
    the shares held by each trust, and as such, is deemed to have beneficial ownership (as determined under Section 13(d) of the
    Exchange Act) of the securities held by each trust. Mr. Jonnie R. Williams, Sr., our founder and the settlor of the Bay Shore Trust,
    does not have voting or dispositive power over the shares held by the Bay Shore Trust.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_015"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of transactions within the last three years to which we have been a party, in which the amount involved exceeded
or will exceed $120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or
an immediate family member thereof, had or will have a direct or indirect material interest. We believe the terms obtained or consideration
that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or amounts
that would be paid or received, as applicable, in arm&#8217;s-length transactions with unrelated third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Line
of Credit and Promissory Note with the Bay Shore Trust</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, we entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by our founder, Jonnie
R. Williams, Sr., and under which various of his family members are beneficiaries (the &#8220;Bay Shore Trust&#8221;). Under this Promissory
Note and Loan Agreement (the &#8220;Bay Shore Note&#8221;), we have the right to borrow up to an aggregate of $5,000,000 from the Bay
Shore Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of our
initial public offering. Our right to borrow funds under the Bay Shore Note is subject to the absence of a material adverse change in
our assets, operations, or prospects. The Bay Share Note, together with accrued interest, will become due and payable on the second anniversary
of the issuance of the note, provided that it may be prepaid at any time without penalty. The Bay Shore Note will accrue interest at
a rate equal to 7% per annum, simple interest, during the first year that the note is outstanding and 10% per annum, simple interest,
thereafter. The Bay Shore Note is unsecured. As of November 30, 2023, the total amount outstanding under the Bay Shore Note was $1.4
million. The total amount outstanding was converted into 674,637 shares of our common stock on November 30, 2023 at a conversion rate
of $2.05 per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) pursuant to a conversion
agreement that resulted in a loss of $3.3 million for the year ended December 31, 2023 and a remaining balance as of December 31, 2023
of $0.1 million. Upon the effectiveness of the initial public offering on February 9, 2024, the agreement was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, we issued to the Bay Shore Trust a common stock purchase warrant
on June 15, 2023, giving the Bay Shore Trust the right to purchase up to 2,439,025 shares of common stock at an exercise price of $3.73
per share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023), which warrant will expire five
years after the date of grant. Upon issuance, the warrant met the criteria to be classified as equity based on an analysis under Accounting
Standards Codification (480) ASC 480, &#8220;<i>Distinguishing Liabilities from Equity</i>&#8221; and will be measured at fair value,
resulting in an initial fair value of approximately $5.95 million upon issuance of the warrant using Black-Scholes valuation techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with MIRALOGX LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January 1, 2023, MIRALOGX and The Starwood Trust, a separate Trust established by our founder, have advanced funds on behalf of Bay Shore
Trust to our company in order to fund operating activities. The total amount advanced and outstanding as of November 30, 2023, was $1.7
million. These advances were converted into 837,841 shares of our common stock on November 30, 2023 at a conversion rate of $2.05 per
share (after giving effect to our 1-for-2.05 reverse stock split that occurred on December 11, 2023) pursuant to a conversion agreement
that resulted in a loss of $4.1 million for the year ended December 31, 2023 and a remaining balance as of December 31, 2023 of $0.3
million. As of December 31, 2024, the remaining balances due to Miralogx and Starwood Trust total $0.055 and $0.037 million respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2023, we entered into the Initial MIRALOGX License Agreement with MIRALOGX, which is an intellectual property development and
holding company established by our founder and the inventor of Telomir-1, Jonnie R. Williams, Sr. See &#8220;Business&#8211; Intellectual
Property&#8221;. MIRALOGX is wholly owned by the Bay Shore Trust, and Mr. Williams does not have voting or dispositive power over the
shares of the Company held by Bay Shore Trust, and Mr. Williams is not an officer or director of the Bay Shore Trust. On November 10,
2023, we entered into an amendment to the Initial MIRALOGX License Agreement, pursuant to which we acquired the license to the non-human
applications of the &#8220;Licensed Products. This amendment was reaffirmed by new management on October 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were also a party to an Agreement for Shared Lease Costs, dated April 1, 2023, with MIRALOGX and MIRA Pharmaceuticals, Inc., under which
we have agreed to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease agreement between MIRALOGX
and Supera Aviation I LLC (&#8220;Supera Aviation&#8221;) based on our usage of the leased aircraft each month. No amounts are payable
by us under this agreement unless and to the extent we choose to utilize the leased aircraft, and we may discontinue the use of the aircraft
and terminate this agreement at any time. Supera Aviation is a company owned by Starwood Trust, a trust established by Mr. Williams.
For the year ended December 31, 2024 and December 31, 2023, the Company incurred $0.4 million and $1.77 million, respectively, in expenses
under the aircraft lease agreement. The aircraft lease was terminated in April 2024 and no other costs will be incurred under this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Starwood
Trust Line of Credit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024 the Company entered into an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with the
Starwood Trust, a separate related party trust established by the Company&#8217;s founder for the benefit of the founder&#8217;s family.
Under the Starwood Note, the Company has the right to borrow up to an aggregate of $5&#160;million from the Starwood Trust at any time
up until the second anniversary of the note. The Company&#8217;s right to borrow funds under the Starwood Note is subject to the absence
of a material adverse change in its assets, operations, or prospects. The Starwood Note, together with accrued interest, is to become
due and payable on the second anniversary of the issuance of the note, provides for prepayment at any time without penalty, and accrues
simple interest at a rate equal&#160;7% per annum. As of December 31, 2024, the Company has not borrowed any amounts under the Starwood
Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on December 9<sup></sup>, 2024, Starwood Trust entered into a stock purchase agreement with the Company to purchase 142,857 shares
of unregistered common stock at $7 a share for a total of $1.0 million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review
and Approval of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted a written policy regarding the review and approval of related party transactions. Our audit committee charter
provides that the audit committee shall review and approve or disapprove any related party transactions, which are transactions between
us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. Our policy regarding transactions between us and related persons will provide
that a related person is defined as a director, executive officer, nominee for director or greater than 5% beneficial owner of our common
stock, in each case since the beginning of the most recently completed year, and any of their immediate family members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the foregoing disclosures are summaries of certain provisions of our related party agreements and are qualified in their entirety
by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements,
they do not necessarily contain all of the information that you may find useful. Copies of certain of the agreements have been filed
as exhibits to the registration statement of which this Annual Report is a part and are available electronically on the website of the
SEC at <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a matter of corporate governance policy, we have not and will not make loans to officers or loan guarantees available to &#8220;promoters&#8221;
as that term is commonly understood by the SEC and state securities authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no
less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors
who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="ZM_016"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees.</b> The aggregate fees billed by Cherry Bekaert LLP for professional services rendered for the audit of our annual financial statements,
review of the financial information included in our Forms 10-Q (where applicable) for the respective periods and other required filings
with the SEC for the years ended December 31, 2024 and December 31, 2023 totaled $0.064 million and $0.034 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company appointed a new audit firm, Salberg &amp; Company P.A (&#8220;Salberg&#8221;) effective December 19, 2024. The aggregate
fees billed by Salberg for professional services rendered for the audit of our annual financial statements, and other required filings
with the SEC for the year ended December 31, 2024 totaled $0.05 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above amounts include interim procedures and audit fees, as well as attendance at audit committee meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit-Related
Fees.</b> The aggregate fees billed by Cherry Bekaert LLP for audit-related fees for the years ended December 31, 2024 and 2023 were
$0.051 million and $0.036 million, respectively. The fees were provided in consideration of services consisting of review and update
procedures associated with registration statements and other SEC filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
Fees.</b> There were no fees billed by Salberg &amp; Company P.A for tax services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
Other Fees. None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of our board of directors has established its pre-approval policies and procedures, pursuant to which the Audit Committee
approved the foregoing audit and non-audit services provided by Cherry Bekaert LLP and Salberg &amp; Company P.A in 2024 . Consistent
with the Audit Committee&#8217;s responsibility for engaging our independent auditors, all audit and permitted non-audit services require
pre-approval by the Audit Committee. The full Audit Committee approves proposed services and fee estimates for these services. The Audit
Committee chairperson has been designated by the Audit Committee to approve any audit-related services arising during the year that were
not pre-approved by the Audit Committee. Any non-audit service must be approved by the full Audit Committee. Services approved by the
Audit Committee chairperson are communicated to the full Audit Committee at its next regular meeting and the Audit Committee reviews
services and fees for the fiscal year at each such meeting. Pursuant to these procedures, the Audit Committee approved the foregoing
services provided by Cherry Bekaert LLP and Salberg &amp; Company P.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 72; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="ZM_017"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZM_018"></span>Item
15. Exhibits, Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information called for by this Item is incorporated herein by reference to the Exhibit Index in this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated Articles of Incorporation of Telomir Pharmaceuticals, Inc.(incorporated by reference to Exhibit 3.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Telomir Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223045454/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.1 to Form S-1/A filed December 19, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated June 15, 2023, between Telomir Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to Exhibit 4.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223045454/ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant, by and between the Company and certain investors from January 2023 through March 2023 (incorporated by reference to Exhibit 4.3 to Form S-1/A filed December 19, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224012049/ex4-4.htm" style="-sec-extract: exhibit">Description of Securities (incorporated by reference to Exhibit 4.4 to Form 10-K filed March 23, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224031606/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Erez Aminov, dated August 12, 2024 (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 13, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement by and between the Company and Michelle Yanez, dated June 18, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Award under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.3 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223040696/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated License Agreement, dated August 11, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC (incorporated by reference to Exhibit 10.4 to Form S-1 filed November 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223040696/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Amended and Restated License Agreement, dated November 10, 2023, by and between Telomir Pharmaceuticals, Inc. and MIRALOGX LLC (incorporated by reference to Exhibit 10.5 to Form S-1 filed November 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note and Loan Agreement, dated June 15, 2023, by and between Telomir Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to Exhibit 10.8 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex14-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">19.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-5.htm" style="-sec-extract: exhibit">Insider Trading Policy (incorporate by reference to Exhibit 99.5 to Form S-1/A filed December 14, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex21-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Registrant (incorporated by reference to Exhibit 21.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex14-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Registrant (incorporated by reference to Exhibit 14.1 to Form 10-K filed March 28, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#poa_01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement by and between the Company and Michelle Yanez, dated June 18, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315224012049/ex97-1.htm" style="-sec-extract: exhibit">Policy Relating to Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Form 10-K filed March 29, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Charter (incorporated by reference to Exhibit 99.1 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance Committee Charter (incorporated by reference to Exhibit 99.2 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee Charter (incorporated by reference to Exhibit 99.3 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance Guidelines (incorporated by reference to Exhibit 99.4 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1971532/000149315223044902/ex99-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Person Transaction Policy and Procedures (incorporated by reference to Exhibit 99.6 to Form S-1/A filed December 14, 2023)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x5E;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    management contract or compensatory plan or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TELOMIR
PHARMACEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ZN_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB Firm ID <span id="xdx_909_edei--AuditorFirmId_c20240101__20241231_zfKvST7izfGi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000054" name="dei:AuditorFirmId">106</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#mi_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB Firm ID
<span id="xdx_90A_edei--AuditorFirmId_c20230101__20231231_zi5ACuUbM254"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000055" name="dei:AuditorFirmId">42</ix:nonNumeric></span>)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">F-2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#ZN_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets as of December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#ZN_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ZN_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement of Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#ZN_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#ZN_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><img src="aud_001.jpg" alt="" style="width: 550px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZN_001"></span><b>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and the Board of Directors of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We have audited the accompanying balance sheet of Telomir Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2024, the
related statements of operations, changes in stockholders&#8217; equity and cash flows for the year then ended, and the related notes
(collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows
for the year then ended, in conformity with accounting principles generally accepted in the United States of America</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going
Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company raised approximately $6.9 million, used approximately $5.1 million of cash in operations and
had a net loss of $16.5 million during the year ended December 31, 2024. These matters raise substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s Plans in regard to these matters are also described in Note 2. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_900_edei--AuditorName_c20240101__20241231_z8EpGLEL3zxk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000056" name="dei:AuditorName">Salberg &amp; Company, P.A.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SALBERG
&amp; COMPANY, P.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2024<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--AuditorLocation_c20240101__20241231_zqBlB1HkvoZ8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000057" name="dei:AuditorLocation">Boca
Raton, Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
4, 2025</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2295
NW Corporate Blvd., Suite 240 &#9679; Boca Raton, FL 33431-7326</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
(561) 995-8270 &#9679; Toll Free: (866) CPA-8500 &#9679; Fax: (561) 995-1920</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.salbergco.com
&#9679; info@salbergco.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Member
National Association of Certified Valuation Analysts &#9679; Registered with the PCAOB</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Member
CPAConnect with Affiliated Offices Worldwide &#9679; Member AICPA Center for Audit Quality</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 76; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="mi_001"></span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
Florida</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt"><span>We have audited the accompanying balance sheet of Telomir Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2023,
and the related statements of operations, stockholders&#8217; equity and cash flows for the year then ended, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December&#160;31, 2023, and the results of its operations and its cash flows for</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the
year then ended</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.2pt">, in conformity
with accounting principles generally accepted in the United States of America</span>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will be able to continue as a going concern. As discussed in
Note 2 to the financial statements, the Company has incurred recurring net losses and recurring negative operating cash flows since inception.
These factors, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters are also described in Note 2 to the financial statements. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provided
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90F_edei--AuditorName_c20230101__20231231_zHDV36BOpSVd"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000058" name="dei:AuditorName">Cherry Bekaert LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
served as the Company&#8217;s auditor from 2023 to 2024.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--AuditorLocation_c20230101__20231231_zwCr22T3y9Bh"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000059" name="dei:AuditorLocation">Tampa,
Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
29, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="ZN_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">BALANCE
SHEETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zplPJud3Tym2" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zPTfhb1bSiuf" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20231231_zWEzYGQoPFbj" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zIzp3Fr61dDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrentAbstract_i01B_zsVeVBiBeoqc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Cash_i02I_maACz2Yf_zfuyQn3EhOM6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,266,131</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,231</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredOfferingCosts_i02I_maACz2Yf_zDjSQnCSyGNd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0070">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,281</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseCurrent_i02I_maACz2Yf_zQs6DH2jIjq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,874</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherReceivablesNetCurrent_i02I_maACz2Yf_zcgbiCEQdzka" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Due
    from related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0076">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtACz2Yf_maAzvm3_zwF9cYdmzxxf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435,225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredCosts_i01I_maAzvm3_zTqPNJ16HBp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred financing costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0082">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,338,543</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzvm3_zQJUjz1kXEA1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,773,768</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zsi6qPDSirC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zSAqjyOySQE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzmND_zxFq9VlcfxLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade accounts payable
    and accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,536</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">707,187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzmND_zPi9y51xKoKd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due to related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,432</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,377</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LinesOfCreditCurrent_i02I_maLCzmND_zUhVdIn0ykKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Related
    party line of credit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzmND_maLzFif_zbRmFX7lCRY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,968</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,335,564</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i01TI_mtLzFif_maLASEzmGR_z1gTZqd1Rtah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,968</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,335,564</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_i01B_z6dmyrygcbEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_maSEzKH3_zUck0dZtaHne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock, <span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_do_c20241231_zbcyInveJ73f" title="Preferred stock, par value"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_do_c20231231_zYXRG3VUes1c" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par
    value, <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zgBmDBBwDeDa" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zxo8YthYWvK8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20241231_zO82wDtfVvX5" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20241231_zalcNwUVSGli" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20231231_zE0y1uOfG3Tf" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20231231_zlA6io2c03Ib" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000127" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_maSEzKH3_zQvvygQdvrva" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common Stock, <span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20241231_zJYpvChGGzA1" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20231231_zngfxbW1yt2e" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value;
    <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zRfFpvYY2ebl" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zPmBvINCiuI6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zTto4efbTZ7l" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zP44wduV1ACc" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zuIyxfLkXzRk" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zf3tXpB9MGck" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,609,814</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2024 and December 31, 2023,
    respectively.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0131">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0132">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maSEzKH3_zrjdHFjiOOJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,502,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzKH3_zDbVf2oqwC5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,064,142</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_mtSEzKH3_maLASEzmGR_zNHvryxyJ4Hb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stockholders&#8217; equity</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,204</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtLASEzmGR_zeGuToJp9rO5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,005</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,773,768</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZN_003"></span>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">STATEMENTS
OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zuA8QEuX6f9l" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zvyUyBK3SYQ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zjyyckmaNcIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_msOEzEen_zsduizaCT4Ng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0162">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0163">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpensesAbstract_iB_z03dgnLNmB1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating costs:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzEen_zsIP0qcjG038" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and
    administrative expenses</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,636,333</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,192</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_i01_maOEzEen_zmPzZdZTYLh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related party travel costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,767,550</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzEen_zlue23QlpRK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,235,341</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,574,306</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtOEzEen_msNILz45g_zla5LUII02P9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,242,174</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,942,048</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeOther_maNILz45g_zejuLAJIMVJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0181">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpenseNonoperating_iN_di_msNILz45g_zsxJ30TjSatl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-01to2024-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,338,542</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,643,049</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maNILz45g_zbqalzXQO8Vh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    on extinguishment of debt</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0186">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,486,767</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_mtNILz45g_z5fKH14Miuze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,071,864</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zZ73BHisxGtc" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z4ZA43RxOzjc" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.56</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zpNNRNfcYtW7" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zzVilQR1hjwj" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.48</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Basic weighted average common stock shares
    outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_ztr39xxJ9PPh" title="Weighted average common stock shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zaN3HS1dp1Sg" title="Weighted average common stock shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,539,219</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_ztlkCyoM46vf" title="Weighted average common stock shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zKkQwfvDJgZe" title="Weighted average common stock shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,304,724</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZN_004"></span><b>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span style="text-transform: uppercase">Statements of Changes in stockholders&#8217;
EQUITY (DEFICIT</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zzut1EejG845" summary="xdx: Statement - Statements of Changes in Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zVt6VXsik6j9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zHDEm9H2C9hk" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Capital</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zRrMekic6rpi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_zLjVIQKwXeed" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Paid-In</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total Stockholders&#8217;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Equity</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Capital</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zD3ufVxKqSTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balances, January 1, 2023</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB0t75lSVxOi" title="Balance, shares" style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,829,269</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0208">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">992,278</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">937,278</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zMKE5YAHyiKa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqoUCfo6oPXk" title="Issuance of common stock, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">268,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zcWeT967uyB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt conversion to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj2CEN7CuECl" title="Debt conversion to common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,512,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,587,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,587,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_zguiql7TZPd9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares added for fractional shares pursuant to reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCKSJyyeArW9" title="Shares added for fractional shares pursuant to reverse stock split, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zzU0WiIqeQIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of Warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,950,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,950,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zbo2tkXXpzmi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,071,864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,071,864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zkieIpsAmx2c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balances, December 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8fvBtLuQxkb" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,609,814</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,502,346</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000248" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,064,142</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zzrp2WQnx4ba" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balances</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBnb84yhMD9j" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,609,814</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,502,346</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,064,142</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,438,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z3AkwI8LVhQ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJE3fsr02El3" title="Issuance of common stock, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zmMNSYvsY8Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5IS8a4rCbGi" title="Exercise of Warrants, shares" style="text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TELO:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zBhgRLbXVWS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,867,276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,867,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z1eEoqgVxNn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20240101__20241231_eus-gaap--StockholdersEquity_iE_z9Wt4AGiuCg9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balances, December 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJfzSwPpNv1j" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zqzpqImapit8" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balances</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBw20O3qYKw4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,762,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,239,895</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,596,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">643,037</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ZN_005"></span><b>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">statements
of cash flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_z1CpVW2NTtk9" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zwcT0f1rn3V6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zAErdP0AyyN9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from Operating
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzJiv_zxOMVwM5nAqf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,071,864</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUzJiv_z7LdmUorH25j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,867,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProvisionForOtherCreditLosses_i02_pp0p0_maNCPBUzJiv_z9tMO8TV3A2c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Credit loss expense- loan
    due from related party</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2024-01-01to2024-12-31" id="Fact000310" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzJiv_z9C39fPqFXwl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on extinguishment
    of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,486,767</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCosts_i02_pp0p0_maNCPBUzJiv_zCnrLUbjnUac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of debt issuance
    costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,338,543</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-12-31" id="Fact000317" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,611,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zSwf1zc94HV2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in operating assets
    and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzJiv_zcWZzwYI8Vuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade accounts payable
    and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,629</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,556</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzJiv_zby8TqdMN8nj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,160</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-012023-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzJiv_maCCERCzRiI_zEMSQ2Vl5kag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,070,428</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,859,796</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zurTXWvZYvP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Flows from Financing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzJzU_zuDfJeD6wSh8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payment of deferred offering
    costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,970</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--RepaymentsOfLinesOfCredit_i01N_di_msNCPBUzJzU_z6kM3PqlRMya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments under related
    party line of credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2024-01-01to2024-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_i01_maNCPBUzJzU_zRDCXzzFRzbg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from (payments
    to) due to/from related party</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">433,945</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-12-31" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,663,164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromLinesOfCredit_i01_maNCPBUzJzU_zfcFb1C2RCX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Borrowings under related
    party line of credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-01-012023-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,452,414</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzJzU_zQX41EKKLTkl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from warrant exercises</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzJzU_zvWJ60FUq4t5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from sale of common stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,832,973</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_maCCERCzRiI_mtNCPBUzJzU_zXDLBZs7HO3b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided
    by financing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000352" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,335,328</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,859,608</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzRiI_zD0w8hKh7oFi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000355" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,264,900</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">188</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zIgeoV6tVKm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash,
    beginning of year</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,419</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zeaba7nirQVk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash,
    end of year</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,266,131</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zBeatcYZsfb3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosure
    of Cash Flow Information</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaid_i01_zOaieuukjyU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for interest</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_i01_z0E37ZDOjmX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for income taxes</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zvspLYHzHhb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental schedule of
    non-cash financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfWarrantsOnRelatedPartyLineOfCredit_i01_zv24lHd7eYo7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants on related party line
    of credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="TELO:IssuanceOfWarrantsOnRelatedPartyLineOfCredit" contextRef="From2023-01-012023-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,950,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AccruedOfferingExpense_i01_z6C1GTJw8Fo3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued offering expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="TELO:AccruedOfferingExpense" contextRef="From2023-01-012023-12-31" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DebtConversionToCommonStock_i01_zvTDVCkNqZM2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt conversion to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="TELO:DebtConversionToCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,100,579</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--AdvancesToAffiliates_i01_zVdm06FudVFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advances to affiliates</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="TELO:AdvancesToAffiliates" contextRef="From2023-01-012023-12-31" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DeferredOfferingCostsChargedToAdditionalPaidinCapital_i01_zAxQSY47Y5F" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs charged to additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital" contextRef="From2024-01-01to2024-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,281</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes to the financial statements are an integral part of these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="ZN_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><i>SUPPLEMENTAL
CASH FLOW INFORMATION</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_c20230101__20231231_z8KILyUA3Uai" title="Non-cash Operating, Financing and Investing Activities">Non-cash
Operating, Financing and Investing Activities</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the fair value of a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zeCj9VghLfp5" title="Fair value of total warrants issued" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_BayShoreTrustMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span> warrants issued to Bay Shore Trust during the year ended December 31, 2023 totaling
approximately $<span id="xdx_901_ecustom--DeferredFinanceCosts_pn4n6_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_ztWKjL8Q08Kh" title="Deferred finance costs" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="TELO:DeferredFinanceCosts" contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember" id="Fact000395" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">5.95</ix:nonFraction></span> million to deferred finance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrued a $<span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--PaymentsForFees_pn4n6_c20230101__20231231_zBWZD5MHbWZ3"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-01-012023-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.09</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million placement fee related to a $<span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--PaymentsForFees_pn5n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWc4Mg9ktzmi"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember" id="Fact000397" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million private placement offering during the
year ended December 31, 2023, whereby <span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zM1ZPFV7cIG2" title="Shares of common stock issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">268,025</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (after giving effect to
our <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211_zpXyA90YBkp9" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2023-12-112023-12-11" id="Fact000400" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-2.05 reverse stock split</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that occurred on December
11, 2023) were issued. See Note 6 for warrant issuances in connection with the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company converted, pursuant to a conversion agreement, the following related party debt of $<span id="xdx_902_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_pn5n6_c20231130__20231130_zx6ozUkidI46" title="Related party debt" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-11-302023-11-30" id="Fact000402" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million to common stock (after giving
effect to our <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211_zzWFBh64mjy1" title="Reverse stock split" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2023-12-112023-12-11" id="Fact000404" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-2.05 reverse stock split</ix:nonNumeric></span> that occurred on December 11, 2023) on November 30, 2023: The Bay Shore Line of Credit &#8211;
see note 4, balance of $<span id="xdx_90F_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zbQY7jooTpka" title="Advances received for conversion" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_ziUG78wQvlG1" title="Advances received for conversion, shares" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,637</ix:nonFraction></span> shares of our common stock and the MIRALOGX balance of $<span id="xdx_901_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zPPJaDUdoOo7" title="Advances received for conversion" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000410" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million. into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zLfY2vN88hjl" title="Advances received for conversion, shares" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">837,841</ix:nonFraction></span> shares
of our common stock. The conversion of the Bay Shore Line of Credit and MIRALOGX balances resulted in a loss on the debt conversion of
$<span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zBykigQccL1k" title="Debt conversion" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,486,767</ix:nonFraction></span> for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $<span id="xdx_904_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwLgX47bRVg4" title="Amounts due from related parties" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000416" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.13</ix:nonFraction></span> million during the year ended December 31, 2023 for advances made to a related party. These advances were deemed
to be not collectible at December 31, 2024 and charged to operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ZN_007"></span>Telomir
Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000418" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zvG6PRXYezK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82C_zsBp44Qr10Z2">Description of business and summary of significant accounting policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. (&#8220;Telomir&#8221; or the &#8220;Company&#8221;) was formed in August 2021 and is a Florida incorporated pre-clinical
stage biopharmaceutical company that is developing its licensed product candidate, Telomir-1, a novel small molecule designed to lengthen
the DNA&#8217;s protective telomere caps, which are crucial in the aging process. The Company&#8217;s goal is to explore the potential
of Telomir-1 starting with ongoing research in animals and then in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomeres
are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity
accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and
age-related diseases. Telomir&#8217;s goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with
the broader aim of promoting longevity and enhancing overall quality of life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantive
operations began in late 2022 and the Company&#8217;s initial Investigative New Drug (&#8220;IND&#8221;) application is anticipated to
be filed with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in second half of 2025. National phase filings are expected to
be made during the first quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
&#160;used herein, the Company&#8217;s common stock, no par value per share, is referred to as the &#8220;Common Stock&#8221; and the
Company&#8217;s preferred stock, no par value per share, is referred to as the &#8220;Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000420" name="TELO:ReverseStockSplitPolicyTextBlock"><p id="xdx_841_ecustom--ReverseStockSplitPolicyTextBlock_zkkpUwRjWbdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective December 11, 2023, the Company completed
a reverse stock split of its outstanding common stock upon the filing of the Company&#8217;s Second Amended and Restated Articles of Incorporation
with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable
upon the exercise of our outstanding warrants, and the exercise price of such warrants, have been adjusted to reflect the reverse stock
split. Unless otherwise noted, all share and per share information in this Report retrospectively reflects the reverse stock split. (See
Note 6 &#8220;Common Stock&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000422" name="TELO:InitialPublicOfferingPolicyTextBlock"><p id="xdx_84F_ecustom--InitialPublicOfferingPolicyTextBlock_zXt79ulMVMX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i><span id="xdx_869_z75ahWt9vHOa">Initial
public offering</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, the Company closed its initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqA7PY2Zzj93" title="IPO units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000424" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Common Stock
at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zg0jBQgUA59l" title="Initial public offering shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-13_us-gaap_IPOMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share for approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTPujBNIWEa3" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million in gross proceeds. After deducting the underwriting commission and other
offering expenses totaling $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwbKKnJV24k9" title="Underwriting commission and other offering expenses"><ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million, the net proceeds to the Company were $<span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeA9PCKl0Il8" title="Initial public offering net proceeds"><ix:nonFraction name="TELO:ProceedsFromInitialPublicOfferingNetProceeds" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000432" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million. The Common Stock began trading on The Nasdaq
Capital Market on February 9, 2024 under the symbol &#8220;TELO&#8221; (See Note 6 &#8220;Common Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000434" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zOQDpgPdBGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoUgJS5DJ0w">Revenue
recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has no source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000436" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zcwsWEOXvTeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z4dX9EFBa1v9">Income
taxes</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting
for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;), which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation
allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred
asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted&#160;ASC 740-10-25, &#8220;Definition of Settlement&#8221;, which provides guidance on how an entity should determine
whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a
tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished.
For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position
is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations
remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities,
generally for three years after they are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000438" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUZxHSB5Cjyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zr5iyJ7pgiwg">Research
and development expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000440" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zKocMBfqSUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zZBMGwwFLEij">Use
of estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000442" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFsiosMfeV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zAxnAwav3f9c">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased,
to be cash equivalents. The Company maintains cash and cash equivalent balances at two financial institutions that are insured by the
Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company&#8217;s account at these institutions are insured by the FDIC up
to $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zknBa6WMXQgf" title="Cash insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. On December 31, 2024 and 2023, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zdzrHETIHRLj" title="Cash"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000446" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million &#160;and $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zCWBxTaWb0Jc" title="Cash"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.0</ix:nonFraction></span>
million, respectively. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually
the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could
have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its
cash to other high quality financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000450" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvYtSxWf6uSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zFNYU0dot5b">Stock-based
compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000452" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVnmNYchwC32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zslnRouUK76f">Fair
Value Measurements and Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000454" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z9pZXaDSS82g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zc3o324Lkjg">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Earnings
(loss) per share is computed in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAzY9wDNiCSl" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></span>
stock warrants and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zMjFmzBmjW1i" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></span>
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvrsUqp6XMrj" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000460" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,774,057</ix:nonFraction></span>
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000462" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zz2S0BKBUbN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_826_zwpn30GsllAh">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern which contemplates the realization
of assets and settlement of liabilities and commitments in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had cash of approximately $<span id="xdx_900_eus-gaap--Cash_iI_pn5n6_c20241231_znS4OfaHuDA8" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span>
million. The Company raised approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zfYfak5AfCXf" title="Raised amount"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-01to2024-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million in 2024 and used approximately $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zPC90RPBAgF3" title="Cash in operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.1</ix:nonFraction></span>
million of cash in operations during the year ended December 31, 2024, had a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zFwtebQi8xx3" title="Net Loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">16.5</ix:nonFraction></span> million in 2024 and had stockholders&#8217; equity of approximately $<span id="xdx_909_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zbIMkwdbg1H4" title="Stockholders equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million at December 31, 2024, versus stockholders&#8217; equity of approximately $<span id="xdx_906_eus-gaap--StockholdersEquity_iI_pn5n6_c20231231_zRqjiHc0Dagf" title="Stockholders equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span>
million at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company&#8217;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#8217;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4 and an initial public offering &#8211; see Note 1. Additional sources of financing may be
sought by the Company. However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if
at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this Annual Report, the Company will continue to generate losses and have insufficient cash and cash equivalents
on hand to support its operations for at least the 12 months following the date the financial statements are issued. &#160;These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for
a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. The Company is seeking to
raise capital through additional debt and/or equity financings to fund our operations in the future. If the Company is unable to raise
additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations.
These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and 2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000476" name="TELO:LicenseAgreementRelatedPartyTextBlock"><p id="xdx_803_ecustom--LicenseAgreementRelatedPartyTextBlock_z2FmDuIvdWXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span id="xdx_823_zIuJuJWzprN7">License agreement, related party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company licenses the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), an
intellectual property development and holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2023, (the &#8220;Effective Date&#8221;), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement, under which the Company has the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell &#8220;Licensed Products&#8221; in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the &#8220;MIRALOGX License Agreement&#8221;). On
November 10, 2023, the Company and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant
to which the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals,
in addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and
commercialization of veterinary, in addition to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License
Agreement, the &#8220;MIRALOGX License Agreement&#8221;). &#8220;Licensed Product&#8221; is defined in the agreement as a drug product
containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl) pyridine or a pharmaceutically acceptable salt, ester, or solvate
thereof. The Company also has the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement
provides for the payment to MIRALOGX of an <span id="xdx_90C_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVopxE5gbCN1" title="Percentage of royalty payable"><ix:nonFraction name="TELO:PercentageOfRoyaltyPayable" contextRef="AsOf2023-08-11_us-gaap_RelatedPartyMember" id="Fact000478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% royalty (payable quarterly) on the Company&#8217;s net sales of Licensed Products by the
Company or its sublicensees and on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in
the license agreement. Further, no payments have been made to date under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the license from MIRALOGX will continue through the date of the expiration of the last-to-expire licensed patent or, if later,
the date of the expiration of the last strategic partnership/sublicensing agreement covering the licensed products. The patent rights
are expected to extend through 2043, and additional patent terms may be awarded, including additional patent terms based on the time
taken for regulatory review of drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of
the patent applications for Telomir-1. Telomir is required to be kept informed by</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIRALOGX
of patent prosecution activities and may select identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent
prosecution and maintenance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000480" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zC1Gl3PLKyg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_82A_zjVG78OMRSxj">Related party balances and transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due
from related parties-</i> During the year ended December 31, 2023, the Company provided working capital advances to companies under common
control. These advances were due on demand and are non-interest bearing. Amounts due from related parties as of December 31, 2023 were
$<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231_zXmRwWBNEgW6" title="Amounts due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.13</ix:nonFraction></span> million. In 2024, the company under common control was dissolved and therefore the amount due become uncollectable and was written
off and reflected as credit loss expense, which is included in general and administration expenses. As of December 31, 2024, there was <span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_pid_dxL_c20241231_zYN7BLzXgjmd" title="Amounts due from related parties::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0484">no</span></span>
amount due from related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due
to related parties-</i> During the years ended December 31, 2024 and December 31, 2023, the Company received working capital
advances from companies under common control. These advances were due on demand and are non-interest bearing. During the year ended
December 31, 2023, advances in the amount of $<span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdwOnBSkqywd"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000485" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
were converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zIKc0uHF7fpj"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">837,841</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of our common stock (after giving effect to our <span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--MiralogxLLCMember_z2SmVAdsoBP4"><ix:nonNumeric contextRef="From2023-12-112023-12-11_custom_MiralogxLLCMember" id="Fact000487" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-2.05
reverse stock split</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that occurred on
December 11, 2023) at a conversion rate of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zFTx3V7H9246"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-31_custom_MiralogxLLCMember" id="Fact000488" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.05</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share resulting in a loss on the conversion of debt of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zmMYbuxcQxZ2"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000489" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.
Following the conversion, $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231_zVKrOBu9aY5"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of advances remained outstanding as of December 31, 2023. During the year ended December 31, 2024, there were advances received by
the Company in the amount of $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zL87h1GcDGy6"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for payments made regarding studies on behalf of Telomir and repayments made to related parties in the amount of $<span id="xdx_909_eus-gaap--OtherLiabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zY8xdMUHvuwa"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31_custom_MiralogxLLCMember" id="Fact000492" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.
As of December 31, 2024 $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241231_zMiulhJzcYx"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
remained outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bay
Shore Trust Line of Credit</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#8217;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &#8220;Bay Shore Note&#8221;), the Company had the right to borrow up to an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zi7lVuBQ1oZ7" title="Line of credit, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000495" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#8217;s
IPO. As of December 31, 2024, the line of credit is no longer available as the IPO was completed in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_z52ibEjCL7k8" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span> shares of Common Stock at an exercise price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zEduPDIyP3x8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000499" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share (See Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company received $<span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0A8JOQexfca"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember" id="Fact000500" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in advances from a line of credit from
Bay Shore Trust. On November 30, 2023, $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsQTH0c899id"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember" id="Fact000501" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zPNZnfjyYOCj"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember" id="Fact000502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">674,637</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Common Stock (after giving effect
to our <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsC3cVibxcU3"><ix:nonNumeric contextRef="From2023-12-112023-12-11_custom_BayShoreTrustMember" id="Fact000503" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-2.05
reverse stock split</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that occurred on December
11, 2023) at a conversion rate of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zS9IsnJOQtLi"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.05</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share resulting in a loss on the conversion
of debt of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_z9oSX84JgDY3"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, with $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKpSLqNLqnmk"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_BayShoreTrustMember" id="Fact000506" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million outstanding as of December 31, 2023.
As of December 31, 2024, the line of credit has been paid in full and is no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Starwood
Trust Line of Credit and Stock Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024 the Company entered into an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with
the Starwood Trust, a separate related party trust established by the Company&#8217;s founder, Jonnie R. Williams, Sr. who is the
sole owner of Bay Shore Trust as well as our largest shareholder, and under which various of his family members are beneficiaries.
Under the Starwood Note, the Company has the right to borrow up to an aggregate of $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzEETtdviqa2" title="Unused line of credit"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-09-24_custom_StarwoodTrustMember" id="Fact000508" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span>&#160;million
from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The Company&#8217;s right to
borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations, or prospects
The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or operations
than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the
note, provides for prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzXwWsW9LIMj" title="Accrue interest at a rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-09-24_custom_StarwoodTrustMember" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>%
per annum. As of December 31, 2024, the Company has not borrowed any amounts under the Starwood Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on December 9, 2024, Starwood Trust entered into a stock purchase agreement with the Company to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBZtnPjOZrTk" title="Purchase of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,857</ix:nonFraction></span> shares of unregistered
common stock at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z4w9gMo6zopf" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-09_custom_StarwoodTrustMember" id="Fact000514" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span> a share for a total of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zDQzQpaPItV9" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000516" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
agreement - See Note 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Travel Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2023 the Company entered into an Agreement For Shared Lease Costs (the &#8220;Shared Agreement&#8221;) with MIRALOGX, LLC, a
related party under which we have agreed to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease
agreement between MIRALOGX and Supera Aviation I LLC (&#8220;Supera Aviation&#8221;) based on our usage of the leased aircraft each month.
No amounts are payable by the Company under this agreement unless and to the extent the Company chooses to utilize the leased aircraft,
and the Company may discontinue the use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned
by Starwood Trust, a trust established by Mr. Williams, the Company&#8217;s founder and largest shareholder. For the year ended December 31, 2024 and December 31, 2023, the Company incurred
$<span id="xdx_902_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zq75LHaJznV2" title="Travel-related expenses"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000518" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.37</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHklkWLzuRij" title="Travel-related expenses"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="Fact000520" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.77</ix:nonFraction></span> million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated in April
2024 and no other costs will be incurred under this agreement (See Note 5 Variable lease costs).</span> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Rental Agreement</b><i>-</i> see Note 5 for Variable lease costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000522" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zO8tcZhDNcE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_826_z4EN3TdXV7W7">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease
began in November 2022 and expired in April 2024. The lease was not renewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the
Company decided to no longer utilize the shared space and moved to a virtual office model and does not have a physical office space
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Variable
lease costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
lease costs primarily include utilities, property taxes, and other operating costs that are passed on from the lessor for the former
corporate headquarters in Baltimore, Maryland. Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses,
which includes pilot expenses, jet fuel and general flight expenses that totaled to $<span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_z1yU3aMLGIkc" title="Variable lease, cost"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember" id="Fact000524" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.32</ix:nonFraction></span> million in 2024 and $<span id="xdx_902_eus-gaap--VariableLeaseCost_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdvd3AT3aK28" title="Variable lease, cost"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember" id="Fact000526" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million in 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
August 1, 2023, the Company&#8217;s accounting and administrative staff began sharing office space with a related party in Tampa, Florida.
During the year ended December 31, 2024, this variable least cost related to the Tampa, Florida space totaled $<span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zccJvG7iXKJj" title="Variable lease, cost"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31_custom_TampaFloridaMember" id="Fact000528" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.02</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000530" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_ziOomy0j7Hm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGf0E7G4Oul5" style="display: none">Schedule
of components of lease expenses</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zwrYw4eRiC66" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zEvQZoq869vl" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zCwbOHzFsha2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,667</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,869</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zo8jRWbaGwHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,656</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,778,884</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_z9C4YbTNQNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">392,323</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,793,753</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zvyZhb8zymTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000541" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFb4r2EpOdTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_827_zOhRK89b3Yb">Stockholders&#8217; equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the authority to issue <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20241231_zPIRkHhhA5O6" title="Issue of shares of capital stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000,000</ix:nonFraction></span> shares of capital stock, consisting of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zQXKDQtbJBZ" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zirdADbPCoA2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zfR5eAAbGPr9" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zvUY1Hc0Qrfi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span>
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 11, 2023, the Company completed a reverse stock split of its outstanding common stock upon the filing of the Company&#8217;s
Second Amended and Restated Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued
in connection with the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded
up to the nearest whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise price of such warrants,
have been adjusted to reflect the reverse stock split. Unless otherwise noted, all share and per share information in this Report retrospectively
reflects the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the year ended December 31, 2023, the Company conducted a private
placement offering in which <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMQYtLCIsPW3" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">268,025</ix:nonFraction></span> shares were issued for a total of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIuPelYnM3R4" title="Net proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember" id="Fact000555" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million in net proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, the Company closed its initial public offering consisting of&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFyphSDXvbb2" title="Initial public offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares at a price of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrVnWyR6tVKa" title="Initial public offering shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-13_us-gaap_IPOMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>&#160;per
share for approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGLDcxtrJlfh" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000561" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span>&#160;million in gross proceeds. After deducting the underwriting commission and other offering expenses
totaling $<span id="xdx_90E_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaGcOftAxbpl" title="Underwriting commission and other offering expenses"><ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000563" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>&#160;million, the net proceeds to the Company were $<span id="xdx_903_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEwddJ2ePlxf" title="Initial public offering net proceeds"><ix:nonFraction name="TELO:ProceedsFromInitialPublicOfferingNetProceeds" contextRef="From2024-02-132024-02-13_us-gaap_IPOMember" id="Fact000565" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span>&#160;million (the &#8220;IPO&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2024, Starwood Trust, a related party, entered into a stock purchase agreement with the Company to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zLRrNQWydoo6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,857</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of unregistered common stock at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziwOXpZKHAW8"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-09_custom_StarwoodTrustMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a share for a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z71nKKdnMyQa"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember" id="Fact000568" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">303,281</ix:nonFraction></span> and offering costs of $<span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zYFt6IiE7Z9j" title="Offering costs"><ix:nonFraction name="TELO:OfferingCosts" contextRef="AsOf2024-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">863,744</ix:nonFraction></span> incurred in 2024 were charged against additional paid
in capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with various transactions and the IPO summarized below, the Company issue stock warrants. Warrant activity for the year ended
December 31, 2024 is summarized below:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000574" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkcpQeEIDEme" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zeRTAB7YUAc2">Schedule
of warrant activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Weighted</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Number of</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"> Average<br/>
 Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Remaining<br/>
 Contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Aggregate</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Warrants</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; padding-bottom: 1pt">Balance Outstanding as January 1, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrQFLfy8V1h" title="Number of Warrants Outstanding, Balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmvO2LtO8dk6" title="Weighted Average Exercise Price, Outstanding Balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<sup></sup></span></td><td style="width: 2%; padding-bottom: 1pt; text-align: left">&#160;<sup></sup></td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDgGQS7xn89" title="Aggregate Intrinsic Value, Outstanding Balance" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Number of Warrants, Granted" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmc8OFiFOIf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062" id="Fact000582" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,774,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Weighted Average Exercise Price, Granted" id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3vuNhLnssra" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zN1bwplKmhrd" title="Weighted Average Remaining Contractual Term (Years), Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062" format="ixt-sec:duryear" id="Fact000586" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted">5.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;<sup id="xdx_F28_zYDCwQPy7Fri">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td title="Number of Warrants Outstanding, Balance" id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvOEQEB9KK6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,774,057</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Weighted Average Exercise Price, Outstanding Balance" id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3ASIi8k3T8" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zfhLVu5dRok2" title="Weighted Average Remaining Contractual Term (Years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" format="ixt-sec:duryear" id="Fact000592" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2F_z3fvAQq91oy3">(1)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzNlIHiuPI" title="Aggregate Intrinsic Value, Outstanding Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDmHdqODkvl" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS5iXwbEsrG" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYFQe0cyo58d" title="Weighted Average Remaining Contractual Term (Years), Granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" format="ixt-sec:duryear" id="Fact000600" name="TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted">3.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xJBKBuDLUd" title="Number of Warrants, Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOIcRigM2Kah" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVl15ciPfzB1" title="Number of Warrants Outstanding, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlRY6O7he8Ib" title="Weighted Average Exercise Price, Outstanding Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000608" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zJFlCq5eWEve" title="Weighted Average Remaining Contractual Term (Years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" format="ixt-sec:duryear" id="Fact000610" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.49</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2C_zVbcXrLIUZfk">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhVghFxQ1jYb" title="Aggregate Intrinsic Value, Outstanding Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztNklRWWLJ86" title="Number of Warrants Exercisable, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,057</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSff51VEGAi" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000616" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zGRodkzsqN91" title="Weighted Average Remaining Contractual Term (Years), Exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" format="ixt-sec:duryear" id="Fact000618" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.49</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F22_zbnDra7E6ho5">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH3HnfC50CQ4" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F09_zCpFSYfkBMLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1A_z2p4qKvqXJFg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000621" xml:lang="en-US">The
warrants herein consist of various contractual terms. The warrants herein consist of </ix:footnote></span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zeu5UwoVUKck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to Bay Shore
Trust that have a remaining contractual term of </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_z2mJjlntxaqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_BayShoreTrustWarrantsMember" format="ixt-sec:duryear" id="Fact000623" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.5</ix:nonNumeric>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years as of December 31, 2023,
and </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zD8zlhPuV63h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,032</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to investors
associated with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
on these warrants</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zbCtIAN0zB32" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1B_zLGI4xf8sBy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000625" xml:lang="en-US">The warrants herein
consist of various contractual terms. The warrants herein consist of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,429,025</ix:nonFraction></span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000629" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.5</ix:nonNumeric></span> years as of December 31, 2024, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,032</ix:nonFraction></span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_UnderwriterWarrantMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_UnderwriterWarrantMember" format="ixt-sec:duryear" id="Fact000635" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.2</ix:nonNumeric></span> years. See disclosures below for more information on these warrants</ix:footnote></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><p id="xdx_8A7_zr08WOXblbtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
placement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase
up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zryETalShkr7" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">268,025</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFeyvmgLQBy8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.42</ix:nonFraction></span> per share. The Company also issued to the placement agent a Common
Stock warrant the right to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zSA8SWVmB5C8" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_PlacementAgentMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,007</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z7yjSJuIgty8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PlacementAgentMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share. Both issuances of warrants
are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an IND filing is
made with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bay
Shore Trust Warrants (Note 4)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the line of credit provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock
purchase warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to&#160;<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zBqQLORtid59" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,439,025</ix:nonFraction></span>&#160;shares
of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zVXaPnYsV1me" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span>&#160;per
share. This warrant will expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zihPsqtsAPF5" title="Exercise price"><ix:nonNumeric contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" format="ixt-sec:durwordsen" id="Fact000649" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span> after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the
risk-free interest rate, which resulted in $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zcq3pca5Ye2c" title="Deferred financing costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2023-06-15_custom_BayShoreTrustMember" id="Fact000651" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">5.95</ix:nonFraction></span>&#160;million
of deferred financing costs. This cost was recorded as deferred financing costs and additional paid in capital on the accompanying
balance sheet and is amortized straight-line over the term of the line of credit (which is 24 months). Associated amortization of
deferred finance costs is recorded to interest expense on the income statement of operations. The line of credit expired upon the
IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the warrant was fully amortized
to interest expense.  As of December 31, 2024, the warrant is fully amortized. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, Bay Shore Trust transferred <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0ujnrZcbGP3" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-22_custom_BayShoreTrustMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> warrants to an unaffiliated party as part of a gift transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024,&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zqU6tShKMJM" title="Shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_BayShoreTrustMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> Common Stock warrants were exercised at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0xgQgSNENc1" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_BayShoreTrustMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.73</ix:nonFraction></span> per share and the Company issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zT6h0BGplEYa" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>&#160;shares
of Common Stock upon such exercise in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zgOxY4g8OnH" title="Issuance of common stock, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">37,300</ix:nonFraction></span> delivered to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890" escape="true" id="Fact000663" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYEdrUFFkl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value warrants during the year ended December 31, 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zNQlbODRAkQe">Schedule of key assumptions used to value warrants</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoRls3dblQQc" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">78.08</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdUXXGqpSvv1" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.91</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zvd22Xkgpc62" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.190</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zrVujNCbtm37" title="Expected term in years"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:durwordsen" id="Fact000671" name="us-gaap:WarrantsAndRightsOutstandingTerm">5 years</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlY7EnTuoCnb" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zFt9jbgoXUx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Underwriter
warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the IPO in February 2024, the Company issued&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4SnU6Fj1PPa" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>&#160;warrants
to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zexPGknPjwB9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>&#160;which
are exercisable immediately and  expire in the four-and-a-half-year period commencing six months after the commencement of
sales in the IPO. The warrants provide for registration
rights (including a one-time demand registration right and piggyback registration rights that expire 5 years from the commencement
of sales of the offering) and customary anti-dilution provisions as permitted under FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUrq87iaGtr1" title="Equity issuance cost"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-02-13_us-gaap_WarrantMember" id="Fact000679" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of equity issuance costs. The warrants were
considered equity issuance costs and therefore there was no financial statement impact during the year ended December 31,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_UnderwriterWarrantMember" escape="true" id="Fact000681" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zN6ZMsXXafga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value underwriter warrants in February 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zFnVrF34jyda">Schedule
of key assumptions used to value warrants</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZSWEQ3GIced" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">84.78</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z00A4ZY80Rnb" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.14</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zYfMJ61WOx1l" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.01</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuyxtAiURn4a" title="Expected term in years"><ix:nonNumeric contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:durwordsen" id="Fact000689" name="us-gaap:WarrantsAndRightsOutstandingTerm">5 years</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zBmlNDvopdSk" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zzYUDaoW94bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Omnibus Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2023 Omnibus Incentive Plan, (&#8220;2023 Omnibus Plan&#8221;).
The 2023 Omnibus Plan authorizes the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code,
to the Company&#8217;s employees and any of its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory
stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#8217;s
employees, directors, and consultants and any of its future subsidiary corporations&#8217; employees and consultants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan provides that <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zl2biEgEf051" title="Common stock are reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,500,000</ix:nonFraction></span> shares of the Company&#8217;s Common Stock are reserved for issuance under the 2023
Omnibus Plan, all of which may be issued pursuant to the exercise of incentive stock options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected
volatility, expected dividends, expected term, and the risk-free interest rate. Expected price volatility is based on the historical
volatilities of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several
public companies in the biotech industry similar to the Company in size, stage of life cycle and product indications. The Company intends
to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information
regarding the volatility of the Company&#8217;s own stock price becomes available, or unless circumstances change such that the identified
companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would
be utilized in the calculation.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of
the vesting term plus contract term. The risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant.
The Company recognizes forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zigEyQcetU3a" title="Number of options, outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,370,170</ix:nonFraction></span>
options to purchase Common Stock, with an aggregate fair market value of approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zX5HFAiAoauj" title="Share based compensation fair market value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" id="Fact000697" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.1</ix:nonFraction></span>
million with a weighted average fair value per share of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_ztwf8n7htUtj" title="Weighted average fair value per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.83</ix:nonFraction></span> were granted to the members of the Company&#8217;s Board of Directors,
executive officers, employees and consultants of the Company. The options have an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zG875OTjM3Nc" title="Weighted average exercise price, outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span>,
a term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zsCjnkPio6z5" title="Share based compensation term of years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" format="ixt-sec:duryear" id="Fact000703" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span>
years from the grant date, and vest over various terms ranging from immediate vesting upon grant to the second anniversary of the
grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000705" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuXwA47tIZf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is option activity during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zA7c3o28gNUh">Schedule
of option activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise
                                            price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per
                                            share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic
                                            value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zg4kJyNCzu23" title="Number of options, outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zNQgxC8r07mb" title="Weighted average exercise price, outstanding" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zKOJTfTGOoik" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231_zbZUaKJE1W7d" title="Number of options, granted" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,370,170</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zRbzBnnWtpS4" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeitures</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zehM2nvOhXgf" title="Number of options, forfeitures" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zqbtoX3hMtjc" title="Weighted average exercise price, forfeitures" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zMvJeG98gjha" title="Number of options, outstanding" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zsdknw8ThdZi" title="Weighted average exercise price, outstanding" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zlT0m5Mjcd83" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z21L7Ivre32h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, options exercisable totaled <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zYmhPm05Yjrb" title="Number of options, exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></span>. The Company recognized approximately $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_zCTuHnz2R2Dg" title="Stock-based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million in stock-based compensation
in 2024. There are approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_z0V0pziN2gnc" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million of unrecognized compensation cost
related to non-vested share-based compensation awards, which will be expensed through 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000733" name="TELO:ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_zWaUpSlV4fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zHm6i420hSc" style="display: none">Schedule of non vested share based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Exercisable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zk8VeZrBbKKd"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_StockOptionsOneMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_z1GdTVbN5gVb" title="Options outstanding, outstanding number of options, shares" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_StockOptionsOneMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zcif95o0vXc9" title="Weighted Average Remaining Contractual Life (Years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_StockOptionsOneMember" format="ixt-sec:duryear" id="Fact000738" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.6</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zA06CWkEzgMf" title="Weighted Average Exercise Price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2024-12-31_custom_StockOptionsOneMember" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zW3b38D0bwIl" title="Number Exercisable" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_StockOptionsOneMember" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,046,335</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zJhWQvF8tu7" title="Aggregate Intrinsic Price" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zpVC2G2WSYrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000746" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSoiUYsJyBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqCjHrG9Q6rc">&#160;Schedule
of key assumptions used to value stock options</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z6JahreGSgk1" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-01to2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.8</ix:nonFraction></span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_z8EJUkRgPZe6" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-01to2024-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.4</ix:nonFraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zE7RrRHL51Ii" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-01to2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_z3b8J3NbvAIg" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4TXimg70jz9" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000756" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.1</ix:nonNumeric></span>
                                            to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z2KJLt1HfmH8" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000758" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.62</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zk269eBnw8P4" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zvLeL9dCE1y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000762" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zU2lOKCZV2lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82E_zRcPGG92Csmb">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000764" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zAZQLuKtNXj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of the Company&#8217;s net deferred tax assets are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zI7bhzV8sYKc" style="display: none">Schedule of net
deferred tax assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zMXOCiSazI9b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_z6uRjoUKEGx2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zxkEFecouGw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry-forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,427,679</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,379</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zSKsopwULW31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Section 174 Qualified Research
    Expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">995,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,248</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_zoEnwvDFjWDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,680,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z82B88yW1pFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">R&amp;D Credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2024-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,278</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGz55t_zbh2V40LzJM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,007</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,724</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_zJfhrPJ5mxMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, gross</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,351</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_z6E9z0XRz0Xc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,351</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_zxl54Vaif8g6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, net</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_zPlDZI0C6c86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    net deferred tax asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zC7Xg1Lwaqqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, in accordance with Internal Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized
over a period of five years. Accordingly, for income tax purposes, and as of December 31, 2024 and December 31, 2023, the Company has
recorded a deferred tax asset totaling approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zfBFohsGHMGf" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20231231_zMcmEnox3OZ3" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million, respectively, related to the timing difference between
GAAP and Tax recognition of these expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000797" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZu7RjI61vG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the provision for income taxes consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zxki7MCncC9l" style="display: none">Schedule of provision for income taxes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zlPsrak2TOx7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzjwNL6Q5od5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred benefit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20241231_zy8iTcXVRNai" title="Deferred benefit" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,483</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20231231_zTau0HsiBJwl" title="Deferred benefit" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,351</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20241231_zK8msu1HI4ub" title="Change in valuation allowance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,182,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20231231_zorsiAR1iVZk" title="Change in valuation allowance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,351</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20241231_zCPnOxDurBk8" title="Total deferred" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20231231_zyORfGHcChAh" title="Total deferred" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0809">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_z2xwL8fB8NH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    provision for income taxes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z3AQanzghgOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 requires that a deferred tax amount be reduced by a valuation allowance if, based on the weight of available evidence it is
more likely than not (a likelihood of more than 50%) that some portion or all of the deferred tax assets will not be realized. The valuation
allowance should be sufficient to reduce the deferred tax asset to the amount that is more likely than not to be realized. The Company
has recorded a full valuation allowance against its deferred tax assets generated by net operating loss carryforwards as it has determined
that such amounts may not be recognizable, given the historical losses of the Company to date. As of December 31, 2024, the Company has
a cumulative federal net operating loss carryforward of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zsiIhHarBsd4" title="Federal net operating loss carryforward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact000814" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.4</ix:nonFraction></span> million. The net operating loss carryforwards have no expiry
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000816" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB2ktK6SmHHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory U.S. federal income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zIu4OOrTJO61">Schedule
of reconciliation of effective income tax rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zlosmuMQ4Ca4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">Year Ended December 31, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iN_di_zxUTYeywogbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,532,716</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzNIc_zLHR4QTi3GZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Tax Benefit at U.S. Federal Statutory Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000820" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,471,870</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z9RgtXrnfnfl" title="Tax Benefit at U.S. Federal Statutory Rate, Percentage" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzNIc_zvsYoTuu9WEa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">State Taxes, Net of Federal Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">718,347</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20240101__20241231_zaZKbHJOThq8" title="State Taxes, Net of Federal Benefit, Percentage" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.35</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzNIc_ztdBygndKvQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,336,132</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20240101__20241231_zILioQKfL3Ah" title="Change in Valuation Allowance, Percentage" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact000830" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">38.32</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationPermanentItems_maITEBzNIc_zD05HJK1IL6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TELO:IncomeTaxRateReconciliationPermanentItems" contextRef="From2024-01-01to2024-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,182,803</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_uPure_maGOLD_c20240101__20241231_zl7QlZ1ca42i" title="Permanent Items, Percentage" style="text-align: right"><ix:nonFraction name="TELO:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="From2024-01-01to2024-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.20</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzNIc_zwWpS0uiJEZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">State Rate Change</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,888</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z6ACJYfNZ1j2" title="State Rate Change, Percentage" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.22</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeTaxExpenseBenefit_iT_dxL_mtITEBzNIc_c20240101__20241231_zAuVQVLODyc8" title="::XDX::-" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20240101__20241231_zRn0InWgXbVd" title="Net actual effective rate, Percentage" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z94oue4GCrw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><p id="xdx_81A_ze1tRAhyOAw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_03"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TELOMIR PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 4, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/S/
    Erez Aminov</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Erez
    Aminov</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Executive Officer</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Principal
    Executive Officer)</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/S/
    Michelle Yanez</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michelle
    Yanez</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Financial Officer</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Principal
    Financial Officer)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="poa_01"></span>In
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Person</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capacity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Erez Aminov</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michelle Yanez, MBA</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4 , 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
    Yanez, MBA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Craig Eagle</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4 , 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Craig Eagle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ned MacPherson.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4 , 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ned
    MacPherson.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew Pratt Whalen, CPA</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4 , 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Pratt Whalen, CPA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew P. Del Giudice</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    4 , 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    P. Del Giudice</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 92; Options: NewSection Last; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

































































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Erez Aminov, Chief Executive Officer and Chairman of Telomir Pharmaceuticals, Inc., certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Telomir Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and audit committee:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 4 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Erez Aminov</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michelle Yanez, MBA, Chief Financial Officer of Telomir Pharmaceuticals, Inc., certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Telomir Pharmaceuticals, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    fourth fiscal quarter in that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and audit committee:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:February
    4, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michelle Yanez</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
    Yanez, MBA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial Officer and</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Erez Aminov, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002,
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 4, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Erez Aminov</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Aminov</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of Telomir Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Michelle Yanez, MBA,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley
Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:February
    4, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michelle Yanez, MBA</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle Yanez, MBA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial Officer and</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" HH# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#YGHHHK_7
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M^ T__P ;H]I3_P"?M'_P?A__ )I#EG_S[J_^"<1_\S$U%0^>/^>=Q_X#3_\
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M?_@:_P#D1>SI_P#/NG_X30_R(_(B](O^_$?_ ,31Y$7I%_WXC_\ B:D\D_\
M/0_D?_BJ/)/_ #T/Y'_XJCW_ /GY/_P-?_(A[.G_ ,^Z?_A-#_(C\B+TB_[\
M1_\ Q-'D1>D7_?B/_P")I)<Q $LS[LC"YWC )&U<D'.,')&/6O$_CO\ M%?!
M?]F/X=ZM\6/CU\1O"_PP^'NC2VMK=>)/%.JQV-O<:E?LZZ?H^F6V'O-8UF_:
M*5;32=*@N]1N#$YAMY%25HSW_P">H[WVFK::;M0BFWHN:<4WIS+5JZ6']O5A
M0HT%6KU90ITJ%' RKUZU6K+DI4:-"A1KUJ]>K+W:6'H4:]>J_P"'0F>V^1%Z
M1?\ ?B/_ .)H\B+TB_[\1_\ Q-?!W[+'_!2_]BC]M#7=3\)?L\?'7P[XP\9:
M392ZG<>"M4M-;\'^,I])@V>?K&F^&O%>FZ3J>K:5 9$2XO=-@NHK=\B<Q@9;
M[I\Y@ Q& 5+CYV+$;L*-H4'YER< 9!&!D\5FJT)1C..)C*$X2JPG'$4IPG3A
M+DE4A4IRJTYPC/W'*%224FHNTVH/JS#*L;E&,Q&79ME>,RK,,)98O YID^*R
MW&X9RA&I%8C!YA@\#BZ+E3G&I!5,+#VE.2J4I5:;4W8\B+TB_P"_$?\ \31Y
M$7I%_P!^(_\ XFGB(D [R,@'&#QGG')!X]P#ZBD>,JI;>3CMR.IQUR?6M/?_
M .?D_P#P8O\ Y$XN2E:_)2M:]_JT+6WOMV\OD-\B+TB_[\1__$T>1%Z1?]^(
M_P#XFHBS[B .!C#!F);/4%0"1CMCKWQ3XPTA922NT9SR0<G '.WD8R<9ZT6J
M:^_4TWO-)^MG&[CYI6#DI.UH4FFDU)8:FXZI-+F3MS:_#;FW36C'>1%Z1?\
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M9QFG^2?^>A_(_P#Q5/W_ /GY/_P-?_(B]G3_ )*?_A-#_(C\B+TB_P"_$?\
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MG)0AS-:)SY(NI9:62JRJ):+:ZT:;****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@")_OK]#_P"@O7Z!?\$LO^3^_P!GO_L+^)?_ %&]1K\_7^^OT/\
MZ"]?H%_P2R_Y/[_9[_["_B7_ -1O4:^4X^_Y(KBW_LE\V_\ 4''GTW!/_)9\
M(_\ 92Y5_P"I^7G]QL'^J7_/I4U0P?ZI?\^E35_EQ'X8_P"&/_I,3_4%?K+_
M -*D(W0_0]3@=.Y[?6ORM_X*@_LBVWQH_95^,.J?"&Q^$/P]^.&D3:#\4K7X
MA^-++2/"^EZY)\.[M-6U'1/'7CQ(8;C2M&UK0K>[LKO4]4FFTR%A;-K2&P2:
M>']4FZ'(R,'@C(/'0CO]*_.;_@J/^RI\5OVR_P!C7XB_ WX)_$'3OAU\3[_4
M_"7B_P +7GB![U?"/BB\\$:];>(/^$)\9?8%DN!X9\2+:K:7DC6UW;07J6,]
M[9W5I!/"WJ9!A,MQ^?93@LYS/^Q<JQ>:Y9A<SSETGB%E&6XC'X2AC\U>'C[U
M?^S<'5Q&.]C%7JO#J'5WQQ,ZU/#8FIAJ2KXFGAZ]3#T).T:^(A2J2H49/HJM
M6-.#?12;Z'YA_P#!'O\ 8MO?CC\ /'W[0O[;W@WX*_$[0OVG;;0=7^&OPCTR
M\T[X@>"/ O@Q-)NX-:U#4K"R5O!NF>.O%L]W8G48-#M8]<T"/2H++4;I=42Y
MAM^0^*(^ ?\ P0R_:6\.>&/V6;3PM\)OAE^UQ\-_%WBSQ_X$^)NI^*=>\"1_
M$'X5:IIVG>$?$GA/6Y;Z[\1Z1>O8^*KG1-:\/17,^A0:6-.U*WLK9X+B1^/^
M"/@C_@H+_P $6/V+/C=\>/CIXO\ @9\2;3XA?$30/&/Q!\#>'+7Q;+HO[.FH
M^(KFV\*7GB_PU?VD5GHGBS1KF%M-U7Q;IJ:1X:MDU,VES;W;0KJ#2^T_L4:5
M^SA_P6K\2?'+XL?M9>"O"?[4/A_X ^(_#/PM^#)U[PR=%^'GAFQUW1(O%GBZ
M[T3P_8:M.S>.M6U"'25\6ZG>WUR%TB#P_IE@D%FUTD_?Q7EN293Q)G.!X;SV
M/$/#]'$SIY1G*PKP<\QPL7"<)5<.X4^6K[2=>4[15.<X_6(1A3KQHTIP=;$5
M<)AZF+P\<'BJL4Z^&B^:-.=FY136EM$T^E[;J[_8[X#_ +7_ ,(_C9K6E^!/
M"WQ"^'_C/X@S> ]/\<:W;_#;7&\2Z)IUO.+:"\62YD2*XM(H;VXVV8O=K7,7
MR(?,5E'UU&^] W'.>5)*D=L%@IZ<'(&&!':O*_AM\!_@I\'%F'PG^$_P\^'!
MN;"PTJZD\%>$=#\-SW>FZ6I33K&[N-*LK:>ZM;,$F"&>21$;YP-W->K*BH,*
M, DL?<DY)/N:^>.D=1110 4444 4[S[JD':?G ;T.WCWYZ8'7/89(_CA_P"#
MG5?B GQ7_9!EUF/41\''\*?$.V\)R!)G\-+\8FU*&741<DG[%#XK;P.ENVA+
M.T=Y/I(UY=-,T,&M+'_9-)&L@ ;/&<88KUX/((->3?&KX#?!W]HGX>:U\*?C
MC\.?"_Q1^'>O&UEU/PGXNTV'4]-DN[%VDL=2MC)MN-/U:PD=I;#5=/GM=0LI
M,O:W,+DFO#XCR7_6'),WR-XNOERSC+ZN GF.'<I5<+"<H22>'4X?6L/4E&V)
MHQJX6K6H2G1IXFDY>T/V'Z/_ (L+P+\:/#KQ<GPU@>,:7 G$$,XK<,YC.C1P
M^:49X3&8&K[#%5\-C:> S?!4L=4QF29E4PM:GE^9T:&)G2J1BXQ_S:OV%[;X
MDW_[;_[),'P>34)OB>GQQ\'76BC22SWT/AZWU".7Q_/=_9V\Y?#,7@U-6;Q.
MUR(M/-@'CN@6$(K_ $VEVACL;< 6)8GD$_= YQM'7!Y5NNVOCW]F[_@GM^QG
M^R'K.L^(OV=_@%X0^'?BG7[-M.U3Q7:OJVN>*Y-+D82/I<'B/Q)J.L:Q8:3)
M(HDET^PO;>TN)0'FB=@"/L@Q[5.!@ ;68L3\B\;NA&]B,GJ6/7.<5XO '!#X
M&X;IY&LTGFM1X[&8^K6=&6$PZGBHX6C&EA</5JXNM0I1HX.G.O%U7'$XJK5K
M*E12C*7ZI]-7Z3N$^EEXPTO$O+^"?]0\MP/"N7\)X7 8S'8/-\VS.AE.+Q^:
M+.<ZS# X'+,''$RQ&8U,#@Z"6+^JY;@<)1>+K.I5IT+X)$8/4A <^I"^@]?8
M?2LZ[NXX[>YDN'AMX((7N)IKB5888H(%$LLTTKL@@ACC!E:>4I&J@EV15)"B
MX?9\I<CRR<KM8KR IQ@@MU8A00%!W#T_!3_@XA^(/Q1\$_L"P:9X'U+6M'\.
M?$7XL^$/ OQ2U;1+B[L;E/!.I0:E<C0[O4=.$4]II?BG5K2TTW4P7ACNH6^P
M--''<.DOUF8XJ.79=C\?4C5E# 9?C\?.G02=>5/ 8/%8NI"FVITXUI0PLHTO
M:7@JC@YWA&9_.OA]PIBO$/CO@K@3+L=@LLQO&W%F0\)X3-,UJ/"Y9EV*S[-,
MMRNCB\;7ER-4J%;,Z3]E23KXBJH8;#7K5J:/U1\#?MH_LC_%+Q]+\+OAU^TM
M\#/'7Q(AGG@_X0GPM\3?"6L^(9;FSD>.ZM[#3[/5I7U*YM-DHNK?3C=31^6S
MO&J*2OT[:.C2N%5@VQ=QY*D[F!(;&"25)(SD=P*_R9!'#X?2WUS0U7PQK'AN
M6VU?P_K6AJNF:MH.IZ/MN=)U#2=0L%BN[6ZLKFV@>V:"0,"H0*X=D?\ U#?V
M-?%GCWQW^R[^S_XT^*EM=6WQ)\3_  >\!:QXS6\1X;F;6[W0+.:ZO+FV?:UO
M<WQ*W=PC1Q/YLS%D4DBO@_#SQ!P_B!A\VQ-'*L;ESRC&4L%.C7Q.&Q]&4*T)
M5:6)ACZ%&@I5N6$HU<-"#A",E5A.<'<_K3Z:WT*LP^ASFOAUAL1X@Y3Q[@O$
M')LUQU&M1R6KPWF^ QV1U,OPV-AB,IKX[,*T\LJPQ]*6$S%RI/ZQ&>68A4\1
M&FZOT]115*:8K)L#,N65<@9 +#(/OGD'TQGUK]%;2M>]V[123;;LVDDD]6D]
M[+35H_B!:RC%;R=E\DY/ULHMV6KZ79=HK.EDG11M<L68@ E5;;G.5RI4E>0
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M/?\ L*R#_P!:#+C^?5/NC\?YFG4U/NC\?YFG5_H:OZ_ _P _'N_5_FPHHHH
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M 4444 %%%% !1110 4444 %%%% !1110!$_WU^A_]!>OT"_X)9?\G]_L]_\
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MNE1E-\:S'+GCYY5''8:>8TZ*Q$L+3G*4_8M+WT_9I/XD[75HM2;5U?\ I?\
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M%*+TNG\33Z<N]WI8'I%R>R:3;V3=[)]6W:RMU^0[S .HQVZ]_3M1Y@[C'?\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!$_WU^A_P#07K]
MO^"67_)_?[/?_87\2_\ J-ZC7Y^O]]?H?_07K] O^"67_)_?[/?_ &%_$O\
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M\%>#$TS6++XL>)=3_P"$SU>S\*:SK%W?:?I?A1?$5U%<V%Q?Z3/K-M'$]M)
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MQ'J?P0\&>+OC!X/^#'[.-W^SYIA\1ZKXH^-%]JW@33?AIX9_X6C>ZA]@@L=
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M;S0207@=@B&UFCN9(Y1+D2)Y9=L9C59'&:NF2<?PIR&.0DC!1DA20=A;&-Q
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M%5C44)QC**35RY0A*2E*$)2BTXN48RY6E:\>:+Y?/EM<_%/_ ((X_L<?M'_
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M=-BDDDM8[:16$@C5XC]I174=[;QSVTT,]O<+YD%S;21S0R1,C$-'*C313AL
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M  M76\G QR?^$,ST./IQ2?\ $0/\2.3_ ,,K^!\L<M_Q=/6N2,8)_P"*,ZC
MP?84_P#B _BM_P!$U#_P[Y1_\N'_ ,1T\+/^BCJ>O]EYIO\ ^"OZ['[(?!G]
MF_XVZ#X5^(WAOXO_ !=C\56WC^\\6Z3=Z9IUWK$EL/ NK^%9]%T31O#VH&XT
MZ]\$7FF:SJ-]J^IZCHL,UU?^;;J9H)((I%^F_@%X$U?X8? KX,?#3Q'J5OJN
MO_#OX5> / FLZI;7-Y=VVI:GX2\+:5H-[?V]UJ&^_N8;N>P>>*XO6>ZF2023
MR22LTC?SJ_\ $01\2O\ HUCP1_X=36_?C_D3.G)X]Z/^(@GXE  #]EGP2
M!_PM77, #H /^$-X ["D_ ?Q6?\ S34?EF^4?_+Q?\1T\+/^BDJ=/^97FG_R
MKN?U"%8R "4P!MZ8R,@\X7GD9_/UI^X?\]!^9_PK^7C_ (B"?B5_T:SX)_\
M#JZY_P#,;1_Q$$_$K_HUGP3_ .'5US_YC:/^(#>*W_1-K_P\91_\N#_B.?A9
M_P!%)4_\->:?_*C^H?</^>@_,_X4;A_ST'YG_"OY>/\ B()^)7_1K/@G_P .
MKKG_ ,QM'_$03\2O^C6?!/\ X=77/_F-H_X@-XK?]$VO_#QE'_RX7_$<_"S_
M **2I_X:\T_^5']0^X?\]!^9_P *-P_YZ#\S_A7\O'_$03\2O^C6?!/_ (=7
M7/\ YC:/^(@GXE?]&L^"?_#JZY_\QM'_ ! ;Q6_Z)M?^'C*/_EP?\1S\+/\
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M:SX)_P##JZY_\QM'_$03\2O^C6?!/_AU=<_^8VG_ ,0&\5?^B:7_ (>,H_\
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M:SX)_P##JZY_\QM'_$03\2O^C6?!/_AU=<_^8VC_ (@-XK?]$VO_  \91_\
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MN<G_ )DWN>3[\TG_ !$#_$G_ *-7\#]_^:J:W_$59O\ F3.[(I/J5!/(%->
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M>*BNB26EC^3I/FG4DFG"4Y2I.*LO8OE]GIWLI.7>3;ZA1113$%%%% !1110
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M3^&-02!4#,%GLO-564%?-MDG6?< WS>8BN&)W!2,+XQX"\8W&G:A8:YXDL-
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M^WK?NSX#%XEXJHYOJW_5AU%%%=AR!1110 4444 %%%% !1110 4444 %%%%
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M] SXN?\ ASM2[]/^8?7[#;&]/Y?XTR3*(SG@*,]"V3D  *OS$DX  Y)P "<
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M<<_L)?\ 0,^+G_ASM2_^5]'_  XY_82_Z!GQ<_\ #G:E_P#*^OV&V-Z?J/\
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M G_(/^''O[")P6TSXN*#W_X6EJ70=3_QXCE2?P/7M7TW^VW^W[\$_P!AK0=
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MZ,/^(;^'^O\ QAO#FEK_ /"=#2^U^U^G?H?CW_PXY_82_P"@9\7/_#G:E_\
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M<ZB3<(;.(AY0J+FM77_VHO@)H?@3XK?$*W^*W@'7-"^"^@ZEKOC^32?%V@W
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MTHZ5[W^J^R<U748Q^URNG?5-K;N_V=O&WPW_ ."0?Q\^(/\ P3]\!:Q8>/?
M?BO5_A[\9O#/B3XR^-H=!^)&FWGQ5O#H'B+1/$?C"32?LGC;3M)AT=-6T*_N
MH+$Z98O+H<P=XXI'_H"^&WQE^'?Q1;Q-;>!?%.B>*9O!NJ0Z/XBD\/:I:ZS9
M65]<0+<11"_LFD@E+1M@*"D@"MNB4+S^'/[%O[-'[)?_  5FT&\_X* ?M5?"
M7PY\=?B?)\5M?\'^ /$&N:9J^@>"-"\!?"35S8^$=*\'>#X]>N8[C06OY;S6
M-<'BB?6Y]3\42WS23?9K2*%?W-^&OP<^%WP7T>]\/?"?P!X0^'7A_4=1GUF_
MTKPAH=AH5C?ZO=A1-J-W#81PFXO)2JAYI&QL.T<Y8?('<>HJP90PZ$ _G2TU
M!A%!.XX&3QR>_0D?3D_4]:=0 4444 %%%% '\J7_  7?^"/Q$TKX]>!OVD9-
M'U[6_A!K'PHM?ACJOB+3=-OM8T[X<^)]"\2:CK\%MX@33H;JZT71O%UIJ)DM
MM8EA333J>G26][+&3$6^5_\ @DM\&OB#\9/VT/A!\4O!FGZH/AC\"+KQ5XV\
M>?$B/2[RR\-B?5_!7B+P?IGP]TK5[NWMX=:UOQ+=:\LNJV.E//#9^']/O)]0
MVN]JC_VA7]C!?1W%M=1V]S:W,)AGM;FWBN+>>-@5>*>&8/#/$RL28ID*YYZ5
MGZ=I.GZ1;1Z?I=CIVEV$;,\=CIFGQ6-HA;YG*6UH(;6-V;YG*Q ,V"RELD^1
M4R+"U<\I9_>O#%4H4U4H4ZB6'Q-6E@I8"A7FI>_",,*XJO2IM0K5Z=.HXR7.
MU_-.9_1HX7S/QZR[QUJY]GL,VP-7!9G+A^%+ U<MKYKEV62R7"XN.,K-8O#X
M:E@Y*M6P48SI2Q%*,HU%1G6P\]Z  0P@ *!%& H! 4;!P >0!T /(Z&DN"1"
MY!P<  XSC+ =._6I5&%4=<*!GCGCV 'Y #T%1S'$3'_=[9_B';(KUK12Y;6B
ME;EBW=12M9-M/1))-N^B;=[L_I6R4;)-I*R2DHMI*RM*T4G9*TDDENDM$O /
MVFOB^?V?_P!G[XR_&E-*76[GX8?#OQ)XPLM)(<17]]IFG2/8VMPR986TMZ(#
M=.OS1VOF%2&Y'\/>L_M9?M<>.O%Z_%SQ+^U3\?=,\?:A*FLB3P7\0]8\.>$_
M"M]<;;VUTKPI\/\ 3Y#X*'AW3/.AL_[+U70]6&KVL#KJ$US]JN';^];QCX5T
M'QSX7\1^#/%>GV6M^%O%NB:GX;\1:+>1,;;4]%UFT>PU"SF9-S(D]K-/$73$
MBEED1DDC#5_.-K'_  ;]>([7QA)IWPW_ &N;7P[\(OMCOH\?BKX.1>,OBUX,
MT/SV^SZ!I?B&3QIIW@OQ5-IUH7L='\1>+/"%V]G%%:2:SHOB3R)TN_#XAP>=
MXNCA(9/CZ6#E#$4JN(;B^:=I1Y)J3M^YIK6M2BY.:=U&;T/Y/^D]P+X[<;8;
M@Z'@WQ'5R>&7X_&RS["X+B&7"^+FL6\+' 9CB,:H3^N8++XT<2Y82*E5^L5I
M8NA0Q56HZ$?U@_X)H_M.>+OVMOV1/ WQ1^(=O8)\3M&\0>//A5\1=0TG3UTK
M0/$OB[X5>,=6\'7WC31-.BD>#3K3QI9Z=8>)[C2+?-IX?U?4]3\/VKS6^EQ7
M,OZ!6F1&P)!Q(^,#&!G@$>O\_>O%/V>/@!\/OV9/@O\ #[X$?":TO-/\"?#G
M16TK2CK%V^L:YJ][>WUWK'B/Q1XEUF7RY-9\6^,?%&HZUXM\7:U(BR:MXDUS
M4]09$6=(8_<(D,:[6(8Y))5=HYZ#&3T^M>Y'G5.FJLXU*G)'VDX)Q3J\L55E
MRNUH2DFZ<4GRW>US^G,DP^9X7)\GPF=8RGF6;X/*LMPV:9E0I?5J.8YE0R_"
M8?'8V.';<H0Q.+H8K$TZ4[.BL6DKR=10DHHHIGJA1110 4444 %%%% 'COQ7
M^&W@[XH>"_&/A?Q=8Z"MIK/A'Q5H!\0:GI.E:A>>&K37=)O-.N]5LKC4XRME
M]A24WV1/ F^W5Y954;E_F7_X(Y_LES>,_P!ISXP>-/C)\>/@C\?_  C^RKI_
MBKX$?";X:^&= :XD\3Z%XC\0:/?Z#\=_%FEZ];#2[SPH\'A_7]#^'%S:6VO0
MGQ)<>-YH-<LQI5C#=_U&_$+P'I/Q(\$>,_A[XAFO(=!\=^%O$/@_69-(NO[/
MU>+2O$VEW6D7T^FW_P YM-1BM[N22TNBDR0W"HY@D4%#_/%^S7_P1-^-W_!/
M=?CC^T-\#OVX_BG\9/C]I?PA\2_#WX&>#-9^%7P_T_P#-\-=*N4\9:-\*/&W
MAO4[_P 1WGB[Q)J7BG1=$_L7QQH>O> T\.71U%=-\/\ V?Q#KMIJ7V7#^!X&
MQ/"W%U?B+/,YR[B["K*:G!.78;*:.89/F%67M5FZS+%RFJN5)4J=*A3]C&HH
M.K2QU'VN(C5ITO/Q$\?'&8"-#"86I@W"K]<K>TE"=%VM3Y*<K>TDW:5U&2YE
M)-Q2BWH_\%"]-_9D_P""17Q ^%'[8W[/G@/P/^S5XC^-WCKQ3\.?C?KW@_PU
M:VW@/QUH-YHMWXFL+7Q3X)AN;31TUFTURT_M'0;_ $>'2#;.=028RQ3K''^D
MW[&G_!0'X9?M10?#'POX8\4_\+#\9>)?A-9_$7Q/XA\-^"O$7ASPGI>^&R9I
M?/U-'L6M+^\NI[?3)8+R9;J6/,2B-F:ORH_X)+_&CQK_ ,%"?C9\3O$_[2?P
ML^(7C+P[\)/AIH^AZ:O[2'AN.]T?PG\4?$.L7=A\0M-\-^%=5T>PT6RU*[72
MI+'5K>73I;W1+>Q2QLYX;&4QO_2OI.@Z)H-M;6.A:-I&B65E;0Z?:VNDZ99:
M;;VMA: K%806UC%!!;VEK$(Q;00I]F3)*0(HP/C3T#=B(.3DYVH",8&/FPP7
M^$,=W''()QS4U00Y^?H 2#MP,@D$G)#,"2"#PQ]=JYQ4] !1110!'+_JV_#_
M -"%?R]_\'"'_)2_V1/^Q%^/W_J3_!&OZA)?]6WX?^A"OY>_^#A#_DI?[(G_
M &(OQ^_]2?X(U^Q^ 7_)T\B_[ N(/_5!F!^->/O_ ":[/?\ L*R#_P!:#+C^
M?5/NC\?YFG4U/NC\?YFG5_H:OZ_ _P _'N_5_FPHHHH **** "BBB@!&Z'Z'
M^51< @]>&  QG*EN@/4DY(]_3%2MT/T/\J9A=RGG R21@GDENAX)R"<$8['C
M(H:=DU]F<6[[."NYKU:M9;-K6V@KZN+O:5.HDUTE9*+>JM%:WL[]DSWO]EOX
M4:#\;/V@/AQ\./%M^^F>$M6UF.;Q==PSBVF;1+0K+>V]I<_\LI;I!Y*2CY@&
MRO(K^F3XC_\ !*__ ()Q:E\/]:M- \(7_A;6I=&NQI'BO1/&&M2:SIVHPV,L
MUEJ<T5[=W.GWB0%6FNHKN$6\ENDT6Z-GC8?R8^%O%^J> O$FG^)-*GFM+O3S
ML6>V<B>T '[JX4X(N A"/) X83(&0K\V*^A/%_\ P42^,LOAF]T"\\;1W<4M
MA)9NVG:/J,=]<Q2I)"RQQSRFV@::TFNDN%F"12)MM2ZV<LMO-_)GCAA/$JMQ
M=E-;AE9\LMK8:A2PD\AJU^2EB5BZ]7$QQ%-5,/2^L.C3H1M*4X>QG=RYDHO^
MK_!#$^&M+A3,L/Q++(99K3QLYXFEGE.DZE6A4P<*>$E0J2IUY_5E66*4FHQJ
M*K%)4W%\\/B.0ZQI?C#6_ @5M7U_0/$>K>&YTTV$(-3GTC4+FT_M*" D>3%J
M%O!'?1^8558YU^=UPQ]93X>>-_L"7:Q6#R,A/V2&\WS*"H?8<J%\U WE2+G
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M\6^#/ MSX4TS5HH=/N8#'(D21B',J8N)& 3.UE.590K,5ZD%BWQMXU^)\?Q
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M'*J>.5!X.1T['H1Z$<$<CBOZ)M4_9=^/W_!0']G9="_:(^#/C+X7?MK?L_\
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M19)(ZKDJ<@D@@X)']!VP:EK[>UOZ_+N?%^C3]-2)_OK]#_Z"]?H%_P $LO\
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MCB\5[18GV-53H8>7LH5?Z*D(*(5Y!52#Z@@$?I45R,P2#Y?N\[@"H ()+9X
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MPV%Q]2-.AB,-EF92I7G4]KS0Y,7"45'$1IR>'G%N!^;O@W2HS%$=F1M!S@8
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M:6UY8WMO-:7EG=PQW-K=VES$\%Q:W-O,KQ3V\\,CQ30RH\<L;LDBLK$'Y&^
MOP-^.?PX\;:K>?$S]H&X^+G@+0=+O-%^&&G7WA.QTCQG]GU[4+?5-5U;XH>*
MK5E_X2_7K9H$LK&XM+>TL[EI[S5KRT@OW6&/[$KY4[#.M[.PTJULK'3[.VL+
M"QMHK.RLK*"*UL[.RM($@MK2UM8%C@M[:WMXHX(((8TBBB1(XT5% #)B7("M
MGY'RHQSD?(!D@[G&=FW'S1G)&"*U**I-)+35=7_PUU\F2U>46V^6+A-*+<9<
M].;FFY+>#7NRA;57=^A^-7[5W_!'SX)?M+_%/6_C/X?^('C/X(>.O&=Q;77Q
M%;P;;Z#K'A_QIJ5M90:='X@N?#^NVMW:Z=XF>TM;>UOM8TXQM?I#";E)I(_,
M/VE^R+^Q_P#"/]BSX:S_  Y^%D>HWSZYK%QXI\;^-?$]]'J/C#QQXGF@BLO[
M9UV^5(8O)L[.VM].TK3+2.+3]*L+>*WLXE!D:3[#HK"-*$*U>O"G1A5Q,(1Q
M%6%&$:U=4FG1C5J)7E3IM7Y4X.34'-UG$^3R[@+@O*.(\SXPRKA3A[+N*L[@
MZ6<9_@LJP^&S/'TI24IJIBJ:513FX47.I%4I5I4T\7+&:)-3.Q<G)VKD^IP.
M:AN(\Q.$)C8[,.IPPVLN,'MP,>GK7,>)_$_AOP?X<U[Q;XKUS2_#OA?POH^I
M:]K^O:O<0V6E:+I&DP37>H:IJ%W*4BM[2R@BEFFD<@!5(^8X%?CSH?\ P75_
M86UCQM#X>GO/BAH/@R>^CTVS^,.N> K[3_AJQFN!$FLW=X)VU6P\-S,P9=;O
M])CMH;=Q=/Y$&9!<ZE*DU&I6I4I-I14IJG*6L(2Y%+5-3J0A%:V<XIV=K]F>
M\4\-<.2P.'XBSW)\FGFU58/+XYMF5#+XX_%MPA/"4)8BK0J2KIU:+?)%1C[2
M,9U*56=*$_N6\_8-_8ZO/B1)\6[K]G+X5S_$)]2.N7&K_P#"*6FR;7'GCF.M
M3Z4H&DW&IO*BR3WC61D9T6=SYF'/UY:(RR L%4K$D6U!M50AP%"@!$7;C:BJ
MH"X &.E6SN;6_AAOK&XM[JSO;:*^M+NWE2>WO(+I1/;7,,Z,ZSV[021R6LJ.
MT3P3(\?5<3N"",.A<1R$L5X9?^6>XXY"N=V..1U..+2G&$O>IJ?OSDH4E'VD
M;7;<8NW/-*"E4;DU:ZYN:T?5H83!X26*J8;"X'!2QF*CB<3]5PV'P=7'XF5.
M?M<16>&HQ>,KXB3A3C4Q$YU,0U3G/$NUGD>,/%_A3P!X<UKQIXZ\5>'/!'@W
MPY9SZGXB\5^+M;TWPUX9T+3H7 FU#6]?UFYLM*TNQAW)YES?7=O"F1F0' /F
M/P7_ &E?V>?VCM/U?5OV>_CS\'OCEI_AZYAM_$%Y\(_B3X1^(4/A^>[\XVEM
MK7_"*:SJDFE37Z6\\MD-0BA-W;QM<VHE@_>5^ /_  <&7_C.;Q-^R9X,OI+Q
M/@YJ?_"P_$%S8G'_  CNO_%[P\F@CP?#X@C=3;ZC>:/H-]XDUGPU87A9%U.'
M[;:Q&\MXF3\G_P!B;6/B+X8_;N_8_P!8^%\NK0_$[Q#\;O"GP^U.TTSSI9_%
M/P$U\7ES^T/HOB^R#@ZYX%T7X<:?J7CY4U];RR\,>-_"/@GQ)IKVVN6.EL/
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MGO\ V%9!_P"M!EQ_/JGW1^/\S3J:GW1^/\S3J_T-7]?@?Y^/=^K_ #84444
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M^AWIC1(VL]6FM-EY>VU_* EP9'V1+*9!'NB#'Z>^)OA70H/&&F^./">E#0?
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M9XB4J?M<NQ5!0]O7EB*E3#U\)*G/#059RB?/"SJ,\C&,G+(>2!@+M<DGC!&
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M4?\ SR/T&\T?W3^1_P#B:/-']T_D?_B:_/G_ (>J_P#!/+_HZCX>?]^/$_\
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MH^'G_?CQ/_\ *"C_ %.XQ_Z)7B7_ ,,6;?\ SJ#_ %PX3_Z*GAS_ ,/^4?\
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M\/?^&BI_\] _XEP\-?\ H'XA_P##M3_^=A_']_PXS_;=_P"AA^!G_A5^(?\
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MG68!!?:>9UAN;&X22!YK2^TK68&:^T?5K.:2QU:..>:TGD$#QK_HMLQ*E=F
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MGMKM98Y-I*R;&1RDA1N) I.PC:VUB:]TU#3DV^9&3%-'ADD7:'B(.8VBD*G
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MU;U/YQQ&:8B48TUJJ=.G336J?)&VEGKKOVZ[(QK;28T"84\+C(Q@'D')&5!
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M22O*]E)J*^W)*T8W;V;7]![>7M7) .0J@?,6"D;RJ@DD XSA21U(QT_SJ_\
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MT!91=:3;/<6:I<2A$\=_91_X(M^-_@1I/BY;C_@H)^T5=>'/B5X:T2SF\'>
M%TGPMX=TC=J-YK]W#!=WC:M/JFG1_P!M:II6CK)9V$EO97DMU*GVBXDBKY>K
M&4)RI/E;C.2DX2YX7C.49<DTVIP<H2<)7?-#DGM-,[]'9I63LTK6LFDTK/5-
M)I-;IJSU3/Z $<,5VE61ERNW!V@ $9()!!!&T]Q@\YJ:N7\(^'+/PCX>\/\
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MAF&8L=@YW<F,94')SD$$ X'4*0#GD9JE;>%(48-L  Y.$P1SDXQE3D@X(?#
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MUGQKKFM:I?Z]>Z9XPTC3I/%$&B:OI]YJ-SJMAI5Q'Y'Z;?#C]OG]G'XO>/\
M1?AU\,/&,_C+Q!K-_-8PV&F>&?%T5U;O8P3RZU<:B]_H%G9:+'X:G@.G^((-
M8O;*\L;MX;:"UN_,$B_&W_!6OX)_LH#]@S5;'Q2]Q\%/#OP*^(7@36OA7J?[
M/UMX8\(:K\.OBGXNUI/AUX>L(=/L+6WTS3/#?B23Q[-8>-=/N([2.YTF\?4T
M$FH6%BZ:O_!&_P <? *W_9L\1_!;X-WU]/>_ CQ1<V_Q2\1ZWXFL_$TGBOQ/
MXLM3XCO/&#>( +=C8:BJR)Y5U!;"PAL@DAD&Z5J4*D%:5.JDK6G*G4BI-[).
M<*=VU9KEC)2BXR3Y90E42::3OOT;2?SC>Z?=6NC]D"0H)/0#--#Y(&UAG/W@
M!@CM@G+?5 P]2*\VN/BW\.8-/L]5O?&WA33M!U>::WT+Q'?>(]'L] UZ>U,P
MNH=)U:XO$LKJ2&2VF3:)0MPL4LEJTT4;2#S_ .!_[0_A?XZZGXLA\):?XC.G
M>%;HV=UK&J^&=6T31[B_-S/;O;Z'JFI00VOB.W*6XN5U/27N+)X94*2L&!+U
M[->;5D^CL^MFFGLT]&DQGI/Q4\?6'PM\">(OB!JGA[QYXLL/#%@]_<>'/ACX
M$\3?$SQWJJ[TC^S^'? O@ZRU+Q)XDO=SK)]@TG3[FZ,22RJJJC,OQ=_P3K_;
ML/[;WPFO?&FJ_"/XR_"[Q#H^JZ]:ZE_PGWP$^+7PC\&:Q9VOC3Q3X<TD^!]=
M^)&FQ6/B^^L['P_%_P )E;:%JM_)X9UR6YT[5(;&6$Q+^A\L9DVX;&,YR"00
MP((."/UR/:N6\*>!?"O@70[7PSX,T'2_"WAZQGO[JST71+.*QTVWN=4U";5=
M1FBMH56-);W4;FXO;EP,RW-Q-*X8R-D ZN.19 Q7(VNR'<,'*G!^4_,!W&X
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M\2Y;D\ =>E?CY_P5I^ O[?'BOPA\(_V,]8_;_P##_P"TY^U-^T-\0?"GB?\
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MEC9:C::?+>S6S74VGPO?VUN+BXTPD6]Z]L984G8+N#'%>]*21E@!SQ@Y&/\
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MI4E%%=CMI;1))?<<Z5E;??5^;;_4****0PHHHH **** "BBB@ HHHH ****
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MS0Z7ID$$"ZA<_P!4CD\@;E')/H<@YR>PQGD8[\ U_,3_ ,%)/^"$'CO]HO\
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M%'X8>'X/'_B*YU7PMI;7_CNYL?B79S7WAO5]=N4\!7O@E(!X>UG4]1TO]?\
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M_'%+D>H_,5&D<DJ2ND<LB01F>>2)&D2"W$BQ&>9HU810!Y$B,KE(U:2,%P7
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MJL^L10Z1_8"+-I>BK:RRPW4[WI9?WVM/WD*.^UF#-AAC'& "N,A00!@ D 8
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MVYDMN9N7*IJ+V?O2O'F=FY*$?=2ZZ.ZMKN1*'+AOG P,L.2=Y?=CH 7&X 8
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M110 4444 %%%% !1110!$_WA]#_)A_,BOT!_X)8D']OK]GO!'&K^)>-R@_\
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MA:Z1+>PVMN-2KN_@[\,M1^(WQ L;7]JG4_AQXIOK#5_A/X9OK+Q?XCM_%7Q
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M4CNDMV5K=9HTD$(91CSA;&Q1I&6RLE\YXY9B+2V_>RQR&6*64"+$TD;$E9)
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M9'Y'D>AYHHJJ+<L-4<FY/ZKC-9-R>E;!6UDV].FNG2PIRE=^]+;^9]H^8O\
M^O\ 'UJ<\ X]#11774_WF:Z>TQ&G3^)'IM^!MO[2_9_G/_(%Z#Z#^5+115O=
M^K_,R6R]%^2"F/U7W.#]#C(_&BBHJ?PZG^"?_I+-*?\ $I_]?(?^E$,9)#9.
M>#UYZ8QU],G'IDTK]&_WC_)C_, _4#THHHS#3!8QK1K"T6FM&G[;"ZIJS3\T
MT_,G!ZYMA(O6+QM9.+UBU['$Z.+O%KR::\AN3M')_A_F*4\+QQPYX]=S#/Y
M#Z"BBEAY2E3P/-*4O]DD_>E*6JQB2?O.6J6SW71H>*C&,\:HQC%?6VO=2CH\
M'*Z]U1T=E=;.RNF(> F./F(X]-S#'Y #Z#'2I& $B8 ''_LW_P!<_F?6BBAK
M6I_W2G\W#%7?J[*[W=E=NR-)[TO^O6;KY*IA[+T5W9;*[LE=C?\ /^?R%.4
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J E$# 2(  A$! Q$!_\0
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MD[48E5RH.< XZT >CP_&[PK-X9N]:^TW*1VEV-/FLI+9UNUN20%A\G&[><C
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MH!!DB!F&'..0!R1R*Y3]G[Q_JWQ-U3Q'K&H7>KQPQ7UQ;6^G3V(AM(8DDVJ
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M%>"[6]U"W:YO6CTV^_L[4+I+*0P64VX*!+)C"@DC!Z5P%EX8\5^)_!WP_P#
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MS?TKTK1_^018_P#7!/\ T$5YK^U7_P FY?$+_L$S?TKTK1_^018_]<$_]!%
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MR!>:AR/]:/\ T$5?W#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW#U%
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M_P#$UL1?"3PU#XK/B!;(B^W^:$W_ +H/_?V^M=AL7T'Y4 >:O\6/ B*S%YL
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M]L_$9O\ F7-&7ZZ@Q_\ 9:KKJ'Q";4W/]D:*DOD@$?:G(QD^U '<_P!BV/\
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M3QJ>OC"/\+)?\: .P_L6Q_Y]DJEI^DV;S7H:W0[9B!QT&!7._P#")>,SU\9
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M$+&101N59>& (SDYS7L,MK;^._!DUK=VEW8V^I6KPR6]TGESQA@5.1DX(ZT
M<WX*^*%WK0U2+7=&&CWMG91ZFL4$_P!H$ELZDJ<[1AQM(*XZ]":XR3]I.Z@T
M)[V?0[*&:9+6YM/^)F'A%O.Y0/.ZJ3&R\;A@]>M=EX.^&&H^%IVO)_$C:IJ+
MI#:/<36:H#:1*0D6T' ;)R7[^E9^A_!BZ\./JVHZ;J]A9^(-0V1->6^C11PI
M"K%MODJP!8D\L3V% '>>$]:;Q%X<L-2=K-VN8PY;3[CSX#_N28&X>^!4>N3Q
MVVL:+)*XC022C<W3_5FH? ?@Z'P)X;ATJ&=KHJ[S2SLH3S)'8LY"CA1DG '
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MA_VT_D*O5BW.KVC:C9,)?E7?D[3Z#VJY_;=E_P ]O_'&_P * +U%4?[;LO\
MGM_XXW^%']MV7_/;_P <;_"@"]15'^V[+_GM_P".-_A1_;=E_P ]O_'&_P *
M +U%4?[;LO\ GM_XXW^%']MV7_/;_P <;_"@"]5!?^0W)_U[K_Z$:7^V[+_G
MM_XXW^%4UU>T_M=W\[Y?(49VGKN/M0!M451_MNR_Y[?^.-_A1_;=E_SV_P#'
M&_PH O451_MNR_Y[?^.-_A1_;=E_SV_\<;_"@"]15'^V[+_GM_XXW^%']MV7
M_/;_ ,<;_"@"]15'^V[+_GM_XXW^%']MV7_/;_QQO\* $T__ (_-0_ZZC_T$
M5?K$L=7M$NKXF7 :0$?*?[H]JN_VW9?\]O\ QQO\* +U%4?[;LO^>W_CC?X4
M?VW9?\]O_'&_PH O451_MNR_Y[?^.-_A0-:LSTFS_P  ;_"@"]161=^+M&L<
M_:-1@@([2-@_E61=?$W2ER+**[U1NWV6!F4_\"Z5Y.*S; 8*7)B*T8R[7][Y
M16K^2.JGA:]97IP;7?I]^QUU4-,_UU__ -=S_P"@BN4/B[7]3S]ETZWTR,])
M+YV9A_P%15:UTR[U"2Y_M+Q+.BF3YHK&,Q*>!SG&17%_:]2M_NF%J3\VO9K_
M ,G<7]T6;?58Q_BU(KY\S_\ );K\4=S>ZI9Z<A>ZNH;=1WE<+_.L"?XCZ0',
M=G]HU.4?P6<+/^O2JUEX8\*VDGF-#]KF[RW>^5C^?%=!!J6FVJ!(62)!T5(R
M!^@I<N=8C>5.BO+FJ/[WR)?<PO@Z?24_NBOU?XHP_P"WO$^I?\>.A1V2'I+J
M$W/_ 'RO-+_PC7B#4N=1\0O I_Y9:?$(\>VX\UO_ -MV7_/;_P <;_"C^V[+
M_GM_XXW^%']B*KKC,14J>7-R+[J?*G\[A]<<?X5.,?E=_?*_X&-:_#G0X7\R
M>W>_EZE[R0R<_0\5T-M96]D@2W@CA4#&(U"_RJO_ &W9?\]O_'&_PH_MNR_Y
M[?\ CC?X5Z6%RW!8'_=:,8>B2?S>[.>KB*U;^)-OU9>HJC_;=E_SV_\ '&_P
MH_MNR_Y[?^.-_A7I'.)HG_(-C^K?^A&K]8ND:O:16$:M-@@M_"?[Q]JN?VW9
M?\]O_'&_PH O451_MNR_Y[?^.-_A1_;=E_SV_P#'&_PH O451_MNR/\ RV_\
M<;_"D;6[)%+-/M4#))5@ /RH OT5RWA_XG^%_%5Q=0:5J\-[+;'$B1@D@>O3
MD>];?]M6?_/;_P <;_"KG"5-\LU9^9$)QJ+F@[HFU'_CPN?^N;?RI;+_ (\X
M/^N:_P JY:[^)GAFXU6\T"+5$DU=$*O;)%(2A*Y )VX!QZFNJLQBS@'<(O\
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M31E05("' )ST-6? 'C*/Q[X6M=:BLY]/6<NIMKG'F1E6*D'!(SD4 =%1110
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M\+G\E_QJ_10!0_M.7_GPN?R7_&C^TY?^?"Y_)?\ &K]% %#^TY?^?"Y_)?\
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MTY?^?"Y_)?\ &K]% %#^TY?^?"Y_)?\ &C^TY?\ GPN?R7_&K]% %#^TY?\
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M#D7X')]=E'^'",?E?\979BP_#;10VZZCGU!^YNYF<?EG%;=EHFGZ<H6ULH(
M.FR, _G2>9J7_/&V_P"_A_PH\S4O^>-M_P!_#_A7=ALIR_!OFP]",7W45?[]
MS&IBJ]56J3;7J7ZH+_R&Y/\ KW7_ -"-'F:E_P \;;_OX?\ "J:O?_VLY\JW
M\SR%XWG&-Q]J]8Y3;HJAYFI?\\;;_OX?\*/,U+_GC;?]_#_A0!?HJAYFI?\
M/&V_[^'_  H\S4O^>-M_W\/^% %^BJ'F:E_SQMO^_A_PH\S4O^>-M_W\/^%
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M9+W_ )__ /R"M'V2]_Y__P#R"M7J* ,6YMKL:C9 WN6._!\H<<5<^R7O_/\
M_P#D%:+O_D*6'_;3^0J]0!1^R7O_ #__ /D%:/LE[_S_ /\ Y!6KU% %'[)>
M_P#/_P#^05H^R7O_ #__ /D%:O44 4?LE[_S_P#_ )!6C[)>_P#/_P#^05J]
M10!1^R7O_/\ _P#D%:IK;7?]KR+]M^;R%.[RATW'BMJJ"_\ (;D_Z]U_]"-
M"_9+W_G_ /\ R"M'V2]_Y_\ _P @K5ZB@"C]DO?^?_\ \@K1]DO?^?\ _P#(
M*U>HH H_9+W_ )__ /R"M'V2]_Y__P#R"M7J* */V2]_Y_\ _P @K1]DO?\
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M)>_\_P#_ .05J]17$=!1^R7O_/\ _P#D%:/LE[_S_P#_ )!6KU% %'[)>_\
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M]XT ;=%4/['B_P">UQ_W^:C^QXO^>UQ_W^:@"_15#^QXO^>UQ_W^:C^QXO\
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MQXO^>UQ_W^:@"_15#^QXO^>UQ_W^:C^QXO\ GM<?]_FH OT50_L>+_GM<?\
M?YJ/['B_Y[7'_?YJ +]%4/['B_Y[7'_?YJ/['B_Y[7'_ '^:@ T3_D&Q_5O_
M $(U?K$TC2XY;"-C+."2W E8?Q&KG]CQ?\]KC_O\U %^BJ']CQ?\]KC_ +_-
M1_8\7_/:X_[_ #4 7Z*H?V/%_P ]KC_O\U']CQ?\]KC_ +_-0!>H/2J!TF+_
M )[7/_?YJ3^RH@/];<^W[YN: )]0S]@N>/\ EFV!^%%G_P ><'_7-<G\!5*]
MTN-;.X(FN"1&QYF;'2KEI_QZ6_'/EK@>G H G]!CZ#TIO')SP>I[FC(QUR/Y
MFD/!.3@XY/9:! 2<XX^AZ"D)!/.1GC/=J.N ![A?7W--+?>.3[L._L!0,7)'
M!QQ^2_\ UZ54,HR"0I_B[G_"ECAS@L-H'1!T^IJ>@!J1K&NU1@4ZBB@ HHHH
M *\>_:T_Y(7K/_7YIW_I=!7L->/?M:?\D+UG_K\T[_TN@H ]AHHHH \I_:K_
M .3<OB%_V"9OZ5Z/IT*7.@VL3C*26RHP]BH!KSC]JO\ Y-R^(7_8)F_I7I6C
M_P#((L?^N"?^@B@#R_3OV;M'TF_L;NT\3^*H)+&,PVP74^(H2VXQ#Y?ND@<>
MU>M@8 '7'K2U3U?5;70M*O-1O9!#:6D332R'^%5&2?R% %RBN,\$?$^S\9B]
M1]/O=$N;6)+IK?4556:W<$I*-K$;2 >.HQR*PG^/-A_PCTFMQ:)J$VFO<PVM
ME,LD ^V-(Q5"H,GR XSE]O% 'J%8^K?\AS1/^NDO_HLU:T349-6TFVO);22P
MDF3>;>5T=D]B4)4_@3535V":WHA8A1YDO)./^69H V:*C^T1?\]4_P"^A1]H
MB_YZI_WT* )**C^T1?\ /5/^^A1]HB_YZI_WT* )**C^T1?\]4_[Z%'VB+_G
MJG_?0H DHJ/[1%_SU3_OH4?:(O\ GJG_ 'T* *MW_P A2P_[:?R%7JS;J>,Z
MG8GS$P/,S\P]!5[[1%_SU3_OH4 245']HB_YZI_WT*/M$7_/5/\ OH4 245'
M]HB_YZI_WT*/M$7_ #U3_OH4 245']HB_P">J?\ ?0H^T1?\]4_[Z% $E4%_
MY#<G_7NO_H1JW]HB_P">J?\ ?0JBL\?]M2'S$QY"\[A_>- &E14?VB+_ )ZI
M_P!]"C[1%_SU3_OH4 245']HB_YZI_WT*/M$7_/5/^^A0!)14?VB+_GJG_?0
MH^T1?\]4_P"^A0!)14?VB+_GJG_?0H^T1?\ /5/^^A0!4T__ (_-0_ZZC_T$
M5?K-L)XQ=WY,B#,HQ\P_NBKWVB+_ )ZI_P!]"@"2BH_M$7_/5/\ OH4?:(O^
M>J?]]"@"2BH_M$7_ #U3_OH4?:(O^>J?]]"@"2BH_M$7_/5/^^A1]HB_YZI_
MWT* )*H:9_KK_P#Z[G_T$5;^T1?\]4_[Z%4=-GC$U]F1!F<_Q#^Z* -*BH_M
M$7_/5/\ OH4?:(O^>J?]]"@"2BH_M$7_ #U3_OH4?:(O^>J?]]"@"2BH_M$7
M_/5/^^A1]HB_YZI_WT* )**C^T1?\]4_[Z%'VB+_ )ZI_P!]"@"IHG_(-C^K
M?^A&K]9NBSQKIT8,B Y;^(?WC5[[1%_SU3_OH4 245']HB_YZI_WT*/M$7_/
M5/\ OH4 24TG\J;]HB_YZI_WT*;]HB_YZH<?[0H >?0_C33GC'4]/84TSQ<?
MO4XY/S#FF^='S^]3GK\PH 9>X^P7..GEMCW..M+:<V4'/'EKDCZ#BH[Z>,V-
MQB1,F)L#<.!BG6G_ !Z6YQD>6NT>O YH FR?8-C_ +Y%-W9 P,C^!?7W-!*A
M3GY@#S_M&DR<G) ./G(_A'I0 C$88DG;_$PZM["I8HLX9A@C[J_W:(H]V'88
M ^ZOI4U !1110 4444 %%%% !7CW[6G_ "0O6?\ K\T[_P!+H*]AKQ[]K3_D
MA>L_]?FG?^ET% 'L-%%% 'E/[5?_ ";E\0O^P3-_2O2M'_Y!%C_UP3_T$5YK
M^U7_ ,FY?$+_ +!,W]*]*T?_ )!%C_UP3_T$4 7*R?%F@)XI\,:KH[RF!;ZV
MDM_-49*;E(!_#K6M10!Y;X3^'7B73Y;F[UF\TNYO;JS@TF06@D6-;2-6&]<\
M^8Q;./NCUKF?#7P%U7PS872+8^%;YA:0Z?'9RV\BVMVB/N^T7"X.9N@& 1R>
M:]XHH Y7X9>#I? G@ZST>:X2>2)G<B$$11;F+>7&#R$7. #V%7];A2?6=%21
M%D0R2_*PR/\ 5FMNL?5O^0YHG_727_T6: +O]E67_/K#_P!\"C^RK+_GUA_[
MX%6Z* *G]E67_/K#_P!\"C^RK+_GUA_[X%6Z* *G]E67_/K#_P!\"C^RK+_G
MUA_[X%6Z* *G]E67_/K#_P!\"C^RK+_GUA_[X%6Z* ,BZTVT74K)1;1!6\S(
MV#GBKG]E67_/K#_WP*9=_P#(4L/^VG\A5Z@"I_95E_SZP_\ ? H_LJR_Y]8?
M^^!5NB@"I_95E_SZP_\ ? H_LJR_Y]8?^^!5NB@"I_95E_SZP_\ ? H_LJR_
MY]8?^^!5NB@"I_95E_SZP_\ ? JFNFVG]L2)]FBV^0IQL'7<:UZH+_R&Y/\
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MQ1ICZA9R"Y)1-^X^4_&1QVJW_P );I/_ #]?^0W_ ,*V** ,?_A+=)_Y^O\
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M<:]=>*? 6@:M>J%N[RSCFEVC +%>2!Z'K^-=)3(88[:%(HD6*)%"HB# 4#H
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M 45^0'VF;_GJ_P#WT:/M,W_/5_\ OHT ?K_17Y ?:9O^>K_]]&C[3-_SU?\
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M )ZO_P!]&C[3-_SU?_OHT ?K_17Y ?:9O^>K_P#?1H^TS?\ /5_^^C0!^O\
M17Y ?:9O^>K_ /?1H^TS?\]7_P"^C0!^O]%?D!]IF_YZO_WT:/M,W_/5_P#O
MHT ?K_17Y ?:9O\ GJ__ 'T:/M,W_/5_^^C0!^O]%?D!]IF_YZO_ -]&C[3-
M_P ]7_[Z- 'Z_P!%?D!]IF_YZO\ ]]&C[3-_SU?_ +Z- 'Z_T5^0'VF;_GJ_
M_?1H^TS?\]7_ .^C0!^O]%?D!]IF_P">K_\ ?1H^TS?\]7_[Z- 'Z_T5^0'V
MF;_GJ_\ WT:/M,W_ #U?_OHT ?K_ $5^0'VF;_GJ_P#WT:/M,W_/5_\ OHT
M?K_2$9K\@?M,W_/5_P#OHT&YE_YZO_WT: /U[*GT]Z38?Z?XU^09N9<?ZU^W
M\1H^TS8/[U^_\1H _7LH<_=R,Y_+I32C@9P<@9_$U^0OVF7'^M?M_$:#<RY'
M[U^O]XT ?KPT3X( [; ?YFK*J%4 < 5^/JW,NY?WK]/[QJ3[3-_SU?\ [Z-
M'Z_T5^0'VF;_ )ZO_P!]&C[3-_SU?_OHT ?K_17Y ?:9O^>K_P#?1H^TS?\
M/5_^^C0!^O\ 17Y ?:9O^>K_ /?1H^TS?\]7_P"^C0!^O]%?D!]IF_YZO_WT
M:/M,W_/5_P#OHT ?K_17Y ?:9O\ GJ__ 'T:/M,W_/5_^^C0!^O]%?D!]IF_
MYZO_ -]&C[3-_P ]7_[Z- 'Z_P!>/_M9C/P*UKVN]//_ )/05^<'VF;_ )ZO
K_P!]&M[P!!%JOCSPU;7L:7EL^IVQ:&=0Z$B12,@\<$ _A0!^L-%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_03.jpg
<TEXT>
begin 644 form10-k_03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 F$# 2(  A$! Q$!_\0
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M_P#PI/\ A5VK?\_UE_X__A7JU%'UVMW_  #ZG2[?B>5?\*OU;_G^LO\ Q_\
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M )_['_Q__"C_ (57J_\ S_6/_C_^%>M44?7*O?\  7U2EV_$\E_X55K'_/\
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M7GOC;P'#=02ZGI,(CN5^:2!!A9!W('8_SKIHXSF?+,PJX6RO \EHI2*2O1.
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MW_-C\SR_,3>1G;GG'TH\V,R>7YB;\9VYYQZXH P/^$3'_0=UK_P+_P#K4?\
M")C_ *#NM?\ @7_]:M\2QM(8Q(A<#)4'D?A3Z .=_P"$3'_0=UK_ ,"__K4?
M\(F/^@[K7_@7_P#6KHJ* .=_X1,?]!W6O_ O_P"M1_PB8_Z#NM?^!?\ ]:NB
MHH YW_A$Q_T'=:_\"_\ ZU'_  B8_P"@[K7_ (%__6KHJ* .=_X1,?\ 0=UK
M_P "_P#ZU'_")C_H.ZU_X%__ %JZ*B@#G?\ A$Q_T'=:_P# O_ZU'_")C_H.
MZU_X%_\ UJZ*B@#G?^$3'_0=UK_P+_\ K4?\(F/^@[K7_@7_ /6KHJ* .=_X
M1,?]!W6O_ O_ .M1_P (F/\ H.ZU_P"!?_UJZ*B@#G?^$3'_ $'=:_\  O\
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M&BN>_P"$2A_Z"^L_^!K4?\(E#_T%]9_\#6H Z&BN>_X1*'_H+ZS_ .!K4?\
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M:@#H:*Y[_A$H?^@OK/\ X&M1_P (E#_T%]9_\#6H Z&BN>_X1*'_ *"^L_\
M@:U'_")0_P#07UG_ ,#6H Z&BN>_X1*'_H+ZS_X&M1_PB4/_ $%]9_\  UJ
M.AHKGO\ A$H?^@OK/_@:U9GB#17T?2'OK35M7,\4D6T/=%@<NH(([C!- ':4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YG\8/^/?2/^ND
MO\EKRRO4_C!_Q[Z/_P!=)?Y+7EE>YA/X2/'Q7\5B4445U',:U7='/_$\T_\
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M_10!@-X3M0I/]H:MT_Y_Y/\ &I?"4T]QX3TR6YDDDF: ;WD/S$^_O6U0  ,
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MV6O_ #\P_P#?8H GHJ#[9:_\_,/_ 'V*?'/#*2(Y4<CJ%8&@"2BBB@ HHHH
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M\+0 NE#1M&TV'3[*[MTMX5VHIG!P/3K5Z.^M)G"174#N>BK("35#_A%?#_\
MT!K'_OPM9.K:!I]CJ.ASZ?ID$,BZ@N]X8@"%V-G)':@#II;RU@?9-<PQMC.U
MY #^M5;R?2K^SEM+B[MVAE4HZ^<!D'J.M8MMHECJ'BO7IM0TZ*?F 1O-%NX\
MOG!/O6I_PBOA_P#Z UC_ -^%H QM)\*^$]&T.ZT>UE@%G=DF:/[0,-S]?PI+
M#PIX3T[PU/H$,T'V"?)EC-P/F/Y_YQ6U_P (KX?_ .@-8_\ ?A:/^$5\/_\
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MGE91D1IC+>PR0*PY/$EY#"\LGAK5@B*68YAX Z_\M*\,_P"$^\:?]#'-_P"
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M]OH **** "BBB@ HHHH *X#XR?\ )/)O^OJW_P#1@KOZX#XR?\D\F_Z^K?\
M]&"D]G_7<UH_Q8>J_-'A=%%%?*G[T%%%% 'M?P2_Y$>;_K_F_F*](KS?X)?\
MB/-_U_S?S%>D5]4ME_78_!:_\6?J_P V%%%%,R"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \R^,'_'OH__ %TE_DM>
M5UZI\8?^/?1_^NDO\EKRHU[6%_A(\G$_Q6+13>:*Z3G-T5=TC_D-6'_7S'_Z
M$*I"KND_\AJP_P"OF+_T(5<_A9C'XD>\T445\R?2!1110 5PGBPWC7.ZZ-E!
M&5>.(,OF,Z^O0XKNZXK4-5AN)YX&MVUB92R^5:PNCJ,_=W?=R/7- '3Z-D:+
M9 ]?)7^57JALU"64"K"80$'[LG)3CH:FH \M^,O_ !\>#/\ L.0_S%>I5Y;\
M9?\ CX\&?]AR'^8KU*@ HHHH **** "BBB@ K@/C)_R3R;_KZM__ $8*[^N
M^,G_ "3R;_KZM_\ T8*3V?\ 7<UH_P 6'JOS1X71117RI^]!1110![7\$O\
MD1YO^O\ F_F*](KS?X)?\B/-_P!?\W\Q7I%?5+9?UV/P6O\ Q9^K_-F7J_B/
M1M ,(U;4K:S,V?+\Y]N['7'YBL*_\=^$[RW$</C"TM&SGS(I5)^G(-<O\7%#
M>(/#X901Y%SU&?\ GG7#^7'_ ,\T_P"^16<ZJ@[6/GL;FWU6K[/DOIW/0-4\
M8:3;VT;V7Q!$LAGC5AF(X0MAC]WL*OKXJ\.+(K'XBA@#DJ7BY]ONUYAY<?\
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M:/\ %AZK\T>%T445\J?O04444 >U_!+_ )$>;_K_ )OYBO2*\W^"7_(CS?\
M7_-_,5Z17U2V7]=C\%K_ ,6?J_S9Y/\ %O\ Y&'P_P#]<+G_ -IUQ%=O\6_^
M1A\/_P#7"Y_]IUQ%<M?XCX/._P#>WZ(****P/&&R?ZI_]T_RKVWX??\ )/M!
M_P"O*/\ E7B4G^J?_=/\J]M^'W_)/M!_Z\H_Y5U4-F?4</\ _+SY?J=)1117
M0?4!1110 4444 %%%% !1110 4444 %%%% $<]Q#:PM-<31PQ+]YY&"J/Q-9
M[>(]%VG;J^GEL<9N5Z_G7)?&O_DEFJ?[T7_H8KY$\Z3^^WYT[*Q-W?0^R?\
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M_P#HP5W]<!\9/^2>3?\ 7U;_ /HP4GL_Z[FM'^+#U7YH\+HHHKY4_>@HHHH
M]K^"7_(CS?\ 7_-_,5Z17F_P2_Y$>;_K_F_F*](KZI;+^NQ^"U_XL_5_FSR?
MXM_\C#X?_P"N%S_[3KB*[?XM_P#(P^'_ /KA<_\ M.N(KEK_ !'P>=_[V_1!
M1116!XPV3_5/_NG^5>V_#[_DGV@_]>4?\J\2D_U3_P"Z?Y5[;\/O^2?:#_UY
M1_RKJH;,^HX?_P"7GR_4Z2BBN,\0?%#PYX9UF32M0:[^U1JKL(H"XP1D<UTI
M-['U!V=%>4:C\6O"E_*CIJ>N6H48VP6Y /N:R)/B;HG]J0"/7_$/V'RG\TF'
MYM^1MQQTQFGR2["NCVZBO)++XJ^%;2Z69]7U^X !'ES094UKQ?&OP=)*J-->
MQ*QP7DM6"K[FCDEV"Z/1**16#H&4Y5AD&EJ1A1110 4444 %%%% 'GWQK_Y)
M7JO^]%_Z&*^0:^OOC7_R2O5?]Z+_ -#%?(-/H2MV%%%%(H*^F_V<O^1*U'_K
M]/\ Z M?,E?3?[.7_(E:C_U^G_T!::V9+W1[)1112*"BH+R\AL+5[F<N(DZE
M$+G\@":QY/&FB0QF26:Y1%ZLUG, /_': -^BL+_A,-'_ +]U_P" 4W_Q-;:.
M)$5USA@",C% #J*** "BBFLZI]Y@/J: '44SSH_^>B?]]"@2QDX$BD_6@!]%
M%% !1110 4444 %%%% !1110!YA\8_\ CVT?_KI+_):\IS[5ZM\8_P#CWT?_
M *Z2_P EKRFO:PO\)'DXG^(PYHI**Z3G-YJMZ./^)YI__7S%_P"A"JQZU;T@
M?\3O3_\ KYC_ /0A52^%F<?B1[W1117S1]$%%%% !1110 4444 >6_&7_CX\
M&?\ 8<A_F*]2KRWXR_Z_P:?^HW#_ #%=OH7B,ZW/<1'1]4L/)_BO8/+#\_P\
MG- &W17+IXS/]HS6DWA_6;>.#>9+J6W A"J"2V[/(P.,5SS_ !M\-B3$5GJL
ML9QB1;;@CUY.:N-.<_A3?H3*<8_$['I-%><W'QI\-PN!%:ZI.,9W):D8]N2*
M6;XT>&HXD9+;5)6;JBVI!7ZY_I5_5ZW\C^Y_Y$>VI_S+[T>BT5YS_P +H\-?
M9?-^S:IYF<>3]E.?SZ?K6UX6^(.D^+7O8[&&[CGM$$CQ31[693GE1GGIC\JF
M5*I%7E%KY,J-2$G9-,ZRN ^,G_)/)O\ KZM__1@KH=!\3/KEQ+$=#U:P6-<^
M9>P"-6]ASR:X#XK^)C>^&KO2CHNK0!+R$?:YK?; VV0=&SWQQ63V?]=SHH_Q
M8>J_-'E-%%%?*G[T%%%% 'M?P2_Y$>;_ *_YOYBO2*\N^"5VQ\(W\ M)\0WD
MK"0@!)"?X5.>2._UKL-&\4R:QJ+V9T#6++8I+37< 2/CL#GDU]4ME_78_!:_
M\6?J_P V<1\6_P#D8?#_ /UPN?\ VG7$5TOQ*U5K_P 6Z9;/IU[:FUCN%\R>
M,!)L[.4(/(X_6N:KEK_$?!YW_O;]$%%%%8'C#9/]4_\ NG^5>V_#[_DGV@_]
M>4?\J\2D_P!4_P#NG^5>L?##6GOO"FFV/]EW\"VMG&/M,\06*4_[!SS750V9
M]1P__P O/E^IW-?.OQ*_Y*AJG_7O!_Z":]HT_P 52W^LG33X>UBVVE@UQ/ %
MA&.^[/.>U>*?$=R_Q0U;,;)MAA W?Q#;U'M7J8+^.CZRE_$1SN3ZT9/K117T
M)Z89/K5>_)_L^XY_@-6*KW__ "#[C_<-3/X614^!^C/K*U_X\X?^N:_RJ6N>
M\,^(GUN(QG1M4L%AC7Y[V$1ASC^'GFEM_%#S^(#I+:#J\6&9?M;P#R#@9SOS
MT-?*'EG#+\7-<G+O:>![RXM][*DJ3C#@,1GI[5FW/C_Q7<7#RIX8UR%6.1&D
MR[5^GRU>\(?\BQ:_[\O_ *-:MNOB<3Q+6HUYTE35HMK=]'8]:EE\9P4G)ZKR
M.,C\<>,Q-,9-!UUHRP\I1(@*C'.3MYYK1L/B1XIL@_F>#M7N]V,>=,OR_3"U
MT5%8?ZU5_P#GW'[V:?V9'^9_@.\+_$:^UKQ%#I&J>&KK2FN(W:"21PP<H,D=
M!VKT"O+XG,?C_P .N$9RL=X0J]6_=C@5U^A^*)-:O7MCH.KV(12QEO(!&GT!
MSR:^NRW%RQ>&C7DK-WV\G8\NO3]E4<$]CG_C7_R2O5?]Z+_T,5\@U]/_ !>\
M3O>>"-7TMM"U>W*N@^U2P 0<..=V>A[5\P5Z'0P6["BBBD,*^F_V<O\ D2M1
M_P"OT_\ H"U\R5]*?LYW#?\ "+:G;BWE(6Y\SS<#83M V@^O&?QIK9DO='M=
M>6?&&XNDNM MH+VZMXIC<&06\QCW[0F,X],FNQTKQ5)J>K&P/A_6+3;NW3W,
M 2(8_P!K/.>V*\Z^*FJ->>)=(LFT^\M_LOVC$TR 1S JGW#GG&.:QK-QI2:W
MLSIP\5*M",MFT<:!=#IJVJ_^!K_XTDD=Q+&8Y-5U1T/56O'(/ZU+17SGUJO_
M #L^L^IX?^1?<,_TS_H+ZM_X&O\ XTTK=8/_ !-M5Z?\_K_XU+2'[I^E'UJO
M_.P^IX?^1?<>X?#R>:Y^'^B37$KRRM; M)(VYFY/4UTU<'\*=7-YX/T^P_LZ
M^@%K;+_I$T6V*;)/W&SS6[9>)WN]>?2FT+5K<J6'VJ: "$X]&![]J^I>Y\6M
MCS'XI?$_Q#X<\7'2-':""*"%'=Y(PYD+#/?IBN O?BOXKU%4%Y+8S!#E=UL.
M/R-6_C22?B=>Y4C$$(Y[_+UKS^O4HX:G.FI,XZE6:DTF=+)X\UR22)RMBIC8
MD!8,!OKSS5B#XD^(;:=)X5T])4.586W0_G7)45K]3I=B/;3[GI&G?&?QI)JE
MHD]W:20O.BN@MP-RE@",]NM?3-?$UBVW4;1@I8B>,[1U/S#BOKO0_$KZW=2P
M'0]6L%B7)DO8!&K'T'/-<&*I1IR2B=-&;DG<WJ*P(/$[S^(7TD:%JR!'*F[>
M + 0.X;/(I-2\4/I^M)IB:%J]T7VXN+> -",^K$\8[UR&YT%%8?B#Q(=!>!1
MHVJ:AYH)S8P>8$QZ\C%:UI<?:[.&X\F6'S4#^7*N'3(Z$=C0!-1110 4444
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M<M1TBQU;[-]NMUF^S3K<0Y)&V1>C<?6KM3[*'8Y_[%PG9_>?/[>&/%K(R_\
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M%6=I6J66HZ=]OME>*V;G=+&8\CUY[>]3W&I6-I&9+F\MX4#;2TD@49ZXY[T
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MY(;MQQQ5;7O#E[JMS EK>I;VXLY+::22/S78-MZ<CGCK7344 <7H/AW5M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\O\ C&1Y&CCOOE./P6O*<5Z%\6M06XU^UL4(/V:'<_LS'I^0%>?9KW<*K4D>
M-B7>JQ,44N:*Z#G-W%)2TE 'H7P_\31PJ-&O'V@L3;NQXY_A_P *]'KYVS@Y
M'!KLM"^(5[IR);WZ&[@48#YQ(H^O>O.Q&%<GSP._#XE17+,]7HKE[;X@>'YT
M!>Y> GJ)(SQ^6:L?\)QX;_Z"D?\ WP_^%<#HU%]EG<JL'U1T%%<__P )QX;_
M .@I'_WP_P#A1_PF_AO_ *"D?_?#_P"%+V53^5_<'M8=T=!17/\ _";^&_\
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(@D2BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %F HH# 2(  A$! Q$!_\0
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M"?#CXE2*KI\,?B=(C %9$^&GCAD88SN#IX?E4CG.=PW9R%[EP^&WQ-_Z)?\
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MZ/>!Z<4XRW_8FRW_ .6G^?:?AM\3TW_\6L^*> ?E"_#'Q]@C Y&/#9SCGUZ
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MX&>,=\#(SBG/\,_B@6X^%GQ1(X&1\,/'Q& 3C'_%-?B /KWS7^@UB3L?\_\
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M^#,#_P"'G,O_ )6-> & 6W%&+_\ #+ES\_\ GX?YW!^&/Q3Q_P DI^+/N/\
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M/\VIOA=\6N@^$/Q?_#X3?$3!!SG/_%,?ID@BD'PJ^+)'_)(?B]^/PH^(8_\
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M%YI^EWWBFZTRVV'5]0DUC5K"TBM;EUL;*P6^U";SY(X() #^@BBOY>?V//\
M@I!_P4'_ &=O^"E]E_P2]_X*CZC\(/BKXB^*GPBO?C)\&?CU\#_#UWX8TX6^
ME:;J>H:KX?US0YH+=+BQ1/#OB&UAO6L+&\MKZP4N;J"]MPGQ1I?_  5<_P""
MR_\ P4 N_P!NG]I__@GMJ/[-?PK_ &3/V'?$WB'1-*^'OQ0\,77BCQ]\;K3P
M7;7VJZQ<?VL$=+"ZU31-&O=7@1)-$AMH[VUTJW%S?*\I=GV _M=HK\V?^"3W
M_!0#3O\ @I;^P[\(?VL(?#/_  A>O>++;4O#WCSPE#.;K3]'^('A.\;1O%$.
MAWEP8I[G0;O4HS=:+-<I'.+2:."X_?QN6_0K^W]&/)UG2ESN(SJ5D  C%&'%
MPRDJZLDF&^5EQ@$\2W9-]O-+\79+YL#<HK ;Q!H>X!=>TDY[#4[ G'&3@S[N
M.Y /7I3/^$ET 9#Z_HR$=GU:P4]!S@SJ0">.AYSCT&D*5:JKTL/7J+O&C6:^
M35*7,O.-UYD2J4XM1E4@FU>SE%?^E2BOQOV3.BHKG/\ A*?#G_0QZ#GT_MK3
M_P#Y(_I3/^$K\-\_\5'H/!P?^)WIO7G_ *>>.AZUI]4QO_0%BO\ PGQ'_P S
M![6E_P _:2]:E-?^Y&=-17-?\)5X=_Z&'0O_  =:=_\ )-'_  E7AW_H8="_
M\'6G?_)-'U3&_P#0%BO_  GQ'_S,'M:/_/ZC_P"#:?\ \F=+17-?\)5X=_Z&
M'0O_  =:=_\ )-'_  E7AW_H8="_\'6G?_)-'U3&_P#0%BO_  GQ'_S,'M*7
M_/ZC_P"#:?\ \F=+17-?\)5X=_Z&'0O_  =:=_\ )-'_  E7AW_H8="_\'6G
M?_)-'U3&_P#0%BO_  GQ'_S,'M:/_/ZC_P"#:?\ \F=+17-?\)5X=_Z&'0O_
M  =:=_\ )-'_  E7AW_H8="_\'6G?_)-'U3&_P#0%BO_  GQ'_S,'M*7_/ZC
M_P"#:?\ \F=+17-?\)5X=_Z&'0O_  =:=_\ )-'_  E7AW_H8="_\'6G?_)-
M'U3&_P#0%BO_  GQ'_S,'M*7_/ZC_P"#:?\ \D=+17-?\)/X?;[OB+0_3 UC
M3VY_X#.<5(OB#2'SY>MZ5)@'_5ZG8$#IC/[[(^A!R3G)Z!/#8N-N;"8E*]FW
M0K*VCMHZ$=W:*U6K5VEJ-3A)VC.,WVIOVLO50I>TF_E'Y[7Z&BL.+5K)X_,7
M4K-T4X9TN[>15."5#LK;!D8;ELD$$#G%/2\,JL8I9)%&274)L7:N1AQD-DJ0
M0N3N;'!P*YG-1E*#356.DJ3<55BW)0BIT^9S@I2<4I2ARQ;]YI)R%SP<G",D
MYQ^*#<858:J*<J,I^VBG*48W=%)-WE:*;6S16>+B1W P4P"XZ$.A"@%N.,EL
MA20P*\\ @R^<_M^55=Z^[*W1V;NM4W91O&THR5I6;MS*\6F[L]+J2NKKW97M
M>2U7+IK%VONK-:--VZ*I&=BZ(6QOW8*E0?EV_P )R2"">0/E[]:5Y)%4D;\Y
MQ]T,!Z]P,'LV1@#/J"7=[6Z:*ZO)ZW5FURM6O:;A=:JZU#6]DKNUTDU?1ZII
MM<CM[R51PO'5733=RBHH6WQJV[=DMSE6Z,PQE21QC& 3C&#R#4M.]]5L]MOT
M;7W-KS8:/5.Z>S5FG\TVON;7FPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH A<?,#[_\ LO\ ]<5^4'_!;..-_P#@G!\;MZ(WEZM\*)4W $JZ_%'P
MAAU]&P64D<E79<C.:_5]R=V.V?\ V7_ZPK\H_P#@M<,_\$X?C@>XU3X5X/I_
MQ=+PAZ_E7U' C:XTX3:V7%&4_P#J93O_ %V/F.,8I\*\31:NO[$S#3UP-5L_
MAF=@ <GKP!@Y)Z<>OX4GFKZ-_P!\FF.0Q&.B]\8R?Q[# /3!/TIN#ZG]/\*_
MT%4%;KWW\D?Q#&2C?3<^J[GBQO3Z6MWTZ_<K_0-^$A_XMC\,O^R?>"SC_N6=
M-Z_K^M?Y]MXY6RO,_P#/O.!S@@&)B<XX/RCC\<GIC_03^$G_ "2[X8YY/_"O
M?!0)]3_PC&GG^N?QK^?OI*.^"X-??'9^O_+7 /\ 4_7/HZ)K'\5NWQ8+A^?I
M_M&877G;O^!Z11117\IG]4D3[@RD;CA6 QR,X/)7@X' X/)(X&,U_/=^U#^Q
M9_P7'\9_''XN_$+X"?\ !5SX0_!#X#ZOXCOM:^'_ ,-_$7P4;6+CX?>#H;:*
M2/3=6\1RQ>7<O:K%<37M_(_E)&=YD0!R/Z%J_GP_X.7_ !/XU\/?\$TKS2-#
M\8ZY\.?AW\1_VCOV=/AE^T'X\\.W5S9ZIX:^!GC/XA:?IGBN[^UVMS9SV^G7
M=^=&TG4XDGA34K.^DTNYG2SO;A7 /SIU#P?_ ,%;]/N9["^_X.3/V";&\M)/
M)N[:Z\/> ;6[MY%90T<D$NJAQ)N!1T95=267ACQ_73\-AK*?#_P''XA\4:=X
MW\0)X0\-)K?C+1HTAT?Q9JHTBU_M#Q'I,4=Q<1)INMW2SZE:(ES.(K>>)4+*
M1C_,P_;V_8B_X)D?LD?%;_@K-\&[SP=H7@KXA?!OPK^QG\5O^">GA;Q+XJ\2
MZYJGQ9AU[4M*3X@>'-(^VZS=7OQ)T[XB+<78\31,TTFGV$T>I>'GMHK=X1_I
M5_ 14'P1^# B\.IX/A/PK^'S0>$XA((O"ZCPCI!&@1B?,S1Z8LCV"O+LE6.U
MB26-9@X ![!3)(XY4>.6-)8Y%9'CD571T<%61T8%65E)#*0002""*?10!_)?
M_P '%GPD^*?CK]K;_@B]<?"_X4^._&WAWP1^U?::QXKNO O@[5=;TCPEIJ^+
M/A\[WVNW.C6L]OH=B+6*]N7N;];>T$5K,QF+?NWUO^#A_P#9+_:5U']HW_@G
M?_P4F^ 7P?\ $G[0V@?L3>.=2G^+OP>^'T3WOQ%O?">H:YHOB./Q)X<TMDD&
MK6\%OH]_IMY#:12W=E>7>G2F&2VFN9[?^K@@D@@G YV\<XSP3UYS^@]\H=VT
M\D')/ ![].,9P,<@@\#GKD _C3_9NT;]I'_@KO\ \%JOA]_P45D_93^-/[)/
M[+'[-?[-WB3X0V=W^T;X>7PKXW\=>,?$>F^+;5K'2/#D<TC7,4-WXWEOY;F.
M[^Q6VEZ9!(\OVZ\-LOP=^S5XI_;/_P""*OPX_P""C?\ P3W\<?\ !/;]I3X^
M>-/VH?''C_4/V</C!\#O#2>*OA+XBTSQ[X=U3P?HFK>)-?@DGFTRWB@U*+4[
MBV:'^T;*XMK_ $?4;>W,0U _Z#N"<@@8.03N))&.H!!QGTW<>] !  P0!@8X
M.0>,]L$=3Z\\>CN[6 _$[_@@7^P]\6_V$/\ @E]\'O@#\>[&'0OBIJ]YXT^(
M7C#POI]X+F?P;+\1=0;4+;PO>WD9-I_PD>D:7]E@US[%<7%G9ZR)X+>>>.(2
M2?,FM?\ !KM^P5X@US7/$>J?&?\ ;?:^\1:WJNNW\5I^TAKUE:1W>L:A<:C<
M1P6J:8WD01R3M#"@=R(PHW$_-7])]?/'[5]M^TM=_L\_%"V_8\O_ (;Z7^TM
M-H4*?"74/B]'J$OPWMO$/]JZ>9W\5Q:7:WFH2:>=(&I)&+6!I!>-;/RJLK+7
MHY)]XMQDO22U6C:TZ-KJP/X3/^"XW_!)3]G?_@F9I7["_B_]G3XF_M0W>J_&
MG]K;PS\*O'D/C_X[^)/$^G7O@VZMH+VZM;:U7^S9+.[FF B>Z25U:&5D9$(4
MO_6GI'_!&S_@G])86=P_P?UEGGMK.X+-\1_B"V6EL[9V8^;XBD;<[EWDW8'F
M.Y550J!_(U_P7*TC_@LGIZ?\$]?^'EWBG]C/Q#\.)?VU? R?#]?V9M.\9:?X
MDA\:LEH;I_$?_"56=I:G0CI'VT6ZVOGS&\\HSO$/+$O^AQH@QH^E\ #^SK#&
M#D$?8X!D9Y XP >>,]Z^HR+CKCGA;"U,%PQQEQ+P[A*M1U:V%R7-L3EN&KU+
M*T\12PU-^VJ0M>$YU4XMMJ%VV\*N&PU9WK4*55V7\6$*D;IMIJ,XRBFK[VOY
MGYC+_P $</V 4^Y\'M47C''Q#\<X[= ==('3L.I)ZG-3#_@C[^P5&,+\)=;
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MMGG%-^S0?Y(_PK_0A;+T7Y'\.GTGJ/%C?$]K2<_^0Y,?IQ7^@O\ "4?\6O\
MAG_V(/@MOP_X1;3E_F/T^E?Y].I?\>%__P!><_\ Z*DK_07^$O\ R2_X9?\
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ME47(/^AOHO\ R"-,_P"P?8\]V_T2'!/?., Y Y'3&* -2BBB@ HHHH ****
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M0?P-?K&_7\?Z+_@:_)S_ (+:<?\ !-[XXG&<:E\+>/7_ (NCX0X_&OI^!_\
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M4+)'+$XFCFC66,Q/'(KQNBR+)&X<AXF1E970E2&!'#*2DN]=TB%B0WS8;/&
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M 4444 %%%% !1110 4444 %%%% !1110! _WQ]?_ &4U^3W_  6TY_X)O?'
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MPSXT\&^([%;_ $C7M%O45Y+>XMW^;SK>:&&ZT^ZMME]I^HP6FHV,T%U:Q3(
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M(QG_ $2'G'0<Y&!P"#WS0!IT444 %%%% !1110 4444 %%%% !1110 4444
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MXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$,G4?[Q_] %?E)_P6O8+_P $X?C@3_T$OA7_ .K/\(5^K3_>'U_]E-?E!_P6
MR_Y1N_'$]QJGPIP>X_XNGX/'7Z<?2OJ.!';C7A)]N*<I_#%0_P CYKB[7A?B
M7I_PBYA_ZA55I]Q_#).0V[))VC@Y/WCT'![<#W.,YVBJAB0DDKR3D\GJ?QJ1
MBS YVGJ0".YSWSP>>O6JV'//[W\#@?@,\#VK_0 _C"FM&_ZT_P"'/K/4O^/"
M]_Z\[G_T4:_T%OA(0?A?\,2#G/P^\%D>X_X1G3SD>O!'YBO\^K4?^/&\/_3I
M<_\ HLU_H)?")2/A=\+\]OAYX+!_'PQI8_\ 937\^_2/_P!RX,_[#>('_P"6
MV!/U+Z/7^_\ %'_8NR#_ -2<>>ET445_+)_405\1?MY_LF^+_P!L/X+V_P .
MOAW^TA\6?V4OB-X;\8Z1\0/ 7QD^#UY!#K^C^)-$L]2L;73M>TV<QP>(_!NI
MQ:I<1Z_X?FN[1=06.W9Y%2V!/V[7XU_\%M_%2:7^R_\ #GP++^UQ\6/V-K3X
MU_M+_"/X*ZI\3/@;X#/Q ^)>K6?Q%;7=+M?!&DP1^(?#+>#[7Q/J$-M;ZAX[
MN+^>W\.VMO-/_9NJ32P6;@'Y&_%;_@L?^W=_P1E^(?@OX.?\%+[[]G/]NWX<
M^+-7_P"$?\*_%7]ECQWX8\+?M8VL:,C07GC_ /9HUB\T^ZO[C[,DD3ZAIL>E
MZ!+J(@LQXMNM0GCMY?Z*?V&?^"@?[+'_  41^%][\5_V6_B"_BS2/#NMMX9\
M=^%O$&B:IX1^(7PV\5&);A?#GCCP;KL-KK&A7T\(FET^Z$-WH>MPP3SZ+JM]
M#;RN/RI_X8 _X)=?\$//V<OB]^W)JGP9U/\ :+^(WPAT:T\6^.?C%\5]<T?X
MJ?'SQ1?W^LZ1I-S>>'M1\;7$>CZ-K$VH7MM?J--CL;X0I<".\8C8_P!>?L'_
M +%ES\-?VQ_VX?\ @H39>,O"DW@7_@H9X8_9?\3_  \^&/A+PA>>$)O VB_#
M_P "ZXMYJ'CKS-0NM/\ $7C+Q)+XEM;Z[UC3H;,"Y?57G@)OT"@'Z[T444 %
M?BG_ ,%=_P!G+_@IE\1F^!/QT_X)F?'1/"_Q)^!7B=]3\9?LZ>+==L?#_P -
M?C]X9NKJSNY;.^U74+6XL[+Q)IHLGT^U%_/I-C=:5JU\(]7M+Z&(/^UE% '\
MJO[/_P"PU_P4Y_;K_P""FOP;_P""BG_!2SX2?"C]D?P7^RW\+O$OPX^$WP'^
M''C[2_B9XO\ %VI^,[37[;6]8UOQ+X>O]9TJST,#7KN\9;S5C>@FRTRUTM?+
MU&9_B?P+_P $V?\ @ME_P31L/V[?V/\ ]AGX&? C]I+]FC]M3Q7XGU;P7\=O
M%/Q8T#P)XB^#6G>-])N_#VH?\))X.\0ZKI>H7FH:5H6JS6$T6EV.OV,EQIXU
M:PN[I[E=/7^X*B@#\L/^"1'_  3UO/\ @FY_P3_^%?[)/B+Q3;^,O%^DV_B7
MQ#\1]?T3[3;Z/<>-/'MY+J7B&R\,W,T5M?-HVBRW TS2[^ZM[6\N8+5+UH82
MRQ)^?.J?\&KO_!,O6]6UK6]0U;]J(WVNZQJ6N7[0_'_QC:0M>ZK?RW]T8((W
M"1Q&>60!&W2! F"<!F_I5KYV_:RM/VEK[]GCXH6O['FK?#W0OVE9=#MA\)]5
M^*MC<:C\/[/7AJ^G&ZD\2VMJ&G>S;11JB1M'%.4NF@<P2 %: /X0O^"Y7_!'
M/]D7_@FL/^">OQ$_9TN?B]<^(OB'^VKX&\$Z^OQ(^)^O>/-/_L>W%MK,?]GV
M.KE[>PO!>0(7O49)2H1,[00W^AGHHQI&F#).-.L!DG.<6<'.>ISU^;YB>>A%
M?YX7_!<+PU_P60T=?^"><O\ P4L^(W[(WC'X>2_MI^"%^'UE^SMX:U_1/$%E
MXV'V<7-SX@GU>UMH;C1VT5KN%(K92ZW$JL_S8%?Z'NB_\@C3 < C3K$$*,*#
M]DAX7D\>G/MSU(!ITF1ZC\Q06 ..IQG ZXSC-1$J"<KW/.2.])MK9-^BO;UU
M7ZA:Y+D>H_,49'J/S%197^[^II,CT'Z_XU/-+_GW/_P%?_+!V?;\5_F39'J/
MS%+4&1_N^XW=.^3D_KC/K4B,#P&W<9!P>A^O^>12=1+XFDWM3:]_RTNU9]-=
MMPM;_+^M/Q'TF1SR..OX4 @]/I7P[^V/_P %#?V6OV#Y/AO;?M$^,==T'6/C
M#J^HZ%\-_#WACPAXA\:>(O%VKZ5!#<WFG:3I'ARQO;N6Y2*XB:.)D5IRS+$'
M*L%M7:3:L^SW0C[AW+QR.<X_"@,IQ@@YZ<_A7XW6_P#P7/\ V$K?4;:W\9K^
MT5\*-"N+N.VO/'OQ6_9F^+_@KX?:'YLGD)/XD\5:CX?-CHM@)BJ2ZA?F"RMV
M9#<S0J<U];?M4?\ !0_]D#]C+X(>$OVC?CU\8-&\/?!GQUJ>C:3X-\;:':7O
MB_3?$EUK]K)J&F2:3)X:M]3>]M;FRBEO!=P@P+#&SL_!I@?;FX8SGCU/% 92
M,@@C&<^Q[_3CK7GGPP^)O@+XS?#KP1\6OACXETWQC\._B-X9TCQGX.\4:3*;
MBPUGP[KEE%?:;J%M(&#1^9;S*)8942>VF6:"XBBFADC7Y:L/^"CO['FJ_MG3
M_L :;\8-*U#]JBS\.WGB34?AU9:?JER-/M=/L&U2[T^]UL67]CQ:Q;Z4!J$^
ME->B[CMWBD:)?,V@ ^Z,@G /(P?P/0T9'J/SK\^/VEO^"FO[(W[+?C2#X6>.
M/%OB?QM\7Y;*/4;GX0_!3P'XI^+_ ,1M)TB5P(]5U_P[X+L;^7P]ISLP$4^M
MW-AY@(:*.12"9OV7?^"F?['_ .UUXUU[X6?#'X@ZIX>^,GABSAU/6?@G\7/"
M&O\ PE^+46CW!E$.N6/@GQK9:7JVL:03#(IU+15U&U@9/+N9(I& H _0$,"
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M9#&RLS_V4Z,,:3IG&/\ B7V..O\ SZP]<^_8< 8'7-)[:.SZ/1_@P+;L-S*
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M?VGOC#:WH0)X6U?QUHNMS:)X1L(F_P!(2/0_#@MX97DGE=YHR61</$O[I_\
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MFHV7AWX=_#?18IH/M?A3PUI^AR-=PZ9:>1;Z@)DOG220!AO?\')?@SPEH_\
MP3>\>_M1:<++PE^T'^R[XN^'/Q,^ 'Q<TI8=-\;>$/&UOXZT6T@TS1];A$=_
M-8^)[>Y;2=5T26XFL]8BG,;VGF;4KZ$^+W_!-?XN^ OVB_'_ .U[_P $W_VA
M]+_9=^+'QKDT^Y_:+^$7Q#\&S?$?]F?X\:WI$)LK'Q_KW@J"_P!+UKP1\2[6
MQQ8S>+O!&HZ<=:@).KVMY(\\T_*V_P#P3)_:$_:I^(_P_P#B!_P5)_:<\/\
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MX+9';_P3=^.)Z_\ $V^%GZ?$[P>?Z5]/P-IQCPJUNN)\J:_\*Z?^;/FN+/\
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M/B%X^^%6G_%;0K;0+OX@?##5/[%\=^&HK;5].UD7GA[5/+D%G<S2:8EG/(0
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MQ/B_:(^'?PZCU)DM)+O6=,M?"_B+2[G4ENM."%(9'E,=XRE8\D@!@?HT8E.
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MDY &/FS\Q #-@9)P*78N ,=  ,\G R,9.3T)!YZ$^M?CEX]_X*>_&O5/VO\
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M)8WVG:E%HGB?0I;^.&*5%V!M2TN]%J[B5CB89#M(A#,#[?XO\"^#/B)X<O\
MPC\0/"OAWQGX5U51%J?AKQ1HNGZ[H>I1Q3+-$MYI>H6]U9W4<<RB2,3P'9(
MP 8#'\X6A>)OC1_P1X\1_';7E^&_@7Q5^QI\0/VK] NM/T+1K/6_#7CGP%H_
MQ<UW3?"VFCPM+)"OA"^TS2=2U&.6:Q\RWN3:6\@MX_,(+?H^'X=\-^-,7%<.
MUL/X;^+G$?%>:T<%P3BL]XFXEX0\9ZV?XC%9MA<IR!\;9AQ16X&XVR#%1XCS
M6*P./P'#W%W#^8X'AR-'*LQX:RG$8SYN-"7!/$F48_ <19QE^ S:53!U\-6Q
M.=YIBZ.;4,/7Q&58_*\\ABJL^&ZU&M-RQ5;#U,%A<1&CAIQK86K@(V]I^&/B
MKXW?\$K_  [XX\+>-/V>;/Q!\%O'_P"UAJUSX2\?>#O&NB6FGZ%I/Q8URT@\
M-V;^%7BBN[?[!,?),"2;0DDA 8#Y?W]L9S<^7,$95DM_,(9"NTOY14#(!PY\
MP@XPZJ''!%>#_M _L_\ PM_:A^%MW\,OBYX?G\0>#M0O-*\1P6]OJ-[I5_:Z
MKH\@U31]2LM1TZ5)[:_L+E(I(G23 E4N,[0P^(_^"06N:]>_L_?$+0M<\2>)
M?%%OX(_:%^-?@G0[_P 6:Q?Z_K-EX>\->)X++1=,EU/4I9[ZXAM;5GBA,SC:
MD. ",&OQ#)Z.(X>SK"<.0J5L5DM? 8U914Q-7!?6,NQ&4NK6S/+ZE"GAZ.)G
M1JPQ]'$X?$SK5VI.5-W33/[5\0\XR3QC\/\ -/&"M@J.1^*'#_%>5X/Q/6"P
M^=5<MXTH<;?V9E7"/$6%Q&8<19MA\!FV"J<(YM1XDP>$P6%P6)6.P>/H3]M+
M$0/UGHHHK[@_FP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (7^]]#G\P!7Y/?\%LP3_P3>^..!G_ (FGPK)'<D_%'P@O'X>]?K"_
MWC^'\A7Y0_\ !:\X_P""<'QP_P"PK\*1^?Q4\'U]-P+_ ,EGPIY\4Y4O5?6Z
M>A\UQAIPMQ+;3_A%S#;_ + :O^;^\_AA&0 #P>Q((! /.,]?EXS^/2ER/4?F
M*E8J0.-R@G)'1<8Y/?@$]/\ "H"JY/[I3R><GGGKU[U_H"TGNKG\84^OR_4^
MF;\DV-X%^ZEK<%B3S@1,1[GC';K^%?Z$'PAS_P *L^&.<Y_X5]X)Z]?^15TS
M^N?QS7^?+?H@T^\^;DVUQU.,GRBH&,X)/4' .<'@#%?Z#?PDY^&'PR/;_A7_
M (+(]P?#&GC^M?SW](V4I8+A-R33>99\TFK77U; 7:NEY[:6/U?Z/T8PQW$L
M4U?^S\AO9IO_ 'G'O76_E=]#TFBBBOY</Z=(7/S@9Z =!DC+ D\\8X Z$@$M
MQC!_G-_X*3?\$GO^")/@31_VA?\ @H?^W1\.-9TNRO+P>-?BUXNB^)7Q'MWU
MW7-9:P\.Z9H?A[PEHFMV]MJ&M>(M1FTS1=)\/Z7:Q)<W<Z32-!%%/.G]'%?B
M+_P7V_9@^+_[4G[#6A>'?@A\.+_XT>-/AI^U!^S?\8;KX+Z==6UD_P 5?"WA
M3XAV%EXI\*W$U[=V=H+9-(UJ?6[F2>;$4&CR2K&[QJC@'\>FK?&#_@UTTV^U
M&UL/^":G_!0#4;+0M0T;3X[^&'Q=906M[XFN(1X=22#4OBE%J&C7?B24H^B6
M]Y#;SZPS!;&.=R$'^CE\&/\ A'O^%1_"L^$=%UCPWX2;X?>#/^$7\.>(4FBU
M_0= _L#3WT?2-9BGGNIDU?3M.:&TU037<\JW-LX9I&9F7^+3_@J+^S_^W/X8
M_:3_ ."BOP8^#?[#?Q0^-7A'_@J[X)_9%E^"?Q8\%6\4/A']FKXE?"'5M(.J
M7?C_ %?2DN[/PGJ/@JWLKFXTF[2]T>/[8D<]C?WVFRW$+_VM_"K1?$7ACX9?
M#CPUXOU+^V?%OA_P)X1T/Q/JV[S!J?B#2] TZQUC4/.8EI?M6H07,RS,2TYE
MW$ELX /0Z*** "BBB@ HHHH *SM6U33-%T^YU76=2L-(TRQ3S;O4M3O;?3["
MT1B(EDN;R[DBMH$,DB1AII$4NZ@'<5!T:^?/VJ?V:?AC^V'\ ?B1^S7\98?$
M=Q\,?BMI%KH?BZ#PGXCU#PGKTNGV6JV&N1)8Z]I9%W8EK[2K03;0T<\/F6\J
M/'*RD _ES_X.LO&7A#Q1X(_X)@1^&O%GAKQ'-:?M_>#99K?0]?TK6)H5?3%1
M)Y8;"[GD1 0R>8R!5+E"P+8/]?FC$'2-+]M.L<GU/V2$]>_!'-?YZW_!<_\
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M/=>-_C7\6]80R^(/%WB'4YF>X^P0W4TUKX<T8RO!H^E".V@57-S)-\Z^,_\
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M#X%VO[.7QA^&NGWGPOT2?PY?^";'PK-+X+U;X:ZOX0E@;PMKWPVUSP\]G?\
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M)_VO?C'IL3)?:8W[0OCWPEJ^@?"WP-KB0.L U7P9)IVM>+9[##7$$AMF>%%
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M'OC'3GTR%E4@'J>G!.>O QU/!X&3@$XP"0U >2<'EQGN0&(3)ZG S^=?"_\
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M2-<65CHR;=(8W:Q:A)/:$WT$,SM&@!]K]>E% Z#KT[\'\?>B@ HHHH ****
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M/^G:X_6+&?I@?F#7^@#\)1CX8?#,>GP_\%C\O#&G5_G]WW_'K=^UK,?R1O\
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M?W_A'PCH6@37=K_9T5S]EOKO1=/AEFM1+&KQP7(*?:?*;8F2&_L=T4@:3I8
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M9&&RMPJ1%F\2\??\$8?^"='Q'^*WC7XX>)?@.\7Q9^(VH2ZIXW\=:!X]\?\
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M(/#FN:9#J-MI<G]HFTU>UTW4[=6G%Q;)<QVTEB+JV8&5A$]?K5X3\2:3XO\
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MX>#$#.2 =1!(&#DC@8.>E2GXG?#4!B?B'X& 498GQ9H "C.,L3J' SQD\9H
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MU @<\?7B@#N*C< DYX.TX/?KDX^F/;K7&/\ $SX;QC,GQ!\$(!U+^*]!4<G
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MMQ@^:,D_=MI?3\,OVL_@5_P4(_9.^%NE?&[X+_MT?M5?M/>(_!_Q'^';:_\
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MO#ZJH&[)8MJ   VMDDX&UL]#CZS^N_X]?4_#-M'NM'UU6CUZ^IW=%< /BO\
M"UBP'Q*\ $JSHP'C'PZ2KQ@F1& U'AD"L74X*@$L!@U(?BC\,E7<WQ%\"!2,
MACXN\/A2#C!R=0QCYEYS_$/44 =W17 K\5OA<Y*K\2? +, S$+XP\/$A5QN8
M@:B2 NY=Q/ W#/44Y_BI\,(@3)\1_ <8 R2_B_P\@ )(!);41@$@C)[@^AH
M[RBN=T3QAX2\3/<Q^'/%/ASQ!)9+&UXFB:WIFJO:+,2(FN5L+JX:!92K",RA
M Y!"YP:Z*@ HHHH **** (7^\?P_D*_);_@M\,_\$UOCH/75?A./IGXJ^#Q7
MZTO]X_A_(5^2W_!;X@?\$UOCIDX_XFOPG_\ 5J^#Z^GX#_Y+/A3_ +*C*O\
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ML*[8XRJ @_T:TQVVKGG[RYV@D@9R>!DG.,< XSDX4%@ ?YU/_!P!_P $2/\
M@GU^P1X7_82U']G#X=>*?#-[\<?VN/#WPG^(,VL>.M>\1)J?@G4=.%S=V%JF
MI2R#3[II'WI>VL;70$8C0HF\U_079_\ !J;_ ,$:;NQLKEO@=\0D>:UMYV5/
MC!XPX::"%V4EKLD@$EAO)(#$'-?JE^W'^P+^RI_P4#7X+>%?VD[74M6N?@C\
M2+7XN_#C3="\9R^&=2M_%EA;?9HKFZLK20SZK8-"L;- \)$9C5XV3S),_>5E
M%';V\=M%Q';)%;HI+$HD4,:QJ2Y+9$80Y8[FSO8*6*@ _A6O?^#5_P"%J?\
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MPR-XB#KJT$-N,V^TS"4(/[LP, #T 'K^M5@VP%SD!(\[5V@,J@,7&XDQ@XP
M[*#QN*\D '\P?Q:_X-9?^"/?A#X4?%#Q5HOP8^(,.M>&OAWXVU_1[EOBWXQE
M%MJFC>&M3U'3YS$;K$HBN[:%S$P(D"E&RK$'\6?^#>'_ ((;?\$]?^"A/[$7
MC'XS_M-?#KQEXK\?:1^T!\0O NGZEI?Q&\2^'K>#PQX>@T@:78MI^FW45M))
M$UW,TEQ*AF=C\I4.V[_0!\7Z5H'BWP]X@\#:_(K:?XP\/ZWX=U&R2Z6WOKS2
M-8TZYTW5$L@CBZ\QK.YF2.:WC=HI&60 E<5\A_L0?L,?LT?\$U?@[K/P;_9Z
MLM6\)?#?5?&NM>/=3'C/Q=-KDP\2^(!:QWSKJNK21"VMV@L[<PVN[:%!\OE'
M% 'XA?M ?\&IG_!,"W^!GQ>D^!GP2\=R_&D?#CQ<?A2EW\8O$Z6S>/DT6[?P
MO'/]OO19-%)JPM5D^UG[,(PYF(3)/RO_ ,$O?^#5S]EO6OV.? E]_P %(_@+
MXRTW]J^?7_&;>,;72_C#J?V:V\/KK]PG@V!4\,:G/HT++H,=O)+%:S2LL\LQ
MFD+M@?VA1W-O<PI/!+'-!+&'AFB=989HI<A9(98B\4H8#<I1_NL&8J&!J:+A
M2.0 > <' P.,Y.><GDMC. Q !H _D>_;1_X-4O\ @GW8?LJ_'2Y_8^^!GCFX
M_:<M_ &K2?!2&^^,.NQV4GCN-0=*6\;6;V/2WMV#2*XOY/()*JS#&Q>&_P""
M>/\ P:M_L6ZK^QY\&[W]O7X">,=,_:MGTK59_BI;Z5\9M:-K#>2ZW=/I\:KX
M=U&;1K>=-#^QQSPV#2^1<":-YV="Q_L9:/<2>!TQQR>.02<X![[0..N:4(1D
M@+G;CDL3G& I8Y.WID@9/7% '\,/_!5?_@U@^$FD>%/V<_\ AV5\ _%M_P")
MKSXZZ38_'U-9^,$XM[;X,7-E(NH7L;>*=1@MTDM]06%GDTUGOXH7+K"R*Y'Z
MI67_  :F_P#!'B6TL6U#X+?$0:@+2S%X1\9/&T@6[6T@^T*&>_+$/<"65-I\
MM.5C5/E%?TE>6<J21D>F0!Z8/+$$]<MQSCTI=AQC"_>SD$@C!R">I8^H) [9
MH _AE_X*(_\ !K%\)M,^,/[%$'[ _P !O&%_\*=4^+*6'[7]QJ?QCNWGT_X6
M?VEHTRWMHWB/4X;\O%IS^((G.AR7=\SK:1):YD1C^K+?\&I'_!&G<7C^"7Q$
M3!V#'QC\:@KDA<[UU"-V5%SN5V8L"%P2"I_I"V-Q@[<>AX);.XD%2 022!SD
M\$BD*,2<[2" .<G(XSN'3)/.X8QTP?O4 ?PG?"__ (-8/AJ?^"K/QFT;XB_L
M^>)S_P $Q8/AA)=?"K4Q\8YUUF7XARV>@)#:L;/41XL8PW8UZ0_;[5;*-(X6
M:>;SHXS^N"_\&HO_  1HW*Y^"?Q$8 @E3\7O%P#CU(6X  YSC Q_=Z"OZ00C
M ]L=2-S=0" .0V0<\G(^AQ4B@@ '&>^,X_#))_4T ?PE_LJ_\&LWPXO/^"BO
M[9>C_M*_L^>*[;]@33[&U_X90OH/C%.U_J%U=WEJ\KSOI&J-K\CV=LEWO36[
M6*.,R0^4TK%TB_7 ?\&I'_!&Q2K'X*?$5@&7(;XQ>,URI8 C<EYO&02 5(/.
M=P/-?T?B,@Y!X/WE))!(^Z>02#V(!48YP3G,K D8'!XY/U&>A'..GOUR.* /
MX9OV$O\ @UA^#^H_M0_MUV?[:_P#\8V_[..E?$I;/]B^\M/C'=?;-4^'S:SK
MCO>W@T75KK4Y&_LA=#4/XACM[Y'::,PAU8G[8_:D_P"#4S_@FW9_LX_&NX_9
MG^!_CJ;]H"+X>>(Y_A E]\8O$BV[^.XK%WT*WD&H7T.G&.YN-T#_ &^5;7YP
M9BJC<O\ 5\B%3DG)(QZ8Z8   7 QU !/>ED4L,# ]SU'(.1D,.WIGT93S0!_
M&1_P31_X-5_V1-8_8X^&5]_P40^ GC'3/VL+J[\33_$*TTOXP:I]FM;/^W[Y
M?#5OY?AK4KK18I!H2V+3QV<T@$SR%V=CNKN?V\/^#5;]@_2?V2?CC??L3? C
MQQJ/[4MIX1>?X-65]\7];-M-XI^W6H6*?^V]1MM*:-[/[3@7\JPAHSTW@'^O
MY%*@@G//')/'XYP2<YQQZ8I&5B20<=,>QZ%N003C@#@8[@T ?R!?L&_\&JW[
M"&J_L?? 2\_;8^ 7C+2_VJKCP:]Q\:[73/C#K@M(O%<NKZC)&@CT#47T1632
M6L5ECL9;F&*X:5'F,B,J?DE_P7L_X(J_L#?L(>(O^"=6F?LW^ /&/A:#]H7]
MJ70/A;\44OOB'XCUZ?6?!VH:IX9ADM+4ZA<2R:;>"._N5M[ZS(F24JX^=5-?
MZ+MU>V6GVTMQ>W-O9VMN%CFN;RYCMH(PX1</<W#QQH,LN"SDDJ0!NP#\)?ME
M_P#!//\ 9;_X*$W/P&UKX_Z3X@\2?\,^_$6T^*GPMN_"GBV]T>SM_%=C?:9?
M13WS:89(-8LFET:SAGMI&:W=#-:ESYA# 'Y:R_\ !J1_P1I:1B/@A\0D5E.V
M)?B_XS(13@?+F^)!)+#)&X22*RD",D?DM^W_ /\ !K!\,-._:3_8?M/V%O@)
MXKU#]GO5/'L]G^V)+J?QBNQ<Z=X)AUC1)8[NUD\0ZG#JD;2Z*NN0K_87VJZ^
MT);Q-!&TT;'^Y9=6TM]072FU'3EU0PI-_97V^W?4/+$?G"3[$)!=D+'N99!$
MR,BB<,0 &TA\YX(#%<@%FY"[>0<#(!?DM&"6./F'- '\X$G_  :D_P#!&G>S
MK\$OB&@,A("_&/QD!&N00%<WIDSR$4NX=3\P9%!)_)/X$?\ !K/\/9O^"HO[
M3FD_&?\ 9^\40?\ !-NS\*Q3?L[:K#\9[L:Q)XHN+'P\&\W[%J3>*9O(NAXC
M24:Q D**MLXGG69!7]UYC).<Y.  <E3P3QP&4+@G(VG)QTQFD\ILYW8R221Z
MGOAMV">^"H Z=3D _G%3_@U+_P""-R[0OP7^(ZJC8&WXQ^-$.W([K=J!QQD(
M,\D YR?RA_8U_P"#6CX;7?[='[<5G^UO\"_%=O\ L56%[9V?[&UQ:?&N\.K7
MUI<:RLMS/>G1M5?7G6WT>/RU.N10F.622)(F(1V_N= "C S@9ZG)Y.>IJ$18
M)Z8(((R0""3\I4 =2=VX$$'CD=0#^<8_\&I?_!&TX+?!CXD* 1NQ\9O&R[N>
MA(O3U/7CG.*_)K_@G=_P:O?"K4/C1^VI9_M[_ /Q5!\'=.^)Z:?^R%=Z?\9;
MK[5??#V'4M7EEOKF+P_J;7DGGZ>=&19=>M[>\5DN8O)+()6_ND.2"!C)'?./
MQQ@_J*8B,O<8[#KM7'W00%Z'G+;B02.,"@#^2[]KK_@U)_X)TVW[,GQQG_94
M^!_C>;]I"+X>:_+\%H=3^,OB&+3I/'\=MOT%+QM5N)-.%LUR LANP(0/]8RC
MYAYG_P $]O\ @U1_8WU#]D?X0W_[>'P4\;Z5^U>]CJD_Q1B\._&C53:1W<FK
MW?\ 9<8;0[R[T9&&E"V::.P=T!<PO(70E?['G!88! ZGGUQQCJ.O7(88SP:5
M00!DY; W'CD_@ /R SZ4X2G3E&=.<Z=2%6%:G5I3J4:U.K2E3G3G"M1K4JL9
M4YTJ<Z<HRIRISCS0FI-L-TXNSC+246KQDNTD]&NA_'E^WO\ \&IW[$]M^R/\
M:;G]B+X-_$'5/VK(- LI?@_!XE^-VLMILVO+K&G_ &H7G_"07BZ/(ATEM0,0
MU&6.,2+&@GB R.R_8_\ ^#5']@2?]E[X'M^UQ\%O'$?[23^ ]*;XT6VB_&WQ
M%+HW_":R":34H[,Z->PZ6UI"QB$*68\I93O#94E?ZV61B=RXSP<$D9(Q@;MK
M;5]<*<G%/4$ ;CDXY/'7\ /Y#Z4.=1RYW5G*;E*<YR49NI.;E.<ZBFIJ4YU)
MSJ2J2<JDJDYRE4DY-L3G&,H1J580J**JQA5J0]IR2@X<[A4B[0C%P4%>#C*\
MHN4:;C_"S_P4>_X-6_A)IWQ*_8TC_P""?GP#\6:C\/\ 4OC!;:=^UE+JOQBG
M$FG_  H:]TDWUY:/XCU.VNH9&LAJD(;0S+=^:(P(<.\T7ZQ2?\&I7_!&MY7G
M7X(_$%0TDDFP_%_QD\89I/NX:\)*;LNHY(5BJC<0*_H_:-F/4#( )!.2/[K9
M!!QR0PP3P,+UJ0@A<+C(QC.<<$=<<\^O//.#TI ?PG?MJ?\ !K+\-;']MK]B
M'3/V/?@!XOO/V.]3UDP_MC7NH?&:Z-]9Z)#K=LP>WDUO4XM;1I-%%PC_ -B"
MZFDE"((@6)7]:W_X-2/^"-)=W7X(_$) TLCA/^%P>-'4%G8HBO)>-*8\,,;W
M=1Y:X([_ -(/E-G((4GKC:<$@AOX 'SQDN,GVQRJQD9R%7*@ J22"K9!R0HQ
MWP%&,8R1T /X4/V@_P#@UD^&L'_!3K]E/2/@-^SUXJN/^"<]WX9>?]IC4+[X
MRS_;['Q!:'7$2"T.H:L/%23SQC0RJZ1;-!*ID9IHMH$OZW+_ ,&I'_!&@2*W
M_"D_B(5$BL(S\8/&6&"* JG-WEE7<6D/S$N27)?=7]'[\$AB6.%. K!!DL P
M('SE<8903C*%]JL&K/.KZ8NHII3:E8)JSQK,NF/>6PU)HCYCETL?--R495=M
M\<3QE(WP[>7B@#^,/_@VF^#O@/\ 9Y_X*7?\%HO@/\+;74-,^''PG^(6A>"O
M!&E:CJESK-QI_A_1O&'BBSL;>34KF1KBZEBC14N9Y<3N!#Y[[D.W^U2O@']F
MG_@G;^R]^R#\=/VF/VEOA!HWB+2/B1^U5XA/BOXS:MX@\5WFK:)<WZZI<ZQ-
M+I>G7A2UT*S%U?7-R88&,"),"&$(+5]VV&JZ=JENEWIMY;:A:2,$2ZL;FWO+
M5F) (6YMI98"5) *B0M\RX4[ER :-%%% !1110!"_P!X^YP/K@&OR3_X+@C/
M_!-7XYCUU;X3CM_T57P?ZX'Y\5^MDG4?[Q_] %?DI_P7 X_X)K?'+@G_ (F_
MPFX'M\5?!Y[\<XQSQGKQ7U' BMQKPGY\495^.*IGS7&'_)+\3>629A;_ ,(*
MQ_"!)P JGD Y'&"#R6.#V&XXX.>,#.#7RP_CQ_P&2K4NW>C%"ORD@#)R1@@8
M/0$X7//;C %0D,3GUYX<@?@-AQ],G'K7^@!_#KDV[M_G_F?:VH-FSNSC_EVN
M#USP8F/ P,$@<'T/3FO]!;X3'/PP^&)_O> /!A^F?#&G]/7[OMU]N?\ /HO\
M_P!GW?M;7'Y")Q[>N,CCUYXK_05^$>3\+OA>3U/P]\%$CL#_ ,(O8<#VK^>O
MI'33P7"7]W,L^C%]D\-@-/NZ^I^Z> E/DQG$M_B>%RJ'_;E/$X_DC\K[[OJV
M>E4445_+A_284444 %%%% !1110 4444 %%%% !7A?[3WQ/O?@G^SE\=?C!I
MEO#=ZG\,/A+\0/'>F6]PH:"74_#'A;5-7TY9U*MNA%[:P-,NTEX@Z#&[(]TK
MA?B=X"\/?%3X=^-_AEXM@DN?"WQ!\*>(/!?B*"&00S2:+XFTJ[T;41#.<B&=
M;:\D>"3#8F1!M8$BFK75]NH/;3<_SF?@A^R;XU_;(_X)"?M6?\%K/B;^U9^T
M_;?MU>#/&GCWX@_#WQ5H?Q5UO3/!_A72OA[J^CO#X6L_"]O,('TR]MKN>&%8
M[JR6P6VLTAMI8DNHKO\ MV_X(]_M*?$']KS_ ()J?LB_M"?%:ZAU#XD?$'X6
M6=QXSU2&-(1J^N:-J>I>'[C6)8HU6-+G5DTJ+4;L(JJ;JYF954,%'\X<7_!!
MK_@KY\(/@A\5O^"9?[.G[7O[/UM_P38^,WC34=8U7Q1XS\*:A_POCPMX.U_4
M[&_U_P +6J6MA-'<SZBEE:1736^H(MX;5_L]]H\%S-;R_P!9/[&/[+G@C]BK
M]ESX*?LL?#J[U#4O"'P5\$Z?X/TW5=5*'4M8GADFOM5UB^6("**XU75[V^OF
M@B'EVZSK!&=D8IOEMHG?_AO^"2N:^K5CZ=HHHJ2@HHHH **** "BBB@ HHHH
M **** "BBB@ KPO]HKQ7\9/!/P2^)/BS]GWX;:/\7OC5HOAJ^N_AQ\-=?\0?
M\(IH/BWQ6@6*QT[5O$?DSMI>FO</YEU=>47\B%XT,+2BXB]TJ,Q*Q)8L<G(&
M>%.%'RX (/RYSG<"S$$<8 /X+_V5?$'_  4/TK_@YH^#/@C_ (*#?&W0_&WQ
M6N_@-X@\5W7@3X0:IK-E\%/AUHWB3P7JFH:7X#\.Z'<BVM-231YE,E[K=U:W
M-Y?WZI.UZ\L:2/\ 4G[:GACQ#_P5;_X+_2_\$SOC3\6?B]X#_9 _9V_9LN/B
MU?\ @+X.^,[[P%>>./'-]9Z5+'J>OZM:QW'F^4?$]I##/+;7;0VEB]O:+;-?
M7$R?HAXB_P""6O[1FK_\%_O#'_!3NWUKX;)^SUH?P:MO ,^BSZQJ1^(;ZRGA
M#5-"D>VT<:<U@L+:A>QMYIU&,& .=C28!YS_ (*!_P#!*[]M,?MZZ%_P5$_X
M);_&+X7> /VF+[X;R_![XM?#WXZ:-/JWPY\<>$)888X-5L)[2VGFAU6W%I8F
M>QNC%YEQI]E-9:G8)!<V>H G?H?(O_! 3XF?&'X#_P#!1S_@IE_P2LU_XI^.
M?B[\ _V:[^P\6_ W4?B=KEWXE\8^#+675X-*N-#76[J1Y9=*O='U;3E>U.Q+
M6]TH2PD"YE0?U\QYP<GN,#.=HV+A>1Q@8S@D$DMQNVK^!/\ P1Q_X)+?&#]B
MKXD_M/\ [8W[8OQA\._&3]M7]L'5+6Y^(U[X&TM=,^'_ (-T&UU*ZU9="\/"
M6SLIKV[U'47MS>7<=EI]G:V&E:?8V\%S*+B^D_?A0 ,#''''; Z?@, 9YQC-
M UMKN.HHHH **** "BBB@ HHHH **** "BBB@ HHHH _G@_X*Q_\$X?CI^W'
M^T?\)_%7QG_:_M_@)_P2U^#O@S4/$7QU\ ^$_'>M_#'QEXHU^V.J7%_K/B'Q
M:BIH<.FB,:1I]I=7TQATK3;:?R;:XU&]#VWX@?\ !);XX?%CX#>+/^"R/Q?_
M &+?BE\:_BE_P2M_9M^!/Q8US]G?Q5\>]8U?Q?8Z]\;/!GA2YU'09O >I:]:
MPRW.D1:K;:C<ZE(MI;0WWA_^RKG5K>TN[WR(OU+_ ."]G_!.'_@J]_P4L\:>
M!OA7^S?\1O@AX/\ V-O"5AI'B#Q#X"\8^+?$F@W_ ,5?B+'>R7-Z?B+;Z+I-
MQ<:QX7TR""UT[1=!BU"&R7==WTJ"[N(I;7Z+_84_8[_X*76OPA^*O[('[>VB
M_L&>%OV-O%GP)\2_";PKX,_8Y\%:_P"!O$^BS>*M+N/#=U-:VK+!X8@@BTF\
MDU![Q]/EOKC6(X[R6:1C(C@'\MX_8V\9:C_P1)UC_@NF_P"UQ^U,?^"A'_"4
MI\84\<#XJZO%X-M]*7XJ6OAB;PG#X23;']D&E3SS02-?/812,NG#2?[-4PU_
M=3_P3&_:#\:?M6?L#?LI_M#?$5+1?'7Q1^#OACQ!XJDLE=+:\UTP-9:CJ44;
M'$*ZE-9B]:!1MAEFD57="N/Y?]1_X(0?\%E?^&;Y?^"5&F?ME_LZC_@FG-XU
M2_3QK<>"+J/X]Q_#^+Q0OB^/PE<6EKIR6]PXU2.WN9+>+58([NXCD+ZI'I3O
MI$O]>W[,/P!\%?LL_ #X1?L[?#IKN3P7\'/ >@^!-!N=0,1U"_M]%LX[:74+
MTP*D NK^X26]N$A41)+<LBGY.0#WFBBB@ HHHH **** "BBB@ HHHH ****
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M%[QI^QY^U%\'+[Q-J_PN^,/CJ[\=/X2\3V_AGQ5JECK7AW5+]8VM+JUUCP[
MQDAM+>:_TV]NM.NS<-';W47WQ^U1_P $%/&$G[,7_!/#P]^P]\?F\#?M1?\
M!,*WLIO@;\1?BSIL6L^&OB'.UU'K&NV'C*RM+6[CT6TU+7C=W.G16%C=6VDZ
M9?2Z48[F.*&X5W[!_P#P2:_;DUC_ (*)P_\ !4O_ (*G_&CX4>./CWX,\#7?
MP[^#_P +O@1HLNF^ O">FZAH]]H<FIZE>75I;3S&STW4]6FLK)6O)VU2]DO;
MO5)XDAM(V^7I^H*_5G]-%%%%2,**** (7/S ?[6?S7_ZU?DQ_P %O #_ ,$V
M/CEGD#5OA0<9QG_BZG@\8SZ>OMQ7ZS/]\?7_ -E-?DU_P6Y!/_!-GXY@<_\
M$U^%'_JU?!]?3\"M_P"N?";Z_P"M&5?^I=-'S/&/_)+<3?\ 8EQ__J#5/X17
M3G>XSA<* >%W<;MP!.0<D_+Z9JL8D))+KR<\-@<^GR'BM0J,;?F Y! 7U^JG
MOS_/--V)Z@>VV/C\TS^=?Z _U_6I_$?)'M^+/K^_P-/N^?\ EUGQ]3$W^/Z^
ME?Z"GPDX^%_PO4=!\/?!6.__ #+%B/Z5_GW7J$V%W@E?]&N!@DYQY+XYY(/U
MYXQTYK_02^$HQ\,?AB/3X?>"O3_H6+(=N/RK^=?I$R3P7"FG_,SS[_U&P&I^
MZ>!+;QO$F_\  RU?^7.8:_>>DT445_,)_1P4444 %%%% !1110 4444 %%%%
M !2$ XSV.>I'YXZCV.1[4M% ##&C#!12,$$$#!4YRI'0J<Y*G()YQFG  # &
M!Z?Y[#H!T X' I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(!!!
M ((P0>00>H([@T44 -VKS@8SDG!/4]^O!XX(Z=L9I#&A&"B],= ..>..V&88
MZ$,PZ$Y?10 U451A0 ..GL HSZX '7/0'J*4 *, 8'^)R?S/)I:* "BBB@ H
MHHH **^!_P#@IU^V;JG_  3[_8C^-W[7&C^ [+XF7_PBTG1M3B\$ZAKDOART
MUH:KXCTG0I$DU>"RU&>U^S)J370\FSG:3R2A4*6=/R0\(_\ !6'_ (+*ZW\)
M? '[1J_\$5+;QK\#O'7@[PS\3+"\^$W[5W@KQE\1]0^'_BK2K;Q#I^KZ)\/E
MTR/7+S4[C1;N*[@T&6T2^1I8X)XX3D  _IGHK\_/^">G_!1S]G;_ (*4? Z7
MXV? K4-;TA_#>M7/A+XJ?#3QU9+H/Q$^$'CC3D#:EX1\=:,TSQVEW /](M=1
MM)KC3+^V25H)]\=S%']A^'OB?\-_%FIW.@^%?B)X'\4:]9JSWFC^'?%WA[6M
M5M(XR0\EUI^G:C-=P1H=WF-) A0G!'RT >@45RNC>+?"WB.[UG3/#_B?P]KF
MH^&[M;#Q!8:+KNFZI?:#>RHSK8ZW:V4]Q+I5TZHS)#?+#,ZJ^T#!-(WC#PHW
MB&\\)KXM\-CQ3IVFIK&H^&AKNF'Q#I^C-AEU:]T<7!U&UTV167;?7%M%:-N7
M;-EE! .KHKS_ ,._%'X:>+=3N-'\*_$;P)XFU:U:1;O2O#_B[P_K.HVS(P65
M)K+3-2NKJ%HFPL@EB4H2 V"37?*<D]1CY<<=NXP3U!QSSD$4 .HHHH C,4;$
MLRABP(.[+ J0%*X)(V$#)3&W=EL;B25,:$Y(YSD\GD]MW/S;?X,YV<;-N!3Z
M* &>6@  50%QA0,*-I!7Y1Q\I *Y'RGE<&E"*"6"@,0%+8^8JN2%+=< EB!G
M&68]6)+J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K(C@AU5@5*D,
MH8%6QN4Y!^5L#(Z' ST%)Y:\\$9!!*LRG!!&,J0<#)V?W#RFTT^B@!A1#U&0
M>H))4XQC*D[3C:,$CC'N<J$4'(4 C)SWY))_]"/TR0.*=10 4444 %%%% $#
M_?'U_P#937Y,_P#!;MMG_!-CXYG_ *BOPG'0'_FJO@_L01[\@U^LS_?'U_\
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M:=X.FL+F6R6.PUR'0/#VK7%]+::X\T7U'_P59^'7[<W_  5?M+3_ ()EQ?\
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M<D!LT 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $+_ 'OJ<?DN?\*_(S_@N1-%'_P30^.@D*_O=8^$
ML2 D#,G_  M?P<P !ZL C' YP"1TK]<W!)&/[QYQP,J .O'^<]*_!3_@X3^)
M6F>&OV+?#7PQDG']N_%OXM^&H+&U5R"=+\!PW'BC6;N5%'S6]K>1Z)#)N( F
MO+<<LZJ/KO#VBZ_''"E."<W'B7+*LU%7<*=/$1JSG+JHQA"4Y2VC&,FW9,^4
MXUJJCPCQ-5DU&^38Z,>9VYI2PLZ4(KNY3DHQ2U<FDD[G\66_N1QU(R>N.<<^
MV!VP!BCS%_NR?K_\53_(F+A/E4,<;B0=H(Z]><=!QR<<#/$16125\X<$CA6Q
MP<>M?WY[5::Q^\_B=T*G\T?P/N@R9!P".HSD]#WYX)P2>1]<#K^]/_!&/]L3
M3O!6N:G^RW\1-;BL-$\4:@=;^$U[?L%M;7Q'=&<:WX7^V$JL9U9EAO=/$IR]
M\UQ;Y4SQ*?P3( ^]]WN>=V O/3'4 _GTS4EM<7-I<V]W:7,UI?6]U!>6=_9R
M-;7EG=P2*T-Y:7$3(]M<PR*DL4T)#1RQAP<BOGN*^&L)Q?DF,R3%<M&-97PV
M*<>=X7%T(RE0QJ@O><JM1152*M+E<HS=G=>]PUQ!B.%\XPV;8>+JNE"-*MAU
M)0]OAN9*K1YG[J]I#FBF]$[2Z(_T3TDW9 5E*@-@CC!)4#GG/7)  QCKD$3C
M'7N0":_FM_8H_P""RT?AO3-.^'/[5ZW^H0VHL=.T?XNZ9;/>WGV=/W$R^.--
MB074@L\P;=8MEE9H/-DNT<D./WT^'/QW^#?Q8L(]5^&WQ0\"^,[.X6-XFT+Q
M)IUU<!&W[3+I_GK?P;MKA!+;INV-MR5;'\/<2<&<0<+XNIALSP&(E3A5FJ6/
MH4JE7"5J3;5.;K4XRC3YU9*G5<)J;4=6KO\ K_(.*\CXBP].OE^-H0J3I0<\
M#5J0AB:=5I.I%4YRC.HH:WG34HV7,[)L]?HJ-'+<XX[$ \],<D=_R]Z:7?/
M7'^\?PZ#!]^:^6YDG9W7FTTO2]GKY'TWS7WK_/\ JZ)J*A\Q_1?S/^%*7;L5
M_)O;^F?QQ1S)[:^FO^0_G%?-?\$EHJ+>?3/T!S^F?Y4\-G.58?4-_A3O\O7?
M[A?CYK5?@.HII8Y[ 8ZG(Y_''M3=S#LI]]X'Z8-*Z"Z[KT>_W$E%0^8_HOYD
M_P!*/,?^ZOX$G\N.?;UI<T?YH_?_ /:A]WWK_,FHJ'?)_<_1_P#XFEWO_= ^
MNX?S%"E%Z*4;^O\ ]J']?UJ2T5$'8]A^&3_6G;F[J?U']#5?CZ:O[M!V_K3_
M #'T4S<?[A_7_"DWD?P-^1/\EI7\FO7_ (<7R9)13-S<_*>G&<]?P%-W2?W!
M_P"/?X4<T>K2]=/T8?)DM%1;W'50/S_KBC>?0?K_ (TN>'\T?O\ _M0_KI_F
M2T5#YC>B_F:/,?T7\S_A3OV3?9I:/TV_(=O./WHFHJ'S']%_,_X4H=L\A<?4
M_P!1BB_D_N_X(M%KS1^]$M%,W^P_//\ (&@L1_"3] Q_]EHOY/[O^")-/8?1
M3 V03M.?3!_J* X[@CZ@_P"'_P!;WI<R\_N'_7]:CZ*B,ASP!CW)_P *-TG]
MT?\ CW^%5IW7WA_7]:DM%1[I.FU?S/\ /&*,R_W5_P"^J-.Z^\"2BH]SC[R?
M3;D_G@&C<WI@>ZOGZ8QD_@,5+E%-IRC==+__ &OZAUM9^MM/ON245%O/M^3#
M]#@TNY^R@_@?_KT<T?YH_?\ _:C2OV^]$E%0^8_HOYG_  I=Y]!^O^-'/#^>
M/W__ &H6\U]Z_P R6BHMY]A^?],TN\^J_DW^%'/!:<R_%_\ MHOZW7^9)14>
M\^J_DU'F>V?QQ_2A2B]G?TOI]Z07_K^F-\L@8!_B+<DX'?[J[0?]T_+G#8SD
MF:H]_M^O_P!:G;CZ?^A?_$T[^3^[_@B33_X9CJ*;N/I_Z%_\32;Q[?F?_B:+
M^3^[_@A=#Z*9O^F/7/\ 0@&EW+Z_SHOZ_P!?,+KN.HJ/<?3_ ,=<_J%YHW-W
M7]#3NNZ'8DHI@?/ '/H?\GIS_A2[F_NG\\?S I<RO;_AOO"]^_W#J*CW/GD+
M[_-S^M*6;LOX\L/_ !T'GV_QH;2W:7G?3\G^0K_/TU'T4S+>WY/_ (49;T'Y
M-_A2YH_S+[W_ )%68^BF;FQGC\F'\Q_.F[V]!^M'/'^:/W_\ +>GS:7ZDM%0
M^8W<+^I_PI=Y]!^O^-'-'^9?>_\ Y$+>:_\  H_YDM%1;W[*"/Q_^O1ND_N#
M_P >_P *.>'\\?O_ /M0L_Z_X<EHIF6]OR;_  H+,.>/R;^N*.>/\R_'_(+,
M?146\^@_7_&C>?0?K_C1S1_FC]__ -J%O-?>O\R6BHMY]!^O^-+N;&<#\F_H
M#G_(^AS1_FC]_P#]J%O1^C3_ "9)1499\< '\&'\Q1N;_9_,?_%4TXO:2^^W
MYI!;T7JTOS9)14>]O]G\Q_C2;SZ#]?\ &ARBMY1^_P#X#"WFO_ E_F2T55FN
MD@0R3-'%&H)>65UBB0#&2\DC*B]>[#-?)_QV_;N_9._9OTS4]1^+'QR^'^AW
M>F0R2?\ "+V/B#3]<\9W]RBL8]-T[PQI-Q<ZG/J5U(IAM;9X8O,DZNB!F'7@
M\!CLQK4\/E^!QF/K57:%/!X7$8EMWM9NE2E"&K_Y>3IZ:WY4Y+DQ>.P6 I3K
M8W&87!TJ<7*=3$XBC1BHI-M^_43:LGM'II?2_P!1:MJ^GZ/8ZAJ>J7<6G:9I
MEG=7^I:E>2)!9V-A96[W5W=W$TA"16\$$;O+*Y5$P Q&X5_!3_P5D_;5A_;*
M_:8NKOPEJLUU\&_A1;7G@WX:)AX+?59KB:WD\5>)RF69FUO4K2WMX)G(WZ;I
MM@(]H+JWM'_!1_\ X+(_$']KNRU7X1?!FUUWX4_ >_9+77$GN?L7CKXB6T,@
M>XM==EM#C1M D=$,WA])_.OD_=WDCJ"M?BA&%"KM1$5%150 CR]CAD3!Z)%R
MJQ'@#'.5!/\ 4GA3X9XGARI+B'B&$?[4K4W2PF6^Y*I@,+4A'VBJU(N5..-J
MW2TDY8>*G2G+G<C^=/$?CW#9]".29.Y5<MI5%5KX^G/DCC,3&4O9RA%\LYX2
MDO+EQ#<:D(N'*3,['.W&"-N3U(/4C XSQ@^WH<5&4A)R5?)Y/7J>O3C\N*B+
ME@%& ",XSR1V![\].."3R>Q;L_Z9M_G\:_<C\BY8]OZ^\^WWY4CU#?\ H+5.
M"LBJH4#8&5PP#!\EU.0?4 @YYP2003P45W4^G^)+\3S)[KT_5D.2<A&954!U
M!9F"X ! 5F(Y!QUZ #IU(KB6SEFEL99]/NY51)+S3YYK"[8<$?Z7:O%=+M_A
M42A$RVQ1N;)16T(QQ%>-&LHSI^\N64*;M:+DM94Y]4NC^6ZY:Z5"E4KTKPJ1
M=-IJ=1+WFD](U*?1]U]VAKIXT\=01;8OB!\08D3:%CB\>^,(XU&% "H-:PO&
M.F!GMZB^.?'[<_\ "Q/B,,*Q&/B%XTZ@\<#70  3D8'7FBBGBLOPE*$9PH4N
M:4W%N5'#35N64MI8-I:I:[]+V)>9XV_+[:5DE;WZWIO]:U'KX^\?;(R?B)\1
M_FR#_P 7"\:'HV.^O8Z>Q!YZ<"K:>.?'J<_\+"^(9PI<_P#%>^,>PS_T'/;'
MI1165'+\'6YG4H4O=M;EHX:&]V[\F#5]NOZB_M+&7_C3V_GK?_-1(OCOQ\T@
M ^(7Q$SY88G_ (3_ ,9+W /*ZX#^&0.U*_CGQZ&53\0OB(W!)W^/_&3#&#C&
M[7#@\'/X<]:**ZH9/ES5WAJ;=^M.@^B_ZA3EQ&;YA!6CB*B22:M.MN[W_P"8
MKR1!/XX\>!01\0/B$.#T\?>,1R QSQK6.WI^/-9,GCKQ\0Y/Q#^(PVDK\OQ"
M\:#N!T&N =_;W%%%;+(LJ:3>#HW:_P"?=#_YE-\'F>-J04IUIR=EJYUNLG_U
M%?U9#(_&WC[&[_A8GQ'(/3/Q$\;#CWQKM/'C;Q_O4#XB?$;!( S\0_&I^8D\
MD_VX#CCI117*\OP2;BL)A;)M*^$P;=DVEJ\%=NR6N_7<N698Q.5JTU;FM[]?
M2W-;_F*\D6F\<^/P@0_$7XC'S/\ JH7C7&1ALG_B>\' QD#FG+XZ\?A6_P"+
MB?$;^(G'Q#\:C) #=?[=SC!]LGK112CEN!G)1>%P]I.SMAL(G;R:P5UMNCGA
MF^82G&,L1-INS3G6U5F_^@KR*DGCOX@X./B+\1QAL#_BX?C7@;@N/^0Y^7MZ
MFJ;^/OB"'*GXB?$<G@#_ (N'XU[C/_0<]_3^5%%:_P!B9:M5AJ:>NJIT$]GV
MPAWPS/&)?Q7V^*MY?]112D^('Q!(S_PL3XC_ 'AT^(GC88.".!_;OH#^?KS5
M67QW\02<'XC?$@D[AD_$7QO@< \#^WN!@XQS^74HI+)LM;5\-3DNTH47TCWP
MOFR:N:XY1O&M*+[J==?^[9;A\:^/E6-S\1?B0PD^91_PL3QMP.,!O^)]@\<>
M_?MC$G\=?$ 2''Q%^) +L<_\7$\;8X7=U_M_(SG'TZ445M6RK+Z,8JGA,.E*
M-WS8?"SU3Y='/!R:TZ+2^MKGG?VUF7O?[54T[U*_;_L*&_\ "=?$$9*_$;XD
M=<<_$7QOT.3@_P#$_.>@Z8Z4?\)U\0F#;OB-\2/E&0/^%B^-\<Y_ZCW?;117
MBRP]"+M&AAXK32.&PB7K98+<ZJ>:8V45*5>;;OKSUNCLO^8KL$?CGXA*3GXD
M?$D90GCXB>-^QP?^8^/P'/UI6\>_$+:<_$?XD] /^2B^-\=@./[?],#_ #BB
MBNZGE>!J4X3E0AS3BI2M3H15W?9+"I+T6A;S+&?\_I=/MUNW_840_P#">?$#
M(_XN-\2<<9_XN+XW_'_F/]_P^E-_X3KX@_-)_P +(^)1.X#!^(OC?!R5Z_\
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M8SZ>]%%<<L-0N_W-#YX;"/HG_P! 1U?VABKV]I+?^>MV_P"PHI/\1/B'@_\
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FNV_\OR7R ;1)G!) W9)R?E)&!Z?,,]N./7,WGC^Z?S%%%!V'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %% HH# 2(  A$! Q$!_\0
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M^8GU=C[$ !0?J?Y<]QG=VDPW ;!8J6"Y)X!'T!('X]/PQ&))'8!1COU)Z_\
M?(J#7V:YO::7LE:ZZ)J]M^HQ01G/KQ]  ,_I2DD<C.0,\<D^V.^?3O\ E03@
MXP3]!G_/2DW9[-Z=/_KTW=ZFC4I/FL]==/\ A_(D\QNX7\"<_AQU]/>D+,_R
M@8!Q\HZ\<Y+#[HX_+@<G%0B1CC"9!YX8$X[G&,\=^G-7((S(3\IP3U.-H&!]
MXY&,<X4XR2,<D57.VK6Z6ZBY9=F"2.@7YO[N<$X'&W/'TQ^8S@C&C#%UDE)V
M@KM.,9P?X,CE<D#('?I@DAHAMX/FD_>R9 !R% !SGY3P>@YQSGM@&G-,\FT%
MHQN95W#.5C9E61U /\"LS8^\Q 4 YJ4DVHNWO-1]YI0]YI?O9/2-+_G[-Z1A
M>3T-8MPBY.\>12G>*O-<MG>E'5RJ[>RBM93:2U9[E^S_ / #XG?M-?$G2_A=
M\*]*6ZU6\C-YK&MWCR6_A_PAH"2*EWXB\1W48#?8H6(MK73HS/>:K=R):V41
ME)W?T&?#[_@B'^SYI>CVJ?$OQY\2?''B%X%.H76AZC9>$-%BN6&7BT^RAL[V
M]$$3?+ UW<33X4M(RYVH_P#X(B?#O2-+_9T\:?%'[/'/XC\=_$?6-#O+TQQB
M>'1O!UM9V=I812'#"!KN]O+EH\J'=B^,A#7[71QG8N2=V,L06V[B26P2Q;&2
M=N02!@'IFOXZ\5?%GBJ'$^:9!D.:8[)<!D>(GEM>>#J>PQ.,QE)+V\JU1TJS
M]E0<E2P\5"-J?+-S;FDOZ[\+O"OAN?#>7YYGN6X3-L=G-*./H0Q--UJ."PE3
M6E"G&-6C:O7M[;$-RE:7-!1]UL_([_ARQ^QH5QYGQ= Z'_BX1;/ITT?KGZ<X
M.>*0?\$5/V,O[WQ?_'XA@#\3_8XQQ^9P.]?KKY9&.>X_B;_$4RZNK2QMKF]O
M9[>SLK.WFN[N\NI8K>UM;:WC:6XN+FXF9(8(((D>6::5TCBC1G=E521^5KQ&
MX_M;_7'B-I;6S&6GW4J*_"7JMC]1_P"(=\"W;_U2R.3=M98%W6EM.:K6_!Q\
M[[K\CC_P14_8R]?B\/I\0P?_ '$'CKSZX'>E7_@BK^QF,X/Q=/0_-\0E_3.C
M_GCVS7ZC7/Q#^']E#X0N+WQMX0L[?X@W=I8> I[OQ'HUM#XVOK^P?5+"S\)2
M37B)XCN[W38Y+^TM](-Y-<6:/<Q(T*EZZ[S(^1QE>HQS]XKQQS\P(]00<T?\
M1%X^_P"BPXD_\.,_\P_XAWP+:W^J&0?^$*_K\3\C_P#ARW^QMP0WQ;&#CGQ_
MD]^F-'/R\\8X]^U/'_!%_P#8X'S!_BSS_P!3YG&..^C$_P#?7U%?K<,/RA('
M X&.< ^W." ?0C!Y%+M/]\_K_C3_ .(A<>O7_7+B%-]\PJW^?NM?<REX><#6
M5N%<CBNRP.B\E_74_),?\$7_ -CKJ)?BSTX_XK]1U'_8'R,=N.*J2?\ !%+]
MC.0DR2?%QBW7_BX6??\ Z Y& >F1U]S7Z[E2.=Y  R>OX]Z82!G+MD$+C!SD
M].,]#S@].,]!2_XB)Q]M_KEQ%_X<*G^0_P#B'G __1+Y)T_Y@3\AC_P1-_8N
M_O?%X?3X@C_Y24X?\$4OV,4 "M\7OK_PL(@\>NW1/?V]J_7?<,9#EAC.5^;@
MC(X#9&0>,CGMUI5._.UVX[X..X]>H((/I^(H_P"(A<>7L^-.(+OH\QK:_+E*
M7A_P0_\ FE\C=M[8%:'Y#G_@BG^QBW!;XO'_ +J$W_RCI%_X(H_L8I@J_P 7
M02>_Q";U[D:,/7J0/KQFOU[VG^^?U_QI"'[$GWS_ /7I_P#$0N//^BRX@_\
M#A5_6*$_#_@?_HELDW_Z 6S\E!_P1@_8Y  \SXM$  <^/SD@ #K_ &/UX_\
MUTT?\$7OV.!SO^+1QV_X3[/MT_L?FOUI#DG W$Y([_PG!.,YQG(!Z$@XIGGC
M.W,G7 (1RI//1@,'&#G&=IX;&:3\0^.TFWQEQ DDVV\QJ[).3>W1)M]DA?\
M$/\ @;_HELC_ /"'I=1VO>UY16B>LEM<_):3_@BW^QLP(+?%O!.<)\0"O3..
M5T8DC]#UJO\ \.5/V,>N?BZ<^OQ#<XQZ?\27(SS_ $]OUT20.P4%^0Q4X(!V
MDAL$\'!!SCL5/<5-M_VF_.C_ (B+QZDN7C'B)II23CF-2S35TU?NK/[AKP_X
M'Z<+9'\L$GNO)O\ KH?CMJ7_  1._8^GM)HM/O\ XOZ9<R1NL5ZGC:*_,#D!
M5?[-=:-Y<A4G<@P%R"9&VD _C9^W'_P3-^(?[(]LWQ \-:Q+\2?@L]W:6MUX
MDEL%MO$?@FXN'C2T7QGIMLD]K-IEW<R"TAU_3%>T-TT,.K6]J#%*_P#8M(64
MX +\+P6Q@$L"<^V < ')%<+\1_ 6A?$[P/XO^'OBBRCU#P_XV\.ZGX;U:WG"
M/NM-2LY;831JRNHN+1Y5NK6;*O!=1QS1G<BX^AX8\7^,\FS? ULQSC%YUE<<
M2OKV7YI4>(4J.*E"EB,5AL0US4,3"G=IQ;]Z$4X^\F?/\3>%/">;95BZ67Y5
MA\GS-T5/!8_+Z?LZJJX13K8?#3IW=L-.:LXV3O)R333O_GXAR(G10ZEAN(<@
ML"1SN8,P)!&&.]\D%BY!W,D<@)!7)!.W(R01@<CMCH > ,DCC)I#:O923V$L
MQF?3;R\TZ6=E :9M.N9+!YBJ;E#2RPM)M!P"0%^3#4_A6(5RT?.,C!P,X!S@
M@$=3[]/XA_=,)P=*$X)J-:E"I!.2DXPJTJ=2"<EI)QA5A%M?$XR?4_BZK"K"
MI5IU*D7*%6K3J-25I3A5JTYM?XIPFU_B0,2KEMIZC' QDH!C.?\ )XJW$XVJ
M1D ,"2> H;DY/09#@<GMP, U"1N.QAZ9Q\P&2,<C&<G&0.QSFIU3DI_#]]C]
M"<<8P<=!Z8!(/2I,O9<J;MMYWWT_4PKLL;J8L-IRO'M@X_/K5*49'('!ZGN"
M,$>O.>>HXSU&*MW,@DN)7'(+!1USP/3KW]^!40C9CUX)QCCG'49YQT)Z=L#M
M4S;25E=MVV;Z/MMZG;!-J]U%7O=NR:MLF]WK=+5M+R(XOE'!P &&.Q ;(QTX
MP<@^E:]LFQ#*W+*I56&3C!()STVC))/W1P,\"H8;=<9('3/'?=GH 02.%[\@
M$^@K7B15A)QD#<H'H22!U]>GH,=*A4]+[-K73[CIC7C&+45K;WGT=MOU_P B
MIRV<'J#EB2%4$')SU)QSGOSR35:=2D;")ADD;B#\IR. "<#..2.W/![:;G:N
M !\V!C ^[D G\ ?KUYYXHRN5^4 =<G.,8&#@''7D $^_' S<*5]W%N_FM-.A
M"Q%2S:DDK]7;].WIZ&>BLADD+!I-A5 ""0Q&0<#D #Y><CL.HJ@T:E3(1\ZM
M@YD'S,>&(C)R0#P"%(R.G7.A.R"3*KN7 W*",;CSG=@#&.,''?CIG.?YV89.
M6)(;D *3D>HX!"MCIR<XZW['R7WLRE5YFV_>;ZIII[+1_(A;[S #."OW>F-J
M@=^A[4Q $Q@'GG)XW;>PSR?0#U/'&2)RI4,HP<IM!'4X&0??!! ((]>E)("N
MT?+P0!@Y^4@_4?P@_A4NG&S^&Z3TYGND]+=[K8I=_1_D^P1R-R2#D'IC^%L\
M'V!'7V'O6C'P>2REL] 23M)P  "3QECQZ=JS%!PQ&.< 9.,[6.[/IQG\*M0R
M;W!!(Y//(.=I]>!U'3KZ5AL:*;;2LM2]MW#<'9L XW# /3(!('H.1T.,U"[H
MHRW<80D#CKD\CH<8]\'@@&K$9&,=-I.,G@ACG(S^1Z]!ZU7$0:0$GD#']Y05
M48QR.QZ^O![4&@BADARY'G%@QY'RECC)Z8R.<YXR.>>:<\F#@\[<-@J" @'(
MP?E?(X(;Y6)((QG%N9S@Y'#$L0,<C@*,#'!)&>G3/KC'NS($*H,RS%8$898B
M2<^7&<#ECO=<J..,<5<5RJI)W7[JHIJ6D)T5"56K"3?6:HI1[NYG)<\J:C9N
M-6DX<NLXUIU84*4XK=J,JSN]DW'NC]&/V%_^";?Q3_;/N9O$TVH-\-O@MI%X
M^GW_ ,0;NQ_M#4M?U*T>W%WHW@_3))+8ZE<01DIJ.N:A(^EV-R#; 7%U$+<_
MN'H__!#']C>SL8+?6-8^,NN7\<,:3:B?&MGI?VAD!!D-M9:"L*LQ8G8S2&(?
M+&55FW?J1\%?A7H'P4^%7PZ^$_A6RBLM$\!^%-*\/P)$D<7VBYL[-/[1U.XC
MC)1KW5-2:YO[QDD=);B\EE$A"J*]6V-Z?R'Z9/\ .OX?XK\7N,<[S7&U<LS7
M%Y+EBKRIX/!9=B50I^PHRE2I5ZK="M*5:M"G&4GS)<GLU&-HWE_8?"_A5PIE
M.682GF6683.,Q]C"IBL9F&%]K65:O&-:I1IWM:C2E4DE%IM5/:7U=E^/"?\
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M/_%B/&;," !'_M*QC:1#PDB%F8_I#7YP_M@?\G9_\$S_ /LNWQC_ /5"^-*
M/T>HJ,N0 2!^O0>W^>AIKRX*@#(8XR,>A/<CT[9(QR,9(3DDE)[/K9V^;MI_
MV]RAVT>O_!WVMMU:)J*K).S<E !P0=PY4@^I!#9!&,$8*G)W8"F?E0H4EC@?
M,I'7 SAL@$X4$*1N(!ZT_37;5--*_1M-Z^0DT^J79.44WZ+F;:\TBQ14/F'
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MOQ7/@..3Q[>&"ZF;PTGB*25_#;1C^Q#:RJ)T^E?^"Q'[*7P$_9<_X)I_L%_
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M^E7%@XY)3!X4$#@XR>0?<_7@>M,TBN5-;Z_I82.*(8*/@D;<,,_,<$@9QCG
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M^#?B]XK\?:7KWB74_B?X2UVQ\;3:_P"'Y?&?BD^ ?"_BGXF66DZ!<_%#Q?\
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M[68YY!RV?6?V-/\ DT_]F@;3@_ [X?$#ON/AV(9"_,V#@$*+@';C]Z@5O/\
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M;S4%GFNKR_:4W#.!;F.VFT+]5OV:M*TW1_\ @@E^W%H6EV%MI^BZ7IW_  4
MT[3M)MHQ'8V&GV_B'QS'!86MN J06D$?[N*WC5(HT^5$5>!^W9-F]//<TEE$
M:=7#\F+PN'J5VZ<[1JXO#8>4H03AS?[PI6G.*]QZJZ.7Q(\%LT\->%.&^*\;
MGF S.AQ*J#PV#PM#'4JF&5?*<-F\/;3Q/[J7+3Q,:,_97_>1E*/N-'[;/^W+
M^QIA7'[6'[.3*>5S\9? 8# 9R6;^V\)R,%C\JJ2Y^5>?A_\ X+->(=#\6?\
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MO]*GZ*C_ .JSX7_];_A]?H?S?_#C_DNO[*O_ &=S^R=_ZO'P97^F"GW1^/\
M,U_F??#C_DNO[*O_ &=S^R=_ZO'P97^F"GW1^/\ ,U_9/T;O^2'S3_L>U_\
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M>#E10J@H%2,1H%4A(P%2/="D5=E_P=CXQ_P3?_[&W]J/_P!5W\.?_K5_H']
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M+J_RQRK_ )1%\"/^Q=@O_369G^O?T#O^4V_I'?\ 9 8C_P!:W(#^O7_@W?\
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M\4Z?JGB"^N-53PD7\)Z'#XBUBY6YAT]]5\A].F"K#-IZLS"7]SM&X_?VJ_\
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M -G _#C_ -4AXTK_ ).OH(_\F8\?O^PVA_ZP>./]H_$__E*GZ*?_ &6?"_\
MZ\#(#^;_ .''_)=?V5?^SN?V3O\ U>/@RO\ 3!3[H_'^9K_,^^''_)=?V5?^
MSN?V3O\ U>/@RO\ 3!3[H_'^9K^R/HW?\D/FG_8]K_\ J%AR_P!K3_RD-P;_
M -FIRS_UI>(AU,D^Z?HW_H+4^HY?N'\?Y&OZ)E\,O\,O_26?Y;/IZQ_]*B?S
M*?\ !R",^%_V0<<_\5?\9#_Y;7@>OY<%&Y@,%E"@\#/S;B%Y'<@G S[^]?U)
M?\''J[O"W[( SC_BK_C%_P"HUX(XK^7N-%3))Z<]@,X(SCZ9X'?FO[>\&/\
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M8[&\Q\%R[',SR*6*R37CA[RXZ_\ X.Q^G_!-_P#[&W]J/_U7?PXKD/VNCCX
M?%#=N&9/"1 "L S+\3/!X_BX9E)*L%8M%CRY%0H177_\'8_3_@F__P!C;^U)
M_P"J[^'-?Z!_0#_Y2.\$_/Q1R+_U#Q)Q?M"$E+!--M_\0RSB-]=EGL-+=UWZ
MGXU?\$/?^4MG['O_ %V^,7_JHM:K^@S]K+_E)3^V;_V*_P"RY_ZK;7:_GS_X
M(>_\I;/V/?\ KM\8O_51:U7]!G[67_*2G]LW_L5_V7/_ %6VNUX7^D-?\E%X
ME?\ 8K\ /_4L_+/V>O\ R<#A#UXX_P#53$^@?^"37_)[7[8?_9NW[,G_ *E?
MQGK^4_6/^2A_&?\ [.#^/G_JVO%U?U8?\$FO^3VOVP_^S=OV9/\ U*_C/7\I
M^L?\E#^,_P#V<'\?/_5M>+J_RQRK_E$7P(_[%V"_]-9F?Z]?0._Y3;^D=_V0
M&(_]:W(#^O7_ (-W_P#E']/_ -G.?M1_^K5U6OW>K\(?^#=__E']/_V<Y^U'
M_P"K5U6OW>K^\>%_^29X<_[$&3?^JS!G^1_C5_R>;Q>_[.GXB?\ K8Y^,?I^
M/\@358?>'OC_ -%(*M-T_/\ ]!:JW\2_0?\ HM*]F?POU7_IZF?F+Z^LO_3,
MF?YW6L-C6=?48_Y&;723SP3KU^?\0?KP>,'+52&+9&/G 'U8'],5?UC(UWQ$
M>2!XFU[ ]O[?U#'TR ,'TQGFJ8Z?BW\S7^FF&]W"X-+;ZC@G\W@\%_F?YTXG
M3%8MK_H+Q7XXO%-DJD>6"1G:.?\ @!Z_ID5)'(K#!.$& 3P">-H&#U(#')Z$
M8 YZ47D5#R3NX) [<$]NQ'J#D=>G"QN",Q[@%Z @]23C .0V3D'KS@#&..@4
M7=)O^M31*[A@'@8*$Y^[D]1@=26'!Z8/%0S2B"-SD95&8G(!.U)&).2<?,H&
M!R-RX^7D2HX PQY[DC R"0/897;QTP,]S3)@-K!L['W!@< 9951N2#PR*%VG
M(!RP!.11S*%Y/7EY96M?F4*E*<H+LYQ4HQENGJDWH$HN<906CG&<+WMRN<*D
M(S\U";C-Q^TM&?L=X,_99_9R\,>$6N?'_P ,S\1/$W@7_@G59_M>^+_MOQ"\
M<>$[+7_'?C/4)]9T70;JY\/7\,6AZ#H6AP?V)'/HMHDE\JRWVJQWM_)+-+XT
MO[*GP?\ VA/"G[.7Q7^#>C^//@+I'QFG^+'AOQ;X$MM#\:_M&)IFM_"S2$U5
MM?\ A^;2[TKQ3J^B>)I'CL%.N7BV>GWQ6Q%^ES/7D=S^W9\4](T#X4Q_#^VL
M?#GC/P7\ ;+]FKXAZ[XA\/>#_B%X=^)OPRT/59;SP?8W7AGQ1X?U*+3;K3=.
M<:9JIDDN$UA?-G&U)!".+B_;K_:I3X@Z+\2H?BC:6GB/PSX(UCX:Z#IUKX%\
M!6'@#2? 7B&6QGU[PM;?#:R\/P>!4TS5[O3-+O=0;^Q!=7=YI.E237+PV*V[
M_C^'X>\0:#KXZAF,,'C%5K2H8G'YQB)86K2C@LPPL<&LK>#Q6"5/$XVOA<?2
MQDZ].O@XT*%*E@\93]M3A^EU\]X)Q$*6&JY=B,70^KP5:A@<KI2Q,)O,<'B)
M5XYC]9I5XUZ&"C6PJP_U:=+%\]>5;%8-QA*?TKXM_P""8GQ+T+Q)XR\#^%/'
M=EXZ\;^%;WX+:O8^$D\$:SH.K:[\,OC3J-SH=C\0)K.[UZ\OM#F\$:]87NE^
M.?"UQ;7OV>WCM]3EUU9+RVMVQ_V4?@-\#O$/[<UW^RS\0M)TW]H'P'?:[XJ\
M"67C^SUSQ?\ #A(M4\%Z-J>I:IXHT#2_#FOW:ZC#>ZGIU[H"6^KZQ?6NH:7
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MA:<:%;"9=1P^:T::PV9U'@H.K"3FX:RE5PCJ2IPQ'QN$U^Q.G?!C]CWP\_[
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M ),M_8)_[.!^''_JD/&E?\G7T$?^3,>/W_8;0_\ 6#QQ_M'XG_\ *5/T4_\
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MJ,E\YW(C;%:0R.H/WWDY+ <!,@< *%48   Q5E@9,L!@8VD<;L^QZ="#GJ2
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M3=P>@R>""?4>G5U)ITJJ2:?LJCOINH/85&%YM-72:NI6LO>@DE;SUU/ZZ/\
M@BK\O[$MH!T7XL_$H#/HMWI@Y_$>U?KDGW1^/\S7Y&?\$5?^3)+7_LK/Q+_]
M+--K]<T^Z/Q_F:_SP\1G?Q XV??B?-&_5SPUV?Z$>'VG W""Z+(,!_Z9F?AA
M_P %[_'OB'PW^QH/!>E>.OAIX,T7XE^(#IOB.SU[XPS_  U^+?B]/#DNG^(M
M,\.?!#PLND:E8?&?7M1NK)[;Q'\,K_4_#C:UI]Q8I9Z]%+Q7UQ_P2P@71_\
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MT&ZCO+:+T+]H7QU\>M=_X* _L'>&?'/[/^D> _A7H'Q^^-4/@3XKVGQD\/\
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MIR?FSD*"P/'<9!(Z@\9Z5$VFE9]>C-8J5XNSM>][/[RVJ! 0.P8G''.%X'?
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MQJ)4_91_9H^8(!\"_A_N5_D*;/#,9DWAL'Y &9L_=&"0!R/)?&68_P#@W_\
MV9V)\O'Q*^ 9W,_DA=W[6L>QFE\R#R\EU(82IR5PQ!YTOAEX!_X*!_L_ZO\
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MUT/6KBXDL#/#I5XUN5% ??&]"2 RY 4D;AD!B54D9SAF5@IZ$@@9(-?G%^V
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MBS]GSQOX-\;:WIFF7%G\,ITAT_7PL5E8:A?+Y\%])(UQI\:QN%_M%^ /BO\
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MOKJ*3XA^.O".BZMJ?@?X>_%#Q+IWA/QGX?\ @E?P^"?B!#KVK6TVIVT_B_\
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M+QO\1?$-M8VUC<^*/&&L>5')JNK7=O:P6GVFY66[%A:V4$]U<SVQNY?I8#
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MP2DTKPMKVF:#8Q2-#X>TJ9M.N+?2M N9(K:+4['3K:TENM)BFT@7%M97DTC
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MZPVA"ZO-+\'Z- L,DVB>!_"RZ;X+\+'4K^#PWHFGP74V_P"@DB2/&,G P,X
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M.?QO\/>%_BM^T8+SQ3K_ (9\?'0=6^)7Q0^&7PQG\/Z5!:?"/P7\1O&^EO\
M%;7X5&E:GJ=KHCR6\'A[4/%>L^"?!NFZ/X6^S:4Z_L@_LB^&OV+?!7Q1_:4_
M:5\/_ ?PK\4GO?'?CS7H/V>_#OBD?!WX,>"KZ#P_>:_X/^$.D:S8IXI_L?Q7
MX@\*P_$B]\.G2F2R\=:_J]EX5LE1FN-2^#/CS_P41^)'[6_B_P#8TTS]DGP'
M\7/A9>_$#6O'.O> _C%=R^*)T\+?$/PYXGU/P#?_  ;^-_PC\+:3J.ARQ_\
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M$D#/4Y/))Y/4GGECECU8EB27444 %,D^Z?;)_)2:?3)/NGZ-_P"@-2E\,O\
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MDR,K_O*?;&1S[?UI"5(()X.1['U&>G?L<TH Q@=, 8Z@@=.N3Q]>>^:^H/S
M.#N]-S?EN-.W-C! Z8!&1VQDCD'L<=#@@]J3I[4*AD/RY[<\C^\".W7KGH-O
M/2@"6 \2+@\=&/?@ @'UR>W?BMJUB(R6+$') &<@=NF#NY!QC')&.*AM+4'&
MX$ ?P\\$;<X[C.0?7YFSU-;$008(.&(!"X V\Y. .#R!SSG%!<$FW=7T_4@G
M@#)GJ1N)XZ,0,#G/RYZ<=<=C6++$$;U Y'U.-O.!D<@8^F,$@#H97!!.0P 9
MFQTX  'TQD <Y[Y/-9T=N9Y"Y;**W SUP-H..IP=K$]N2,$\C5TUW*LN96TL
MF].NI):PBWBWR;B\@+#(*]\Y]LGH..#@CDDP.&=MC'"D;0>0?E.X$^G  ]RW
M/3 NS\KD'(PRCG@94D=>.W7L" >E9CLQ?&\C@8(XW?4 @ C(&#@D8/(J$N63
M2UNM_P 2Y*2=DDU:+U=MU<B8EB3C:5S(#R 2N5"#IG/WB,Y(/W>13, (#O(R
M <87(X''0\@<<C]:>^<@,V?XN3GG[HX)./KQDXQG'%>4 J,#J<].ORMBKNK[
MI?-%0CS)W;35MK/=/OZ V<Q\L><GKW*<'VQGK4J8&3D\%,;O7)'<=!D$C%-W
MJ0=I!(&< X/'(]#UQSVJ2,;N6#'IMW<X(R3@C..@!Z9/!]*PN;)*Z5DM5LE_
MD64Z.>Q8@#N."1QGN#C Z8 [U><%89#S\VWTR"&(  '(QN(Y/)&1TJM @;;_
M +N<G^\0IX]PN2.PP/2K<[;8F[$L@!]\C^G<^E1/2%1]J<W]T6S3E2L[MZQZ
M?WZ9_6#_ ,$7#N_8JM3Q_P E9^).<'('^EZ9_G';WZU^M:?='X_S-?DA_P $
M623^Q5;D]_BW\2OTNM+'],=^0:_6]/NC\?YFO\]O$E_\;"XV_O<39K/TO4PN
MA_??AZ[\"<(/_J08#_TU47Z#J***^*/L1I7^Z%!]2.V<]L=^?KSUIH5QG'EC
M/)PIY(Z$\U)10 P*W&2HQT 7@=N,\CT],?C1LY!R,C.#M&1G!.#UY(&?7 ]!
M3Z* &%2!P1D<CY!UP>W'KZCKC-, <GDC!R#^ZQP>2,[CU/)XYJ:B@"E>V-M?
MV[6M[;6U[:R/%));7=K%=6[O#,EQ"[P2AHV>*XBCGB<J3'-&DJ8=58<AX_\
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M.[GG=SQDG((YQG.1[^HSG&*LSVOF(98#AURK*> PQ_!GHYQR>#CG(!S4=JH
M&3]Q6SWXXP",'MCH>H(YH.:3DY_W4]]=;/16[.UG^-RX% 5>0>Q'!!P=I/J
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MVN^,]<DS:V5A86<OB+Q+>7VK2Z?I&E6%AI&EVL\[M#8V%N9Y)[DRW$OU%10
M8'I[?@.@_"BBB@ HHHH *9)]T_1O_06I]1R_</X_R-*7PR_PR_)A:[2\X_\
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MC7U7/)Z:?<?F8L4>\!SP@YQ_%D'G<,8X^IY_#&A$@!!;:I&2 =V3UQD $''
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MD%1N...>G![8J-@4 !4@9Y'4 8;.T@#)R<CCKZ]:#/D:W2M9]?)_K8R9) "
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MF_E^M24AZK]?Z&EK_-1))*W]6O\ YG^@:V7]=1K,%QP3GTQ[9ZD< 98^P/?
M+?-7GA@,9R0-I/\ =#9VELY&,]1UQS39<97< 5PP.3C(/WEYR&!3<2..!]X
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M ).!QMY\39F__)L,?WQX>7_U%X0OJ_[ P%WW_=U0?[K?[I_D:^,OV_\ PO\
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MEW;PS6<<22RPK^BQ53U&>ASSG@@CGKP1Q_\ 7-?G?\?8T_X>&?\ !.L!1@^
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MNN2,4D#,4#$.2_4$D$X8>C*1GCWXK-F ?HNP<88]R0>#_LD9P.!Q@9[VXWW
MQ @],;01C)PW3VSDY[D]1D-F78I4<#HP7DG.#E0>?8^V0.@S45JD]=_R,)-V
M;;;?1]4M-/S^\PY0P8X/W>25P#P6'(P01C.?;UX KR, H8G.2<+D?WN<=\G[
MV0>"!C&1G0D*#+%&)"DC. 5ZGY@.=Q.2#G&"!P6%9AVY)4J[[LG@@*.-H0=R
MJD9'7.!WP25E)KSV^XRYI=V(&V[<*54=&^]GDL,CC([_ ->F+23[8U!;AF4E
M1GELX!8<Y()7D%1GD@GDT6* _>^]D$G@YSD]>/0'C'/7K49DW-NSG:P('3)#
M9) _V@ !GGC%(ZJ;;W;?NK]#5WEE+$Y'<'H?X1QE>A&[@8!P2#W621AB)FW!
MN-PZ)D'#<#IC( Y[GZ45N%VY+%6YR/Q/8]^I^7OURQ"EYQF/ (#*0<Y!R0IS
MR2.>!CU..2!0:I7T[C)!LP3E@,X.<9+8&%QD  8P.G)(X%9SSONW(<$CIVX/
M'4^W.2 >.,FM0E&WQN0I(PC'H'SRR@<9'&1D8.>.*SWM6!)*YZ EL#/'7.0.
MG&0<=< CFAF$J<U*\6TUU5MNSOY_?8DBN,YW'.Y<G/7H3QSW!SP.V..<,=DD
MFMR<_-?V/(Q@%;^W5>QZ@\\\GD$8P8"C(.5Z#K@$8  &"#D>Q[]>QJ&.13/;
MJ5;/V^S:(XX4#4K;!! ]><G(Z#-9UM:55/5>QQ%T_/"XJ+^^+:?DV=>%NL10
MNVVJF&N_^ZA@/TL?Z:P)+8/;_P"V#^0%/J,??/X?SEK'\2ZY:^&="U;Q#?0Z
MG<6.AZ=?:O>P:-I>H:WJLUKIUI->30Z=H^E6UYJ.J7LR0F.UL+&WEN[N=H[>
MWCDFD1&_S1BVT[^7Y._XG^@:V7H;+H'X).""K+P0RGJ#D$C(RI((."><X(:T
M*/NW9.X\\C! R0N,8*YP2I&'P-X89!_,GX8?\%(-6^(GCWPSX;U#]AO]M3P'
MX#\<W&GKX0^+&N^%?A'XGTN72=6O6TW2O%OBKX>_#'XO>.?C!X%\%:A>121K
MXJ\3> +;3-,E98?$,NBW"W%M;?IM$6*MN;<=[@'Y>@. ,*S 8^Z03G()(&<"
MAAY*=3RV -Q"[@!NR 0HZ[WSW D<+M4X'YO_ /!0D :_^P>HZ+^WI\&L @$?
M+X>\: ?*1M[]@,=L9-?I+7YM_P#!0G_D8/V$?^S]/@W_ .H]XSH _2(H#UR>
MOX@]01C!&/EY!(&<')S2%.<Y/0@#"G&>N"5)YZ8)(QT' P^B@!JHJ9P,?@!@
M#. , <#)QG)Y/-.HHH **** "F2,4 (QUP<\8&"2<XP,8S\V <8!W$ OK@_B
MCI/BO7OAQXZT7P)XI3P/XVU7PEX@T_PCXRDLHM2A\+>)+O2KN'1M?GL)X+F&
M\@TF_>"]FMI876:.%D 5RK* =D\SH"Q7@ DC!)!!&1NX0@=#SN/) QC/P%_P
M46\#_LNZI^SKXC^/O[5OP3M?CAX7_8[M]2_:9\)>&UENTUG2?&'PVTV37=-U
MCPV8=5TFTEUJ$VHCM(]6FETB9B!?6TT0 'Q-\,/@7_P4$\*ZA^S_ #^/O^"L
MGPQ\9V_P[^"'Q8\"_%ZPAT7P99)\3_BOXM>__P"%<_$&#SXIS8VW@;['X?AG
ML]3&H:A>/'KIM+JU2]E2>Y^T)\/OCO\ #'_@AI^UEX+_ &E/V@M)_:D^+.E_
MLN?M!?V]\:]$T>UT?1O%FF3V6N3^'([2PM_,C;^RM">STR\FEFNY)[ZVNC)<
M.FQ4SK*I"G5J0TY:,YQ=1-0]O2<JBI7:C=5*<8\W*VU&3=D]2J2A.M2HR<G"
MM.$)RI6=2E>M1B[+5)U*-2K[&Z:=6DEKLOQ*G_X*%?\ !*^\\.ZS;7/_  1]
M^)DFBZ]\=1^UKK=E_P )]X*C-[^T%%#=ZBWQ2D1/B*DL?B2$7$\AL86CT-)7
MV)I.88R/Z?/^">/@C]ET_!&V_:<_9>^!]K\$K']M8:;^T9\0])EFNI=<U[QG
MXGMY+EM7\2&35M5TZ+5D6>='CT-K71MI)M+6-"C#^ BVP/"TB%U9?^$=E9$V
M\H/[-F7:&/&T$L@ P-N!T&*_O;_X)',%_P""9_[$0P%1OV>O #-M5%PSZ<P)
MPH 4G:2>  <GKDU^)^#_ (BY]Q[B>):><X; T:63UL \%++[\U=5JV-C5HUK
MRM>*I0A.-D^:'Q*[;_T1^GE]%3PT^C3E_A/B_#[&<68NKQP\ZJYJ^)<SH8^E
M3HY9EG#./HQP5&CE.7RHSJ5LXKT:E.>(Q$J:C[.4YR@YO]*:9)]T_1O_ $!J
M?3)/NGZ-_P"@-7[?+X9?X9?^DL_SK?3UC_Z5$_E__P"#E,9\+_L=#)_Y&[XU
M=/\ L6? E?RGE@@+'GDX'?J>!^IYZ<]J_JP_X.4\_P#",?L=<X \7?&O/3_H
M6? G<],5_*<VT [B&7YN2#PV[&<#K@$>Q+>@./[4\'O^3>Y+_P!A6<?^K/$'
M\H>*'_);9K_V#Y5_ZK,,1%L$A^&XS@''08Q]1C\<]J@PNXE^!N)7/1OF8_B.
M5/\ ];.;3,>5!.<Y) Z#G !/<#:.G3\:K-ER0G)7<&SQRQZ]\\J2>G4>^/TT
M_/P4@,6;A?F()Z$LV01_P'/X9H#3 #F3IV"X_#CI2B)F&5<%!R%)&2,$;0.N
MXCIW ZC<0*LA.!R>@ZCG\>>OK0!]V8!_S_/U_&I(W*,!U'/&?X<?,,9'I\N.
M,D].*CR!S_D_3UJ:.%FPW.<9Z@#!'S8QSP"QSN'3UKZ@_+[,M"7<<I@ @<GG
MGDGTZY)!]/K@57GDW$ <?+P2?TZ#C=U'H?4"K*Q&/@99<=!R ??//TY/IVJ%
MHE.,%<#/WNWL.AX]#DB@WII2Y5U=]M]+L8@,@R1R1D^@ R!^)QP2>._3FZ@$
M2E@>HSC'8Y S]2V>?3':HHT"@*, D]1[GMZX'2ILY*QD<%02<YPH/RGCK@="
M.<D5Q5)*Z3DM$]&^[]?(]*C#E3=GLEKZ]^K[OO<)7)((^7V#=<=B>.6R>OH/
M>J4DSJQ& 3QGGGDE0,XZYYSQ@$C I[D808Y+*2!@$C!&1CIR<#H03VJ)@IR0
MKAAT).0!G<1QP<\X).<D9.>F?M%'1/?71)FLH*2UM=:+;6^NOEY]/P(EV@G<
MP)VG QG<<K\I.XA<^O;G STB#.7.T  'E,\+SG[V.<]N.@((-1Y!8@ '<6YX
M[MP#SGG/?OQ4J#;NW  9&,X[#M6D:FFJD]7KHOP.?V<HNZBVULN5Z_=]^@\C
M<?F[ =,@=QT]\"I41=HP!EL')XP2,]?0#\\>M1#&3CI@?S:GJS8*GE0#SC!7
M'W<]B.#CC/>I;NV]=7W_ ,G8Z8_#&ZL[*Z:UOKO=7^\G4#<1Z*PX]R ,8]0<
MC_$5?B8(G*\G+#U.XGCV(&#^?I4")C)(/'()X)QR#G@<?PKC!.21DYJTB_Q$
MGACCD # [X'<Y7GL?7!I&:IM[.+UMI=Z_+KY$4TZJFYE.004!( 9O3.#QC)S
MTX[YP>:FE:60N5^9AR@R2F7'4@\YZ\#Y<' '?8U N[(J@[%P#C:/F&>>>G(/
MZCZY4B;"=P*EE' ^\?G7//W5!SSQR3WZTI.T*C6O[JK:VOV)#]DWHVMXWW3L
MI0?7^O4_K>_X(I_+^Q)9C&/^+L_$L]<]+S3,_GZ=NGO7ZZI]T?C_ #-?D7_P
M15#?\,26>0 ?^%L_$L #C@WFF'G/0CGCGTR.E?KJO3\3_,U_GWXBK_C/^-&]
M_P#67,].OQX:_P"2/[UX 7+P/PBE9K^P<#JNZIU%_7>S9\7?M:?M%_$SX'3?
M"GPG\'OAM\-_B=\2_C-XA\1>'/">E_%GX]:/\"?"EI/X9\.W?BK5)Y-2'A3X
M@^,/$]S#HUG?WJZ1X.\#ZO=06UA/<:K?Z=%);&2U^R/^TAXO^/GP:_X6_P#$
MSP5\-_ASH3VXU?0_''PS^/'A[XX?!'Q_X0BM9&N?&_@OXAQ:!X$U>PTBRN;"
M\LM8TOQQX,\*:MH=W;W$-U#<>7)<CX/_ ."Q2Z]X>A_9<^+'PU^-WPG_ &;_
M (W_  Z\:_$BW^''QE^*7[2OP4^ MKI&E^,_"-AI/CCPWIOAWX]_#WXB> OB
MS:>*-,MM/AU72AI%EKOAE]-TW6M.U.%9[N"Z\_\ V:/@GHW[7W_!$;PS\)_V
M>[:\\)GQY+XHUK'QD\3)X^T+XM>/?!O[3^M^-OBQ=^,?&_@C2/#FC^,?A-^T
MMXW\-^+[E/%7P^T#1?"-_P##OX@V]UX,\-6OAV+3]'/QA]>?NG-XO\)VR^&W
MN/%'AVW3QC-%!X2:?6]+B'BF>ZM&U&W@\.%[I5UR6>Q!OH8]+-V\MFAN(U:'
M+CX4_: 95_X*(?\ !.P$@#_A!/VWP-Q ^[X-^"Q(7/4  ENN,'.,5\+^+/\
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MOQ$\.?MZ_M@7VL>$=1\):A8:9XE\6_"76/#=TDWQ!\+Z=<:7K6FQ_!NQGO\
M3;K1-0O-.DVZE;7%R91=2W#3(EQ+_8_$RHTF3P=NT@%MP!Y<@*2"=Z9&=@!
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M!1C.0/X36>ISE=X"IEB,'#)GYAD#IT(SV)!-.^?*E<LAPR\#@'G&3R,<8[=
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M,>WQR^-@/;MD'\:_QT^@MGV>YMXF^/.%S?.LWS+#8/)ZCPN!S',<TQ]'#O\
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M9/S/]%-5[/S_  _X)#JV[+U?_!1]]V\).9&P220.> 21VX'WN<]1C%:1*!"
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MWX5?!CQ>U[+;74VI^,=&$_B?3XCIFCW<$UK,X^D/^"1OQ1\$_$#]B?X-^&=
M\6:GXN\;?";PQIW@GXQWNJ_%/3OCM+#\5$2XO/%,]E\:_#5UJW@'X@:+KM]+
M+KWANX^'VM7?AW0_#.HZ/X>M['P^--_L&PSO^"NO[5\G[)W[(OBOQ1X<U3X+
M2_$WQ+=V&D^ _"'QJE\*WVG^+4L;^RN?%B^%/!OBWQ'X3TCX@>+="T&1[_3?
M"-QXDT2"]GD9VO9)4AM9>C_8L_:WTK4_^"<?PT_:[_:*N_A+\(O"*>"/$?C/
MQ%>^!)M*C\!^'O"-IXPUW2_#,JZ5X4U'Q/I6F>*]2TR+2[?7?!?A?6?%/V3Q
MQ>7OAG1[O4=0\NT/QI]>?I60#C/8Y'UYK\[/V@<?\/#/^"=1+!0O@']N!R<@
M$X\%_!=3U(;"AB2RYVE0#C<"/8/$?[='[)?A3P[\#/%VO_'+P9IOA?\ :3N[
M&R^"OB":;4&TCQG/J<VG6-FPOHK"2WT&V?5=:T;0WN_$DFD6\'B'5M/T"=X]
M7NH;-_'OV@./^"AG_!.[HV/ 7[<47!Y!_P"$-^"S;3C+#/EDE55N0K<D#,MO
M5VORM-?X5'GJOM[L4W;=I62;L!^=OQ8_X+/_ !X\*_'S]HCX3?#_ /9-^'_B
M?PU\"?C9K?P9A\6>)?CK?:#JOB6\\/:-X4U6]UN7PWI7@'7DT:WD_P"$D\BP
MTN?4)+^^^QK-#!G5+..3ZX_9%_;D\6_MN?LZ_M;ZIXZ^$^C_  E\3_!UO%OP
M]U+2/#_C9_'NBZO'J'PDL_&-KJMCK4^@Z$Y_<ZVEI(@LY;>7R1<07$\,J,?Y
M]?B1EOVM?^"@8.X#_AN'XL+&)-N%!\'_  V27;'C8(I'>1W59")XV8RM#)-+
M';_IY_P2)9C\!?\ @IJSG<Q^)>K.3U8E_P!FOPFY+-SOD)),DAY=R7*@DBOZ
M;\0?";A/AOP-X X_RVEF"XBXCKY5',YU<PG6P<I8_ YQ7E['!RH4X483G@J2
MC&-:?+)-N24VCQL-C\15S3%85N'L:*E"&CNTHIW;M_,W=7U2;.!_8^^"7P1N
MOV5_V;KJ]^"GP5NKVZ^!GP_GN;F\^$GP\N[RXNKGPU9&::Z>?PTUW/<S^26G
MEE9KF616=V=S,ZY/BZTMH?\ @WX_99L[:TMK>T@^(G[/45O8V]M9Q6D,$?[5
M=ND-K!:,B644,2!(XD5(Q&%1D9'5&7U_]C=8Q^R=^S.[*H!^!'P[7#< @^&(
M#C8#C!.W)QV4D=*\I\9@?\. ?V702 /^%C?L]DDJ'_YNKMV VO<6JMTP ;B'
M)/,BU_F)X+5JU?-/$>-6=2K&C"O"C2<ZU91Y\RSR3:EB<544>636B4;)-QOR
MQB_ZWXTHX>EC_!WV6'ITIU<YX<G6K1P^'H.<EBN'&E+V$5*3E>^J:V;:UM\?
M_M<_\D(^)QWJ-MWX1+'*$\_%+P=),0F0 TJM)(SB)9':3=+(9&D"_2O_  <W
M?M*_M(?L^6G[!]C^S]^T!\7/@/'X_P#%?[0L?C6X^$WBVX\(WWB:'PMX+^']
M_P"'[?6+JWBD:[M=+NK_ %"6WMI%,:O?3O@R")D^9?VN&+? ;XFET<AKCP>1
MN;H7^)O@W.TD(Y5?FY>&.5@RM-#9S&6RM>Q_X.RAE_\ @G""3\WBW]J53_X0
M'PU)/Z#C_P#57]T_0BR/)^)_'WPIR'B'*LOSW(LX\3,EPV991FF$HX[+\RP,
M\NJQJX;%83$*5&O2G*G%N%6+C>FI.+25U^T Q.(P>*RO&8*M4P^)H>'>:5L/
M5IU'2G&K#/E.'+-1<J;>JORK?=7N? ?_  1G_;9_;:^(O_!3O]F7X<?%#]L?
M]I/XJ_#SQ;#\58O$?@;XC_$R_P#%/A?5TTKX=:QJFER7NE7=JD32V.HV\%Y:
MR1;)(I4"[V52&_7#]JK_ )23_MF\;?\ BFOV6\K@K@_\*RUC(P22.??GK@9P
M/Y^/^"'('_#W#]D( =%^,2DGD''PIUY@<<'MW.<XR2!@_P!!/[5HQ_P4I_;.
M_P"Q;_9;/Y_#'6#_ %KY+]OIPAPMP/BO$?(.#>&\@X5R*E@/ 3%4LIX=RK#9
M+@5B\5C.;%XB>"P-.EA'6K2HT)RJJ'M'HFY2YV_R_P"@!F&.S/Q!X4Q>88FO
MB\1.AQM3]K6Q$Z[]G2RR;@KSIP?_ "]DENTET3LOH3_@DQ_R>I^V3_V;W^S#
M_P"I1\;*_E,U;_D?OC1_V<#\?_\ U;_B^OZL_P#@DQ_R>I^V3_V;W^S#_P"I
M1\;*_E,U;_D?OC1_V<#\?_\ U;_B^O\ -C*O^41/ C_L PG_ *;S,_UO^@=_
MRF]]([_LWU;_ -:S(C^O7_@W<_Y1]R_]G-?M1?\ JU-4K]X*_!__ (-W/^4?
M<O\ V<U^U%_ZM35*_>"O[OX5_P"28X;_ .Q!DO\ ZK,&?Y'>-/\ R>7Q>_[.
MGXB?^MCGQ&WWC_NC^4E0M_K(_P#>C_\ 06J9OO'_ '1_*2H6_P!9'_O1_P#H
M+5[4^GR_]/0/S)_&O5_^F)G^<MJ)']KZZK;?^1A\2XP=G!UO6, G&03R2>Y]
M!FL<DECCYE/ +'D;L<'.>HQG^E7=88?VWKZ]-OB'Q$-V?[VNZG&<<#H9,\G/
MRXR,\4 ^1G!PV#@J2.<#KT_/'OC/'^EV'?\ LN#77ZE@]/\ N4PG^:/\]<3"
M4<9B[JU\7B[;/?&8JVS\RR   ,@DDD@'J2IR/PZ#V%+N"C))('&#G@X! 4$D
M\@\CV]!56-^0Q4#&[I_N\#/N6 Z<>_9T[E$!Y!9P2!@$?*HX)'KD=!W!Q6QA
M*$G*R6NUKK??OVU%=N&.<%C@>H. !QZX 8^G/I6;),R+\N 1G!7GNO0]<X;&
M>_/..:E$A*E@N ,\ELX;@9QC)R".?;'UIS8)P"/E*X'7/')Z^F#]5Z9YJX?%
M\G^A%DG[^G;S?;9^8BW<C$@YR,\$\\$CK]3D'H>3R.::\SOE0, @@]CM/!.#
MZ^O7(&>@J$ KG"KSU.YN?<_(<=<]?QIZ@N<C"@<[B<\8RWRCT],]NW&74Z?/
M]#2'/+97CIU2VO:^NNW5778:0?NY7';/)]N.GM4B'CK]S).1D?Q#([?=!&/8
M+Z8@(+$@<$./G.<$#)X&1@8 (Y/7%2Q*-K*QR2&(/]XD@D#TXR,\YR3T%9FG
MLM+OE[O=ON^^WI85R<!D(+%F&T_+CH<XYQ[^VWT%9<N]7RVXJ6<%<#C+,,<=
M021R.>@P<KG04$ ':202PY 'W2 /J<XS[\]*J3#[S$,2W\.0,#+>QSC:QQWR
M!VR=8-62ZK_,PE%W=E=7T:T6W2]G]Z1GLJ@$[!MW%"3G@CUSZX')!&<9/I5E
M1D+J71LACE#D'()Z[00?; S@XYQFU<MM@6%1\\CENN"O!SNZY./3'Z<YX5RW
MEQC=(<>7DD D\@D\\#N,G.1\P&343:;]%;YW9HH1T5X\UD[6E?9/HFNO?\!)
M'91N7A5 QS\K$G:0#_%MR,X^53G)X%.&&7<2V64@CG.-I&0O(!)!P!SUS]ZH
M9V)<1L?W: A2H."Y!+X&3G')&,C( ]PZ%V;:&7<0"N V-V%W8/7&<*.I[CC.
M#)I&,E)-K2_==GYC% CW/N&TD!RQ.0"3D8QG)]>^,DY!QH)G8% X^89[ ')&
M/4<C]:SYHF+LC9*D*Q 'W#NW<Y89P&)S@9./3BU'*6^5. "%&X#.>IZ=@.<^
MAQVR0U+(Q.)8F.%)8J2>0RE>_7T 'TJK&A#VR_<_XF%@N,Y!+:C;$9QQC [=
M#T'I8C4A"Y;!+$8QGYOF#$\@#O[ #N:3C[5:XZ-?Z80#TYO+?G\/IT'7K6=9
MVHU6W9*C7O\ ^$^)-L-_O%'_ *^X;_U/P)_ID@_,!W.3^1;_ !%8OB;0=-\4
MZ#JWAG6K5KW1?$&G7VC:O9I=7MC)=:=J-K+:7<$=]IT]K?V4DD$KK'=VEU;7
M-NQ$T$\4J(XV@,R#V5S_ ./8_K61XCTR36M#U;1X-6U+0+G5-.OM/MM=T5K>
M/6=&GO+66WCU329+NWN[5-2L3)]ILVN+2ZA$\:>;;7$>Z)_\T(;>MO\ VX_T
M"[>B/YXOV8-5_8%^*'[;%U^S_P"$_P!H3_@H=\2?%GP)\;^+H?AMX)^,_P <
M/B9KG[/TWB/X2RPVWBJS\":K/JL?C#Q3HG@S5;:?1X]-^(>K7.@ZG<>&9A;P
M:QI=I875Q_1A%F126P0&P1@@Y&3G:0I5MP6124!&<KD$,?Y$_P#@EQX5UCP/
M_P %A_COH6O?%/3/B/\ %FQA_:'T/XU_$KQ3XC^!EWJ?QQ\*Z'XIT.+X-W_@
M'0_ ?PL\'_$P>-O!'APVFG?'V^\8W&E:!=^*H;Z31+CQ#;?V8R_UW0?ZL<YQ
MQSP1@ ;6&%VE1\I&U2,?,BME18"[&'?. <>N<\YP>0P).P_(IQ@<#'YO_P#!
M0G_D/_L(\8_XSS^#G YQ_P 4[XTZ  Y([  Y/ !Z']):_-O_ (*$_P#(P?L(
MX_Z/T^#A_+P]XT/;)_($^@I/5-=T_P F!^(G_!3@Y_X*A?$V,?OI!^RY\!A]
MG5V<OGQC\1.3 QDM5^8[E6<1^8<"57MGD,E7_@F@P/\ P5.^"X\T.Q_9%_:C
MY#,0 ?'?P#D*@DEI,&17/F[BV\7&U9IIR;7_  4Y#'_@I_\ $U-Q 3]EOX$!
M6=]\<>WQ?\0V4RIA'59)=JNZW,:R1EH@%G='JG_P3.R?^"IGP7+*ZAOV1OVI
M0"W+-_Q7GP!9VD;:J/O)#;4 99A,TB+YB)%_?$&G]"J;_P"H;&._-I:7%M:$
M?=Z/FBU?>V_NI,^8?_)0Q_P2Z?W9]?O_ $U/MO0F)_;5_P""EJL\A"?'GX*,
M ET6,7_&+7PV8.8OM3"V4A"6<16Q;8),N8A)#Z?^Q[C_ (>6_$C Q_QA#X$7
M& /N?&CQ#'C "[0I39Y>U?*VF$1Q",11^8:$ _[:O_!2X?O6V?'KX)DB(JQ7
M/[+/PU&2OGY1.[,RQ8**1N 9H_3_ -CW;_P\L^)&W;C_ (8A\"'Y<A1N^-'B
M%L*#@A0" JD J %*H1L7_&;(O^4A\]2WC5SNZ]<JRNWY]&_,_K'.;?\ $"<G
MV^+)^_\ S^QW3[M=^A^7N@29^*_[9!;S7,'[:/[021R*T<R6S-XAT]0D\J3S
MO912"61(K=OL<DC7#6_V8MJEO!K'Z#?\$;&_XOY_P4>'.3XE_938MG*DS?!O
M7IVP2Q.79S(S9/GO(;Q7G6Y6YF_/CP\2?BS^V9S(PB_;0_:!!*A/E#^(=.01
M3$7-SL@'F,8\I:2.TLJBQ+O;P:[^@O\ P1L/_%_?^"D"Y*X\3?LIL4QSF3X-
MZ],S$D]9B_GL "#O+H]U'(E[<?K65?\ )4\0?XLWTO\ WJ?_  Q^S>+W_**W
MA;U]_@I;6M_PA9F[7Z]]S^!OQ:,?$/XPX'/_  OCX_,#G_JM'CK/'YG'(-?V
M3_\ !O)_RB-_:_SU_P"%G?M*Y_\ #9:7C],?C7\;/BW_ )*'\8?^R[?'_P#]
M71X[K^R;_@WD_P"41O[7_P#V4[]I3_U6.E5_OU]/[_E"KZ+_ /U^\./_ %RM
M _R0\./^3@\:>N<_^M!7/F[]E?\ Y-R^ ?\ V2SP!_Z8M/K[7^''_*MW^U-_
MV3'_ (*#_P#J\_C57Q1^RO\ \FY? /\ [)9X _\ 3%I]?:_PX_Y5N_VIO^R8
M_P#!0?\ ]7G\:J_X\/H#?\G7^D#_ -BBI_Z\[BX_V%^EK_R;_P &?^QO2_\
M66X=/Y=H/^14?_L 3_\ IMFK^]S_ ()%_P#*-#]B3_LWCX?_ /IL%?P1P?\
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M?^18 PORD]"><'.>><#KSV]LYQ3N.[$#KN^7 ^O'?G!SCV]:ZREOFWD 'K@
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M_)<<(?\ 7GCC_P!5<#Z#_P""3'_)ZG[9/_9O?[,/_J4?&ROY3-6_Y'[XT?\
M9P/Q_P#_ %;_ (OK^K/_ (),?\GJ?MD_]F]_LP_^I1\;*_E,U;_D?OC1_P!G
M _'_ /\ 5O\ B^O\M<J_Y1$\"/\ L PG_IO,S_7OZ!W_ "F]]([_ +-]6_\
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MEW!B%QGC X(S\W3:<'H -O4=@/T]<W5I]K*Q\&I0:WL[ZW26G397?WV0XAE
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M?,5!7T^4]AT&.]5(" QR<<X_%MF/SVG\CZ<WT("9/  &?;"K43=E;NOU_P"
M='-%V2[.[U[JVEE;0I=&)'!W-SCG[Q^AS[YZ9'>G@LRLF1M)!.%.2>01D'//
M.[GL,@DTAY+?4U)']P?5O_0C61>D7M?1/MOKV97E>1(W01)\\;+DA206(P^1
MSGY>HY!;Y<]Z!&X;1GD=C@8'(R>,#CC/N!WK0N7"#/?'(]L\'\\K^.3G&*K1
M(N",D,0!@8))QTQCH"< #'.<GFI<HK=[:;/_ "*Y>;7:^MM[#HTSA5& 2H8@
M'N0.N.2><'TR?05J06RKB27  )VJ.<C!7D8Y Y;/;'3(R'PVHC4/(1O)''\"
M@@?,%R>01P#C//%3.VTJ$(8[1DG/J2?^^B<CGL:B$6[-Z)-.]NBW?HN_W YZ
M-6[K?Y=@9^07Z@# &,  G/7 ^\%[^W(YJ%I0 >@QLZ<@#>,=.X]!P>@J)Y#A
MN0-I );IP>@ & #D>I['U%*63AN,'Y<\DDDL#R<8!()/?.!C&*WE"+C)<Z7-
M"I&^EUS4YJZ5];=NMQ1C>S5V^>*LO\=/7\6_D?UO?\$7CN_8JM2!_P U7^)@
MQZ'[;IIQQQ],=J_6Q/NC\?YFOR._X(KDG]B>VW?]%8^)G/KBYTO! [?X\\=!
M^N2]/Q/\S7^>OB&[\>\9.VDN(LRGZ7J4%;_R5ZG]W\!:<%<*+K'(L"O6U*HK
M^6VWF?D/_P %M=9AT/\ 8'\77;6,M[<W?Q7^!.EZ3/9->P:]HNLZA\3O#UII
MWB+PC<V?Q#^$]M;>+=%GD2_T&YUKXD>#-"6]AB&I:Y:6S!VXG]A[4/A)_P $
M^_\ @FA!\<]5TOXS:OIVM:C=^+_$WA>X:/Q!X_\ &7Q*\<_$Z;P1X>T#P+X#
M'QL^+_A#P[XB^(?B_6M'L#H^D?%S4-$U#Q/J]SK^N:[;R7M_=1>P_P#!5[X)
M?MR?'K]GR'P#^Q3K?P;L[Z]O=8D^)WACXI>'?#.H^(/&.B)II;PO8_#'Q#X_
M\*^/_AMX0\1Z9XC$5_=ZKXR\!ZS'<V4,2:;J&BWD(NG=^Q[^R#X/US_@F'\'
MOV2_CQ\(?'_@NSNOAU:Z;\5OA]XV\66TGC[1_BC9^+I_%OBCQ;I'C;X?ZR+3
M3[EOBC9S_$#X=ZWX0O-+32;-_#MWI5KI;VRZ=;_'GUQZ5+_P45^! \#?LA>.
MUT;XMM8?MH_%G2?@I\,M-3X?7<M_X0\=7]YKNF:K8_%J\M]1N/#G@6+PWJ_A
MS5="U<S>(-0NKS6K;[)X9M];5IKJW\>^)?QK^#_Q'_X*8_L-^#/ 'Q0\ ^-/
M%_@#P3^W%9^./"_AKQ5HFMZ_X2O!X7^#EBUOXAT>PU"?4-*<7UM=6A2YMT/V
MFVGMMZR0S+7TKX?_ &$?V=/"_A#X8^ =+\,>)'\(?![XD?#;XN?#K1=1\=^,
M-4L?#/Q&^%%M?IX9\2VZ7VLR-=7%]?:MJVN>*HKKS;?Q7XAU*\UW5XY=1\J8
M>-_&OPKX9T/_ (*,_L :GHGAS0-%U/6_ W[<=QK&I:5HFEV%_JLI\)_!N7=J
ME[:6$5SJ!:64W#&>='DF42M<2$,DT_S_ /7NO]_U>7Z!W_KH?S;_ !)"R?M9
M_P#!00L6D3_AN'XMJ$<B0;!X-^',<T3"4I&$D82J(MP@,4H2::,/+'7Z>_\
M!(L_\6'_ ."G#$Y8_$W669N268_LW>%2SDNJ.Q9MS%I8XY6)+2Q12%XU_,'X
MD97]K;_@H"!P/^&Y/BJ78'S$W-X4^&I5E"P6+X4-&)(C<W#F:.6)-7LXW6+3
M_P!.O^"1(S\!/^"F^!C/Q(U4 <$C'[-7A1=I(CA#$8P6$%N&/S+;6RD6\7]T
M^+]O^)6?"3O]9X6N[;K^S>);)/RMK^/0^:P%_P"V\?\ ]O\ X).WS-/]C?\
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M3'_@H/\ ^KS^-5?\>/T!O^3K_2!_[%%3_P!>=Q<?["_2U_Y-_P"#/_8WI?\
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M[=GD@YYVJ#\PSP&ZCMP*U>S]'^1DDKI=+I?*Z3_"Y3<DDXR/FQTSC!QTY![
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MI[2VLT@AFAN+:_CMM3LX?V)?V&O^"DO@WXI_ S]N'PJG[#^KZ;K?[-7B'3-
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M54\/+EIRYDE_)G#)&/"I4.K,?#<TP0$AMC:;(<88+\Z[@&49*L&4\BO[W?\
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M1)_8EL6)R3\5_B823Z_:M+'X?AW]S7ZZ#I^)_F:_@+C_ /Y+GB[_ +'V/_\
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M[:2;=HKF=DM9<STWOJ39)IK2U[6;2UW;2DHM^;BVNC5W?]!_^">O_!37X?\
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MVO97?WA>R<MU'7>ZTZ(G>(LOITXZ?WOH,]^H/O@FH!')$254#&&"@ # &0"
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MZI_&W]OGQ7\1OVK=2_9P_9BU?PU\5-(.A:%X,\:Z!XE^"5]XAU+X&?%:YO\
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MW\.4'/[-7Q##8SM;QUX=!/./^@<>,\9[D$ 54?\ X.!OAPA(;]F;XBY!P/\
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MH"" >.@<# )/8$Y!Y[]1W$*L0#C@')PPQ@]R#T]"1R/IFM!XXP.0< $ EL9
MZ8YR00,[>_;UIC0PL=S-N.!SN4@!?8G)]3@<TQ2Y=&FM;WW\O+\C+FE=0,'(
M(()7@]"#TZ 9!Q[G& ,5)%(#%\G/S+C_ '@ ,=0>0&R.^1CK5MHX"P"A3GJ!
MC! !SZ@'!."<>G(S3/+2,$H JYS@X.">^ 1R #SC.,^E9S3=[+[+_)FE%J,D
MVTDWUOV\D^Y4G8$[ER,J<GITVX//90<_G662=I;J0I('H!_#^'0]SWK5=2Y)
M&,$$[3G^(DD?CP#GTK*F 4''&3@]L@,HR?\ >4Y)[@\UQGHIIJZV>QFS[MVX
MD#D]".F>#SS_ 'VQGKUS@57<,2!R%P<X/)Z9./;M[U:D1SAC@C.2!TY& ,^A
MR>>A/N1F'8R@$\Y''#9QC/'KVR!GKZ#C?FC;XOSOLO(Y*])RJ*:5UIKIOV5[
M6\_S%C&YE0Y!SN&WG)R6Y^A  /3!/X(@):4@#*X"XSLSN#9R><X!!.>0,9%3
MVXP6;H?F';'S KC/?  /!_B[4[R0$V#'8G(ZD>N,$_C_ ")%#G'V<HWU>RL^
MZ\C)4Y.:;7N]7==GY][%9L*2Q(+. N <XPO)'?.>.O?/7D,16#?(PRI^?('S
M9))8<<>@QDXQSVJT(Q$RM@'GH?F/0GCC(Z?K3=K/(6/RY&,@$+C& !T[XSW^
M4G':LHQYG;Y_U]YI)2M9+1:IZ7VUZ^O348T:ELQ[E4KA5Y.. >A[ #.<YZ]\
M 6&C<0EX0IN$"R1;CA3/"RR0ABV!L\Q4!)/0EO44X*H)P,;B1@Y&T<D@<#TY
MQT.!T IP<*@9ER"X&U6()ZX7(!V\ =B1G(!S6LJ<)PC%J<ESI34&HM4YPJ4J
MC@VU^\C&HW"5]'?:Y$9N$Z=Y1C352G4G9?O>:E+VE+DE;2DYQ2K1O>2<%9V=
MO]%W]E;X^>%OVE?@'\+?C-X7U&&\M_%_AG3&UF& @RZ3XLLK067B?0[Z/<7@
MGT[6H[N%8G5&DC6WN$#1W$._Z.1PQX.<!2=PP1GH/F (. 2!Z<\&O\^;]CO]
MO[X]?L0>(=0OOA=J]IK7@[Q#-%/XN^%WBPW,WA'7[J,01IJUHMM*MSX>\1FV
MA6T&KZ8R^? 1;:A:7R1QO'^VV@_\'&_@Z/3K9?$O[*WC1=6$:I=KH'Q"T-],
M68$[EMFO=%AF,>2QC+?.P.)!E<C^/>)_!7BW 9MC(Y!@HYQDU6M5K8*5*KA*
M.(I4JU6I4]CB8XG$8=^VIRFUS4^:G*"A9QES17]0<-^+?#6-RS!O/*\LGS2G
M0C2Q<9T\14H5)T?W<9TGAJ6(7)4IPA*TK24G*^A_3,I(9\LI!(V\CISQ^' Y
MK"\2^&]"\7Z+K'AOQ/H^C^(_#GB#2[S1-=T#7M/M-6T;6M&U.VEM-1TK5-,O
M4EL=1T^]MII8;NQO[>YM;J-S%)&%.X?SIK_P<<?"\Y'_  RS\3!@?]#]X8YS
MG!R-,Y!QU/X=Z/\ B(Z^%P _XQ:^(YR<?-X_\+DY],G2F^H /?US7SR\)O$*
M.G^K6*TZO&97?76VF9=+V^1](O$S@9J_]OX9>F&S!+33_H 6]KG]&&BZ'I7A
MW2-*T'0=)TO0]$T6PL]+T?1]'M(-.TK1]+T^!+73M,T[3;41V=K8:?:HD%O:
MV\<-M D:+;P(JJ!?FMX[F*6"XBAGMYX3;SVUP%FAF@D79+%+"^8GBEC=XIHV
M#1RJ%W1L/EK^<(?\''/PP/\ S:S\1AQD?\5]X5Y] /\ B4]_7IZ\Y%,?_@XZ
M^&:?\VI_$DCN?^$^\*#'/)_Y!/0#DD=O>C_B$_B%_P!$UB/_  LRO_YXB_XB
M=P+>W^L.'OM_NN8__,!_1?K'A_2?$.B:OX9UO3[+4_#NNZ1?Z!J^D7<8>RU'
M1M4LY].O]-NHO,/FVMW9W$L%Q&/+#PR%!CFOBWP-_P $ZOV8_AQ\5==^(GA+
MP-I%CX4UJX\.^)[+X"W6@^$M4^"'@7XM^&8'TJU^-WPH\(W_ (?EF^%?Q(U3
MPM*WA3Q/=^!-2T/0O$^GVVF7VK:%-K5@NIR?D]_Q$??#+_HU/XD_4^/_  F!
M^NE=_>D/_!R!\,!Q_P ,J?$G/I_PGWA3TSVTD^WYBG_Q";Q"_P"B;Q'_ (69
M7_\ /$;\3>!EK_K!0T_ZA<Q_^8#^DR%!'O)(!D;>W(Y?&TL 2[ %50*ID<(H
M"+M50*'4EPPV$;<<G&">I+!MV"OR[0",X8YQBOYKV_X.1/A>G7]E/XE?^%]X
M4]A_T"O<=,U"_P#P<D_#!>G[*'Q+;IT\?^$QU..<Z3_^LGCOA?\ $)_$+_HF
ML1_X697_ //$2\3N!7HN(<._^Y7,?_F _>']H+]FGX(_M4> 3\+/V@?A[HOQ
M2^'C:K;:Y)X2\0W.J)H]QK-C!=V^F:E=6NG:A9)=W>DO>/J6E37XO?[,UJ"S
MUS3H[36=.TV^M?#OV7?V#/A7^S7JTOCV_FA^+WQS339O!D/[1GCGP_H]O\9]
M5^%NE32V_@'PGX[\3Z4(8/&WB+P5X5:S\#R_$J^T^U\7^+?#.BZ3;>)KF^E@
M>27\B_\ B),^&/\ T:=\2_\ PX/A/_Y4T?\ $2=\+P"3^R?\3. 3_P C_P"$
M\<#U&D]/>A^$WB"]^&L0_P#N;RM_^]$'XF\"K?B##K_N5S'_ .8#Z&_;I_9M
M_P""@'QC^(GC[PG'\5+F[_9N_:(M-!^#WP]TOX.Z?J-E)^RE=Z#XBTSQ=I?Q
M(^./A74-?T^;X]>!OC!J.FWO@CXOR^'M7\'ZM\,_"\VE1>"VNX9]9U.7]#?V
M)?V1]#_9$^$\'A!-0L?$/Q \2+8:Q\5?&FG0:IIEEXO\46=HNEV5Y%IE]J>H
MSR'2=#M]/\/)XDU>>^\9>+;;2K?6_&FMZQKUQ=7;?C&W_!R7\*B"I_9-^)C[
MBVY6\?\ A,[BZG>"&T@@"0$B15 #*3D$$@R+_P ')WPN!)/[*'Q0).?O_$'P
MJW!(. #I15<D#@<# [4?\0F\05MPUB/EB\K_ /GB"\3>!7MQ!AW_ -RN8_\
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MBE _SL0,#!QSD#K@>_\ ]>BB@"(_>VD9S@_3'/3IS@\^AJ(G.Y< ;4W9QR<
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M]?THHK.3=VNT;[+?[CCYY?S/[RQ')F%R47*8&<#)Y(R3Z]>:IL<OL  P2=V
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M>G?ICKWS1175':7^%?\ MIRU/BC_ (WOKW'JY7 Z@DCV&&/3\^GM0!C/OC]
M!_3/U-%%)[LYJNDFNEWIZ/00-L ( .0 0>A[Y_3_ #@4R3//MM)QD9W,PQUX
M Z\?3IQ110]WZO\ -FL$G)>5VON$3[BCC#1[B.W1<C\=QR>>PI_EI_=%%%'3
-^NR);;E*_?\ K\C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y @0# 2(  A$! Q$!_\0
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MM%4OL5Q_T$;C_OE/_B:/L5Q_T$;C_OE/_B:++N%WV+M%4OL5Q_T$;C_OE/\
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MO4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M***]X\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV,M/Y>#TP#@9QGVKJ:Y7QW!>W&DP):QW4\/FDW%M:3>7-*FQL!3D$X;!(!Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%'5?]1#_ -?$?_H0J]5'5?\ 40_]?$?_ *$*O4^B)6X4444B@KDO'ZW3Z1;I
M";EH&F(G@M)A%-*NUL!#D$X;:2 <D"NMKDO&>HZ<^EM;RIH]T5G6*0:C.$CA
M8C()P"=V.0!@T )X(;59HI)[ZVO;6#[/;Q)'>G]XTB+AWVY. >.O7&:ZZN/\
M"1VT<%X+?Q!#J0+*?L]NY:*UX^ZNXEL'W-=A0 4444 %%%% !5&__P!?8_\
M7P/_ $%JO51O_P#7V/\ U\#_ -!:G'<4MB]1112&%%%% !1110 4444 !Z5X
MQ+_KI/\ ?;^=>SGI7C$O^ND_WV_G7AYOM#YGO9-O/Y#:***\(^@$/2O9;?\
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MO]P?RKV\IWG\CP,Y^Q\R6BBBO>/ "BBB@ HHHH **** "BBB@ HHHH **0D
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M^@:/^_O_ -:LNS\6+::K<WJZ-;*9L8*/AEP.>W>M_JE;^4Q^M4NYZ=17"?\
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M5YU7HO@#_D"S_P#7<_R%<6-_A'9@_P"*:.M^(HM$FACDMY)3*I8%2!C%9?\
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MY]:ZA]5M4UJ/26=EO)(&N$4J<,@(!P>F02./>DLM6L[^:\CMY=QLY_L\Q((
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M61S5:LZLN:;NQG[_ /Z9_K1^_P#^F?ZU)16ID1_O_P#IG^M'[_\ Z9_K4E%
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MP&!G S@<U6\#:9<Q:G83SRM#=P6KI?1+8R1M*YQDRR,Q5R&!((SU/:O2J*
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V @D# 2(  A$! Q$!_\0
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M(V=K<Y4LPRP /S!5//O]*@AUC57N%1XN-Z+&/L[#[2A<J7S_  84!L&NHHH
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445A0:Y,^K/;RK
M"D2RR(RX(>-5'#L>F&[?4<F@#=HKEV\2W8GFC-O&@68Q@E2PB4.%WR$'(&#D
M# R.]+#XCO)+A8VAA&'15 5LW"ERI>/T  W=^* .GHH%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4XE,+
M>5((WQPQ7=C\,BJNCSW%UI5M<W+H[SQ+(=B;0N0#CJ:O/]QOI5#0?^1>TW_K
MVC_]!% &A1110 4444 %%%% !1110 4444 %)CWI:* $Q2XHHH  ,4444 %%
M%% !1110 4444 %%%% !1110 445&LT;G"2(Q] P- $E% .:* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1Y2#T]0:/93_ )7]P>TAW1T]%8__  E>A_\ 01B_(_X4?\)7H?\ T$8OR/\
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MOK]17MR_='TKQ%?OK]17MR_='TKRLPWB>G@/M#A10**\P](**** "BH9;J"
M@331QD] [@9_.I5(89&"#T(H 6BBB@ HHHH **** "BBB@ HHHH **** "H+
MN<VUI+/MW;%+8SC-3U3U7_D%W/\ US-88B3A2E*.Z3_(N"3DDS(_X2=O^?0?
M]]__ %J/^$G;_GT'_??_ -:L"BOS;^W<?_S\_!?Y'T'U*AV-_P#X2=O^?0?]
M]_\ UJS[KQ+>G4(##%<+!SYJIL(Z<<D9Z]:H44XY_CUO._R7^0G@:'8W_P#A
M)F_Y]!_WW_\ 6H_X2=O^?0?]]_\ UJP**G^WL?\ \_/P7^0_J5#^4W_^$G;_
M )]!_P!]_P#UJU].O3?V@G*;,L1C.>E<376>'O\ D%+_ +[?SKW<CS/%8K$N
M%:5U9]$<6-P].E3YH+6YJUXM\0?^1TO/]R/_ -!%>T]J\6^(/_(Z7G^Y'_Z"
M*_1<N_C?)GS^*^ YBBBBOH#RPHHHH **** .D\ _\CI8_23_ - ->VUXEX!_
MY'2Q^DG_ * :]MKY_,?XWR/3PGP!1117G'6%87B+1I]6A5,Z=+ HR8+ZV+KN
M_O!@P*FMVL'Q?JEMI?ANZFNH1,CC8(WMVF5B3T95[?E0!E:9X7U33KEIK6#0
M;&5EVM<16\LTF/0%F&!78H"J*&;<P'+8QD^M><Z5ID7]J016>LZ[&\I;]W86
M;V]K" ,[F68,,=ASWZ5Z-&&6-59B[ 8+'&3[\4 .HHHH **** "BBB@ HHHH
M **** "BBB@ KB?B)_JM/_WG_D*[:N)^(G^JT_\ WG_D*Z,+_%B<^)_A,X2B
MBBOH#P@HHHH **** %7[Z_45[<OW1]*\17[Z_45[<OW1]*\K,-XGIX#[0X45
M'*Y2%W'55)K@QX\U# _T2V_-O\:\.MB:=&W.]SVZ&%JU[^S6QZ!17 ?\)YJ'
M_/I;?^/?XT?\)YJ'_/I;?^/?XUS_ -I8?O\ @=/]F8GM^)U&NQQN=.+HK'[;
M&.1GUK6 P,#I7FM_XTO9_LF^UM_W=RCC!;J,^]7/^$\O_P#GTMO_ ![_ !I_
MVCA[7O\ @+^S<3>UOQ._HK@/^$\U#_GTMO\ Q[_&C_A/-0_Y]+;_ ,>_QH_M
M+#]_P'_9F)[?B=_0:PO#6M3ZU;SR3Q1QF-PH"9YXSWK=KLIU(U(J<=F<-2G*
MG)PENC#UGQ!_9%U'#]F,N]-^=^W'./2L[_A-A_SX'_O[_P#6JMXS_P"0G;_]
M<?\ V8US=:&9UO\ PFP_Y\#_ -_?_K4V3QJ&C8&Q=<CJLO(^G%<I10!O:7XQ
MDCBD\Z"YF<NW^NDQA=QVX^4=L5?_ .$V'_/@?^_O_P!:N2HH ZW_ (38?\^!
M_P"_O_UJEM/%XNKR&W^Q%?-<)N\W.,GZ5QM6])_Y#-E_UW3^= 'I]4]5_P"0
M7<_]<S5RJ>J_\@NY_P"N9KFQ?\"?H_R9=/XUZG$T445^.L^L"BBB@ HHHH *
MZSP]_P @I?\ ?;^=<G76>'O^04O^^W\Z^FX9_P!\?HSSLQ_A?,U>U>+?$'_D
M=+S_ '(__017M/:O%OB#_P CI>?[D?\ Z"*_5LN_C?)GR^*^ YBBBBOH#RPH
MHHH **** .D\ _\ (Z6/TD_] ->VUXEX!_Y'2Q^DG_H!KVVOG\Q_C?(]/"?
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MX3.$HHHKZ \(**** "BBB@!5^^OU%>W+]T?2O$5^^OU%>W+]T?2O*S#>)Z>
M^T,N/^/6;_</\J\:'05[+<?\>LW^X?Y5XT.@KX_-OL?,^QR;[?R%HHHKPSWP
MHHHH **** .Z\ _\>5[_ -=1_P"@UU]<AX!_X\KW_KJ/_0:Z^OKL%_N\3XW'
M?[Q/U.)\9_\ (3M_^N/_ +,:YNND\9_\A.W_ .N/_LQKFZZSC"BBB@ HHHH
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M(F.Q6.'8\_-MZ\8J&'7-2>X5&B4?.BQCR&'VE2Y4N#GY<* V#FNGHH ****
M"BBB@ HHHH **** "N)^(G^JT_\ WG_D*[:N)^(G^JT__>?^0KHPO\6)SXG^
M$SA****^@/""BBB@ HHHH 5?OK]17MR_='TKQ%?OK]17MR_='TKRLPWB>G@/
MM#+C_CUF_P!P_P J\:'05[+<?\>LW^X?Y5XT.@KX_-OL?,^QR;[?R%HHHKPS
MWPHHHH **** .Z\ _P#'E>_]=1_Z#77UR'@'_CRO?^NH_P#0:Z^OKL%_N\3X
MW'?[Q/U.)\9_\A.W_P"N/_LQKFZZ3QG_ ,A.W_ZX_P#LQKFZZSC"BBB@ HHH
MH *MZ3_R&;+_ *[I_.JE6])_Y#-E_P!=T_G0!Z?5/5?^07<_]<S5RJ>J_P#(
M+N?^N9KFQ?\  GZ/\F73^->IQ-%%%?CK/K HHHH **** "NL\/?\@I?]]OYU
MR==9X>_Y!2_[[?SKZ;AG_?'Z,\[,?X7S-7M7BWQ!_P"1TO/]R/\ ]!%>T]J\
M6^(/_(Z7G^Y'_P"@BOU;+OXWR9\OBO@.8HHHKZ \L**** "BBB@#I/ /_(Z6
M/TD_] ->VUXEX!_Y'2Q^DG_H!KVVOG\Q_C?(]/"? %%%%><=84444 %%%% !
M1110 44&HH9'D#;X7BP<#<0<CUX)H EHHHH **** "BBB@ HHHH *XGXB?ZK
M3_\ >?\ D*[:N;\5Z%=ZVEJ+5XE\HL6\QB.N/0>U;X>2C439AB(N5-I'F5%=
M1_P@6K_\];3_ +[/^%'_  @6K_\ /6T_[[/^%>S]9H_S'D?5ZO\ *<O174?\
M(%J__/6T_P"^S_A1_P (%J__ #UM/^^S_A1]9H_S!]7J_P IR]%=1_P@6K_\
M];3_ +[/^%'_  @6K_\ /6T_[[/^%'UFC_,'U>K_ "G,+]]?J*]N7[H^E><C
MP'JX8'S;3@_WS_A7HR@@#->=C:D)M<KN=^#IRA?F5AEQ_P >LW^X?Y5XT.@K
MV:9"\+H.K*0/RKSX>!]5P/WEK_WV?\*^8S*C4J\O(KGU&5UZ=+F]H[7L<W17
M2_\ "#ZK_P ]+7_OL_X4?\(/JO\ ?M?^^S_A7D_4L1_*SV?KV&_G1S5%=+_P
M@^J_W[;_ +[/^%'_  @^J_W[;_OL_P"%'U+$?R,/KV&_G1S5%=+_ ,(/JO\
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M)BY49Q6[3_(N#M)-G"T5K_\ ".7W]Z'_ +Z/^%'_  CE]_>A_P"^C_A7Y?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"EJ>G_VC;I&)C"\<R3(X4'#*P(X/;BH_L>I_P#047_P&'^-:-% &=]C
MU/\ Z"B_^ P_QH^QZG_T%%_\!A_C6C10!G?8]3_Z"B_^ P_QH^QZG_T%%_\
M 8?XUHT4 9WV/4_^@HO_ (##_&C['J?_ $%%_P# 8?XUHT4 9WV/4_\ H*+_
M . P_P :/L>I_P#047_P&'^-:-% &=]CU/\ Z"B_^ P_QH^R:G_T%%_\!A_C
M6C10!G?9-3_Z"B_^ P_QH^R:G_T%%_\  8?XUHT4 9WV34_^@HO_ (##_&C[
M'J?_ $%%_P# 8?XUHT4 9WV34_\ H*+_ . P_P :/LFI_P#047_P&'^-:-%
M&=]DU/\ Z"B_^ P_QH^R:G_T%%_\!A_C6C10!G?8]3_Z"B_^ P_QH^QZG_T%
M%_\  8?XUHT4 9WV/4_^@HO_ (##_&C['J?_ $%%_P# 8?XUHT4 9WV/4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R6))XGBD4-&ZE64]P
M>"*SSX?TLP6D(M%1;-/+MS&S(T28QM#*00, <9["BB@!YT336GBF:SB>2*!K
M=6<;OW;$%E.>H.!G-16WAO2+-@T-D@(B,*[F9MB'JJY)V@^@Q110!-#HNG6Y
ML3#:1)]@C,5K@?ZI2 "!]0!^510^'=(MWB>*PA1H1*(R ?E\TYD_[Z/)HHH
MN65C;Z=9065G$L-M @CBC7HJCH!5.\\/:9?W\5]=6[27,))BD\YP4)&#MP>,
MC@XZT44 2:?I,5A>7]V)9I9KV422&1LA0 %55'0  ?4\DU?(HHH YG2O >AZ
M7I]G:^0]PUHQ>*::1MZ,23E<'"]3TQGO6C/X9T6ZM'M9]-MY;=[DW;1NN09B
E<E_KFBB@"Y%I]K#J$]_' BW5PB)+*.KJN=H/TW'\ZM444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>aud_001.jpg
<TEXT>
begin 644 aud_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A!T@# 2(  A$! Q$!_\0
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M "[J/J<9H$\1&?-3_OH4#N245'YT>?\ 6)_WT*%FC=MJR(3Z!A0%R2BBDS0
MM%,>5$/S2(OU.*3SXSTD3'KN% $E%1&>,=9$'U84Y'#KN5E8>H.10 ^BD!I:
M "BBB@ HHI#P* %HICN$&68*/4GBFB>,C_6(?^!"@"6BHO.3_GHG_?0H^T1#
MK+&/^!"@5R6BHO/B/ FC/_ A3PV1D$'Z4#'44F>:,F@!:*** "BBB@ HHHH
M**,U#/<1VT$D\SB.*-2SLW0"@":BJ&E:Q9:W8B]T^=9H"Q4,/45?IM-.S$FF
MKH****0PHHHH **** "BBB@ HHHH S-3T'2M;\O^T[""[\K.SS5SMSUJ@/ G
MA7OH-C_W[JIXR\<VW@W[']IMY)OM.[&SMBN7_P"%WZ5VTZXKHITJ\HWA>QSS
MJ48RM*USL_\ A!/"G_0!L?\ OU1_P@GA3_H V/\ WZKC/^%X:5_T#KC\Z/\
MA>&E?] ZX_.M/8XGL_O(]KA_+[CL_P#A!/"G_0!L?^_5'_"">%/^@#8_]^JX
MS_A>&E?] ZX_.C_A>&E?] ZX_.CV.)[/[P]KA_+[CL_^$$\*?] &Q_[]4?\
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MW@_PW#X7\/V]A&!YN-TSXY9SUKH:QQ.(=65EL;8>@J<;O<0"EHHKD.H****
M"@]*** .>\7>%QXJTD6+7LMJ%??OB/7V->.^,/ .L^$-/%[!JTMW9@[6Y*E/
MUZ5]!USGCJW2Z\%:K%)PIA)_(UU8>O*$E%;'-7HQG%RZGS*=1O<?\?=P<=/W
MAKT+3_A-X@U?3H+V;4UC,R!U4N3P>F:\S7^'KG(YKZUT'_D :<3_ ,^R?R%>
MEC*LJ27)U//PE.-1OF/&;CX/^)[4;['48I& Y'FE:Y^YOO'/@^91<75_:IG"
M[CNC>OI<_C^%5;ZPM=2M7M;VWCGA<8*.,UPQQLMJB31V2P<?L.S/'?#OQIN8
MY5AU^W62,X'GPC!'X=Z]AT_4;35+*.[LIUF@<9#*<_G7SW\1/ S^$[Y9[;+Z
M;<,?+8_\LS_=-+\-/%LOAS7X[.>0_P!GW;!)%)X1NS"MZN&IU*?M*1C2Q$X3
M]G5/H[-+3,YZ?G3QTKRCTPHHHH **** $8XKS+XQ>(O[/T*/2(7(FOC\X':,
M=:]*FD2*)I';"("S'T KYC\5ZE>>,/%&H7]K$\\,*G8%Z+$O&:[,'24ZG,]D
M<F+J<L++=G9_!37!!>7FB2G"R 2P@G@$=1^->V#I7R5H&JRZ)K=EJ,+<P2AC
MGN.]?6%I=17MG#=0,&BE0.I'<&KQU/EFI]R,%4YH<O8FHHHK@.X**** "BBB
M@ HHHH **** /&_CK][1/K+_ $KQRO<OC#H6KZVVD?V7I\]WY1D\SRESMSC%
M>7_\(%XL/3P_?8]T'^->[A*D%12;/%Q5.;JMI'.T5T7_  @/BW_H7[W_ +X'
M^-'_  @/BW_H7[W_ +X'^-=7M8=U]YR^RGV9SM%=%_P@/BW_ *%^]_[X'^-'
M_" ^+?\ H7[W_O@?XT>UAW7WA[*?9G.T5T7_  @/BW_H7[W_ +X'^-'_  @/
MBW_H7[W_ +X'^-'M8=U]X>RGV9SM%3W=G<6%S+:W<+PW$3;9(W'*FH#UJT[Z
MHAJP?CBC/?H.@SWHKH?!6@MXC\5V=BR$PAM\Q_V!UI2DHIR8X1<GRH]%^%/@
M)5B3Q#JL.YVYM8F'W1_>->GZUK-GH.E3:C?2;(8AGW8]@/>KL<*0Q)#$H5$4
M*H'85X-\8/$KZAX@&D0R'[/9_?4="_?->%%2Q5;WOZ1[4G'#4M#F_%WC/4O%
ME^9)Y#'9J?W-NIX4>I]ZYJE/6DKW8QC!<L59'BRDY.["BBBJ)"BBB@ J6WN9
MK2=)K>9XI%.5=#@@U%10-.Q[A\/OB@-2>/2=<D5+G[L5P>!)['WKU3KTZ5\>
M D$$=0>".HKWSX5>-6URQ.D7\N;ZU7Y&/61/\17CXS"J/[R&QZV$Q+E[DCOM
M3@^TZ5=P#K)"R_F*^2+A/+NIH_[DC+^1K[!Z\5\E:Y;FUU_4(2,%;A_U)IY<
M]9(G,%I%F?1117KGE'JWP+_Y#6K_ /7NG_H5>XCI7AWP+_Y#6K_]>Z?^A5[B
M.E?/XW^,_D>[@_X*"BBBN0ZPHHHH **** "LCQ2Y3PMJC X/V9_Y5KU3U6U^
MW:5=VF,F:%D'U(JHNTDR9*\6CY[^$U]#:>.+19L 3QLBL>QQ7T=GVKY#DCGT
MR_:(,\5Q:RD C@J5->T>$/B]974*6?B!OLURH ^T ?(_U]#7J8VA*;52.IYN
M$K1BG"1ZM15:UOK6]A66UN(IHR,AD8'BK&<]*\D]0#TJGJ-C'J6FW%E,/DGC
M*'VSWJYU-&WZT)VU0FKJQPGPS\,:CX6L-4L[_&U[G= 5.<H!C-=V*-HI0,5<
MYN<G)[LF$5"*B@HHHJ"PKG?&_B!/#GABZO"P$S*8X1W+&NAR:\)^*NM2>(O%
M5MX>L<NL#!"%Y!D;O^%=&&I^TJ6>RW,,14Y(-K<O?!GP^]U>W7B.[4O@E(6;
M^)C]YOZ5R/Q*T'^P?&%PD:E8+H^?&W;G[WZU] ^'-'BT'0+/38@ (HQNQW;N
M?SKCOC#H']I>&%U&)<S6#;CZLAZBNFEB;XB_1Z'+4P_[BW5:F#\%-?\ ^/O0
MYW'_ #V@!].XKV05\H>&M7?0O$=GJ,9XBE&X?[)ZU]5VT\=U;1W$+;HI5#H?
M4$9%3CZ?+4YNY>"J<T.5]"6BBBN [@I#2TAH \2^.O\ R%=&_P"N,G\Q7/\
MPF_Y'RW_ .N9KH/CK_R%=&_ZXR?S%<_\)O\ D?+?_KF:]NG_ +H_0\>?^]?,
M^CJ***\0]@**** "BBB@ KY4\9?\CMK?_7Y)_.OJNOE3QE_R.VM_]?DG\Z]+
M+OCEZ'GX_P"!>I[)\%O^1)?_ *^7KT8=Z\X^"Q'_  A3C/(N7KT8'WKDQ/\
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M#NF+>^,C<NN5M(2ZGT8G _2OH0#G-:8Z5FJ4=D9X.-TZCW8M%%%>>=X4444
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MX2BBBO7/*/5O@7_R&M7_ .O=/_0J]Q'2O#O@7_R&M7_Z]T_]"KW$=*^?QO\
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M:>(:U=T=GX#TGPYI>D!="NH;MGYEN%(W.?Z"NN' KY,#:KX;U=D#SV5] V"
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M)6[T*9NG[Z'/ZBO3QL/:4E/JCS\)/DJN'1GL2]*6D%+7C'KA1110!X7\<O\
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M%;UH;R)I+<G]U<J/E8?T-<^,,1@BOH8R4E>.IX,HN+LPHHHJB0HHHH ****
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M^9]'4445XA[ 4444 %%)GM0#F@!:^5/&7_([:W_U^2?SKZKKY4\9?\CMK?\
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M %CA0(H'M5K%5/&57)M/0F&$IJ*36IY+_P *,L/^@O-_W[%!^!ECC_D+S?\
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MCX5_\E(_"7^M?0PKYZ^%?_)2/PE_K7T**6._B+T16#_AOU%HHHKA.T*#10:
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M_I7CWUKTJ&#52"FV>?6Q;IS<4CZI_P"$S\-_]!JT_P"^Z/\ A,_#?_0:M/\
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M2>(?%-C9!"8MXDF(Z*H.370>-/%M[X_U>'3=)MY7M$?$,0',C?WC7J?P_P#
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MH!6>)DY[$C@U\I:GIL^D:C<:;=*5EA<HP;N.Q_*OKH]:\_\ B+\/5\36YO\
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M"?2O0B :,5$\55FK-E0PU.+ND-[&O*?$'PR\0^(=2GN+O70\!?,4+9P@KUC
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MAW.NS1FN1_X6=X/_ .@S#^1H_P"%G>#_ /H,P_D:/8U/Y6'M8=SKLT9KD?\
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MVL.YUV:,UR/_  L[P?\ ]!F'\C1_PL[P?_T&8?R-'L:G\K#VL.YUV:,UR/\
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M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
M2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%
M&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[
M(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK
M_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH
M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
M2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%
M&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[
M(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK
M_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH
M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
M2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%
M&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[
M(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK
M_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH
M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
M2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%
M&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[
M(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK
M_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH
M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
M2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%
M&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[
M(YO_ (0'PK_T!+7_ +XH_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK
M_P! 2U_[XH_X0'PK_P! 2U_[XKI,48H]K4[L/9P[(YO_ (0'PK_T!+7_ +XH
M_P"$!\*_] 2U_P"^*Z3%&*/:U.[#V<.R.;_X0'PK_P! 2U_[XH_X0'PK_P!
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MM?\ OBC_ (0'PK_T!+7_ +XKI,48H]K4[L/9P[(YO_A ?"O_ $!+7_OBC_A
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MF#_@H****Y#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=R(.=%2@HW['4_"_Q;KGBJ2_DU26&2"' CV1!""?I[5R/Q>_Y'W3#_TS4?\
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M_7NG_H5>XCI7S^-_C/Y'NX/^"@HHHKD.L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@T7"S(Z*D\B?_GA+_P!\&CR)_P#GA+_WP:+A9D=%2>1/_P \)?\ O@T>1/\
M\\)?^^#1<+,]2^!?_(:U?_KW3_T*O<1TKQ#X&QR)K6K[XW7-NGWE(_BKV\=*
M^?QO\9_(]S!_P4%%%%<AUA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <=XYZV7_  +^E<A117?1^ X:OQA1116ID%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =3X
M'_X_;S_KF/YUVXHHK@K?&=U'X HHHK(U"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>telo-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeCibP9z5Z8yekhvWB/bQnqfykhZz56VyEiKQF2gQwJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:TELO="http://telomirpharma.com/20241231" elementFormDefault="qualified" targetNamespace="http://telomirpharma.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://telomirpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Description of business and summary of significant accounting policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999016 - Disclosure - Going Concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" id="LicenseAgreementRelatedParty">
          <link:definition>999017 - Disclosure - License agreement, related party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" id="RelatedPartyBalancesAndTransactions">
          <link:definition>999018 - Disclosure - Related party balances and transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/Leases" id="Leases">
          <link:definition>999019 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999020 - Disclosure - Stockholders&#8217; equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999021 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999023 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999024 - Disclosure - Stockholders&#8217; equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999025 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999027 - Disclosure - Going Concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" id="LicenseAgreementRelatedPartyDetailsNarrative">
          <link:definition>999028 - Disclosure - License agreement, related party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" id="RelatedPartyBalancesAndTransactionsDetailsNarrative">
          <link:definition>999029 - Disclosure - Related party balances and transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" id="ScheduleOfComponentsOfLeaseExpensesDetails">
          <link:definition>999030 - Disclosure - Schedule of components of lease expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999031 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999032 - Disclosure - Schedule of warrant activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" id="ScheduleOfWarrantActivityDetailsParenthetical">
          <link:definition>999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" id="ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails">
          <link:definition>999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" id="ScheduleOfOptionActivityDetails">
          <link:definition>999035 - Disclosure - Schedule of option activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" id="ScheduleOfNonVestedShareBasedCompensationDetails">
          <link:definition>999036 - Disclosure - Schedule of non vested share based compensation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" id="ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails">
          <link:definition>999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999038 - Disclosure - Stockholders&#8217; equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" id="ScheduleOfNetDeferredTaxAssetsDetails">
          <link:definition>999039 - Disclosure - Schedule of net deferred tax assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>999040 - Disclosure - Schedule of provision for income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" id="ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails">
          <link:definition>999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999042 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="telo-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="TELO_BayShoreTrustMember" name="BayShoreTrustMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_MiralogxLLCMember" name="MiralogxLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StarwoodTrustMember" name="StarwoodTrustMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TampaFloridaMember" name="TampaFloridaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" name="TwoThousandTwentyThreeOmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" name="BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_UnderwriterWarrantMember" name="UnderwriterWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_BayShoreTrustWarrantsMember" name="BayShoreTrustWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" name="TwoThousandTwentyThreePrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" name="MeasurementInputFairMarketValueUnderlyingCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockOptionsOneMember" name="StockOptionsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" name="IssuanceOfWarrantsOnRelatedPartyLineOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_AccruedOfferingExpense" name="AccruedOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DebtConversionToCommonStock" name="DebtConversionToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_AdvancesToAffiliates" name="AdvancesToAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" name="DeferredOfferingCostsChargedToAdditionalPaidinCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DeferredFinanceCosts" name="DeferredFinanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" name="DisclosureLicenseAgreementRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_LicenseAgreementRelatedPartyTextBlock" name="LicenseAgreementRelatedPartyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_ProceedsFromInitialPublicOfferingNetProceeds" name="ProceedsFromInitialPublicOfferingNetProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_PercentageOfRoyaltyPayable" name="PercentageOfRoyaltyPayable" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_OfferingCosts" name="OfferingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_IncomeTaxRateReconciliationPermanentItems" name="IncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_IncomeTaxRateReconciliationDeferredTrueUps" name="IncomeTaxRateReconciliationDeferredTrueUps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps" name="EffectiveIncomeTaxReconciliationDeferredTrueUps" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>telo-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://telomirpharma.com/role/Cover" xlink:href="telo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheets" xlink:href="telo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:href="telo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfOperations" xlink:href="telo-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="telo-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:href="telo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="telo-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcern" xlink:href="telo-20241231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/Leases" xlink:href="telo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquity" xlink:href="telo-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxes" xlink:href="telo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesTables" xlink:href="telo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityTables" xlink:href="telo-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesTables" xlink:href="telo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:href="telo-20241231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="telo-20241231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:href="telo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:href="telo-20241231.xsd#ScheduleOfNonVestedShareBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="telo-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="telo-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="telo-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="telo-20241231.xsd#ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="telo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Description of business and summary of significant accounting policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999016 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999017 - Disclosure - License agreement, related party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:title="999018 - Disclosure - Related party balances and transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related party balances and transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999030 - Disclosure - Schedule of components of lease expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999032 - Disclosure - Schedule of warrant activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:title="999035 - Disclosure - Schedule of option activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:title="999036 - Disclosure - Schedule of non vested share based compensation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - Stockholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999039 - Disclosure - Schedule of net deferred tax assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999040 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:title="999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IncomeTaxRateReconciliationPermanentItems" xlink:label="loc_TELOIncomeTaxRateReconciliationPermanentItems" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_TELOIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_TELOEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TELOEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>telo-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://telomirpharma.com/role/Cover" xlink:href="telo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheets" xlink:href="telo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:href="telo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfOperations" xlink:href="telo-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="telo-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:href="telo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="telo-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcern" xlink:href="telo-20241231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/Leases" xlink:href="telo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquity" xlink:href="telo-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxes" xlink:href="telo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesTables" xlink:href="telo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityTables" xlink:href="telo-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesTables" xlink:href="telo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:href="telo-20241231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="telo-20241231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:href="telo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:href="telo-20241231.xsd#ScheduleOfNonVestedShareBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="telo-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="telo-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="telo-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="telo-20241231.xsd#ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="telo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_TELOStockIssuedDuringPeriodValueReverseStockSplits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueReverseStockSplits_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DeferredFinanceCosts" xlink:label="loc_TELODeferredFinanceCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELODeferredFinanceCosts_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Description of business and summary of significant accounting policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999016 - Disclosure - Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999017 - Disclosure - License agreement, related party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:title="999018 - Disclosure - Related party balances and transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:label="loc_TELOScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="loc_TELOPercentageOfRoyaltyPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_TELOPercentageOfRoyaltyPayable_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related party balances and transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense_190" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999030 - Disclosure - Schedule of components of lease expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TampaFloridaMember" xlink:label="loc_TELOTampaFloridaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_TELOTampaFloridaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapVariableLeaseCost_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999032 - Disclosure - Schedule of warrant activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="loc_TELOBayShoreTrustWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOBayShoreTrustWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOUnderwriterWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:title="999035 - Disclosure - Schedule of option activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:title="999036 - Disclosure - Schedule of non vested share based compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockOptionsOneMember" xlink:label="loc_TELOStockOptionsOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_TELOStockOptionsOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PlacementAgentMember" xlink:label="loc_TELOPlacementAgentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOPlacementAgentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:label="loc_TELOBoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOBoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_OfferingCosts" xlink:label="loc_TELOOfferingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOOfferingCosts_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_200" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_200" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_200" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_200" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_200" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_200" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_200" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_200" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999039 - Disclosure - Schedule of net deferred tax assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999040 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:title="999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>telo-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="TELO_BayShoreTrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustMember" xlink:to="TELO_BayShoreTrustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BayShoreTrustMember_lbl" xml:lang="en-US">Bay Shore Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="TELO_MiralogxLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MiralogxLLCMember" xlink:to="TELO_MiralogxLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MiralogxLLCMember_lbl" xml:lang="en-US">Miralogx LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StarwoodTrustMember" xlink:label="TELO_StarwoodTrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StarwoodTrustMember" xlink:to="TELO_StarwoodTrustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StarwoodTrustMember_lbl" xml:lang="en-US">Starwood Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TampaFloridaMember" xlink:label="TELO_TampaFloridaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TampaFloridaMember" xlink:to="TELO_TampaFloridaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TampaFloridaMember_lbl" xml:lang="en-US">Tampa, Florida [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PlacementAgentMember" xlink:label="TELO_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PlacementAgentMember" xlink:to="TELO_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_lbl" xml:lang="en-US">2023 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:label="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:to="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_lbl" xml:lang="en-US">Board of Directors, Executive Officers, Employees and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="TELO_UnderwriterWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_UnderwriterWarrantMember" xlink:to="TELO_UnderwriterWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_UnderwriterWarrantMember_lbl" xml:lang="en-US">Underwriter Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="TELO_BayShoreTrustWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustWarrantsMember" xlink:to="TELO_BayShoreTrustWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_BayShoreTrustWarrantsMember_lbl" xml:lang="en-US">Bay Shore Trust Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:to="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_lbl" xml:lang="en-US">2023 Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:to="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_lbl" xml:lang="en-US">Measurement Input Fair Market Value Underlying Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockOptionsOneMember" xlink:label="TELO_StockOptionsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockOptionsOneMember" xlink:to="TELO_StockOptionsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockOptionsOneMember_lbl" xml:lang="en-US">Stock Options One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Trade accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Related party line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, no par value; 300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Related party travel costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common stock shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common stock shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt conversion to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt conversion to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="TELO_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="TELO_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Shares added for fractional shares pursuant to reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares added for fractional shares pursuant to reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of Warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from Operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Credit loss expense- loan due from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Trade accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Payments under related party line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from (payments to) due to/from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Borrowings under related party line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" xlink:label="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" xlink:to="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit_lbl" xml:lang="en-US">Issuance of warrants on related party line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_AccruedOfferingExpense" xlink:label="TELO_AccruedOfferingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AccruedOfferingExpense" xlink:to="TELO_AccruedOfferingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_AccruedOfferingExpense_lbl" xml:lang="en-US">Accrued offering expense</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DebtConversionToCommonStock" xlink:label="TELO_DebtConversionToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DebtConversionToCommonStock" xlink:to="TELO_DebtConversionToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TELO_DebtConversionToCommonStock_lbl" xml:lang="en-US">Debt conversion to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_AdvancesToAffiliates" xlink:label="TELO_AdvancesToAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AdvancesToAffiliates" xlink:to="TELO_AdvancesToAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_AdvancesToAffiliates_lbl" xml:lang="en-US">Advances to affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:label="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:to="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital_lbl" xml:lang="en-US">Deferred offering costs charged to additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Fair value of total warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DeferredFinanceCosts" xlink:label="TELO_DeferredFinanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DeferredFinanceCosts" xlink:to="TELO_DeferredFinanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DeferredFinanceCosts_lbl" xml:lang="en-US">Deferred finance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for Other Fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Related party debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Advances received for conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Advances received for conversion, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Debt conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Amounts due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_NoInsiderTradingFlag" xlink:label="TELO_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_NoInsiderTradingFlag" xlink:to="TELO_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of business and summary of significant accounting policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="TELO_DisclosureLicenseAgreementRelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DisclosureLicenseAgreementRelatedPartyAbstract_lbl" xml:lang="en-US">License Agreement Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_LicenseAgreementRelatedPartyTextBlock" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyTextBlock" xlink:to="TELO_LicenseAgreementRelatedPartyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock_lbl" xml:lang="en-US">License agreement, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related party balances and transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="TELO_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLeasesAbstract" xlink:to="TELO_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ReverseStockSplitPolicyTextBlock" xlink:label="TELO_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ReverseStockSplitPolicyTextBlock" xlink:to="TELO_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">[custom:ReverseStockSplitPolicyTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_InitialPublicOfferingPolicyTextBlock" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_InitialPublicOfferingPolicyTextBlock" xlink:to="TELO_InitialPublicOfferingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US">Initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of key assumptions used to value stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:label="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:to="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_lbl" xml:lang="en-US">Schedule of non vested share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">IPO units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Initial public offering shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting commission and other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:to="TELO_ProceedsFromInitialPublicOfferingNetProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds_lbl" xml:lang="en-US">Initial public offering net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Raised amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash in operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="TELO_PercentageOfRoyaltyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PercentageOfRoyaltyPayable" xlink:to="TELO_PercentageOfRoyaltyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_PercentageOfRoyaltyPayable_lbl" xml:lang="en-US">Percentage of royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_2_lbl" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-Term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Unused line of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Accrue interest at a rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Purchase of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_2_lbl" xml:lang="en-US">Travel-related expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DisclosureLeasesAbstract" xlink:to="TELO_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TELO_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VariableLeaseCost_2_lbl" xml:lang="en-US">Variable lease, cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants Exercisable, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Expected term in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeitures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding, outstanding number of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Aggregate Intrinsic Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Issue of shares of capital stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Equity issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_OfferingCosts" xlink:label="TELO_OfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OfferingCosts" xlink:to="TELO_OfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_OfferingCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock are reserved for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of options, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Share based compensation fair market value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share based compensation term of years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Section 174 Qualified Research Expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">R&amp;D Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total net deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total provision for income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Book Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax Benefit at U.S. Federal Statutory Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax Benefit at U.S. Federal Statutory Rate, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State Taxes, Net of Federal Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State Taxes, Net of Federal Benefit, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IncomeTaxRateReconciliationPermanentItems" xlink:label="TELO_IncomeTaxRateReconciliationPermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IncomeTaxRateReconciliationPermanentItems" xlink:to="TELO_IncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_IncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US">Permanent Items</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US">Permanent Items, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">State Rate Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">State Rate Change, Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Net actual effective rate, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="TELO_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Stock issued during period value reverse stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" xlink:to="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit_doc" xml:lang="en-US">Issuance of warrants on related party line of credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AccruedOfferingExpense" xlink:to="TELO_AccruedOfferingExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_AccruedOfferingExpense_doc" xml:lang="en-US">Accrued offering expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DebtConversionToCommonStock" xlink:to="TELO_DebtConversionToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_DebtConversionToCommonStock_doc" xml:lang="en-US">Debt conversion to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_AdvancesToAffiliates" xlink:to="TELO_AdvancesToAffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_AdvancesToAffiliates_doc" xml:lang="en-US">Advances to affiliates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustMember" xlink:to="TELO_BayShoreTrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BayShoreTrustMember_doc" xml:lang="en-US">Bay Shore Trust [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DeferredFinanceCosts" xlink:to="TELO_DeferredFinanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_DeferredFinanceCosts_doc" xml:lang="en-US">Deferred finance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MiralogxLLCMember" xlink:to="TELO_MiralogxLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MiralogxLLCMember_doc" xml:lang="en-US">Miralogx LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_InitialPublicOfferingPolicyTextBlock" xlink:to="TELO_InitialPublicOfferingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_InitialPublicOfferingPolicyTextBlock_doc" xml:lang="en-US">Initial Public Offering [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:to="TELO_ProceedsFromInitialPublicOfferingNetProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ProceedsFromInitialPublicOfferingNetProceeds_doc" xml:lang="en-US">Proceeds from initial public offering net proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_LicenseAgreementRelatedPartyTextBlock" xlink:to="TELO_LicenseAgreementRelatedPartyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_LicenseAgreementRelatedPartyTextBlock_doc" xml:lang="en-US">License Agreement Related Party [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PercentageOfRoyaltyPayable" xlink:to="TELO_PercentageOfRoyaltyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_PercentageOfRoyaltyPayable_doc" xml:lang="en-US">Percentage of royalty payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StarwoodTrustMember" xlink:to="TELO_StarwoodTrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StarwoodTrustMember_doc" xml:lang="en-US">Starwood Trust [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:to="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_doc" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Option [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_StockOptionsOneMember" xlink:to="TELO_StockOptionsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_StockOptionsOneMember_doc" xml:lang="en-US">Stock Options One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_NoInsiderTradingFlag" xlink:to="TELO_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TampaFloridaMember" xlink:to="TELO_TampaFloridaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TampaFloridaMember_doc" xml:lang="en-US">Tampa, Florida [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_PlacementAgentMember" xlink:to="TELO_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:to="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_doc" xml:lang="en-US">Board of Directors, Executive Officers, Employees and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:to="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember_doc" xml:lang="en-US">Measurement Input Fair Market Value Underlying Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_UnderwriterWarrantMember" xlink:to="TELO_UnderwriterWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_UnderwriterWarrantMember_doc" xml:lang="en-US">Underwriter Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_BayShoreTrustWarrantsMember" xlink:to="TELO_BayShoreTrustWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_BayShoreTrustWarrantsMember_doc" xml:lang="en-US">Bay Shore Trust Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:to="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember_doc" xml:lang="en-US">2023 Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:to="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember_doc" xml:lang="en-US">2023 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IncomeTaxRateReconciliationDeferredTrueUps" xlink:label="TELO_IncomeTaxRateReconciliationDeferredTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_IncomeTaxRateReconciliationDeferredTrueUps" xlink:to="TELO_IncomeTaxRateReconciliationDeferredTrueUps_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_IncomeTaxRateReconciliationDeferredTrueUps_doc" xml:lang="en-US">Income Tax Rate Reconciliation Deferred True Ups</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Items.</link:label>
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:label="TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_EffectiveIncomeTaxReconciliationDeferredTrueUps_doc" xml:lang="en-US">Effective Income Tax Reconciliation Deferred True Ups.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_ReverseStockSplitPolicyTextBlock" xlink:to="TELO_ReverseStockSplitPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_ReverseStockSplitPolicyTextBlock_doc" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_OfferingCosts" xlink:to="TELO_OfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TELO_OfferingCosts_doc" xml:lang="en-US">Offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_DebtConversionToCommonStock" xlink:to="TELO_DebtConversionToCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_DebtConversionToCommonStock_3_lbl" xml:lang="en-US">DebtConversionToCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_2_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_3_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_3_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>telo-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://telomirpharma.com/role/Cover" xlink:href="telo-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheets" xlink:href="telo-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:href="telo-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfOperations" xlink:href="telo-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="telo-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:href="telo-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="telo-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcern" xlink:href="telo-20241231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/Leases" xlink:href="telo-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquity" xlink:href="telo-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxes" xlink:href="telo-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesTables" xlink:href="telo-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityTables" xlink:href="telo-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesTables" xlink:href="telo-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="telo-20241231.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:href="telo-20241231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:href="telo-20241231.xsd#LicenseAgreementRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:href="telo-20241231.xsd#RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="telo-20241231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:href="telo-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:href="telo-20241231.xsd#ScheduleOfWarrantActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:href="telo-20241231.xsd#ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:href="telo-20241231.xsd#ScheduleOfNonVestedShareBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:href="telo-20241231.xsd#ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="telo-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="telo-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="telo-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="telo-20241231.xsd#ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="telo-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_TELOStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELOStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit" xlink:label="loc_TELOIssuanceOfWarrantsOnRelatedPartyLineOfCredit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TELOIssuanceOfWarrantsOnRelatedPartyLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_AccruedOfferingExpense" xlink:label="loc_TELOAccruedOfferingExpense" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TELOAccruedOfferingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DebtConversionToCommonStock" xlink:label="loc_TELODebtConversionToCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TELODebtConversionToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_AdvancesToAffiliates" xlink:label="loc_TELOAdvancesToAffiliates" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TELOAdvancesToAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:label="loc_TELODeferredOfferingCostsChargedToAdditionalPaidinCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_TELODeferredOfferingCostsChargedToAdditionalPaidinCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DeferredFinanceCosts" xlink:label="loc_TELODeferredFinanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TELODeferredFinanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_NoInsiderTradingFlag" xlink:label="loc_TELONoInsiderTradingFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_TELONoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Description of business and summary of significant accounting policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcern" xlink:title="999016 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999017 - Disclosure - License agreement, related party">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_LicenseAgreementRelatedPartyTextBlock" xlink:label="loc_TELOLicenseAgreementRelatedPartyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="loc_TELOLicenseAgreementRelatedPartyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions" xlink:title="999018 - Disclosure - Related party balances and transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999020 - Disclosure - Stockholders&#8217; equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ReverseStockSplitPolicyTextBlock" xlink:label="loc_TELOReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TELOReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_InitialPublicOfferingPolicyTextBlock" xlink:label="loc_TELOInitialPublicOfferingPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TELOInitialPublicOfferingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesTables" xlink:title="999023 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999024 - Disclosure - Stockholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:label="loc_TELOScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesTables" xlink:title="999025 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/GoingConcernDetailsNarrative" xlink:title="999027 - Disclosure - Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999028 - Disclosure - License agreement, related party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLicenseAgreementRelatedPartyAbstract" xlink:label="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLicenseAgreementRelatedPartyAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PercentageOfRoyaltyPayable" xlink:label="loc_TELOPercentageOfRoyaltyPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_TELOPercentageOfRoyaltyPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative" xlink:title="999029 - Disclosure - Related party balances and transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="999030 - Disclosure - Schedule of components of lease expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LeasesDetailsNarrative" xlink:title="999031 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_DisclosureLeasesAbstract" xlink:label="loc_TELODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TELODisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MiralogxLLCMember" xlink:label="loc_TELOMiralogxLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOMiralogxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TampaFloridaMember" xlink:label="loc_TELOTampaFloridaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_TELOTampaFloridaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999032 - Disclosure - Schedule of warrant activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_TELOSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical" xlink:title="999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustWarrantsMember" xlink:label="loc_TELOBayShoreTrustWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOBayShoreTrustWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:label="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOTwoThousandTwentyThreePrivatePlacementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails" xlink:title="999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_UnderwriterWarrantMember" xlink:label="loc_TELOUnderwriterWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_TELOUnderwriterWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:label="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TELOMeasurementInputFairMarketValueUnderlyingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfOptionActivityDetails" xlink:title="999035 - Disclosure - Schedule of option activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails" xlink:title="999036 - Disclosure - Schedule of non vested share based compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StockOptionsOneMember" xlink:label="loc_TELOStockOptionsOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_TELOStockOptionsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails" xlink:title="999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999038 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_StarwoodTrustMember" xlink:label="loc_TELOStarwoodTrustMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOStarwoodTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BayShoreTrustMember" xlink:label="loc_TELOBayShoreTrustMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_TELOBayShoreTrustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_PlacementAgentMember" xlink:label="loc_TELOPlacementAgentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:label="loc_TELOBoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TELOBoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:label="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TELOTwoThousandTwentyThreeOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOtherUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_ProceedsFromInitialPublicOfferingNetProceeds" xlink:label="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOProceedsFromInitialPublicOfferingNetProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_OfferingCosts" xlink:label="loc_TELOOfferingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_TELOOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999039 - Disclosure - Schedule of net deferred tax assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999040 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails" xlink:title="999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_IncomeTaxRateReconciliationPermanentItems" xlink:label="loc_TELOIncomeTaxRateReconciliationPermanentItems" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TELOIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="telo-20241231.xsd#TELO_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_TELOEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TELOEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469779343920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 04, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Telomir
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001971532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-2606031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100
    SE 2nd St<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    200 #1009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">396-6723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TELO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,762,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">106<span></span>
</td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Salberg & Company, P.A.<span></span>
</td>
<td class="text">Cherry Bekaert LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boca
Raton, Florida<span></span>
</td>
<td class="text">Tampa,
Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776021936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,266,131<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">303,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">57,874<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,324,005<span></span>
</td>
<td class="nump">435,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,338,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,324,005<span></span>
</td>
<td class="nump">4,773,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued liabilities</a></td>
<td class="nump">587,536<span></span>
</td>
<td class="nump">707,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">93,432<span></span>
</td>
<td class="nump">527,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Related party line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">101,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">680,968<span></span>
</td>
<td class="nump">1,335,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">680,968<span></span>
</td>
<td class="nump">1,335,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, no par value; 300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">31,239,895<span></span>
</td>
<td class="nump">17,502,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(30,596,858)<span></span>
</td>
<td class="num">(14,064,142)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">643,037<span></span>
</td>
<td class="nump">3,438,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,324,005<span></span>
</td>
<td class="nump">$ 4,773,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776071744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">29,762,671<span></span>
</td>
<td class="nump">28,609,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">29,762,671<span></span>
</td>
<td class="nump">28,609,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776386320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">9,636,333<span></span>
</td>
<td class="nump">600,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Related party travel costs</a></td>
<td class="nump">370,500<span></span>
</td>
<td class="nump">1,767,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,235,341<span></span>
</td>
<td class="nump">1,574,306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="nump">12,242,174<span></span>
</td>
<td class="nump">3,942,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(4,338,542)<span></span>
</td>
<td class="num">(1,643,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,486,767)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,532,716)<span></span>
</td>
<td class="num">$ (13,071,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock shares outstanding basic</a></td>
<td class="nump">29,539,219<span></span>
</td>
<td class="nump">27,304,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock shares outstanding diluted</a></td>
<td class="nump">29,539,219<span></span>
</td>
<td class="nump">27,304,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776094704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="num">$ (992,278)<span></span>
</td>
<td class="num">$ (937,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">26,829,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">910,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="nump">268,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Debt conversion to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,587,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,587,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt conversion to common stock, shares</a></td>
<td class="nump">1,512,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_StockIssuedDuringPeriodValueReverseStockSplits', window );">Shares added for fractional shares pursuant to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares added for fractional shares pursuant to reverse stock split, shares</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,950,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,071,864)<span></span>
</td>
<td class="num">(13,071,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,502,346<span></span>
</td>
<td class="num">(14,064,142)<span></span>
</td>
<td class="nump">3,438,204<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">28,609,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="nump">1,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,532,716)<span></span>
</td>
<td class="num">(16,532,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of Warrants, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,867,276<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,867,276<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,239,895<span></span>
</td>
<td class="num">$ (30,596,858)<span></span>
</td>
<td class="nump">$ 643,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">29,762,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775820608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,532,716)<span></span>
</td>
<td class="num">$ (13,071,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,867,276<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit loss expense- loan due from related party</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,486,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">4,338,543<span></span>
</td>
<td class="nump">1,611,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Trade accounts payable and accrued expenses</a></td>
<td class="nump">183,629<span></span>
</td>
<td class="nump">114,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(57,160)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,070,428)<span></span>
</td>
<td class="num">(3,859,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(255,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments under related party line of credit</a></td>
<td class="num">(101,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (payments to) due to/from related party</a></td>
<td class="num">(433,945)<span></span>
</td>
<td class="nump">1,663,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings under related party line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,452,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">37,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">6,832,973<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,335,328<span></span>
</td>
<td class="nump">3,859,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">1,264,900<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of year</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of year</a></td>
<td class="nump">1,266,131<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit', window );">Issuance of warrants on related party line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_AccruedOfferingExpense', window );">Accrued offering expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DebtConversionToCommonStock', window );">Debt conversion to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,100,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_AdvancesToAffiliates', window );">Advances to affiliates</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital', window );">Deferred offering costs charged to additional paid-in capital</a></td>
<td class="nump">$ 303,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_AccruedOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued offering expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_AccruedOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_AdvancesToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances to affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_AdvancesToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DebtConversionToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt conversion to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DebtConversionToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants on related party line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776089616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="nump">$ 90,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock issued | shares</a></td>
<td class="nump">28,609,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Related party debt</a></td>
<td class="nump">$ 1,663,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt conversion</a></td>
<td class="num">(7,486,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock issued | shares</a></td>
<td class="nump">268,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of total warrants issued | shares</a></td>
<td class="nump">2,439,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DeferredFinanceCosts', window );">Deferred finance costs</a></td>
<td class="nump">$ 5,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Advances received for conversion</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Advances received for conversion, shares | shares</a></td>
<td class="nump">674,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember', window );">Miralogx LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Advances received for conversion</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Advances received for conversion, shares | shares</a></td>
<td class="nump">837,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt conversion</a></td>
<td class="nump">$ 7,486,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayShoreTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_MiralogxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469784226768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (16,532,716)<span></span>
</td>
<td class="num">$ (13,071,864)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780673008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469781079328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
1C. Cybersecurity.</b></span>We
recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is
defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud,
extortion, harm to employees and violation of data privacy or security laws.<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zqebkt8Y6Xvi">Identifying
and assessing cybersecurity risk is integrated into our overall risk management systems and processes.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zXUoPgJAApkl">Cybersecurity risks related to
our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including
third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity
incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable
data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement
appropriate changes.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zdsPmK3jxePe">Our
risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from
third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zL3oPVtJjeWa">Cybersecurity
risks are evaluated when determining the selection and oversight of applicable third-party service providers and potential fourth-party
risks when handling and/or processing our employee, business or customer data.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Cybersecurity risks related to
our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including
third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity
incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable
data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement
appropriate changes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469781232704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of business and summary of significant accounting policies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zvG6PRXYezK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82C_zsBp44Qr10Z2">Description of business and summary of significant accounting policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomir
Pharmaceuticals, Inc. (&#8220;Telomir&#8221; or the &#8220;Company&#8221;) was formed in August 2021 and is a Florida incorporated pre-clinical
stage biopharmaceutical company that is developing its licensed product candidate, Telomir-1, a novel small molecule designed to lengthen
the DNA&#8217;s protective telomere caps, which are crucial in the aging process. The Company&#8217;s goal is to explore the potential
of Telomir-1 starting with ongoing research in animals and then in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telomeres
are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity
accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and
age-related diseases. Telomir&#8217;s goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with
the broader aim of promoting longevity and enhancing overall quality of life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantive
operations began in late 2022 and the Company&#8217;s initial Investigative New Drug (&#8220;IND&#8221;) application is anticipated to
be filed with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in second half of 2025. National phase filings are expected to
be made during the first quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
&#160;used herein, the Company&#8217;s common stock, no par value per share, is referred to as the &#8220;Common Stock&#8221; and the
Company&#8217;s preferred stock, no par value per share, is referred to as the &#8220;Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--ReverseStockSplitPolicyTextBlock_zkkpUwRjWbdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective December 11, 2023, the Company completed
a reverse stock split of its outstanding common stock upon the filing of the Company&#8217;s Second Amended and Restated Articles of Incorporation
with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable
upon the exercise of our outstanding warrants, and the exercise price of such warrants, have been adjusted to reflect the reverse stock
split. Unless otherwise noted, all share and per share information in this Report retrospectively reflects the reverse stock split. (See
Note 6 &#8220;Common Stock&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--InitialPublicOfferingPolicyTextBlock_zXt79ulMVMX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i><span id="xdx_869_z75ahWt9vHOa">Initial
public offering</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, the Company closed its initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqA7PY2Zzj93" title="IPO units, shares">1,000,000</span> shares of Common Stock
at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zg0jBQgUA59l" title="Initial public offering shares">7.00</span> per share for approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTPujBNIWEa3" title="Gross proceeds">7.0</span> million in gross proceeds. After deducting the underwriting commission and other
offering expenses totaling $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwbKKnJV24k9" title="Underwriting commission and other offering expenses">1.2</span> million, the net proceeds to the Company were $<span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeA9PCKl0Il8" title="Initial public offering net proceeds">5.8</span> million. The Common Stock began trading on The Nasdaq
Capital Market on February 9, 2024 under the symbol &#8220;TELO&#8221; (See Note 6 &#8220;Common Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zOQDpgPdBGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoUgJS5DJ0w">Revenue
recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has no source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zcwsWEOXvTeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z4dX9EFBa1v9">Income
taxes</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting
for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;), which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation
allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred
asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted&#160;ASC 740-10-25, &#8220;Definition of Settlement&#8221;, which provides guidance on how an entity should determine
whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a
tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished.
For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position
is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations
remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities,
generally for three years after they are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUZxHSB5Cjyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zr5iyJ7pgiwg">Research
and development expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--UseOfEstimates_zKocMBfqSUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zZBMGwwFLEij">Use
of estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFsiosMfeV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zAxnAwav3f9c">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased,
to be cash equivalents. The Company maintains cash and cash equivalent balances at two financial institutions that are insured by the
Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company&#8217;s account at these institutions are insured by the FDIC up
to $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zknBa6WMXQgf" title="Cash insured amount">250,000</span>. On December 31, 2024 and 2023, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zdzrHETIHRLj" title="Cash">1.0</span> million &#160;and $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zCWBxTaWb0Jc" title="Cash">0.0</span>
million, respectively. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually
the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could
have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its
cash to other high quality financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvYtSxWf6uSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zFNYU0dot5b">Stock-based
compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVnmNYchwC32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zslnRouUK76f">Fair
Value Measurements and Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z9pZXaDSS82g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zc3o324Lkjg">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Earnings
(loss) per share is computed in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAzY9wDNiCSl" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span>
stock warrants and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zMjFmzBmjW1i" title="Antidilutive securities excluded from computation of earnings per share">2,352,670</span>
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvrsUqp6XMrj" title="Antidilutive securities excluded from computation of earnings per share">2,774,057</span>
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780883808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zz2S0BKBUbN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_826_zwpn30GsllAh">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern which contemplates the realization
of assets and settlement of liabilities and commitments in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had cash of approximately $<span id="xdx_900_eus-gaap--Cash_iI_pn5n6_c20241231_znS4OfaHuDA8" title="Cash">1.3</span>
million. The Company raised approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zfYfak5AfCXf" title="Raised amount">6.9</span> million in 2024 and used approximately $<span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zPC90RPBAgF3" title="Cash in operations">5.1</span>
million of cash in operations during the year ended December 31, 2024, had a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zFwtebQi8xx3" title="Net Loss">16.5</span> million in 2024 and had stockholders&#8217; equity of approximately $<span id="xdx_909_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zbIMkwdbg1H4" title="Stockholders equity">0.6</span>
million at December 31, 2024, versus stockholders&#8217; equity of approximately $<span id="xdx_906_eus-gaap--StockholdersEquity_iI_pn5n6_c20231231_zRqjiHc0Dagf" title="Stockholders equity">3.4</span>
million at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company&#8217;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#8217;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4 and an initial public offering &#8211; see Note 1. Additional sources of financing may be
sought by the Company. However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if
at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this Annual Report, the Company will continue to generate losses and have insufficient cash and cash equivalents
on hand to support its operations for at least the 12 months following the date the financial statements are issued. &#160;These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for
a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. The Company is seeking to
raise capital through additional debt and/or equity financings to fund our operations in the future. If the Company is unable to raise
additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations.
These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and 2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780249888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreement, related party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLicenseAgreementRelatedPartyAbstract', window );"><strong>License Agreement Related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_LicenseAgreementRelatedPartyTextBlock', window );">License agreement, related party</a></td>
<td class="text"><p id="xdx_803_ecustom--LicenseAgreementRelatedPartyTextBlock_z2FmDuIvdWXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span id="xdx_823_zIuJuJWzprN7">License agreement, related party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company licenses the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (&#8220;MIRALOGX&#8221;), an
intellectual property development and holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2023, (the &#8220;Effective Date&#8221;), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement, under which the Company has the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell &#8220;Licensed Products&#8221; in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the &#8220;MIRALOGX License Agreement&#8221;). On
November 10, 2023, the Company and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant
to which the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals,
in addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and
commercialization of veterinary, in addition to human, therapeutic treatments and uses (together with the &#8220;Initial MIRALOGX License
Agreement, the &#8220;MIRALOGX License Agreement&#8221;). &#8220;Licensed Product&#8221; is defined in the agreement as a drug product
containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl) pyridine or a pharmaceutically acceptable salt, ester, or solvate
thereof. The Company also has the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement
provides for the payment to MIRALOGX of an <span id="xdx_90C_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVopxE5gbCN1" title="Percentage of royalty payable">8</span>% royalty (payable quarterly) on the Company&#8217;s net sales of Licensed Products by the
Company or its sublicensees and on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in
the license agreement. Further, no payments have been made to date under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the license from MIRALOGX will continue through the date of the expiration of the last-to-expire licensed patent or, if later,
the date of the expiration of the last strategic partnership/sublicensing agreement covering the licensed products. The patent rights
are expected to extend through 2043, and additional patent terms may be awarded, including additional patent terms based on the time
taken for regulatory review of drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of
the patent applications for Telomir-1. Telomir is required to be kept informed by</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIRALOGX
of patent prosecution activities and may select identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent
prosecution and maintenance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLicenseAgreementRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLicenseAgreementRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_LicenseAgreementRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Related Party [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_LicenseAgreementRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469781081840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party balances and transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party balances and transactions</a></td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zC1Gl3PLKyg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_82A_zjVG78OMRSxj">Related party balances and transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due
from related parties-</i> During the year ended December 31, 2023, the Company provided working capital advances to companies under common
control. These advances were due on demand and are non-interest bearing. Amounts due from related parties as of December 31, 2023 were
$<span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231_zXmRwWBNEgW6" title="Amounts due from related parties">0.13</span> million. In 2024, the company under common control was dissolved and therefore the amount due become uncollectable and was written
off and reflected as credit loss expense, which is included in general and administration expenses. As of December 31, 2024, there was <span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_pid_dxL_c20241231_zYN7BLzXgjmd" title="Amounts due from related parties::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0484">no</span></span>
amount due from related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due
to related parties-</i> During the years ended December 31, 2024 and December 31, 2023, the Company received working capital
advances from companies under common control. These advances were due on demand and are non-interest bearing. During the year ended
December 31, 2023, advances in the amount of $<span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdwOnBSkqywd">1.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
were converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zIKc0uHF7fpj">837,841 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of our common stock (after giving effect to our <span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--MiralogxLLCMember_z2SmVAdsoBP4">1-for-2.05
reverse stock split</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that occurred on
December 11, 2023) at a conversion rate of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zFTx3V7H9246">2.05 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share resulting in a loss on the conversion of debt of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zmMYbuxcQxZ2">4.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.
Following the conversion, $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231_zVKrOBu9aY5">0.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of advances remained outstanding as of December 31, 2023. During the year ended December 31, 2024, there were advances received by
the Company in the amount of $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zL87h1GcDGy6">0.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for payments made regarding studies on behalf of Telomir and repayments made to related parties in the amount of $<span id="xdx_909_eus-gaap--OtherLiabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zY8xdMUHvuwa">0.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.
As of December 31, 2024 $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241231_zMiulhJzcYx">0.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
remained outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bay
Shore Trust Line of Credit</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#8217;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &#8220;Bay Shore Note&#8221;), the Company had the right to borrow up to an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zi7lVuBQ1oZ7" title="Line of credit, maximum borrowing capacity">5</span> million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#8217;s
IPO. As of December 31, 2024, the line of credit is no longer available as the IPO was completed in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_z52ibEjCL7k8" title="Shares of common stock">2,439,025</span> shares of Common Stock at an exercise price
of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zEduPDIyP3x8" title="Exercise price">3.73</span> per share (See Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company received $<span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0A8JOQexfca">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in advances from a line of credit from
Bay Shore Trust. On November 30, 2023, $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsQTH0c899id">1.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zPNZnfjyYOCj">674,637
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Common Stock (after giving effect
to our <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsC3cVibxcU3">1-for-2.05
reverse stock split</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that occurred on December
11, 2023) at a conversion rate of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zS9IsnJOQtLi">2.05
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share resulting in a loss on the conversion
of debt of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_z9oSX84JgDY3">3.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, with $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKpSLqNLqnmk">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million outstanding as of December 31, 2023.
As of December 31, 2024, the line of credit has been paid in full and is no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Starwood
Trust Line of Credit and Stock Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024 the Company entered into an unsecured Promissory Note and Loan Agreement (&#8220;the Starwood Note&#8221;) with
the Starwood Trust, a separate related party trust established by the Company&#8217;s founder, Jonnie R. Williams, Sr. who is the
sole owner of Bay Shore Trust as well as our largest shareholder, and under which various of his family members are beneficiaries.
Under the Starwood Note, the Company has the right to borrow up to an aggregate of $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzEETtdviqa2" title="Unused line of credit">5</span>&#160;million
from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The Company&#8217;s right to
borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations, or prospects
The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or operations
than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the
note, provides for prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzXwWsW9LIMj" title="Accrue interest at a rate">7</span>%
per annum. As of December 31, 2024, the Company has not borrowed any amounts under the Starwood Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on December 9, 2024, Starwood Trust entered into a stock purchase agreement with the Company to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBZtnPjOZrTk" title="Purchase of shares">142,857</span> shares of unregistered
common stock at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z4w9gMo6zopf" title="Share price">7</span> a share for a total of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zDQzQpaPItV9" title="Proceeds from issuance of common stock">1.0</span> million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
agreement - See Note 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Travel Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2023 the Company entered into an Agreement For Shared Lease Costs (the &#8220;Shared Agreement&#8221;) with MIRALOGX, LLC, a
related party under which we have agreed to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease
agreement between MIRALOGX and Supera Aviation I LLC (&#8220;Supera Aviation&#8221;) based on our usage of the leased aircraft each month.
No amounts are payable by the Company under this agreement unless and to the extent the Company chooses to utilize the leased aircraft,
and the Company may discontinue the use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned
by Starwood Trust, a trust established by Mr. Williams, the Company&#8217;s founder and largest shareholder. For the year ended December 31, 2024 and December 31, 2023, the Company incurred
$<span id="xdx_902_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zq75LHaJznV2" title="Travel-related expenses">0.37</span> million and $<span id="xdx_905_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHklkWLzuRij" title="Travel-related expenses">1.77</span> million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated in April
2024 and no other costs will be incurred under this agreement (See Note 5 Variable lease costs).</span> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Rental Agreement</b><i>-</i> see Note 5 for Variable lease costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780042864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zO8tcZhDNcE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_826_z4EN3TdXV7W7">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease
began in November 2022 and expired in April 2024. The lease was not renewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the
Company decided to no longer utilize the shared space and moved to a virtual office model and does not have a physical office space
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Variable
lease costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
lease costs primarily include utilities, property taxes, and other operating costs that are passed on from the lessor for the former
corporate headquarters in Baltimore, Maryland. Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses,
which includes pilot expenses, jet fuel and general flight expenses that totaled to $<span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_z1yU3aMLGIkc" title="Variable lease, cost">0.32</span> million in 2024 and $<span id="xdx_902_eus-gaap--VariableLeaseCost_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdvd3AT3aK28" title="Variable lease, cost">1.3</span> million in 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
August 1, 2023, the Company&#8217;s accounting and administrative staff began sharing office space with a related party in Tampa, Florida.
During the year ended December 31, 2024, this variable least cost related to the Tampa, Florida space totaled $<span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zccJvG7iXKJj" title="Variable lease, cost">0.02</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_ziOomy0j7Hm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGf0E7G4Oul5" style="display: none">Schedule
of components of lease expenses</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zwrYw4eRiC66" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zEvQZoq869vl" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zCwbOHzFsha2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,667</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,869</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zo8jRWbaGwHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336,656</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,778,884</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_z9C4YbTNQNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,323</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,793,753</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zvyZhb8zymTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469784238608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; equity</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFb4r2EpOdTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_827_zOhRK89b3Yb">Stockholders&#8217; equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the authority to issue <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20241231_zPIRkHhhA5O6" title="Issue of shares of capital stock">400,000,000</span> shares of capital stock, consisting of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zQXKDQtbJBZ" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zirdADbPCoA2" title="Common stock, shares authorized">300,000,000</span></span> shares of Common Stock and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zfR5eAAbGPr9" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zvUY1Hc0Qrfi" title="Preferred stock, shares authorized">100,000,000</span></span>
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
December 11, 2023, the Company completed a reverse stock split of its outstanding common stock upon the filing of the Company&#8217;s
Second Amended and Restated Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued
in connection with the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded
up to the nearest whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise price of such warrants,
have been adjusted to reflect the reverse stock split. Unless otherwise noted, all share and per share information in this Report retrospectively
reflects the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the year ended December 31, 2023, the Company conducted a private
placement offering in which <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMQYtLCIsPW3" title="Number of shares issued">268,025</span> shares were issued for a total of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIuPelYnM3R4" title="Net proceeds">0.9</span> million in net proceeds to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, the Company closed its initial public offering consisting of&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFyphSDXvbb2" title="Initial public offering shares">1,000,000</span>&#160;shares at a price of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrVnWyR6tVKa" title="Initial public offering shares">7.00</span>&#160;per
share for approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGLDcxtrJlfh" title="Gross proceeds">7.0</span>&#160;million in gross proceeds. After deducting the underwriting commission and other offering expenses
totaling $<span id="xdx_90E_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaGcOftAxbpl" title="Underwriting commission and other offering expenses">1.2</span>&#160;million, the net proceeds to the Company were $<span id="xdx_903_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEwddJ2ePlxf" title="Initial public offering net proceeds">5.8</span>&#160;million (the &#8220;IPO&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2024, Starwood Trust, a related party, entered into a stock purchase agreement with the Company to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zLRrNQWydoo6">142,857
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of unregistered common stock at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziwOXpZKHAW8">7
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a share for a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z71nKKdnMyQa">1.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in proceeds to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs">303,281</span> and offering costs of $<span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zYFt6IiE7Z9j" title="Offering costs">863,744</span> incurred in 2024 were charged against additional paid
in capital.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with various transactions and the IPO summarized below, the Company issue stock warrants. Warrant activity for the year ended
December 31, 2024 is summarized below:</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkcpQeEIDEme" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zeRTAB7YUAc2">Schedule
of warrant activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Weighted</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Number of</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"> Average<br/>
 Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Remaining<br/>
 Contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Aggregate</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Warrants</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; padding-bottom: 1pt">Balance Outstanding as January 1, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrQFLfy8V1h" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of Warrants Outstanding, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmvO2LtO8dk6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<sup></sup></span></td><td style="width: 2%; padding-bottom: 1pt; text-align: left">&#160;<sup></sup></td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDgGQS7xn89" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmc8OFiFOIf" style="text-align: right" title="Number of Warrants, Granted">2,774,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3vuNhLnssra" style="text-align: right" title="Weighted Average Exercise Price, Granted">4.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zN1bwplKmhrd" title="Weighted Average Remaining Contractual Term (Years), Granted">5.0</span></td><td style="text-align: left">&#160;<sup id="xdx_F28_zYDCwQPy7Fri">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvOEQEB9KK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance">2,774,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3ASIi8k3T8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance">4.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zfhLVu5dRok2" title="Weighted Average Remaining Contractual Term (Years)">4.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2F_z3fvAQq91oy3">(1)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzNlIHiuPI" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0594">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDmHdqODkvl" style="text-align: right" title="Number of Warrants, Granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS5iXwbEsrG" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYFQe0cyo58d" title="Weighted Average Remaining Contractual Term (Years), Granted">3.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xJBKBuDLUd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOIcRigM2Kah" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">3.73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVl15ciPfzB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance">2,814,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlRY6O7he8Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance">4.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zJFlCq5eWEve" title="Weighted Average Remaining Contractual Term (Years)">3.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2C_zVbcXrLIUZfk">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhVghFxQ1jYb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztNklRWWLJ86" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Balance">2,814,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSff51VEGAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">4.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zGRodkzsqN91" title="Weighted Average Remaining Contractual Term (Years), Exercisable">3.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F22_zbnDra7E6ho5">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH3HnfC50CQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F09_zCpFSYfkBMLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_z2p4qKvqXJFg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants herein consist of various contractual terms. The warrants herein consist of </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zeu5UwoVUKck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,025
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to Bay Shore
Trust that have a remaining contractual term of </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_z2mJjlntxaqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years as of December 31, 2023,
and </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zD8zlhPuV63h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335,032
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to investors
associated with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
on these warrants</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zbCtIAN0zB32" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_zLGI4xf8sBy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants herein
consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term">3.5</span> years as of December 31, 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued">335,032</span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued">50,000</span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p id="xdx_8A7_zr08WOXblbtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
placement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase
up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zryETalShkr7" title="Purchase of common stock">268,025</span> shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFeyvmgLQBy8" title="Exercise price">15.42</span> per share. The Company also issued to the placement agent a Common
Stock warrant the right to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zSA8SWVmB5C8" title="Purchase of common stock">67,007</span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z7yjSJuIgty8" title="Exercise price">3.73</span> per share. Both issuances of warrants
are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an IND filing is
made with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bay
Shore Trust Warrants (Note 4)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the line of credit provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock
purchase warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to&#160;<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zBqQLORtid59" title="Shares of common stock">2,439,025</span>&#160;shares
of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zVXaPnYsV1me" title="Exercise price">3.73</span>&#160;per
share. This warrant will expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zihPsqtsAPF5" title="Exercise price">five
years</span> after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the
risk-free interest rate, which resulted in $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zcq3pca5Ye2c" title="Deferred financing costs">5.95</span>&#160;million
of deferred financing costs. This cost was recorded as deferred financing costs and additional paid in capital on the accompanying
balance sheet and is amortized straight-line over the term of the line of credit (which is 24 months). Associated amortization of
deferred finance costs is recorded to interest expense on the income statement of operations. The line of credit expired upon the
IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the warrant was fully amortized
to interest expense.  As of December 31, 2024, the warrant is fully amortized. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, Bay Shore Trust transferred <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0ujnrZcbGP3" title="Shares of common stock">100,000</span> warrants to an unaffiliated party as part of a gift transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024,&#160;<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zqU6tShKMJM" title="Shares of common stock">10,000</span> Common Stock warrants were exercised at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0xgQgSNENc1" title="Exercise price">3.73</span> per share and the Company issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zT6h0BGplEYa" title="Issuance of common stock">10,000</span>&#160;shares
of Common Stock upon such exercise in exchange for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zgOxY4g8OnH" title="Issuance of common stock, value">37,300</span> delivered to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYEdrUFFkl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value warrants during the year ended December 31, 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zNQlbODRAkQe">Schedule of key assumptions used to value warrants</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoRls3dblQQc" title="Warrant measurement input">78.08</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdUXXGqpSvv1" title="Warrant measurement input">3.91</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zvd22Xkgpc62" title="Warrant measurement input">1.190</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zrVujNCbtm37" title="Expected term in years">5 years</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlY7EnTuoCnb" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zFt9jbgoXUx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Underwriter
warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the IPO in February 2024, the Company issued&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4SnU6Fj1PPa" title="Warrants to purchase common stock">50,000</span>&#160;warrants
to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zexPGknPjwB9" title="Exercise price">7.00</span>&#160;which
are exercisable immediately and  expire in the four-and-a-half-year period commencing six months after the commencement of
sales in the IPO. The warrants provide for registration
rights (including a one-time demand registration right and piggyback registration rights that expire 5 years from the commencement
of sales of the offering) and customary anti-dilution provisions as permitted under FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUrq87iaGtr1" title="Equity issuance cost">0.2</span> million of equity issuance costs. The warrants were
considered equity issuance costs and therefore there was no financial statement impact during the year ended December 31,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zN6ZMsXXafga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value underwriter warrants in February 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zFnVrF34jyda">Schedule
of key assumptions used to value warrants</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZSWEQ3GIced" title="Warrant measurement input">84.78</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z00A4ZY80Rnb" title="Warrant measurement input">4.14</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zYfMJ61WOx1l" title="Warrant measurement input">7.01</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuyxtAiURn4a" title="Expected term in years">5 years</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zBmlNDvopdSk" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zzYUDaoW94bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Omnibus Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2023 Omnibus Incentive Plan, (&#8220;2023 Omnibus Plan&#8221;).
The 2023 Omnibus Plan authorizes the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code,
to the Company&#8217;s employees and any of its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory
stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#8217;s
employees, directors, and consultants and any of its future subsidiary corporations&#8217; employees and consultants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Omnibus Plan provides that <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zl2biEgEf051" title="Common stock are reserved for issuance">6,500,000</span> shares of the Company&#8217;s Common Stock are reserved for issuance under the 2023
Omnibus Plan, all of which may be issued pursuant to the exercise of incentive stock options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-based
compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected
volatility, expected dividends, expected term, and the risk-free interest rate. Expected price volatility is based on the historical
volatilities of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several
public companies in the biotech industry similar to the Company in size, stage of life cycle and product indications. The Company intends
to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information
regarding the volatility of the Company&#8217;s own stock price becomes available, or unless circumstances change such that the identified
companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would
be utilized in the calculation.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of
the vesting term plus contract term. The risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant.
The Company recognizes forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zigEyQcetU3a" title="Number of options, outstanding">2,370,170</span>
options to purchase Common Stock, with an aggregate fair market value of approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zX5HFAiAoauj" title="Share based compensation fair market value">9.1</span>
million with a weighted average fair value per share of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_ztwf8n7htUtj" title="Weighted average fair value per share">3.83</span> were granted to the members of the Company&#8217;s Board of Directors,
executive officers, employees and consultants of the Company. The options have an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zG875OTjM3Nc" title="Weighted average exercise price, outstanding">5.02</span>,
a term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zsCjnkPio6z5" title="Share based compensation term of years">10</span>
years from the grant date, and vest over various terms ranging from immediate vesting upon grant to the second anniversary of the
grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuXwA47tIZf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is option activity during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zA7c3o28gNUh">Schedule
of option activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise
                                            price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per
                                            share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic
                                            value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zg4kJyNCzu23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zNQgxC8r07mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zKOJTfTGOoik" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231_zbZUaKJE1W7d" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif">2,370,170</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zRbzBnnWtpS4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeitures</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zehM2nvOhXgf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeitures"><span style="font-family: Times New Roman, Times, Serif">(17,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zqbtoX3hMtjc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeitures"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zMvJeG98gjha" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"><span style="font-family: Times New Roman, Times, Serif">2,352,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zsdknw8ThdZi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zlT0m5Mjcd83" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_z21L7Ivre32h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, options exercisable totaled <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zYmhPm05Yjrb" title="Number of options, exercisable">2,352,670</span>. The Company recognized approximately $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_zCTuHnz2R2Dg" title="Stock-based compensation">6.9</span> million in stock-based compensation
in 2024. There are approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_z0V0pziN2gnc" title="Unrecognized compensation costs">2.2</span> million of unrecognized compensation cost
related to non-vested share-based compensation awards, which will be expensed through 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_zWaUpSlV4fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zHm6i420hSc" style="display: none">Schedule of non vested share based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Exercisable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zk8VeZrBbKKd">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_z1GdTVbN5gVb" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Options outstanding, outstanding number of options, shares"><span style="font-family: Times New Roman, Times, Serif">2,352,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zcif95o0vXc9" title="Weighted Average Remaining Contractual Life (Years)">9.6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zA06CWkEzgMf" title="Weighted Average Exercise Price">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zW3b38D0bwIl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,046,335</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zJhWQvF8tu7" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Aggregate Intrinsic Price"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zpVC2G2WSYrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSoiUYsJyBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqCjHrG9Q6rc">&#160;Schedule
of key assumptions used to value stock options</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z6JahreGSgk1" title="Expected volatility, minimum">88.8</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_z8EJUkRgPZe6" title="Expected volatility, maximum">90.4</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zE7RrRHL51Ii" title="Risk-free interest rate">3.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_z3b8J3NbvAIg" title="Exercise price">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4TXimg70jz9" title="Expected term">5.1</span>
                                            to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z2KJLt1HfmH8" title="Expected term">5.62</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zk269eBnw8P4" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zvLeL9dCE1y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780173920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zU2lOKCZV2lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82E_zRcPGG92Csmb">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zAZQLuKtNXj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of the Company&#8217;s net deferred tax assets are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zI7bhzV8sYKc" style="display: none">Schedule of net
deferred tax assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zMXOCiSazI9b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_z6uRjoUKEGx2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zxkEFecouGw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry-forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,427,679</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">288,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zSKsopwULW31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Section 174 Qualified Research
    Expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">995,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">526,248</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_zoEnwvDFjWDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,680,019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z82B88yW1pFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">R&amp;D Credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGz55t_zbh2V40LzJM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,724</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_zJfhrPJ5mxMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, gross</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_z6E9z0XRz0Xc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_zxl54Vaif8g6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, net</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_zPlDZI0C6c86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    net deferred tax asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zC7Xg1Lwaqqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, in accordance with Internal Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized
over a period of five years. Accordingly, for income tax purposes, and as of December 31, 2024 and December 31, 2023, the Company has
recorded a deferred tax asset totaling approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zfBFohsGHMGf" title="Deferred tax asset">1.0</span> million and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20231231_zMcmEnox3OZ3" title="Deferred tax asset">0.5</span> million, respectively, related to the timing difference between
GAAP and Tax recognition of these expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZu7RjI61vG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the provision for income taxes consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zxki7MCncC9l" style="display: none">Schedule of provision for income taxes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zlPsrak2TOx7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzjwNL6Q5od5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred benefit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20241231_zy8iTcXVRNai" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"><span style="font-family: Times New Roman, Times, Serif">(7,182,483</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20231231_zTau0HsiBJwl" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"><span style="font-family: Times New Roman, Times, Serif">(846,351</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20241231_zK8msu1HI4ub" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20231231_zorsiAR1iVZk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20241231_zCPnOxDurBk8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20231231_zyORfGHcChAh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0809">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_z2xwL8fB8NH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    provision for income taxes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_z3AQanzghgOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740 requires that a deferred tax amount be reduced by a valuation allowance if, based on the weight of available evidence it is
more likely than not (a likelihood of more than 50%) that some portion or all of the deferred tax assets will not be realized. The valuation
allowance should be sufficient to reduce the deferred tax asset to the amount that is more likely than not to be realized. The Company
has recorded a full valuation allowance against its deferred tax assets generated by net operating loss carryforwards as it has determined
that such amounts may not be recognizable, given the historical losses of the Company to date. As of December 31, 2024, the Company has
a cumulative federal net operating loss carryforward of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zsiIhHarBsd4" title="Federal net operating loss carryforward">17.4</span> million. The net operating loss carryforwards have no expiry
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB2ktK6SmHHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory U.S. federal income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zIu4OOrTJO61">Schedule
of reconciliation of effective income tax rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zlosmuMQ4Ca4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">Year Ended December 31, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iN_di_zxUTYeywogbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,532,716</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzNIc_zLHR4QTi3GZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Tax Benefit at U.S. Federal Statutory Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,471,870</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z9RgtXrnfnfl" style="text-align: right" title="Tax Benefit at U.S. Federal Statutory Rate, Percentage">21.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzNIc_zvsYoTuu9WEa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">State Taxes, Net of Federal Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(718,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20240101__20241231_zaZKbHJOThq8" style="text-align: right" title="State Taxes, Net of Federal Benefit, Percentage">4.35</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzNIc_ztdBygndKvQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,336,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20240101__20241231_zILioQKfL3Ah" style="text-align: right" title="Change in Valuation Allowance, Percentage">(38.32</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationPermanentItems_maITEBzNIc_zD05HJK1IL6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,182,803</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_uPure_maGOLD_c20240101__20241231_zl7QlZ1ca42i" style="text-align: right" title="Permanent Items, Percentage">13.20</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzNIc_zwWpS0uiJEZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">State Rate Change</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z6ACJYfNZ1j2" style="border-bottom: Black 1pt solid; text-align: right" title="State Rate Change, Percentage">(0.22</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeTaxExpenseBenefit_iT_dxL_mtITEBzNIc_c20240101__20241231_zAuVQVLODyc8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20240101__20241231_zRn0InWgXbVd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net actual effective rate, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_z94oue4GCrw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775738416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ReverseStockSplitPolicyTextBlock', window );">[custom:ReverseStockSplitPolicyTextBlock]</a></td>
<td class="text"><p id="xdx_841_ecustom--ReverseStockSplitPolicyTextBlock_zkkpUwRjWbdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective December 11, 2023, the Company completed
a reverse stock split of its outstanding common stock upon the filing of the Company&#8217;s Second Amended and Restated Articles of Incorporation
with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable
upon the exercise of our outstanding warrants, and the exercise price of such warrants, have been adjusted to reflect the reverse stock
split. Unless otherwise noted, all share and per share information in this Report retrospectively reflects the reverse stock split. (See
Note 6 &#8220;Common Stock&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_InitialPublicOfferingPolicyTextBlock', window );">Initial public offering</a></td>
<td class="text"><p id="xdx_84F_ecustom--InitialPublicOfferingPolicyTextBlock_zXt79ulMVMX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i><span id="xdx_869_z75ahWt9vHOa">Initial
public offering</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2024, the Company closed its initial public offering (the &#8220;IPO&#8221;) consisting of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqA7PY2Zzj93" title="IPO units, shares">1,000,000</span> shares of Common Stock
at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zg0jBQgUA59l" title="Initial public offering shares">7.00</span> per share for approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTPujBNIWEa3" title="Gross proceeds">7.0</span> million in gross proceeds. After deducting the underwriting commission and other
offering expenses totaling $<span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwbKKnJV24k9" title="Underwriting commission and other offering expenses">1.2</span> million, the net proceeds to the Company were $<span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeA9PCKl0Il8" title="Initial public offering net proceeds">5.8</span> million. The Common Stock began trading on The Nasdaq
Capital Market on February 9, 2024 under the symbol &#8220;TELO&#8221; (See Note 6 &#8220;Common Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zOQDpgPdBGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoUgJS5DJ0w">Revenue
recognition</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has no source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zcwsWEOXvTeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z4dX9EFBa1v9">Income
taxes</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes pursuant to the provision of Accounting Standards Codification (&#8220;ASC&#8221;) 740-10, &#8220;Accounting
for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;), which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation
allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred
asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted&#160;ASC 740-10-25, &#8220;Definition of Settlement&#8221;, which provides guidance on how an entity should determine
whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a
tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished.
For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position
is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations
remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities,
generally for three years after they are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUZxHSB5Cjyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zr5iyJ7pgiwg">Research
and development expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zKocMBfqSUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zZBMGwwFLEij">Use
of estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFsiosMfeV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zAxnAwav3f9c">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased,
to be cash equivalents. The Company maintains cash and cash equivalent balances at two financial institutions that are insured by the
Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company&#8217;s account at these institutions are insured by the FDIC up
to $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zknBa6WMXQgf" title="Cash insured amount">250,000</span>. On December 31, 2024 and 2023, the Company had cash in excess of FDIC limits of approximately $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zdzrHETIHRLj" title="Cash">1.0</span> million &#160;and $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zCWBxTaWb0Jc" title="Cash">0.0</span>
million, respectively. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually
the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could
have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its
cash to other high quality financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvYtSxWf6uSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zFNYU0dot5b">Stock-based
compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation under the provisions of FASB&#160;ASC 718, &#8220;Compensation - Stock Compensation&#8221;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telomir
                                            Pharmaceuticals, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">notes
to the financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DECEMBER
31, 2024 and  2023</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVnmNYchwC32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zslnRouUK76f">Fair
Value Measurements and Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z9pZXaDSS82g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zc3o324Lkjg">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Earnings
(loss) per share is computed in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221; Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAzY9wDNiCSl" title="Antidilutive securities excluded from computation of earnings per share">2,814,057</span>
stock warrants and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zMjFmzBmjW1i" title="Antidilutive securities excluded from computation of earnings per share">2,352,670</span>
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvrsUqp6XMrj" title="Antidilutive securities excluded from computation of earnings per share">2,774,057</span>
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_InitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_InitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780259056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expenses</a></td>
<td class="text"><p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_ziOomy0j7Hm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGf0E7G4Oul5" style="display: none">Schedule
of components of lease expenses</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20240101__20241231_zwrYw4eRiC66" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zEvQZoq869vl" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease Costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zCwbOHzFsha2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,667</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,869</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zo8jRWbaGwHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336,656</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,778,884</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_z9C4YbTNQNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total lease cost</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,323</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,793,753</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775574784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkcpQeEIDEme" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zeRTAB7YUAc2">Schedule
of warrant activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Weighted</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Number of</b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"> Average<br/>
 Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Remaining<br/>
 Contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Aggregate</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Warrants</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; padding-bottom: 1pt">Balance Outstanding as January 1, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrQFLfy8V1h" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of Warrants Outstanding, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmvO2LtO8dk6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<sup></sup></span></td><td style="width: 2%; padding-bottom: 1pt; text-align: left">&#160;<sup></sup></td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDgGQS7xn89" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmc8OFiFOIf" style="text-align: right" title="Number of Warrants, Granted">2,774,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3vuNhLnssra" style="text-align: right" title="Weighted Average Exercise Price, Granted">4.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zN1bwplKmhrd" title="Weighted Average Remaining Contractual Term (Years), Granted">5.0</span></td><td style="text-align: left">&#160;<sup id="xdx_F28_zYDCwQPy7Fri">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvOEQEB9KK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance">2,774,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3ASIi8k3T8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance">4.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zfhLVu5dRok2" title="Weighted Average Remaining Contractual Term (Years)">4.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2F_z3fvAQq91oy3">(1)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzNlIHiuPI" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0594">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDmHdqODkvl" style="text-align: right" title="Number of Warrants, Granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS5iXwbEsrG" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYFQe0cyo58d" title="Weighted Average Remaining Contractual Term (Years), Granted">3.2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xJBKBuDLUd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOIcRigM2Kah" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">3.73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance Outstanding as December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVl15ciPfzB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance">2,814,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlRY6O7he8Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance">4.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zJFlCq5eWEve" title="Weighted Average Remaining Contractual Term (Years)">3.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F2C_zVbcXrLIUZfk">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhVghFxQ1jYb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztNklRWWLJ86" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Balance">2,814,057</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSff51VEGAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">4.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zGRodkzsqN91" title="Weighted Average Remaining Contractual Term (Years), Exercisable">3.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;<sup id="xdx_F22_zbnDra7E6ho5">(2)</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH3HnfC50CQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0620">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F09_zCpFSYfkBMLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_z2p4qKvqXJFg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants herein consist of various contractual terms. The warrants herein consist of </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zeu5UwoVUKck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,025
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to Bay Shore
Trust that have a remaining contractual term of </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_z2mJjlntxaqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years as of December 31, 2023,
and </span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zD8zlhPuV63h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335,032
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants issued to investors
associated with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
on these warrants</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zbCtIAN0zB32" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_zLGI4xf8sBy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants herein
consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term">3.5</span> years as of December 31, 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued">335,032</span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued">50,000</span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of key assumptions used to value stock options</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSoiUYsJyBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zqCjHrG9Q6rc">&#160;Schedule
of key assumptions used to value stock options</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z6JahreGSgk1" title="Expected volatility, minimum">88.8</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_z8EJUkRgPZe6" title="Expected volatility, maximum">90.4</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zE7RrRHL51Ii" title="Risk-free interest rate">3.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_z3b8J3NbvAIg" title="Exercise price">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4TXimg70jz9" title="Expected term">5.1</span>
                                            to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z2KJLt1HfmH8" title="Expected term">5.62</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zk269eBnw8P4" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuXwA47tIZf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is option activity during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zA7c3o28gNUh">Schedule
of option activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise
                                            price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per
                                            share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>intrinsic
                                            value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding as January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zg4kJyNCzu23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zNQgxC8r07mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zKOJTfTGOoik" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231_zbZUaKJE1W7d" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif">2,370,170</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zRbzBnnWtpS4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Forfeitures</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zehM2nvOhXgf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeitures"><span style="font-family: Times New Roman, Times, Serif">(17,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zqbtoX3hMtjc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeitures"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zMvJeG98gjha" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"><span style="font-family: Times New Roman, Times, Serif">2,352,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zsdknw8ThdZi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zlT0m5Mjcd83" title="Outstanding aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock', window );">Schedule of non vested share based compensation</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_zWaUpSlV4fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zHm6i420hSc" style="display: none">Schedule of non vested share based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    Exercisable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"></span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zk8VeZrBbKKd">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_z1GdTVbN5gVb" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Options outstanding, outstanding number of options, shares"><span style="font-family: Times New Roman, Times, Serif">2,352,670</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zcif95o0vXc9" title="Weighted Average Remaining Contractual Life (Years)">9.6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zA06CWkEzgMf" title="Weighted Average Exercise Price">5.02</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zW3b38D0bwIl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,046,335</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zJhWQvF8tu7" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Aggregate Intrinsic Price"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of key assumptions used to value stock options</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYEdrUFFkl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value warrants during the year ended December 31, 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zNQlbODRAkQe">Schedule of key assumptions used to value warrants</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoRls3dblQQc" title="Warrant measurement input">78.08</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdUXXGqpSvv1" title="Warrant measurement input">3.91</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zvd22Xkgpc62" title="Warrant measurement input">1.190</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zrVujNCbtm37" title="Expected term in years">5 years</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlY7EnTuoCnb" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of key assumptions used to value stock options</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zN6ZMsXXafga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
assumptions used to value underwriter warrants in February 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zFnVrF34jyda">Schedule
of key assumptions used to value warrants</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Expected price volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZSWEQ3GIced" title="Warrant measurement input">84.78</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z00A4ZY80Rnb" title="Warrant measurement input">4.14</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Market Value of underlying Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zYfMJ61WOx1l" title="Warrant measurement input">7.01</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuyxtAiURn4a" title="Expected term in years">5 years</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zBmlNDvopdSk" title="Warrant measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Payment Award Stock Option [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469871550320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zAZQLuKtNXj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of the Company&#8217;s net deferred tax assets are as follows as of December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zI7bhzV8sYKc" style="display: none">Schedule of net
deferred tax assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zMXOCiSazI9b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20231231_z6uRjoUKEGx2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zxkEFecouGw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss carry-forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,427,679</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">288,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zSKsopwULW31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Section 174 Qualified Research
    Expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">995,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">526,248</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_zoEnwvDFjWDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock Compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,680,019</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z82B88yW1pFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">R&amp;D Credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0776">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGz55t_zbh2V40LzJM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,724</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_zJfhrPJ5mxMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, gross</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_z6E9z0XRz0Xc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_zxl54Vaif8g6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets, net</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_zPlDZI0C6c86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    net deferred tax asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZu7RjI61vG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the provision for income taxes consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zxki7MCncC9l" style="display: none">Schedule of provision for income taxes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zlPsrak2TOx7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20231231_zzjwNL6Q5od5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred benefit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20241231_zy8iTcXVRNai" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"><span style="font-family: Times New Roman, Times, Serif">(7,182,483</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20231231_zTau0HsiBJwl" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"><span style="font-family: Times New Roman, Times, Serif">(846,351</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20241231_zK8msu1HI4ub" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">7,182,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20231231_zorsiAR1iVZk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">846,351</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20241231_zCPnOxDurBk8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20231231_zyORfGHcChAh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0809">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_z2xwL8fB8NH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    provision for income taxes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of effective income tax rate</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB2ktK6SmHHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory U.S. federal income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zIu4OOrTJO61">Schedule
of reconciliation of effective income tax rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zlosmuMQ4Ca4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin: 0">Year Ended December 31, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iN_di_zxUTYeywogbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,532,716</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzNIc_zLHR4QTi3GZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Tax Benefit at U.S. Federal Statutory Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,471,870</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z9RgtXrnfnfl" style="text-align: right" title="Tax Benefit at U.S. Federal Statutory Rate, Percentage">21.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzNIc_zvsYoTuu9WEa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">State Taxes, Net of Federal Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(718,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20240101__20241231_zaZKbHJOThq8" style="text-align: right" title="State Taxes, Net of Federal Benefit, Percentage">4.35</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzNIc_ztdBygndKvQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,336,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20240101__20241231_zILioQKfL3Ah" style="text-align: right" title="Change in Valuation Allowance, Percentage">(38.32</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationPermanentItems_maITEBzNIc_zD05HJK1IL6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Permanent Items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,182,803</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_uPure_maGOLD_c20240101__20241231_zl7QlZ1ca42i" style="text-align: right" title="Permanent Items, Percentage">13.20</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzNIc_zwWpS0uiJEZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">State Rate Change</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z6ACJYfNZ1j2" style="border-bottom: Black 1pt solid; text-align: right" title="State Rate Change, Percentage">(0.22</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net actual effective rate</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeTaxExpenseBenefit_iT_dxL_mtITEBzNIc_c20240101__20241231_zAuVQVLODyc8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20240101__20241231_zRn0InWgXbVd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net actual effective rate, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775812128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business and summary of significant accounting policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,814,057<span></span>
</td>
<td class="nump">2,774,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,352,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">IPO units, shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting commission and other offering expenses</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds', window );">Initial public offering net proceeds</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromInitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477550/944-720-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776417680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,266,131<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Raised amount</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash in operations</a></td>
<td class="nump">5,070,428<span></span>
</td>
<td class="nump">3,859,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">16,532,716<span></span>
</td>
<td class="nump">13,071,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity</a></td>
<td class="nump">$ 643,037<span></span>
</td>
<td class="nump">$ 3,438,204<span></span>
</td>
<td class="num">$ (937,278)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780418144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License agreement, related party (Details Narrative)<br></strong></div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_PercentageOfRoyaltyPayable', window );">Percentage of royalty payable</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_PercentageOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_PercentageOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469774933232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party balances and transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2024</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amounts due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,452,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2.05 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,832,973<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,500<span></span>
</td>
<td class="nump">1,767,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Amounts due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="nump">$ 1,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,857<span></span>
</td>
<td class="nump">268,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember', window );">Miralogx LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2.05
reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Unused line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2.05
reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember', window );">Starwood Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Unused line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrue interest at a rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of shares</a></td>
<td class="nump">142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_MiralogxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayShoreTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_StarwoodTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775009808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of components of lease expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease</a></td>
<td class="nump">$ 55,667<span></span>
</td>
<td class="nump">$ 14,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">336,656<span></span>
</td>
<td class="nump">1,778,884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 392,323<span></span>
</td>
<td class="nump">$ 1,793,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469868954864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">$ 336,656<span></span>
</td>
<td class="nump">$ 1,778,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=TELO_TampaFloridaMember', window );">Tampa, Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember', window );">Miralogx LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=TELO_TampaFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=TELO_TampaFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_MiralogxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_MiralogxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469774372464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of warrant activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,774,057<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">2,774,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,814,057<span></span>
</td>
<td class="nump">2,774,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Warrants Exercisable, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,814,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
warrants herein consist of various contractual terms. The warrants herein consist of</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The warrants herein
consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term">3.5</span> years as of December 31, 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued">335,032</span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued">50,000</span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469774377328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of warrant activity (Details) (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember', window );">Bay Shore Trust Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">2,439,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember', window );">Bay Shore Trust Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">2,429,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember', window );">2023 Private Placement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">335,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants remaining contractual term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_BayShoreTrustWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469775974400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of key assumptions used to value warrants (Details)<br></strong></div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input Fair Market Value Underlying Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">84.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member] | Measurement Input Fair Market Value Underlying Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember', window );">Underwriter Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=TELO_UnderwriterWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776203168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of option activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted | shares</a></td>
<td class="nump">2,370,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeitures | shares</a></td>
<td class="num">(17,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeitures | $ / shares</a></td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding | shares</a></td>
<td class="nump">2,352,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance | $ / shares</a></td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469781256304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of non vested share based compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Price</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=TELO_StockOptionsOneMember', window );">Stock Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, outstanding number of options, shares</a></td>
<td class="nump">2,352,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable</a></td>
<td class="nump">1,046,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Price</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=TELO_StockOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=TELO_StockOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780342720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of key assumptions used to value stock options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">88.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">90.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469774117904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issue of shares of capital stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,832,973<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Equity issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">303,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_OfferingCosts', window );">Offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863,744<span></span>
</td>
<td class="nump">863,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,832,973<span></span>
</td>
<td class="nump">$ 910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,352,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember', window );">2023 Omnibus Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock are reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Equity issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share based compensation term of years</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TELO_PlacementAgentMember', window );">Placement Agent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember', window );">Board of Directors, Executive Officers, Employees and Consultants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Share based compensation fair market value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share based compensation term of years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember', window );">Starwood Trust [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember', window );">Bay Shore Trust [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of total warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">2,439,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting commission and other offering expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds', window );">Initial public offering net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of total warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The warrants herein
consist of various contractual terms. The warrants herein consist of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued">2,429,025</span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term">3.5</span> years as of December 31, 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued">335,032</span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued">50,000</span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term">3.2</span> years. See disclosures below for more information on these warrants</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_ProceedsFromInitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_ProceedsFromInitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477550/944-720-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TELO_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TELO_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_StarwoodTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_StarwoodTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=TELO_BayShoreTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=TELO_BayShoreTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469782148032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of net deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forward</a></td>
<td class="nump">$ 4,427,679<span></span>
</td>
<td class="nump">$ 288,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 Qualified Research Expenditures</a></td>
<td class="nump">995,500<span></span>
</td>
<td class="nump">526,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">1,680,019<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">R&amp;D Credit</a></td>
<td class="nump">51,278<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">28,007<span></span>
</td>
<td class="nump">31,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">7,182,483<span></span>
</td>
<td class="nump">846,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(7,182,483)<span></span>
</td>
<td class="num">(846,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776359680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred benefit</a></td>
<td class="num">$ (7,182,483)<span></span>
</td>
<td class="num">$ (846,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">7,182,483<span></span>
</td>
<td class="nump">846,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469776363184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation of effective income tax rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Book Loss</a></td>
<td class="nump">$ 16,532,716<span></span>
</td>
<td class="nump">$ 13,071,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax Benefit at U.S. Federal Statutory Rate</a></td>
<td class="num">$ (3,471,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax Benefit at U.S. Federal Statutory Rate, Percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes, Net of Federal Benefit</a></td>
<td class="num">$ (718,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes, Net of Federal Benefit, Percentage</a></td>
<td class="nump">4.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="nump">$ 6,336,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance, Percentage</a></td>
<td class="num">(38.32%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_IncomeTaxRateReconciliationPermanentItems', window );">Permanent Items</a></td>
<td class="num">$ (2,182,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TELO_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent Items, Percentage</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">State Rate Change</a></td>
<td class="nump">$ 36,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State Rate Change, Percentage</a></td>
<td class="num">(0.22%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net actual effective rate, Percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TELO_IncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TELO_IncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TELO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46469780257552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Deferred tax asset</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M3=V9P ZT^HU6WX4^FU.UM@G<><65EUG/+S-,H@C[>#)Z:7.WV;6,#C@%#:?
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M7!8P S.A#>#]DG/U?*,7Z*;J]%]02P,$%     @ LX5$6N6,A@<]!0  -Q\
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MEP3GA"D#^7Y!J7B^42>;V[/RZ?]02P,$%     @ LX5$6J9RKUBP!@  *1X
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M7O8DP!6-HK [,8?*)_]K#DF1H6*9+^?C'3OLI$;HEQKGS4=[^W7BV1'TFSJ
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MC1:$BTJ.HN3M2U*RZ@*.#[V(''+FXS_4#--!Z0?3 "!Y$ER:C#:(W3H(3-&
M8&:A.I!VIU):,+2FK@/3:6"E#Q(\B,-P%0C62IJG?FVO\U3UR%L)>TU,+P33
MSUO@:LAH1(\+=VW=H%L(\K1C-=P#?NOVVEK!3"E; =*T2A(-548WT7J;.'_O
M\+V%P9S,B<ODH-2#,W9E1D,G"#@4Z C,#H]P#9P[D)7Q>V+2^4@7>#H_TC_Z
MW&TN!V;@6O$?;8E-1M]14D+%>HYW:O@$4SY7CE<H;OR7#*-O$E-2] :5F(*M
M M'*<61/TSV<!$2K%P+B*2#VNL>#O,H;ABQ/M1J(=MZ6YB8^51]MQ;72_91[
MU':WM7&8[^SUEJ#)5\W*5M9DHS63-=AK1Y,&:$]P?D$QT;8C+7Z!%L7D5DEL
M#/D@2RC_!016VJPO/NK;QA>)-U LR#)Z0^(P3B[PEG.^2\];_D>^Y.=GZTUV
M",+\.I?\B$[.HUW[K$W'"LBH[0\#^A%H_OI5M K?7Q">S,*32_3\BR+MI!TG
M[15G]3F9ET&H>SBG)S@I(@&Z]JUB2*%ZB6,]S:MS-V[&(OSK/K;R+=.U%4LX
M5#8T7+R]HD2/[3$:J#I?D@>%ML#]M+$O"FCG8/<KI?!HN /F-RK_ U!+ P04
M    " "SA41:ZS8\U;L$   C#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6SM5TU3(S<0O?M7J)RJG+RV,2Q0Q+B*C]V$ [442Y(#E8,\T_:HT$B.
MI+'QO]_7TGBP"0S9A.->L#[[O>Y^W8/&*^L>?$$4Q&.IC3_M%B$L3@8#GQ54
M2M^W"S+8F5E7RH"IFP_\PI',XZ52#T;#X>&@E,IT)^.X=N,F8UL%K0S=..&K
MLI1N?4[:KDZ[>]W-PJV:%X$7!I/Q0L[I*X7?%S<.LT%C)5<E&:^L$8YFI]VS
MO9/S8SX?#_RA:.6WQH(]F5K[P).K_+0[9$*D*0ML0>)G21>D-1L"C;]KF]T&
MDB]NCS?6/T??X<M4>KJP^D^5A^*T>]P5.<UDI<.M7?U&M3\?V5YFM8]_Q:H^
M.^R*K/+!EO5E,"B52;_RL8[#O[DPJB^,(N\$%%E>RB G8V=7PO%I6.-!=#7>
M!CEE."E?@\.NPKTPN5A/R7G**J?"6MPJ_R"NI4$Z$/@@I,D%3LM \[6X5#[3
MUE>.QH, :#8PR&J8\P0S>@5F;R2NK0F%%Y],3OFN@0$X-\1'&^+GHU:+EY3U
MQ?Y>3XR&HX,6>_M-(/:CO?W_$HA>$X5>C,FO=DG.2).1N#^;>NQEX:^7HI(P
M#U[&Y(([\0N9T6D7%>7)+:D[^?FGO</A+RT>'30>';19?R.U-\YFY#UY@<H6
M9SSRRLQ[XBK'MIJMXX2=C9<P$W<%RCYX<7]'CT&<:YL]O.AT.ZTM^QTV+S?0
M(MLA[)BP\D(9Q)V#G_/0"ELYP>&76J<SY9-3?NT#E3[27FP<[(N+?QCV:"@Z
MV@RVPQ:G%2C@>$\$R@JC,JD%.A]PT3NPNG!J*;-UM)S9<J%5S+[ROD((I<,P
M^:5@,[J5YX[A@5 X6\T+(46)5J$^S)!P1I8+4)19 ;<R7>4<CU H!^;2@6:*
M"[L%> X"!*?%U9TXPUDH$J.-2STQ;P392T%YQM/1DOM97]Q9[EED\AY^X6JJ
M<3!=6,/!V$U"!]2B7Z"P@FE96N3)AH(<W )C?P(4DU>P$YWA%KL;J]W0)QK"
MSG92A4AH1+P.M63_-FM339T<C:W7X!"<LFLB@:I3)JH4K%2 BB$"%Y6JY<K7
MCLTKG0QO95RP128<-M\&P^)*GSB>-X3C!@"CO#HQ8_ .9D162#-G<7VI7.>Y
M#G$,DBV%U-[6B81*MK,;19CJ:X6(D6/P=.+#TXEMFZ!=2RS1*E50<V:2]#QS
MMMS2CP*>KR NZ<42Z;8.:+[BH)*K@5,>-\J/UPPVF;#-5(S52H4B5ESEB;.V
M39#[E<HXW78)9NYYH742,:X-6DI=)8,%F:@\5\;DP2*)K8\TTX*4/7],&?!)
M!NW8J>214 0(93(#YU"DPS6/B(RDY9IA\3N 8NHFP2OLY49;O:>HX%#Z#"-4
M+)M^2V?^V'3FC^_2F:^>6M_]9RWG+W;;=JC@*FIA?-@P/GQWQF]\);X'\$?+
M_M&RWZ]EM]3#45,/1_^C'NZB)FZB)CZ9.9;;"K@=Z8T"/FX('W\OX6V67YJ>
MR^&K_T6K\[M5WJ\[T8[^FA.#K8<+"R$^SSQT4YF0WC#-:O,"/$L/GZ?CZ?EX
M+5E'7FB:X>JP?X2^Z-*3+$V"7<1GT-0&=/,X+/"*)<<'L#^ST%8]88#F73SY
M!E!+ P04    " "SA41:[Q+J0L@0   U+   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RU6EUOV\H1?>>O6/@612X@RY(<Q\'-!^#8<6N@R0VBI'TH
M^K B5](V%,F[NXSL_OJ>F5DN24M.BWX\.)$H<G9F=N;,F5F^WM?NF]\:$]3]
MKJS\FY-M",TO9V<^WYJ=]M.Z,15^6==NIP.^NLV9;YS1!3^T*\\6L]F+LYVV
MU<G;UWSMDWO[NFY#:2OSR2G?[G;:/;PS9;U_<S(_Z2Y\MIMMH MG;U\W>F.6
M)GQM/CE\.TM2"KLSE;=UI9Q9OSFYFO_R[CG=SS?\V9J]'WQ69,FJKK_1E[OB
MS<F,%#*ER0-)T/CON[DV94F"H,9O4>9)6I(>''[NI-^R[;!EI;VYKLN_V")L
MWYR\/%&%6>NV#)_K_1]-M.>"Y.5UZ?E?M9=[+[%BWOI0[^+#^+ZSE?RO[Z,?
M!@^\G#WQP"(^L&"]92'6\D8'_?:UJ_?*T=V01A_85'X:RMF*-F49''ZU>"Z\
MO3$^=[9A#]5KM6H];O!>Z:KH-HJN>[NI[-KFN@IP9%ZW5;#51C5U:7-K_.NS
M %U(XED>UWTGZRZ>6'>^4!_J*FR]>E\5IA@+.(,1R9)%9\F[Q0\EWIA\JL[G
M$[68+9[_0-YY\LPYRSM_0MY5;^:G:*;ZZ]7*!X=(^MLQBT7>\^/R*+M^\8W.
MS9L3I(\W[KLY>?O[G^8O9J]^H.WSI.WS'TG_/^[C#]<];M7'.IAL/E7_&Z74
MK]\AEA+\"S!D9UWV::N1D+EI QXJ_43=5=C[9[__Z>5B,7L5[^)O\U>J=BIL
MC8H_7M>[1E</\<>?U5Y[1=!F"F4K==5ND'(407-6TD)7=5O6SA8:O^>U:VJG
M VZ&L:<YG$$*9#X O]3*ULU(,97+8EA?!Y)5F._0K2'C;/ *Y@'=6%A=M'E0
M\$"!E8*9=*:>(IZUJFH\I_Q.EZ7:U0"TMC001G[#TZ%6I:DV,++*R-*;CU=D
MWOSRE2?)P3#PJ4 2C3-8I8'+]EN;;Y6F[Z[-+;2%_?2XWK#S79UCJZ;J"RX-
MG,92-S7=[FEE<]_ /8:?;+ 6M@X.P:8F Q2\XWA#]S9L55UM:OI"P:(=5,"R
MNK*P3>*"S*!KVW:G*UH_JNTSW2W3VV3P )E#4:15OG7UKO:X'0A9&-4V=!WN
M4-[\UIH*!O$2+,"2\"L?UX'5<'KG(J_\MG8P9B(Z[TR P:AYM*H-#QFB%'4%
MD4"61)W(79U;.16JT$NG55%A.T-9JB8[<TBE$,BW&OJ1OCE@D2"&1&/KV]W*
M.+I>F(VI>$T8#H$95#YUIN1P+*PG.9V_)/H?[U4,/]9F@WH-BS8MGJ^1AKJ!
M"=]Q*Y)A&'RXVM1>HFR%H.//R(&R?!#G<,BM7 V'.Z7MCE1M:!_8@!+;;<AE
MO*BIR$JZCH F&>JW5I?T*QXJ[=I,U;(%P@((8&0&YD'FUG#@RFS878K,I?Q<
M=,%R$)S(28I!8,)WXX/=B,,^ CYN7+M)*''W\2:! (Q'+O)2G/)8/K<-.S;4
M&<Q>VQ*?>==HR:_3Y53=UG7!2K#8JP+%V5)Q8"G=*K<W5VD5:.\-=K=06UVN
MR638<3%5'_D1: ST\+P6/.0Y-9%=B/2D!D=UT;HNZM;6 :W@0\2JBP)?4%1G
M+6W3%J%L$</'O 1HVD%/\(O\VP0 HQKM%/:_12Q#E@>0(2'@#) DXYP$ +!R
M#*4D8DDB.K"-FY(]7JY)8OZ;%3^EGX:+3M5G!+:#Z_BJ6F(S@WJ_7D>0 #$P
MG$1S(0?G(X\P2)<&3LXTEA9!K*3R+ AN); &H:7 +,CW0^<!9>HJ[D;)H;T^
MZO"E;/T5""WX#COJ,^*3@^P*^)B7AF'L+E49!$660JXK0A#C@$92.)?T. *H
M5FM&#(XB=B0@AJ >N;RW2#/$CO6^E2('/:K(B9/X(X9/6$=*4M_FV^QP!?R!
M^I+):^3[4V)$$1+5:>)0X,D%@&?L,#U6&1*(6[<H;A'RI/+$I4AYO2I-EIQM
M[HW+ 7KDAKIUH^W9:^>0PWZ2,"+=W3@K*$LV#6[<:@3*RJ#TZ.+OH  2?0@W
MZAX.3<O8M*GZ6I7$9VK<X/8DOT)E*2;B-5(](G\,;WA?VB@&&C($X?[98+<#
MY =7^T9BMGSHUO9/^15\9VE,1E1+O?A!2OX\14@Q(F9-NP+,P7HD$?GIURJ[
M-2O74C3-SX4X/\J-DO&>XK^#U<="G@WR\^[3KPGM$&4>>!@S8CZ9S6;TIRZG
M\H^:3Q?J8OJ2D[=J3>:0(!M:! 9\Z2$$31 RO@IP">"1<,-COV43G3PZ51^L
M1T$N=67JUC-1VQ&65'G9<D38*E!9#Q%?>*%_$*(3V4#P$8U:/8Q,OV,A6=#W
MB+^A/I&A,FV,2RFYJVD=PA0D-H8U553K(_D=M!-+"E3M"H_%"B:^HYIQM;Q.
M7KQ\/CN=SR:=@WLA&:TN.JHOM'J'P ,I\>E.6$=.',B0A3<0I@B6C40OQ2*J
M#J4,0-<S5RE0D_7*<H%F?J#Q-&P#M<V)-Y :18?(0T]([OY03*=$#.]^ZYGI
M= 5 WXL4/Q)#/<$ZTOJN0F;K-K2.U^?02X2/X-CL"% 1Y? V1,L/*Q/VE/ D
M)0<0/##AVLG>=L!!XJCI%X9Y5!746RYC MC(_'K/5,YZ"8!"L 0)(^YX -R%
MHS:23;)%((U@=R@5 6J6%F&.J.868D=DN[3?""+05E2$.-)?")#VDC/Q/Z,N
MW43(:\"V$/<C5H]E26=_)&27UYF$D.IX)@P9!#(I_!6VND!LLH]&-,R>=Q/.
M^0NE&!D)@&M=);R&^11#C2-6\T#*M9T@"I,5\)R)!.@X5U^0RDXFI'V#S!@
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MWQY.A$L?#.DAV"Y>T@L;<.6/PP;?6.1X >9KB^B&!]Y@_=5V^B]02P,$%
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M<-:$"9(RWI:9,,0$S-@+9QWRPN+2LO;&E:IU)B&28&KU>Y)&$'?HHXW3/N^
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M"_>IJFM5VLN%2%$DZ ">SQ2T\Q^(0?L7&%?_!E!+ P04    " "SA41:LQ.
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M*O*Z]K7E\SE:05Z5::B37A54)9$8H&V0#C^LE-]1%B<J*;+[(YD&&F';-M6
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MMPJPW-("_+XVR%+Q"QW0OFI[^5]02P,$%     @ LX5$6NPL6+.# @  N 4
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M?:PS9MI0EA\Y/3=R#+0T@?:;$TR5:2%=-^J%ADKJP3WHPP^]WB!RZEPQ>EO
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M]N_P>_6#V!M@N2<&V-4 ^V" 8YT8X%0#G+9K<*L![N& X8D!PVK \'# Z,2
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M4I^1[<%2LOU>UGA1RD>SV[E/H'DQ5*-0C56:=@"HZ<3.IN7&3><]0*?'H9I
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M&3P*)%=51<3O,91\,W(\9[?Q1)>%,AMNFM1D"3-0S_6CT)';L>2T B8I9TC
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M,[6<%H#>QSZ- )U]H%PR>?]!FJ/W B+^74=FYJNM]Z7:QCF?$Q\N&M(#![:
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M+-MT"WRU9O2UU=M:N^\<W1H_0H;5YU6*,:=&C=4U G.2_:UU[K:Z[F:*+Z'
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MO(6D)=IM*>M),^'-*: 1;K9QOVEC#[DM^>MZ3=O%R+.;4D+*(:QCRUK;PXJ
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M':<+IPGR+6C(1KJ*C]B>'_/DM!5,_RZ@ RS$[:UWELD16EVK*IOBT3&]XS2
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M>U5B=Z+X.G_;X)XKQ9/\< E4N\K<H+]?<*Z>3\P+#.4+*[/_ 5!+ P04
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MG%==4S60+"\[E263JN\I/Q/5:0+7"]3_%6-R.] .FMXU^ 502P,$%     @
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MN?F;0&D7F/F5$/K4L0&:_Y/D#U!+ P04    " "SA41:R\%Z5^0-  !LK@
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M#^+4SANT4(-J'E3SH1J%:@%48U"-HS0US+)U,]VWVGF#EF]0S8-J/E2C4"V
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MN/8H)O3R+:CF034?JE&H%D U!M4X2E/C+(LD>_I61S&AEW!!-0^J^5"-0K4
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MW/9D>R-K.UILFTO-M=!X16J:&[S%@C0!^'XEA+[KF'M2?R_.?P%02P,$%
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ML<TL+I? L;(P$_#Y7 B]N3$+U/];&/T'4$L#!!0    ( +.%1%IK=LS>50(
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MYCVX]SZ*U^^I>//_N]$C4$L#!!0    ( +.%1%J7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ LX5$6I2<I<34 P
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MG[A=DUJ5S<&?=3_C9U]02P$"% ,4    " "SA41:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +.%
M1%HS[I43[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( +.%1%J97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ LX5$6EZ!<P>B
M"   !$$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( +.%1%K^B"ZSZ 0  !\4   8              "
M@>80  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "SA41:
M^XH+J]$"  #&"0  &               @($$%@  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ LX5$6E%.8SPN!   80\  !@
M     ("!"QD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M +.%1%KEC(8'/04  #<?   8              " @6\=  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "SA41:IG*O6+ &   I'@  &
M            @('B(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ LX5$6BG8-PK: P  40X  !@              ("!R"D  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +.%1%K>4!]U3 (  *,%
M   8              " @=@M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "SA41:3NLOZ0L"  "O!   &               @(%:,
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ LX5$6NLV/-6[
M!   (P\  !D              ("!FS(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "SA41:[Q+J0L@0   U+   &0
M@(&--P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +.%
M1%JR#F'A]@4  ,$-   9              " @8Q(  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ LX5$6HY.Y;T;!@  $ \  !D
M         ("!N4X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "SA41:6==$.U$'  #1$P  &0              @($+50  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +.%1%I8$76AH00  )H*
M   9              " @9-<  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ LX5$6FX9U;E7#   C2$  !D              ("!:V$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "SA41:LQ.
M1C &  !^#@  &0              @('Y;0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( +.%1%ICP7N&)@\  '8K   9
M  " @6!T  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MLX5$6NPL6+.# @  N 4  !D              ("!O8,  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "SA41:&LLG!S4&   J%0  &0
M            @(%WA@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( +.%1%K?^[)JGP0  )@+   9              " @>.,  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ LX5$6O)K%--_!
M[1<  !D              ("!N9$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "SA41:\RD#!2\#  """@  &0              @(%O
ME@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +.%1%I_
M%E!&, (  -@$   9              " @=69  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ LX5$6FZBH<!'"P  M)   !D
M     ("!/)P  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +.%1%K@PD'VQ 0  +PB   9              "
M@;FV  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ LX5$
M6AQN$T@> P  QPH  !D              ("!M+L  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "SA41:\!!DK:4#  "5#0  &0
M        @($)OP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( +.%1%H!\3O3Y0(  *L(   9              " @>7"  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ LX5$6LO!>E?D#0  ;*X
M !D              ("! <8  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "SA41:RI<PP%4#   C"P  &0              @($<U
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +.%1%J'+X!6
MO@(  # (   9              " @:C7  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ LX5$6N*JX,_[ P  9Q   !D
M ("!G=H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "S
MA41::W;,WE4"  #9!0  &0              @('/W@  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +.%1%H1$3 6.@,  ,P3   -
M          "  5OA  !X;"]S='EL97,N>&UL4$L! A0#%     @ LX5$6I>*
MNQS     $P(   L              ( !P.0  %]R96QS+RYR96QS4$L! A0#
M%     @ LX5$6I2<I<34 P  IAD   \              ( !J>4  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( +.%1%JWO<)+@0$  "D7   :
M      "  :KI  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( +.%1%ICUHH4FP$  )07   3              "  6/K  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     N "X >0P  "_M      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Description of business and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of business and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - License agreement, related party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LicenseAgreementRelatedParty</Role>
      <ShortName>License agreement, related party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Related party balances and transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions</Role>
      <ShortName>Related party balances and transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Stockholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of business and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Stockholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/IncomeTaxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Description of business and summary of significant accounting policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/GoingConcern</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - License agreement, related party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative</Role>
      <ShortName>License agreement, related party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/LicenseAgreementRelatedParty</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Related party balances and transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative</Role>
      <ShortName>Related party balances and transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Schedule of components of lease expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails</Role>
      <ShortName>Schedule of components of lease expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/LeasesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Schedule of warrant activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of warrant activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical</Role>
      <ShortName>Schedule of warrant activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails</Role>
      <ShortName>Schedule of key assumptions used to value warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfOptionActivityDetails</Role>
      <ShortName>Schedule of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of non vested share based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails</Role>
      <ShortName>Schedule of non vested share based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails</Role>
      <ShortName>Schedule of key assumptions used to value stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Stockholders??? equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Schedule of net deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of net deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of reconciliation of effective income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://telomirpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://telomirpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>telo-20241231.xsd</File>
    <File>telo-20241231_cal.xml</File>
    <File>telo-20241231_def.xml</File>
    <File>telo-20241231_lab.xml</File>
    <File>telo-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>aud_001.jpg</File>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_03.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="404">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "TELO",
   "nsuri": "http://telomirpharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "telo-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "telo-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "telo-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "telo-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "telo-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 22,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 12,
   "hidden": {
    "total": 83,
    "http://fasb.org/us-gaap/2024": 68,
    "http://telomirpharma.com/20241231": 12,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 85,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 446,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 404,
    "http://xbrl.sec.gov/dei/2024": 42,
    "http://xbrl.sec.gov/cyd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://telomirpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://telomirpharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://telomirpharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://telomirpharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://telomirpharma.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Statements of Cash Flows (Parenthetical)",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Description of business and summary of significant accounting policies",
     "shortName": "Description of business and summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://telomirpharma.com/role/GoingConcern",
     "longName": "999016 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://telomirpharma.com/role/LicenseAgreementRelatedParty",
     "longName": "999017 - Disclosure - License agreement, related party",
     "shortName": "License agreement, related party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:LicenseAgreementRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:LicenseAgreementRelatedPartyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions",
     "longName": "999018 - Disclosure - Related party balances and transactions",
     "shortName": "Related party balances and transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://telomirpharma.com/role/Leases",
     "longName": "999019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://telomirpharma.com/role/StockholdersEquity",
     "longName": "999020 - Disclosure - Stockholders\u2019 equity",
     "shortName": "Stockholders\u2019 equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://telomirpharma.com/role/IncomeTaxes",
     "longName": "999021 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999022 - Disclosure - Description of business and summary of significant accounting policies (Policies)",
     "shortName": "Description of business and summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:ReverseStockSplitPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TELO:ReverseStockSplitPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://telomirpharma.com/role/LeasesTables",
     "longName": "999023 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://telomirpharma.com/role/StockholdersEquityTables",
     "longName": "999024 - Disclosure - Stockholders\u2019 equity (Tables)",
     "shortName": "Stockholders\u2019 equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://telomirpharma.com/role/IncomeTaxesTables",
     "longName": "999025 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999026 - Disclosure - Description of business and summary of significant accounting policies (Details Narrative)",
     "shortName": "Description of business and summary of significant accounting policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
     "longName": "999027 - Disclosure - Going Concern (Details Narrative)",
     "shortName": "Going Concern (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
     "longName": "999028 - Disclosure - License agreement, related party (Details Narrative)",
     "shortName": "License agreement, related party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-11_us-gaap_RelatedPartyMember",
      "name": "TELO:PercentageOfRoyaltyPayable",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TELO:LicenseAgreementRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-11_us-gaap_RelatedPartyMember",
      "name": "TELO:PercentageOfRoyaltyPayable",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TELO:LicenseAgreementRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
     "longName": "999029 - Disclosure - Related party balances and transactions (Details Narrative)",
     "shortName": "Related party balances and transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails",
     "longName": "999030 - Disclosure - Schedule of components of lease expenses (Details)",
     "shortName": "Schedule of components of lease expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://telomirpharma.com/role/LeasesDetailsNarrative",
     "longName": "999031 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TampaFloridaMember",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999032 - Disclosure - Schedule of warrant activity (Details)",
     "shortName": "Schedule of warrant activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_WarrantMember11697890",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
     "longName": "999033 - Disclosure - Schedule of warrant activity (Details) (Parenthetical)",
     "shortName": "Schedule of warrant activity (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_BayShoreTrustWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_BayShoreTrustWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
     "longName": "999034 - Disclosure - Schedule of key assumptions used to value warrants (Details)",
     "shortName": "Schedule of key assumptions used to value warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails",
     "longName": "999035 - Disclosure - Schedule of option activity (Details)",
     "shortName": "Schedule of option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails",
     "longName": "999036 - Disclosure - Schedule of non vested share based compensation (Details)",
     "shortName": "Schedule of non vested share based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_StockOptionsOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "TELO:ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_StockOptionsOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "TELO:ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails",
     "longName": "999037 - Disclosure -  Schedule of key assumptions used to value stock options (Details)",
     "shortName": "Schedule of key assumptions used to value stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999038 - Disclosure - Stockholders\u2019 equity (Details Narrative)",
     "shortName": "Stockholders\u2019 equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
     "longName": "999039 - Disclosure - Schedule of net deferred tax assets (Details)",
     "shortName": "Schedule of net deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "999040 - Disclosure - Schedule of provision for income taxes (Details)",
     "shortName": "Schedule of provision for income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails",
     "longName": "999041 - Disclosure - Schedule of reconciliation of effective income tax rate (Details)",
     "shortName": "Schedule of reconciliation of effective income tax rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999042 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "TELO_AccruedOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "AccruedOfferingExpense",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued offering expense",
        "documentation": "Accrued offering expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r497",
      "r737"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r639",
      "r640",
      "r641",
      "r642",
      "r682",
      "r738"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash from operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r208"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r76"
     ]
    },
    "TELO_AdvancesToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "AdvancesToAffiliates",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances to affiliates",
        "documentation": "Advances to affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r557",
      "r571",
      "r597"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r560",
      "r574",
      "r600"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r592",
      "r601",
      "r605",
      "r613"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r185",
      "r634",
      "r689"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r94",
      "r106",
      "r120",
      "r148",
      "r150",
      "r156",
      "r157",
      "r163",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r285",
      "r287",
      "r302",
      "r359",
      "r416",
      "r484",
      "r485",
      "r497",
      "r518",
      "r647",
      "r648",
      "r696"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r120",
      "r163",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r285",
      "r287",
      "r302",
      "r497",
      "r647",
      "r648",
      "r696"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "TELO_BayShoreTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "BayShoreTrustMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Shore Trust [Member]",
        "documentation": "Bay Shore Trust [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_BayShoreTrustWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "BayShoreTrustWarrantsMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Shore Trust Warrants [Member]",
        "documentation": "Bay Shore Trust Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors, Executive Officers, Employees and Consultants [Member]",
        "documentation": "Board of Directors, Executive Officers, Employees and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of business and summary of significant accounting policies",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r362",
      "r389",
      "r411",
      "r497",
      "r518",
      "r630"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of year",
        "periodEndLabel": "Cash, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r68",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r68"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of total warrants issued",
        "verboseLabel": "Shares of common stock",
        "terseLabel": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock are reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r639",
      "r640",
      "r642",
      "r682",
      "r735",
      "r738"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r403"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Shares of common stock issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r403",
      "r422",
      "r738",
      "r739"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, no par value; 300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r364",
      "r497"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances received for conversion",
        "verboseLabel": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances received for conversion, shares",
        "verboseLabel": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540",
      "r623"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540",
      "r623"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r625"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r625"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r618"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r619"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r619"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r617"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r620"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r622"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r622"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540",
      "r623"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r624"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r538",
      "r621"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "TELO_DebtConversionToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "DebtConversionToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt conversion to common stock",
        "documentation": "Debt conversion to common stock.",
        "label": "DebtConversionToCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r186"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r183"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrue interest at a rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r182"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r631"
     ]
    },
    "TELO_DeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "DeferredFinanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred finance costs",
        "documentation": "Deferred finance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred financing costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r687",
      "r688",
      "r690"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "verboseLabel": "Equity issuance cost",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "TELO_DeferredOfferingCostsChargedToAdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "DeferredOfferingCostsChargedToAdditionalPaidinCapital",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs charged to additional paid-in capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross",
        "negatedTotalLabel": "Deferred benefit",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 Qualified Research Expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "negatedTotalLabel": "Total deferred",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry-forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D Credit",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Change in valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Components Of Lease Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_DisclosureLicenseAgreementRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "DisclosureLicenseAgreementRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553",
      "r593"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r138",
      "r140",
      "r142",
      "r143",
      "r144",
      "r147",
      "r281",
      "r284",
      "r297",
      "r298",
      "r358",
      "r370",
      "r482"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r147",
      "r281",
      "r284",
      "r297",
      "r298",
      "r358",
      "r370",
      "r482"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r146"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net actual effective rate, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r491"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Benefit at U.S. Federal Statutory Rate, Percentage",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r253",
      "r272",
      "r491"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r491",
      "r638",
      "r678"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Rate Change, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r491",
      "r638",
      "r678"
     ]
    },
    "TELO_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent Items, Percentage",
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxes, Net of Federal Benefit, Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r491",
      "r638",
      "r678"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation costs",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r102",
      "r112",
      "r113",
      "r114",
      "r124",
      "r125",
      "r126",
      "r128",
      "r133",
      "r135",
      "r137",
      "r149",
      "r164",
      "r165",
      "r168",
      "r201",
      "r270",
      "r271",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r315",
      "r369",
      "r374",
      "r375",
      "r376",
      "r388",
      "r446"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r557",
      "r571",
      "r597"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r554",
      "r568",
      "r594"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements and Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r601"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r601"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r601"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r601"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r601"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Debt conversion",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r426"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532",
      "r553"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r248",
      "r253",
      "r258",
      "r259",
      "r260",
      "r261",
      "r266",
      "r273",
      "r275",
      "r276",
      "r277",
      "r384",
      "r491"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r136",
      "r137",
      "r148",
      "r154",
      "r157",
      "r252",
      "r253",
      "r274",
      "r371",
      "r491"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r250",
      "r251",
      "r261",
      "r262",
      "r265",
      "r269",
      "r381"
     ]
    },
    "TELO_IncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "IncomeTaxRateReconciliationPermanentItems",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r491",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Rate Change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r253",
      "r256",
      "r491"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Benefit at U.S. Federal Statutory Rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r491"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxes, Net of Federal Benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r491",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r117",
      "r267",
      "r268"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r561",
      "r575",
      "r592",
      "r601",
      "r605",
      "r613"
     ]
    },
    "TELO_InitialPublicOfferingPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "InitialPublicOfferingPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering",
        "documentation": "Initial Public Offering [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r616"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r616"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r616"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r632"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r693"
     ]
    },
    "TELO_IssuanceOfWarrantsOnRelatedPartyLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "IssuanceOfWarrantsOnRelatedPartyLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants on related party line of credit",
        "documentation": "Issuance of warrants on related party line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r496"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of lease expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r48",
      "r49",
      "r50",
      "r53",
      "r54",
      "r55",
      "r56",
      "r120",
      "r163",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r286",
      "r287",
      "r288",
      "r302",
      "r402",
      "r483",
      "r518",
      "r647",
      "r696",
      "r697"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r89",
      "r366",
      "r497",
      "r637",
      "r644",
      "r686"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r105",
      "r120",
      "r163",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r286",
      "r287",
      "r288",
      "r302",
      "r497",
      "r647",
      "r696",
      "r697"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_LicenseAgreementRelatedPartyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "LicenseAgreementRelatedPartyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License agreement, related party",
        "documentation": "License Agreement Related Party [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused line of credit",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r52"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party line of credit",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r86"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r566"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r567"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r567"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r567"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r567"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r206",
      "r245",
      "r301",
      "r326",
      "r372",
      "r373",
      "r379",
      "r394",
      "r395",
      "r454",
      "r456",
      "r458",
      "r459",
      "r461",
      "r475",
      "r476",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r506",
      "r649",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685"
     ]
    },
    "TELO_MeasurementInputFairMarketValueUnderlyingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "MeasurementInputFairMarketValueUnderlyingCommonStockMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Fair Market Value Underlying Common Stock [Member]",
        "documentation": "Measurement Input Fair Market Value Underlying Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r492"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r492"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r206",
      "r245",
      "r301",
      "r326",
      "r372",
      "r373",
      "r379",
      "r394",
      "r395",
      "r454",
      "r456",
      "r458",
      "r459",
      "r461",
      "r475",
      "r476",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r506",
      "r649",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ]
    },
    "TELO_MiralogxLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "MiralogxLLCMember",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miralogx LLC [Member]",
        "documentation": "Miralogx LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfReconciliationOfEffectiveIncomeTaxRateDetails",
      "http://telomirpharma.com/role/StatementsOfCashFlows",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://telomirpharma.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net Loss",
        "negatedTerseLabel": "Book Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70",
      "r91",
      "r103",
      "r109",
      "r110",
      "r114",
      "r120",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r141",
      "r163",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r281",
      "r284",
      "r298",
      "r302",
      "r368",
      "r424",
      "r444",
      "r445",
      "r516",
      "r647"
     ]
    },
    "TELO_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No Insider Trading Flag"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental schedule of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_OfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "OfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs",
        "documentation": "Offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r496"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r41",
      "r42",
      "r83"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Equity [Table]",
        "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r41",
      "r42",
      "r83"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r360",
      "r398",
      "r399",
      "r518",
      "r705",
      "r736"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r497"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related parties",
        "verboseLabel": "Amounts due from related parties",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_OtherUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherUnderwritingExpense",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting commission and other offering expenses",
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r706"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r548",
      "r559",
      "r573",
      "r599"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r562",
      "r576",
      "r602"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r562",
      "r576",
      "r602"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred offering costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "TELO_PercentageOfRoyaltyPayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "PercentageOfRoyaltyPayable",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of royalty payable",
        "documentation": "Percentage of royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r188"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r403"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r188"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r403",
      "r422",
      "r738",
      "r739"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r363",
      "r497"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r166",
      "r167",
      "r480"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_ProceedsFromInitialPublicOfferingNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "ProceedsFromInitialPublicOfferingNetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering net proceeds",
        "documentation": "Proceeds from initial public offering net proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlows",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raised amount",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r382"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings under related party line of credit",
        "verboseLabel": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r636"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (payments to) due to/from related party",
        "verboseLabel": "Related party debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit loss expense- loan due from related party",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r90"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r204",
      "r206",
      "r234",
      "r235",
      "r236",
      "r245",
      "r301",
      "r324",
      "r325",
      "r326",
      "r372",
      "r373",
      "r379",
      "r394",
      "r395",
      "r454",
      "r456",
      "r458",
      "r459",
      "r461",
      "r475",
      "r476",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r506",
      "r510",
      "r646",
      "r649",
      "r684",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r204",
      "r206",
      "r234",
      "r235",
      "r236",
      "r245",
      "r301",
      "r324",
      "r325",
      "r326",
      "r372",
      "r373",
      "r379",
      "r394",
      "r395",
      "r454",
      "r456",
      "r458",
      "r459",
      "r461",
      "r475",
      "r476",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r506",
      "r510",
      "r646",
      "r649",
      "r684",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r543",
      "r554",
      "r568",
      "r594"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r205",
      "r319",
      "r320",
      "r361",
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r421",
      "r423",
      "r453"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r319",
      "r320",
      "r321",
      "r322",
      "r361",
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r421",
      "r423",
      "r453"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r427",
      "r428",
      "r431"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r205",
      "r319",
      "r320",
      "r361",
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r421",
      "r423",
      "r453",
      "r695"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party balances and transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r385",
      "r386",
      "r387",
      "r429",
      "r430",
      "r431",
      "r450",
      "r452"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments under related party line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r636"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r477",
      "r484",
      "r704"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r544",
      "r555",
      "r569",
      "r595"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r556",
      "r570",
      "r596"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r552",
      "r563",
      "r577",
      "r603"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r76",
      "r365",
      "r377",
      "r378",
      "r383",
      "r404",
      "r497"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r124",
      "r125",
      "r126",
      "r128",
      "r133",
      "r135",
      "r137",
      "r164",
      "r165",
      "r168",
      "r270",
      "r271",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r291",
      "r292",
      "r294",
      "r296",
      "r309",
      "r311",
      "r374",
      "r376",
      "r388",
      "r738"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r148",
      "r151",
      "r152",
      "r155",
      "r157",
      "r158",
      "r159",
      "r161",
      "r202",
      "r203",
      "r327"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r478",
      "r481"
     ]
    },
    "TELO_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ReverseStockSplitPolicyTextBlock]",
        "documentation": "Reverse Stock Split [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provision for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of effective income tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r491",
      "r678"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r427",
      "r428",
      "r431"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r78"
     ]
    },
    "TELO_ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non vested share based compensation",
        "documentation": "Schedule Of Share Based Payment Award Stock Option [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of key assumptions used to value stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r159",
      "r160",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r391",
      "r392",
      "r393",
      "r455",
      "r457",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r479",
      "r488",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants Outstanding, Balance",
        "periodEndLabel": "Number of Warrants Outstanding, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of shares of capital stock",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Exercisable, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Number of options, outstanding",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value per share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails",
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Balance",
        "label": "Aggregate Intrinsic Price",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, outstanding",
        "periodEndLabel": "Number of options, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Balance",
        "label": "Weighted average exercise price, outstanding",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeitures",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfOptionActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r212",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, outstanding number of options, shares",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering shares",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value1",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (Years)",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (Years), Granted",
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term (Years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "label": "Share based compensation term of years",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (Years)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "TELO_StarwoodTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "StarwoodTrustMember",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Starwood Trust [Member]",
        "documentation": "Starwood Trust [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r61",
      "r62",
      "r102",
      "r112",
      "r113",
      "r114",
      "r124",
      "r125",
      "r126",
      "r128",
      "r133",
      "r135",
      "r137",
      "r149",
      "r164",
      "r165",
      "r168",
      "r201",
      "r270",
      "r271",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r315",
      "r369",
      "r374",
      "r375",
      "r376",
      "r388",
      "r446"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r391",
      "r392",
      "r393",
      "r455",
      "r457",
      "r460",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r479",
      "r488",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r149",
      "r311",
      "r327",
      "r380",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r511"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueStockOptionsDetails",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r149",
      "r162",
      "r311",
      "r327",
      "r380",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r511"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r547",
      "r558",
      "r572",
      "r598"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion to common stock, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r58",
      "r61",
      "r76",
      "r184"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net, shares",
        "verboseLabel": "IPO units, shares",
        "terseLabel": "Purchase of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r76",
      "r382",
      "r446",
      "r463"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares added for fractional shares pursuant to reverse stock split, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercisable",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r76",
      "r218"
     ]
    },
    "TELO_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Warrants, shares",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion to common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r61",
      "r62",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation fair market value",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net",
        "verboseLabel": "Issuance of common stock, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r57",
      "r58",
      "r76",
      "r388",
      "r446",
      "r463",
      "r517"
     ]
    },
    "TELO_StockIssuedDuringPeriodValueReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares added for fractional shares pursuant to reverse stock split",
        "documentation": "Stock issued during period value reverse stock splits."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Warrants",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "TELO_StockOptionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "StockOptionsOneMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfNonVestedShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options One [Member]",
        "documentation": "Stock Options One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://telomirpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets",
      "http://telomirpharma.com/role/GoingConcernDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Stockholders equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r73",
      "r405",
      "r422",
      "r447",
      "r448",
      "r497",
      "r518",
      "r637",
      "r644",
      "r686",
      "r738"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://telomirpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r119",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r295",
      "r449",
      "r451",
      "r464"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "verboseLabel": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://telomirpharma.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "TELO_TampaFloridaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "TampaFloridaMember",
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tampa, Florida [Member]",
        "documentation": "Tampa, Florida [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r694"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/RelatedPartyBalancesAndTransactionsDetailsNarrative",
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party travel costs",
        "verboseLabel": "Travel-related expenses",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "TELO_TwoThousandTwentyThreeOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "TwoThousandTwentyThreeOmnibusIncentivePlanMember",
     "presentation": [
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Omnibus Incentive Plan [Member]",
        "documentation": "2023 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_TwoThousandTwentyThreePrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "TwoThousandTwentyThreePrivatePlacementWarrantsMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Private Placement [Member]",
        "documentation": "2023 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TELO_UnderwriterWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://telomirpharma.com/20241231",
     "localname": "UnderwriterWarrantMember",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Warrant [Member]",
        "documentation": "Underwriter Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r97",
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://telomirpharma.com/role/LeasesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease costs",
        "verboseLabel": "Variable lease, cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r496"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://telomirpharma.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://telomirpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://telomirpharma.com/role/ScheduleOfKeyAssumptionsUsedToValueWarrantsDetails",
      "http://telomirpharma.com/role/ScheduleOfWarrantActivityDetailsParenthetical",
      "http://telomirpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants remaining contractual term",
        "verboseLabel": "Expected term in years",
        "terseLabel": "Exercise price",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r144"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://telomirpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common stock shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r144"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://telomirpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "720",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477550/944-720-25-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001493152-25-004872-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-004872-xbrl.zip
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MZMT9BI")I7\!9XO<]B'(R3/.X*6CP@WC>$%XDF$V.W)(225A<_.A/NQSW_!
MS0_@7BJ%PB.@TS4_I!>5E=G=MKA1'_8#5*CWP_79>W61?%>$FS\_X+@RHZ8\
M3WL]E09>.>OQVN*7JD'DA.+69!$I)&*QXO>!4.]@D<VZGV*2>829F0IQM!>)
MMV'\?,K\WPL@1(P'723@VX7,]T?*&"9,?G%)[LO@>/>!O>LIAN]NO*R]RDLI
M.J$D#H^VX[HA]UHBK ";6ZV[VNBOG*BVM"=T"1MK'M24BUKV@D\559"G)"Z
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MQ ,G^)--CP$SWNR@LH#PW]*QZKJBZQ;0LY.PRPZ<T4%EW<*,2IMY]X0]'9'
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MP\@_&6X<$BYC,\U0-<A][:VS22?][_+S=(;9"CT[J=8\Y.YN>SK<D6JL'>G
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M<,KCGYFY8#6D^AYQ03I&&[*.R_9^H)+P^DV[:.QC%2KGT-&!^@\*._X;0A7
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M]MYO.V?;1/>[&^^^/DCBF3%7ZG!R_YP\6Q9\?U-C8D!D3^A1#8\L1&+<$LR
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MS=UZ%IVBCCBB$3D]3@^9'2FR>F-5/#)RC9W]G([I,%P,O-\Y102<E\M12WT
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MAKIB,K&C44E>])$A\H'B3]EQWS).FRC-M5[4(,D#V$[U'44%-ZGE6W6^2P0
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M(0 Z!C4( */H3OH;GXT_F0A^:@N1OY49:5-?X>2VSE_UN*!+P9 YQU':;>I
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M@67!@R @U'>\ZVP8=RD)DFY>8?'*BI:+_)\^*N3_TW\F$&'Z?P!02P,$%
M  @ LX5$6G;GL*)V!P  ?#8   H   !E>#,Q+3$N:'1M[5M=;]LV%'TOT/_
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MPRG/)H+UX!<OBP3S.WS+&X='K\1KU_[P*/)7_E)2CI%Y&Z=!&/G-FNE[*R1
M]PSD4:R-%M\8+<9H-./;K$ -4BFMNXV\Z11M=R?"=R+\WF7_/'_Q:"CYZ^?A
MT?K"H.LJ##OY];#C"4@>AKQ ^-ZT"0G$L8#_\,.5HD\5&AT@#LZDH>BZU)(B
M<YU10K[2G?4HKT7"G5="Y9M.)2@5 !5*!&H ,BJ1$;<.[=C(2'(M:1;2"U2G
M.S+JJ3"D%YTG+[TKR4PG))010&6A JAESHDM1<))46""#LE*?**%U[-U+8Z_
MQH(J(MZCO8B^B]"^1;IN$];X^?)SXXB]1M/-8_U];*U@K"A+54'SF8R(A-RH
MC).\X08$IOR.F,EU5!$$O)5\+!-I%Z22[QJ;'(?CDJ.)I_N-JJMLP,-Q4NJZ
MG%I>Z!Q<-4[?AR$BI4/ATL6)R*#8$U 6)2(GAT!5D ][6L)QR!P:9D?,IX,5
M/A-B#F8\*2BFK$X>1!PC=Y0S6)FY(P=<9@H;1$M_N4H+;P02BIIHB"!G?/(Y
M5H5] ,8F09TO:PO*L>.'CU/8F%)XRMZ=?Q%^30"J[>%@A!V5G@Q6]$RHU/>V
M65'IEK73B669TKJ2.RGU"9&-)*4*PT*3.=>DVWJO'DZJC$4A/8Q#AP8&R#X6
MD'_H_]4]:&(P%.'F5NT2?0C*N!/7[.9I_&L/;<K-4O%2H')D%E$IC1'IW,J4
M<7;!$GDE\,L=O]YJ%'SV8K7O)_ N-=^EYFO+?O3M'^.Y9VI1Y;""50"DH%QW
M%:M82&1_@'(5FJ5P7\MJE_@X,ENKM(_>[@)]IJFT5NR.T79<W1VC/8E'Z24E
MAREAEG 8=+I-A^6A%&!XJ>B7)UESP:](G?LTU>ESEVJ[QZ[54Z4-_$9-U_CS
M)JZ7GNT.B< CM#9BJ1#N]3%E@HXF\&9@2>#S!(,5,$4*EX"INQF5&NW.)W&[
M'. K@/5<SKEZ6?DB0:P1U *8LW"!&(1P#_Y+Y@1>),MLII*9(*6<\4GY$H,N
M8[=(\T0M!$KG4^4#-K_!2_#H/W*)*@G9D'C[NYC[C<;<HX,?MYKEPH1;'M6I
M&&LDA0OV,WMS\.9HNT'XJ+;,8V6M2EMLG/#PBAVB#_<H9*NOQPZ[3=/TL&OO
M9G::P^[.[3\9+-J)\L%\N1V[K7@B6.X=Y9(?__FB\FZ/G@S6JPO_[*?*Q-<V
MZO67BO*/_%G)G8$?\']H--BI%$G48A<05&UT\+% YD(-V^P\=V^YM=@9-Y8U
M&M6F]8=_WOS@9AEP?LGM6A Z7@M"*\%1%QBW!4@YPKW*X9;"6(]0*PK=08R;
M"YZ(V+586F.MZ]7J5390[7^GB96H%J6VE$U:2[]>7ZD0_#*?@GPI,Z:OR.CK
M,?\Y&7UU]B]02P,$%     @ LX5$6BYAM-6(!P  )S@   H   !E>#,Q+3(N
M:'1M[5MM3QNY%OY>J?_!B[2K5IH0H&4_)-E(@83=Z-*":'2E?G1F/(DOGI?:
MGH3LK[_/L6<F@<"%W@VE:8,$83+V\6/[/.<\9UXZ?XT^G'=?O^K\->CU\<GH
MIS,:CLX'W4[3?^)LLSS=.;GH?V:?1I_/!W_LQ5EJ6^SP(+=L)!-AV$<Q9U=9
MPM/ ?Q&P3T++> \=T?6RZI=P/9%IBQWL=7]+QR9O=YJ7=YH\U72;U<;0M/YM
M,RMN;(,K.<$I+2=3N]?MG%U\'*T.T(AY(M6B]=@0KJV1?PN/")9.NH.;J1Q+
M^_K5N\/]HT[S!(M%YKO//)50I%;H#<^EVH2MGL3IX&HT/!N>]D;#BX_;/)=J
M-[X%^O\4QLIXL4GXP^#UJP\RG JE!/O,4_%WP#Z<] )V.I4B9F<RY6DHN6(7
M<2Q#H5D6LY%062(UNYQRG?!0%%:&7&&081KN!UAC32B9G7+;>JZ%>?XM'/5.
MS@?L='!^_NFR=SK\^.<?>P=[[OBRU^]7QU\]F[F,[)2:'OS:9N-,1T(WPDPI
MGAL JO[;<[&],[KZ^@%FM/S8C\II;);OE9FB,^K_WX /]H^.9;K)93_<KY=\
MU/\G")^;(A[:E,\$TV(FQ5Q$<&YI&$_3 M30(L^T95G*SC*=H%?C7X_2I+TZ
M=_RY^EXV?),K=[0E.WS"C8@\/&QBLF#7:397(IJ(P&]TN<-1!K-I9D'3U'*9
MP@$6K$BM+@0SEEN1(+W0UG,$+>09BILQ#_$5XF8B+;;&MUMKD(I0&,/UPJ-
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MJQM 3X@9*Q+$7QKBNHYJ]V@$'J&W$;5$>#"^E+4TNB"2@2&!E_0&*V"*!.$
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M\.V!R(Z. ,7.(A'BALW?$(#(Y&\I$4!1*Q>FU*'AA@K,R%T-.=([T8 DX+$
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M0.E_O8V6*(U2,65;V3*WUQMM"%_FGM]+T5@]%E*/@_+G0^HQTC]02P,$%
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ME.SQ+&SU1)E%TK=:I"H%'E?1MO80V"V#7>TUA*E"^A)?/656$ E"DQ-O$H7
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M/O$<C %A1G]JVB,&!P[?_V9RB8FI\'8>F)9YRURW^<WS;^'CS H 11VX@16
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M.<F%,ZQ[\'O93C.+T]VU_8O>Y;5YLCADK:$QMX+-%Z0KSY8\T XFWUCXB9X
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M@61QQ\*6361T!LVOKJ6_\$G?4SX3&_X8(;R,QX?_-LQ;;/0RI<ZO<.CPLQ_
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MTL#JI%3.%O!*70<0!8C^(P5V(UZ2.BXI,=RK2FDBH[4I_%@B[FNY0.*MU$"
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M4M.@[^4\:"WC/(UH!/V,M+YX!V/,S9AKT4XI4,"+V9M2:2:"_)U)@  VL9N
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M5)IU!C$*-!W 4OD1[;+48N4MM1>QB5U[7+HK8FZN]3"M)('*A54O+8$UK*P
MDWJ3"1AI74LE=F;*C2=- 6,I04@$4A[=6+*HFLNTXCDDO[I^'V#I1.D0@WR?
MSYJ]+]=">H"N@FK/JASF$T_5EZ5@&'ULYC%S6-QT#@/<=MMM$S[I4ND'1^*_
MSB&AX 69@2*I0-ZQ^8;:5,+/H><'LDDE\BG]^VW#(+>N)7O9RWK.-D5$ .L-
MJ(8B(P_FW_>VM\V^G@8Y4;OM;@<;,7#5/BQ. D@Q3M@9M)[.NA]B7HIQA9@7
M8J1JQV7#O&9CH%1AD#A&S"*:!JH&>F5]FQ-5HH6ER7LJ+R#MFZ4@,6F, DPR
M?*^ .#?FQQ0+'GS#"8ZF$U\[<K#'+IRU?V,%LJXR/J1<M;>,0M^PUF8M'RS1
M0F3-"^4Y5Y4B0&Q,H@>28 $**II3,5860:7@.."\(&1X 48Q2)&5,L2H/Z@O
M,8-TZKS<_7$Z7[#,!@862!%4N34O(\?Q4CEU0$O<BMPDJQ!,=7H(#"ME4"4_
M2RKX*MZ2&/=;9H\"(N(P")JFC!"6+815^&2AW(5CYL67V(2&I!-'2F6Z*9FG
MT'!,B0"*X.AJ^K(8!8LEL3E[>(\DEIB<66#<%_!&@9>R]!;MFCI+C+F.*X:N
M:JN4>WVGN[7OM#S?Z>Y/Y3NM$M?ZP13_M14H/[A66"9B(ULEXI7EAW*:G+YV
MA4Y=^F'CG>KE+47F6]^<C:!$=Y/BL6@;F#4)I#DA_/J/%H JJ":OC'"J N^3
M,/5TH&PF&05.C$*H,^'T20^^&5!(E_:4$:P32P"7 2!5?0I &8WCZ T:NRB"
MOHZ;?UF_SA [^TDIMD;,5T5,69O>$@(-L>@5L&9"VZ>-5-Q[<5'&,U &L1AC
M0#VZF'G5BTNL4M2,#P0^"%550\I[N<'H%EOX S?BH&S)@'S#PK*.J8JCN?:;
M&=R754^QWXK#S .+@3HXLOJ8GQ5@<W;L3H<LXA;$Z":HNB!%RBQ,20THTXLT
M6$4'I&Z5GI,Q :T+69"LW*J"_CGUT(N /])BL)_+-U5X#[/-\&P:NK68_$'V
M\U3SR;&O=$"']IGX%(BQ;C.$TVK(OC::[ND,!2-DUEAU\XZ$K-&BF=\#FQ2D
MVM,#913<KIRQ>V40[KHP+41Y1#+=93P2@&:R)5S552>,,SFPF/"=+$:2BZ96
M386RWHX@HG9J0<M(DD$&5!TS9PI*F3B08ZNXHAC&":I38)YGO$,$=$0FF5H3
MC('+3W1=Y9;Y+S:-,ST,:<VL,SWJ0-DZ4'9) K,R<82GFF%A@*"+9</.%5*3
MG^Z=>:6(2DQE2"B8"9^-G;QC/Z0!9\ITF<@A$52MH72<(+F1!1G2T5V1IS^D
MX[Q4F$1,IL:IP-RXGQ%:<Y3A&^V;ND.9\L](:4#U9*-NUS&CQ@)J-(D9XW _
MWTYT:2,?-9;\4*!B"8/,@=[4R,NT:\M(I7YBLJ2B]6F*'Q/4ZR'J2E*42#69
M0!EM*B).G':@I+N+#:F TS<EP@3W$[4638*H3MH;--!%-]#;2M%F#W0<0RH$
MDMNMIR-63"JWCG0KF,B*4W*^+#M7;,,&T_V6) _(-LUC'L@8KG35#"P5Q61&
M0NSGKBE53:EJ2O4RD>V?E-:D:%2B^*&C-1?T01%OH3278'F -'5)]QQ(-+&Q
MKP-8T$:15K.(/*E6*C01U<VFJ)>+;IB.-,0GVVQ,-2H>_CX_5NY>7^]>[>LM
MS]>[5_MZESO.LWK]_HH]M.W-?"'_)7:3+[TG_WZ/[:;VV,[8G>V6,L$3FS(U
M[ZO<2BO<4'$.>FR] GK\O,?]\CBYE<;)^4$4L>=<F>)2]OO:(_MB8NF%\(=P
MUS*NT&21U@RN1OYM8%[$^GQOR)JZ_(X.DWG5)(ER8H]>V?LMN[>#DD5]'YBT
M%$GS42Y&I=#!2A$FL0\Z+M>H3]5\4^R6?INJQ&90@P#TO7OQ2(%6!'5+#5W)
M^%9X\%7948,F]5>$.4U,-I/#*Z,(5FY^N3PSTWTW.&7KNXG__0L3'A/FU=1S
M ,)8P["(3*0G3^WH#EJ)*UU^W&&X3S2G0M4UXS74W>G'3#D,Q\SA5DIU31OU
M93BW\>:6NTXS!&7BK:E]AW4NXC(MY!&YB#+<05$KC3H =Q_X/H'1AW6^WR3H
MAA<3L)]C:95% '2/7Z;KM\HR7\PQ$NNF"G.G'"4,G9?P12HW7(LA*P58J::X
M9A]09L!IIM(A+?LMANA/U\[N:=8#GLE!P-3(R6@:)&;:E%-<)RK'GBFL+&SK
M6/_0XJZ)?5,Y;"RKP?W'%X*J?B4W3I7(-G1\(C&9F*5( D^IZA0[A-&+$]?R
MO,<US,7\WXB[3A(;E+@,=#Q&U:*#[C'OW6O?Z[1K U]Y!KY.N[;PO2:A+*14
MF1TJ%>/.=98>J"Z4I3='@\GX.H\C=&A<*G=F/(1YE13#N%"]""[]/BS"/- U
M0>!ZR!92^>7'59F7W/IDWU5V)#7WP[@41U"7.JRP0I$LLOF(K$X/1'ZH&Q(E
MU5!4ZSL,[N79AG<]]_N(P42$]@XU2 '5$:RGEDP,/F2H94AF8[SIG1Z^G<D=
MUH5:\ 8V$M=-452Z*'81M-S 1QXVI6X/.E15NZ,HTA$A1G68ON&"$@4&$AHR
MR=#6#6@7!MP#HNY]!_VKSX5CPB^8%Q:9D-XS66EEX%KCL2531^/*,YGJ+R Z
M<JHBR\?CR&-)/"4)C;IRS4RZ*NIY02"!'H,]=14_I4D&B2ZIOH(0CQ$#%K5=
MPB!L$%M+KK_RDQ,L196,BY$%\KI-);ZPG65*_[^OL/LC!*N/'.G3R"/1'U[Y
M%#HMBLV59@0VZW U4JG <.!]*]2-6W09]SQHI<P&V(=0H,HNQ;Z<5 @[D5;-
M2HVK?15;WN.$*BE-E=UXK-A43RW#[I/!9F,Y<K&EV0B5.>)9C!@O')AZ_W1*
MC^I*XK'R0@$5 224Z;Q/"1<#E"2,N.:6 T*%[.L" TR!*9E7$V8C'KZY/+]Z
M&U<[RIH/\*M9$B[I?U&)\$>>]9-.-;7YC]SU_OX<@:A@BU17)QQ1^#*R5;T
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M9GJHS&8R(()LSR</=)J?;1:?U/R5*9F)3S+?KJ!.0W[A654*/JE#/<XO::U
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MS$]JG-Y0,-*-&E@J'AY1<-?I-)25O,_"6PR7B50'5$TPC$DD@DC%$\H&1K<
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M1SRQ!%&&-$.*PI$O)#?#7-105UYQ?>1[?T9 :AVNC.:8*!)DS7)DP8D$S#_
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MW$34$IU^_29[=?9O$<P2@6!1X81';#0X0T?YUO5('"MA"2#O$X/A3"?S2U$
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MH5BB(M-!+X5[:Y.GZ4S]/1\/+VC5("Y6!C!::AGC 6O:47 >/6S+8V5X%Z7
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MN$JAJ( Y?2/ W-D)#;DSCRE_0V?IKFT9JF,L*4R/(/2A*#=(LR-]%S6:P+C
MC5XK+>US"U4TZI72C0:*3G*L6&&O3YZ#"SCDZ8EGY(EMXZG20Q^A/+=+ WXR
M%&]D\L <YY-'4?<9@!E.*HV",Q]L5K.AA2)@"&3*\+M)/VL^EU"*@H(09)WA
M51,7)HX86DU/9/;: JFH$(18JP?:2:J];\Z<[[&GY\2*BC(Q(!WE^JL^ 98V
M^9^2IQ-A=ERN<YN6?O0/]:D4@N)[Y"6.2INJ9 *T4Q-]63N:80[EK"]D8B7]
M0&<B,^L!X,O9[LK2W87^ HZ?D.+:'P9-HNJ#12O7@X8P".[63X1AF'.54TZ<
M5 *I9?(+/[/<U6-;/O-QM32\=YZ 4U"4$KA%#R2@+,'#1_R9$DLAW-;V#B2\
M4$)*B3ID*'LTP?&3'7GO/@-W]M('_9 @AI629'4K?^)IL.+#+4O53>F[%]_@
MHGR#J0L8*A]1'5 ZU@)GO%IWI&38R*YLMPMA"CN#(?6KE2@S@:6%SW*<X&2.
MDQX<4:4)FOF$EIG-LX6@L!:C8XH!;&RO3.(TNDNX^$QBBME)TBSD8I*>SJ,-
M=N@TY]KZA4B?<'IH6@<]/<P35NF>'J.H9)W4^"6RBG!)&TGF10O%2B$CER&X
M1!/RT(F[PBE0Q28&Q*:TU\6K;&M,'9/"F;7T^NIM]$R95C#)7ZU*X: -^?%M
MU=%12O?M!N'Q?_G1R]_QT)337E)Z]JHLQ\E#J87NIM8FM^EK8\0QTL;T16@/
M!?^3G3U]H?B9)NGQHXG',]FV[.7,G2@SN>(N+>6AUB8YT:19.LXGLQ;+LFV?
MCGTRRMMK>EU+&&&BI18M8 3=?WVTJ_#'O7/#)*$-6W!*JR!UR)G<?#93UK2X
MT<:X4"E<G >*)72B*RXL0?4(,'4@TM_$=9'&H4\(^B9:<SRA.86!DA) S9X"
M0JY5(#)(S@2S[ZS_P0$.;/\=LX,L+NT%6)GY@E:R3.(>"(%&-2,C"#A7I%)[
M1JP9V"?6[MCJ^6QMU($>P*"X(;WR/Y[!*@@ED;@$,BV1_.('2RHD9RLI_PV5
M@*A<\O.O/UM8.6M>I-X0BBR_^#E4=/+]SL]07L_ __B[W__QD4;^CL>J1$\\
M/D>[O-U7FT ,ZX/ 6]<RBLI2SMH1*K1P3O1KI B.Q*3K[JJ-Q=(JZAW#,VH@
MI%0LEBF(_75X'+_D6O%+YKK=I6^A*]HTRU#/#W59:U<V@==CDM%TCK&MQ_)6
M^L)1D!LZ\L@#Y]V&[DL.6T?6=%F65[PLKWBHRUJ[L@F\'A.HA50>GQJ\ "O4
M]*IJNY$/N7B!5[TLKWBHRUJ[L@F\'A/(D"$>7='W[494+#U0JB[&9K/3"@*:
M/VX#%2D 8N@BV)C"K.;TR4X"9:_<T#&;2X7D'OZ+0WY3"(#1'<'?0%ZF#,0G
M TV<@JYHU^#TL 3K^;[Z:964OE?Y.%2>3T0T BJDUY;==,V[Z8J'NJRU*YO
MZ['<%K^S%21CRDV=FK\$9PDXT,2GM=K:"BU*/?"PBEN4%J(_Y?OV+C3"<8\?
MD >="5(.Q4_RCV5I7_/2ON*A+FOMRB;P>LRH\*B+YPF=3+:+L>#\=A4WUG=C
M#0=7?Y7[+GVFI1=@F?S88Z/^Q)>,5,WW8!KL(NQ+O,"U'>RQZ]K2U+: &^89
M86+0@F#H/5PAZNPV5(IBH-(N#- @,CKFMC7(XC,".3W<-?KITC7ZB%VCGRY=
MHY=MD-X=2^;1#2EJ6IJ!4A[4D[^>DE<('P_3.RS8N:<'UGLFTJ.HJ@.$6^;"
MVQNZP.;F^N&I?8 8Q+K/0L-<1C8!RDAQZT8$_YVVGW$^+5*[V4>2B5%B;H:N
MJ3Z*QG3G^=S!D-:S$4-KHMT40N[%G@%^<XM_,I )C\A#5$HIK0T:\WSC#+<
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M>CJLX73Q@ITUN3*'$3/+:I5_]<4K0Q""!9I\6@KZ"L5HG^CDFL<]MP$.7=6
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MT--=RRQM&N8^8D^SW3 !*"M1TRU]TT[R?O@7>#II@24S!QIN>C$W^5?<L0M
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MXJP (S+AFE](6MYOARQ;,J,T"'Q'R"#2\@3#D1F7LE5>8FOHSIFB"93.=*]
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M:G^N1\2A)D<NL6M$V;"HA4E9Q9D7&WC=Z_**A[JLM2N;P.NQ@9-^BFEY/0I
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M>TZR$<*"-XF+.,N??.VV8Y2HKP9HP7Q9C%<_JL5J7=R4?*A6ZP>U6E*'V@I
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MYUBP1L_3]K!<XFHJ@8I_PM0HN6H5*RG.V):HQ/W5%Z_FN(12D\-R2B(ZK#V
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M=-4!?\U@K64)1:ND8#%#[&IZ^[6[U4V:F*1@H&7Y8XK7HGE*!@?+U9.R1T;
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M)4*>)O]RC=&9H,)0G*$'?<:0/_$Z:-6VF*7-' XZ*>;)!-8F'W":<>D(/M&
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ML+]$O1;YT76;(TA:6:FYF_7*-L %=#XKYDP )UXM9:(R7;#IWN5&F:8=)J5
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MXO?_B#>J49GVH%YT,!],L"84H_KF5A\.^'# AP-^#P_X/-64)%^ %4XT@1*
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MNDB"*,JP>G>XVAT2*Y%5NDNHO9A</*G6M63X[$%T-GD43DN076K-B,=W O^
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M1JMU"7&.)!&<:A\_T$1)&-V5F*B@X+*1EX$CMV?*:C/V9YLU7QWJWY:EN7N
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M+TCF8F$2!;.8. J-^7GQB/E($$-8,OA.JY*3"N@5'-5@'@18R899"E98&->
MI>7C:_\4M:)P+E!GH 3#T;K;$)P!W7OW+OI^KKT-7G53HHGU*N(I9=D\E]$Z
M/6JKQQNU$2B] =[]7/Q#.KJ-1$3;$"Z]A ILF4@(SF-Z&K=;[XR7C3+8'E)0
MNA*9#"J+T[FQY2P]8G YO\GE%]'9PH  N2Y2SD?.(3]>:%'=C-S@:4:E,J1
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M^$T9$/^<H-!A[YIX5G(6@R6?Q$L3[_"-8V(6**S'P7U0?@@?I8\O",D$;7;
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MX$O?'XRVMQ$8(L8"%;]8^OW>;P3V&P:7'E=LP5>>@Q"'W)BVV3S 1.<C#FG
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MM(,WWL5NGN8I-R?/SY2N3'K;SY-?2E*"WPQ<I?_C=IS(YYY/2J*>;6!9,-Z
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MASE2XA],*;0N7+66"_%@%CO!"]!O1D8X R("4:N#">3EEQ\,N%T97-;UZ<P
M%A(U2<54XO9DF*IC[[0UZ*ZAPO<"U]L+7S)/JXJ)Y[C'5\^D:JTXMW;!PA'(
M C$A[$7V#BGPAH1F$.UBDF)S0PK%$( 2\1V$'&&4$->?X)[G1;[5*$>A!LS8
MSX[7$U8F!?-(EI=,-UB^1^ECZ5 69D5^JLH )+-')''4CU+\PG2:4CW>&=IG
M%#4 Q_:LF,"U Y]:<(^QBZ7*]JP4U_GG]R].4(9'P2=<5MS:.0I+6M$R8/NY
MBD!9V!I9IV@""(8%I]#,BYJLJG7<5_^$S9IS=OJ;=3S&"@W Q,._$NQD[;(@
M(*?_ [*;.@2+6*N<V\'UG,JN]0IDO=07< 4XI#)6DQCES]K2!FQDY&6BM-<8
MNRGPV)9[4Z,0#^Y">),'#O]$_"*X_R@?I=? C\74$P#V+Y-ZHO!_R9=J]]-:
M>/VG&\<K/*D).T2GAU%B%(ZC0>@ FP2"<@$!;IU+T[1RD:64MZ2S)0$Q/(Q9
M?$[(IPAOK?[S$'$-"D^.-*R;%_T-3G. 9\3#ED78#@S!D[0.H'7S4_U#B+>@
MS!+?%]<PA:+$JW/G\#D, =2XEC ?KQ&^$?4$5Q'CZ<'E+HDYH2">!'8BK;((
MW-HNZA*;O].JF7MX?WO_T=C=Q'$YCG.EM]Y_R=225@S^LKN]O?L\Q(_9H8*_
M+U]IQ 0$\%%S/$' )!X5*MZ5J.;;Z]JA]DWDXZ<B2;9>@2;Y'/Z&KSVI2LPU
M?T3KGQLF'1."$#[^H00EPM.R(]^!,_%H\EBN,-KP@-NP6CEKC-2 9$3B/O#
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M950,%<% RV),77A0>.FX(;H7 YX_=D,@PE%4(79?&E=PI44N9:Z/*+8=TZO
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M">[08F^,VPO;AP*5O_/P^,==LC;Y236;HV1/>\#FC[Q<^#N'^[M>)!9H0$E
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M8NO-Q:(Q[SC/9O0!V5_I?;(Q6_&NJ%2=' 3'^_M(9E=;XRW-H2/J%7<,!JQ
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MU4%Q[PRX-_QD=$3NZ,:N".YR:'S(K!7/J:=@:FO#J $"_R>[@JI*::00)0>
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M:J.HW*[/Q 2$E2K/E=BD&BESG5HIX4IDB.#DA  R12K#.*92 !YB.5KJZ-?
MLAW6E$41./NA;<CCIV1W974.^[JB"4[;T-JO!KHE"!8-2&2^&WBX@ MXMF=
MH4RO*98D8*6LGAND6JQT6% R;$ YMX52Y.!FI\J:RW,7?B$2/ E1*X?F75J@
MW UJFN+IQ>".J8H$R&'PGI,;$(N,T=GLS<0G7)*>,.CT=>S4?<#QF?P,)(M8
MBIY'L1"0J6'5L<B1F*$^:A3"W28H6B"^'J!"V5 ='=C@!2$=4'>=2$!!V&#K
M0&-]_U]K<63ON<"R&39+T1)/1S\T+02I;@FZ@*"R1U,^U4C";J#%P4-S/5;0
M(ZE*$YR7!FFY62M<:VZ/V'A+D24[\<*/@#VK6M0=)5'&6@$S*VNL:>"]ML6I
M+Y&D FL'ZAZ\5:&Z1R#D@2K:#?HC^DU@_C)1AAY+)O2T3'C5(:C=MZU2*Z3:
M+%\A$+2."8!H;:]G;6DYQ59U)*!)*G<>%R%01ZH&WBHR"X-&^C.NUZW%I"NV
MM4V\K8UU-&5C%_24(I0F.9Q:A Z,+'^"1UU*)C9HPI]D>)QL@3&M5J^UVABW
M&C46R4O5@5KC'Q$'X/I8HHAE"V6 Q?N2RW*A95IN&+S<68O0S1A:X>&<,C@9
M36%@8(B*YF"A) J\8ELR//M JH\& 7BN3K"(?)1& )(1$H Q_!LN\)9C[]7.
MM<?.N;9&Y]ICYUS[6JN=7L,WL<_%T=\>_.O-O_>'1P_,].M<W&O@E][P8* -
M)0O_W64*LM<TGB-Q.U.&I.<R!:F-="U^3J3LC4BUAX:*?BKSB14H"Z^ V)"C
MC+]549A;QI,UZS7-68A<%K(D':V<DIE,6;UT.Q6+K[$8F]F(0SIC;?X: 4@[
ML>JEIAY;J8<[,3Q#.Q&+_84'0CQU_\3WT(X*G'6"E0V51W=4HR//2JW(,GH*
M&W+\HP;6ZHB\PK-$DUN0J2!&5BBTMEVHAFGQQ:[N0M-8 3U=TIT+MB[Z*.O,
M!_Y+ZB/'>DTJ9EH#PD@FVFZLP @\#&N68[49NE;S[!)D:AR=GEQD'->-O[+)
M$U8T5[ZN1E7RIO<,3I(/TL_F\ZP 84M),P2-Z:"#4 54!GU.%;]J1Q::@D*\
MW/<IFMQ?QOD-A(*;+_!FXD,[X[PM,+#\LIQE<IWX0RN_E/%D6N(@2?3%N_C@
M&4H3B$OU=>.4 [QRC72"9K9&8_JGOMI< _+P*^*]KTQN@7W&7__VX* MRMU\
MMYJ(R'+85T![2I6BN%(K7.*W LWZN*5+#!7HYHHM[=B_]1YS1[*4.] 5T+Z7
M.8X!8H].IS_#1M2*/[Z2H[S"X-(C<AL>;]")+J>_=5.<+O4\GXQV#O:/@H/#
M1\'!\?%N=^[;%=NNE)TO7<Z+!I\UYCX"0GL;6EM])_C8H:E]Y<JNO'KV/#EN
M[7U,=!<+<H>Q,8?Q-63@#[;2M4] "34G:!)9(_ O<_F7?XH-A2]6[)2:^.#'
MN^$^S5F&ZUW=E2B@ISQIS?FU>#<,]O<?!R>/5O&E;[=4=X8WG?1P</#H7H_O
MQWL4(]8(]ILXG&)LL?]/D<J_'$.Z<J*#H^#P\=!)!QMP&!VVB_^[+9+".J^W
M*,LI//QCBC7L'49=S?</@N/]?7>]UWD8__>+9^K=;;Y?OJTN]@N9^+_$503*
M_?>!4.YV]_\P'/.^F6H?49[2&Q&^GY('RB&5N^'].(RMN.'WRM#/<A%/_)=B
MDCA&?O5$1X\>!H_V5QGGW#V_9Z([.#FZ^Z-8GW6MQ;8==FRK"\<=Q@8=1I_=
MZJ=)8G+R&J%L*K1!)0W7,6S^SHF.T-MU*'F-J^WX^'%P^,@9U3?C/(X'PT/'
MS1UV;!P#<8>Q08=QS]S\:^C9CW::A8M^VUB4<H>Q08>Q 1RYPX#X/(]AI#?A
MVRHI%]0N=&>(\G4U;_L*'2JUI.S]X/'1XV!X?.#N]D8<R.'18'@/*L]]Q*0Y
M3-E6+N .8X,.8[,]U?_W@Z0B\5BG;BGI5*6Z8M=QRCLE.(8_.ES;5%QSA[%!
MA]%N0;6V9.+A/O44:F7,'QP.'M]]HR'7Q/K^>T&SLK3R6MX<[#N&\S4W#N6V
M;5@,X3@XVC\)C@Z'.FU_*I.Z4*=8^.=3+&GP,0=85(V$8?#H^# X.7[<]<F9
M3+"7C/_W@?]'G"2QF!7^;_%8E@"7__\^OGYO#17O$A@<^-\8C#U!"95#>I,/
MM%X:</6#87!X<!R<')WP-Y$!X$V<BR2;?/9_^^T,"QMP6:36*E3;ELZ$<JZP
M %,<!(>'CX/]@V,-ENF*9+>Z$?ZER+'0]56[9MKEV-7&5(LJ'''@GP) ^*;D
M;%(L^0;RQK1S, 3PQGML;5U=V4'5;\"!L, ]5F+ >A%<SP&+61$05B$'O3:J
M3E'RR%0IO: "#@%7PY4S+HQ&'5LZQ916Y3<NN6O*Y1YB!QNN?4$ V)5R]0.[
MFL<R5 -:[]^S-(VE_Z'>&[@-^8"+)X\S7:\]4N.599+E>O@VOA,@IJ07K4SM
M7I:OV+RNC>L8^GXZ(6YAV>VEFD3'=UF3Z'!@J@]182$LPP:H7#1*#7T$"E!P
M XXB4/T.V9'MOP9LFV-A9RZH]LW+#UU1]Z['./'-5MHL6(3%L=L% TL+-ZA8
MCBHXF@AB#%B;DDM1 N4TM285"96IZC2S"&IF1EUAJ* 'ENC)$JR"B<5R9"0C
M[*9%_2?X!_^'X<%^L+^_STAIAJ#ZNUP\J*M<4&17X%2NG:[21OB]HH8U6>8^
M,6G-ZWS>6W\FJ>T@U3W.Q@&LD=L](KC<Y$M-[%-C"?5O4]U=]_\"JHY;D\3R
M0M:%$E6#.]6; [8ZQAKNU.% %YBG9AW4IY9+AW)9)-,5@W88ODP5.Z*Z1C2^
M?8"M?APP;LZU'45NNO9P$\D+$2?T$S6=Q.,J/*OM[NAF (E\INLB[24RG2!,
M;80"/JI+Q@-VY:J]FOSF%8VWD]2LN:S?;X"TV%GA#*38F(6[]WDV V$SRQ?^
MVPSNC\'$E@3A>G5L3N&Z=ZGW]RJ5_O!8=^H BD-5?JC &FD*[7/%L_XM P!.
M33>L54>-E5Y)PO6QN/ HB8MI73E9B;2!$GR]9<&7FFF1V,OT_T+D<5813<?"
M;PT"S7T@C/A.E=;M^OHMR'1Y_8'_NVJ@ 0/6*_56K;1[2'Q;CQ@81DA=2-#$
M1+5TLSP'PEO-N;&2+R8PYD15 _SAF+@=_,\? PQZ*[V&_F15WN91E%Z14>^G
M-,;ZXE@]2:D$I/=AM=(E%8'6IMI<  L'E@3_KN99JNKV4\7?NFZP%Z<QMB #
M!1).,$2&*[%*]<!_A\7,6PL<PX'974E:T\:%W6"*9()1(1685FLVU<W35ZI4
MG%(C U$4U/D,6YT));9FV-\@HSI^!;?\X"F%FA(K(4XD5>WGKBIAF%>,W<28
M3><K6#C6-.=CGXL%<\%TQ39[*[8YI2E-MRE6H:TN5)+8IWV8"%56E3Z(VP+T
M77L-9ML(1(:\[B@J2D_X6 89&UC!GL&&/OP10TP1SFH68#>!>2*ME5KEQ<=Q
M#D.@",<P:MBID815]Q$W8[A_Y; >R494;+X3^!CQ@20M&9'- +;J+:B<)%<=
M[FO*0T)+5N+ALYAH@[$2H;#CQ0_#P9$W0]J1I0S!RG'P=3A*--EI"G?R\"@X
M.7QH57]<ZI<+_U@"F,Y0C87]*>@D$"M^.!CL']-^T8C^#I?AG\07"(!4S6FY
M.N=P;YSE>_1!+AGC5<U)$*>4 28+*<PX0BA>@,Q%4 R'#,5NRZQ3P^/5S0II
M&%A;E:@F.<)/LH*6^L/AX-!76V=:)Q%64%>?>L+#H5XVW@,8;09R*RYH)!+"
M?Z[AMO0^[<C^8.B;\_E=4QK>"KA0U.U#WZ=N8H.+-_7A'M/01XPR]3+Q;'6O
MG?NMM;EI9< ?[KLRX.LK _YPWY4!=V)STQGA-91U3;P2%!;'<!>P7VLM!*QR
M2EQ*W9E3R4)+-O,F&P)2#_)0(;7QWH,G+?%=<9EN:[XECIJA6)0\"(Z:7H-V
M#6026+3Q'^68F$4>X!\/#[W[8G:!-C4IYX6R&<VQ5_$8:UJR28IAL,MM4U-/
MQ7JTQ,;L0P\UD[Q#81Z3"*K[7V!]4MU,2S<*'8F"(40Y'H2V11%KD??4-%3Q
MSDW'N[,LHF9.W$;FZ-'^KG]Z?N;#/P*M2_P</WO!G?(J4))P[WZ+@1HE[#(@
MI> E3?[S3_$SW0^(&O:HMJTS*0H4L/"DQB+.05D"^A]XS/;)RI=R/WKFK_4[
M)'G/ 5D_QS/V\?QP/'A\;*2"RMXTC>EZV[!7UX3YQ]YY.,VP]1^.RFLM93A-
M8R"7]VK4Z37I6K.=QC;Q>Z3_O'G]X?2W=[_\+[H:G2EF<WC*.38D]?XN4A)Q
MAYJ@F^/"RXZJ#9"5_#++HMK"4F!#)R1T'Z\UM;#!.KK JQPI71WNZ4A.13*F
MRMJ::7B*:61:&YJCPHI=47/2Q#+Z6FOBJ"BB*$_DJD,%,U/B*AKJY2IM4.EU
M#QMZ76& +[0)NZ'*/3I\&#PZ&JY%E?-M5<[[IJI<K>-X5ZER1[66=2>JG,^J
MW&%])*>=+RK%;&G<PE>M;TVT P+0Q&>%-C#-_O$Q/<=_@G:N%Z9:-@"S3Q:.
MJ6P([7J7>J?5!(]O.%QE2$:4>*V$CYH'@1B9PDUIF9+U\Z#N#T:B2XDU2<,2
MC5T@K\"]++&_+J!"-M=]=#QT_"'2:9*UFAR:8 IL&9*6'$WQ$0:;Q?G>,%@5
MD &[4)N 5:]2<G:!1/;: M%[KT!4XMJ@7C:LYQ+@!%$+@TQ6*PC4)BBW@F5N
M']+AU;10=RK&7=$1'M=/&?.$(JV;FM:]6U;$GPS\=Q:9'>X'W@KG0LKMH]E*
M=5,<"1J$LFYT&.HFA]1VFC]2@Z99NC>M )4]Y:@T?>DL>[Z:B#Q94:7,R7%A
M@8A,"2V=XSB?\;&E<$=F=2,G(%"Z]_GP$1-#1Z0VA$C](3V2&4129#H^03EC
M:O*#?/.<8_-^DZ@?GV4%>APB\E.?@MZ;U+)94YZFFP-_^._A^YD(947&*_CX
M=1H. MN3Y6D7$3%V;LLIF#8!74/Q0RA]6G=B,F)65:"M)T2H?([>P/!!#8.F
M:SYH=V$.THJ?T"IJ(^E(EI<8H*$_H?9(YQ6.[Y]>Q*RWO:8XQ!UU+UI/36=J
MHP8CW R7MH-(>F2 H% WD,'*Z0#(@HXK((^=<K1XW/>^JIUQ-<A52DD"1*TS
MU6*J5$UC0>7,^)K#;B=PVEWS,U6#M]$+ Z026U/':<7O5H4!6[]/>V(LR6UP
M+-_-8&GG*)1&LQY#W)=E]DZOJ$UW!]ZKZT6X(P[::@MJ08/4@U[!0B=(4D=&
MCB+1"N1K(UD%#=&*HCCD9^P7*@NO]KZLPBN6^5M/FP9Y')$OD($\S50_;<9G
M;<LP$'>APY;;]?O#('X>/=-XK91%# KQ35#(!D0-]OJL[D%H/Y?SDDG'P9$B
M*#;E:,MJQHM[DY@0S3U*VV9A!TJ8J!'O"I.&CA!3W+J+:EH0FUY\6L+7:C#'
MA92:T*O']>NTA0/O=T/G&A WZ2G&H]\FM(,1QRCF.KZCI?=:7,6#D="&G%P3
MX8'N>J:[[>5?%Y316-WJF SOFI@,:@!]LYB,]GY>$Y(1%VQ_QY@,[\8Q&:M"
M7QHQ&=24DP,Q%FU^WH[%4.D"!%[AM>(>V&I4QU_P.=L1&-<82&R$0A6+#XN,
M9 LC(RT?&L4F.2ZXP0MZ5>6(W(%GF_D>_ZQ*4L#_U5C0H@&MP+N6TT\LA]MI
M#+(=>L.C@^#1L0YGP2N,<;:3N."QVUZ]'Q[Z6M? >R&4 0XIUW"P;\1%N.QP
M?S XN]!$0DV^1?KMU3$50Q=3L<:8BJ&+J?A:Z?N;ME9?TQH^R(M87I+"?8H^
MZ NF/3I#Z3V)?;83L\?+W3H^]Z[*O5&&S0C@R*P:J%$VQ\,3_F4>EZ4$U@$4
M,%SX*!7GD8Y/R>GH6<*RCKXM\=='SP''HL*$ V1C.#9)HSG0),^(=R:<M?TF
M<+DD69Y6*@.Z_@L9ZFH@M$N"FJG;*2W*L.95;*DR(W#%UU8>E-$0NC.B*(-)
MA0RC$28LV4C82H]J94>UYO10KORB3"7<YN4CZUBLOV*Q-*4Z$'99MH'CU-LQ
MI3Y1B5R-/L%R:E< TC%FWK*$4KL><A]V47"H#R=WM;-WFQY@3[6L1\L6&B1#
M%)<*=+LK'1&N%?DKE=HPRXJ2LIQ23.A6<?$ +QKDE&:0:ITCSE=ECGWS?"9'
MPJY8D$J2]8QA ! ^0QQ ,W&284@5VZF+:C;CK!(,C5.IM83BA78E(:8U"8<1
MV?F:X#BH*7(\&2=4QFC;+0&GRP7:P',YADM(* DJ0))H7&S.A-GKUN #_[D,
M!1JR2XJ1L%(Y&?@L!71LK("HD,G9L\:B:/Z%'V6DDJ: _06HUC%=@)06;4$5
MI[!A,Q7KA==\D55$M^!B1VA9'U?) !2%>6O?- #U]M29H^,XD9&'P7:?I_$(
M+0Q*WV E1@5<%B5L,[O<QH:P DTY!;T;;O\'.<_RDJWQ>!1F^^O\1HENVCQ+
M41A&1RP;%2[EJ(A+;3GPSE^>H9+T<_SL\O)R4,AP,,&&NO&S+=)Z^GV!3PN/
M3%0E4_LPR^'DD0A/T .>DAF(>5F=F,7^;!4[B7_,Q"<.WB5D,[7;@<-01.^D
M$ACL**6='PLO*@LGW,U9!O,7RK+I"2V$R'R&.,CL!Y",C#G A3)CN"0$2R/&
M9[M*A*C*:<;__H8,Y.!H\/#X[@O_]!L#D\0;5V6U0B#4,A)RAQ6YZF,*VY Y
M2AILF5'9ZX&2KK1?SL?0@P1EC-I91F&VF+J=9A[Y2<?B(E-9W2@6A3IOVZ2:
MDPFZ2LU8K?SK1EBQ$HH)7_&>_0=QTF3AQZ9*A-4#P;O\_^R]:WO:3K(O^IY/
MH>TULT[^YV '(:[)3)Z-,4Y(?(MON;SA$:@!Q4(BDK -G_Y4=;=N($ (@<'6
MWC-K'!ND[NJZ]Z^J^H9C/YC;J7LY4]Y%($ H^KZ^02OKY0X:G"PJ75;F3V\@
MLP[(3@-W5,,MP2\U[L:Z*PC\,570<?N2E#;9EZ1P)%R9X'*K0S@J#I9'(,\I
MX8P'3W@$&;%>N.G(!A3?2V5L-JW_8%\UC+0S>(;TV!@6P(UQNWBV;5 H3(W4
M^\0TQ^"R/LC@#@IG9U?\1L;H@NB#1@#.L#@7@.Y#DXE*B]_DL:">ZQ^9>7O@
M;8*=QZC/=0LMK'R@@;[CV;N?\3NM*NLJ1IUQ?."I@9I4S!U^%]X]]2E:R'62
M_W'7X%/(H+550^$:GMYHF83#T%"[ZCV.NG=LO1^7:ZV&ZF"9>8;CR)6FD!P(
MDBV$0SG2^'.'-U13@)TISVMC&GJY=SK > ::3<RC(<J0,3XB#^%IL@:<T1/^
M5QX,/[K?N#JJ>9@M]@GWKMVMM?7ASGD9[5%07#-3XNJ\:Q,R&DMLYDJ-7S[<
M\J5794)>'?MC'RJY3;.N_+Z;:V3F,:H#=NNHL#0,QO!,"@@^5,8B$.R+ '_"
M-+/"BA?LF<3O@!#$3KZR0.JU^Q.'_!)H3;^",L.ADY>CWXENA*G=1=1PABH5
M<=;HEN887;I6^C8*.G9K@5FWKF#IL*M)Z5\LF^>@?3<5HR$"D#-^8; LH\.B
M-ZHIP[-C?L>$ZE&F7%-!V!-!N)6?@^QO$L9/NC'-_O-] LKN\K/+9NGI[\GI
M8V;IDLHNY0'APM#)JPN+7Z5/0PT8"B'W0+@O'')9CI>T?D K7G@,37+H7HG3
MY+63EO,,0%@1%-JTJ3=GW 1>\'J+N4@,@Z\?LG^Y9LC?N"+$JM(TS5QM P:.
MFD^\]Z'6#,M676=^:GD>8A5L)WZ\S5IGH,HB>D_N45,XE6FDJS5H=A2]/W<G
M0RPUL-$BANR)QQ>9 &UY$GYJ4=QVC^#AT^?(J4E)-#2PQL1] :X 5#(>)NVC
MX+H9>,GL:%[Z9)8MJ?L1#*K)K\61'>@UF$(L8%IJW\-722\(?9"%H)_C+<M4
M:8L&7^LOK^D7]6PP3^M19>[[CH0:O&6&LL( D8M3F6)[#OV.W/3>],=G),9/
M%)DU*QV,\++.]MJEA!^1365(!QE'IVBDP69Y . 6?$Y_AWE:5F;Z,#U7L:M:
M'6 82CJ9%S316UC^Z"/ARB>.[-3]PAKVUG#1S"0BAON:_IYOS1>#,_,I.#-!
M<&;^;8(S]TQ6MN<Y,<Z:N2DJ;^:FZ*IV?9MIWN\QTO.5@'.GCKOB'C>[RRL>
M"0V.T<F"9#KYW1L7FG/3 8]VI&WR,D\J'!6\<46O0=:V&*7X;\(0!<53^-0C
M4RT!3YF.?]%=5 U.K#$)N/C34#5T83@ST-D1S^RF'[Z-5VIXH_;M];DD6]&V
MZV^!/YUB+O# /PBC(:)-9!QZA3?S%R>-GYG;2Z'Q\TOSN'E[LZ\;?=53Q9AK
M.CM8;,JS;4][MJOO*%E%P[4"7?:%$1@?E,",M(07NWQ.87+DWK#:\M/]Q ,$
M+QD?&I\_UYIZE^3&I2,Q"2;;+ENMRS:RT =[_-^#OFT/K0_OW_O@RN]K9J>O
M/A+K/5%ZLOE>D6WYO5@MBT4I_SZ7RXF%JB06\WDI5RA4<_GWY%DZ%(_Z]L!5
MBH?PI$-XK2EW8)$<EYUH[T-6RET;L+LX-J.*7F+!+Y'--(8?;[J>"+\YX]VZ
MPEONO LX+M,>B^.M +O@/ZF;<G,HOJ\Q!+H/)U'@_?G<\Y-?M_CD4_%94WSR
MVQ6?4+DY'FORD[542(142N*0O) :F;A24H3_#U)2V+:1H;Q+:XOY4'(9H1KN
M#=0/WM$ZFCP4ELI#]8W)0VHUUK,:A6U;C3KK!')#.X%<.>U#N!@X'0^GQ@LX
M-2V+30K:H>GI U'%*I^:F8!82:E8K6EFI)<Q,TO$"^NI=,45J #R&W[O5,IB
M:V*+ D5HU9;3'I[5 _1-8]3K"^<R/)S]*JJ42:GQ"DA9X>U)67+Y\03DM9 3
M\[E"E<IK(8J\G@2G%=]XA;-11:#@B@!>3G )X*(D,0CP/XSO=S%AMO%3%7-I
MA+.F1P=\M>40A]J RX&NMD<6NF+86>*1"%<:/#^:7."QOP8/;&]N%X'@>=]]
M52IKJYD-"599>A%9:PR&FL$ZB-9FNJM/NW,-DTR$VD#5C4>WESP?F)'GY28Q
MY)/6J3+Q!#/H/- S7KLJG]L0JC1NBB=0^4)%?!GC%2Y0B\.D<[73QX$KPB]9
M)Y-@TJ*RNF %AZ2XJ<$Z=J.'Q?"N0CB*%L6OXKJ-SAQ&IXOV#LM>PF+V!@.G
MI'W$+:?]G/P$2TQ<LA"J]H2%*:S7=").9)K&FQ*48BHHZPK*"R7R$,X(TN .
M</6-.(@J#<O2;6].&DJI-,23AERIRL.=2&FR#6,,0D:S!8,;=R#1E!^W_/[(
M/Z8VNJ 5_(+&Q<R;0_?FQ*R<BMFZ8E9\ 3&CQN7".!)HJ+^:Y/FG+FY7]HJI
M[/EEKY+*WKH.7V6[LK=\J-4\5,2J A8/'(%,E3J2?BE+47AK2]G687AU0Z']
M,)S1R=@F J?MLCRYW5<[4>]PQ>4@O'V0![&*7+P6^SI,M^O<5JU&\Z>:K$$6
M#GZALR>NV# */UO,Y8IJ->B)+.2*'62'!&^#Q50]KLFP>7';ZO%,M6CKS)M1
M&V1 =0<V7//^;I'33GCZZVI'WN)A-R=@K3S 34I[A"38(T1*>X3LO#R\EMKG
MY-$&FZIV!JV;2"'$2Y8X[Y0%WGZ DI@%#L0GLR#3RL[')AO'Z>3?= #_/T-#
M;N7$1%-8QA.;@U0#'\74"8N9V(@#[ M,6PKBI!HTMCO,>8D6-+_I,(@\2TX,
MD_#8/.]&'/C-&^K2<,<W7CKC&_V=2L6*<'=T<U3'5I!T_H\@2L4<[>'.QX;Z
M/^U\1LKE'7#6C6RV99U8AY?/&O!WK4.5=3Z7R_^_N\O/&]>D4D)^QQXS>7Z+
M3.YU.TN9?(M,GG_+FCR%]::PWNTX3&]:S,"6Y%_680JTD@XW)5F_+;D*L275
M7&FY+3EZ,_S\MGVC_,OZ1BD_)\L[U?);U,\[6J]>+4=SJ/@5-IUI10<Q&/!S
M!V=4TVFZ#=,T=&*,+&W,BC% #M!?(;K%1"R:NX.LL2#E6-WYNO9$Y:3Z%N4D
M:<#&EL.%Z2$9];YLXFSWB/Q??160H$1EX W[/DG)P)9+]"Z, ?A0[L2:NHMY
M^HSV0J=C+M>0D+0V;TI"TEKQM25DR[5Y ==H#5%("_.F1"&MYUY;%+9<F!=J
M'3Z/5(5HB*^.+@N%5!:"LI 6J:XM"Z7MR@*?&"U<L;F!MSCQ1&8))!Y_HS]U
MY4U1CBP<I9V#TJ:C5';HEM,'UTMX3M/__L]SL;$?B;4K'*-)4UATB51$CG8S
MS;1Q6OQ_>W%B)T0W;&+1]<'GY1Z[G>W YU!'"X:)<U>9IXUED4/L 0._I$UL
MV8?##WC#VFX[ ]X65Q,4TFJ"!*L)"F^PFF#S-QWA,]S<Q?CWO:-%#3B%<F^G
MT<'B;QMGE^?-Z\S5E]KU>:W>N+MMUFMG-UFA>5'?W%3,="ABM"VXDP]/FQ>U
MBWJS=B;<W-9N&^>-BWV>@KC@<%Z)!\^L)KP*C&K/-$:Z@J\SS ^"V6N_R^<*
MV;Q4R>:+Q7]V(YO@8?Y_7[1RB/EW0&>LO]B0T#FOO,8$(E!$0;0A8A5JG0YL
MC]X%G*KF  -+X=U5O79Y3/\M-$\$;TSOL_+<JN:J+:(0]?"07J49)GZLJ;0Z
M>/.;$W-BJX4_B7E);$VZWQYO;LOJI/M9A46JSQ]T0[\8#6 7'>H% IM>X[)/
M36. WSK,B? ?VZ _B_E#23R@+SX%;S$'_Z]8.!!TL.W_/8 5? @L )NBE/[S
M/O .ASG_2<9;YEQ8J R?@R)FJKU^LKWA#L6-!3;S>?M'7[7).@R=>)\ 3EC?
M<[=$BD3%W!7.@9JT<&:FA;,V5S@E5S@E)IQJL58?W;7/\R!5$8138L))?PH3
MS>("T2SDYTMFTLQR>IC?*Z'9_?QMXNIM=J%[+=;4YN:3)-"QK-%[EIL^(;:%
MX$70%6XV6!(Y1AVSS2B/TUGA'3WVTT-I'ZU:*J"O0D"E) ET@VT2,3]))?-R
M2-C,8 L^:5(4\9C(IB6PSHJO0' +J>"F@KL=P5U:UDZEN; 1:78;U_<-32&F
MQ6NYA,;?D6J/A7<GI*MV5/N?URKFQ53,4S%_(?M<W)Q]KLM67SC5C*=7:Y]+
MJ>"F@OM"@EM.%IMNP^<1#.66^7FRO#?B6'FKJ(7BF\4JX!^GD K3:>M$  9[
M0):5B;#S;179 <#'9WB5_B[LNC49Z,,*+^;'H YZ@F5V_GL@CQ2\;3CZ,^P=
M"+)F__?@8.J BL7<\/G@_9N@S@9NP=V;%^?.U=&3;7[!DUG]@B<%;*R^A_7?
MLG'JW!H9VEK EUJ@,0;^\MC V7B8WU=-TK$-$T.6#\F1</.;8_,H,J'S*/9H
M'V&(])U><.!)]%T*Z1@L$_V!35O$&IV#3Y=#58??90S6"FFA:[TWN]_/X_KT
M@PA]^9$(,MZ0$Z8"Y$Z']8Y"0]#F=W\6WOVA7E@\[^4=/@#SE/G<1U\'JKSX
M\9]Y]X99?&G&Y,4L5B!58KA7&5FATT<4MB6HN/_9I"AA25'48QU,L'1G$BSX
M@\Z2+%E7WSGO9=#P=^B18A.61Z+Q\ABTCQ  PN)]6^NZ/.NMU]GG$5!",$8F
M+)[R.=V?$/8-86@2"TUQ5U9-;9S%K<F:EAG !TS\*/QY"*NQIA\Q-"S5:443
MZ"8VC\+>;JV1QDBKXO]X-T7X"?R51[O,7-K!,CN&#G\>(,6?5+M/>8:[#D/6
M&T>#H^H1'5Z@ 2GA[X2VNU&9T-_IE-VHQ-/EU"@00^8"E"KJ75#4GPTXSTS=
M /DW]50E;]YU 3T84+ZA2H/JZS8V$@3U,911/\F6-1K0/CM]V0YHA"=5TRA\
M2M5'A+:=$GIXJO@[/-4CH68)BFIU1I;%I!-37AG:-&&>VLH&WF#**GY3'@Y-
MXUE%U07B_J_2454 (FA4_XU"/E \$IT/H/A3M0-O#VJD3%^&+PHZ6![-L*B>
M^)=8.BJZWU1&)MLVUU)S,NA' I#6(G"4MHW.+EVS8(W:L"D@#>Q.,49M6Y#;
MQL@.ZYZ8D=NJALH.R+*0FN=N79';>!%'25.K99(>^M:,LK[5P!&"VK<,02%6
MQU3;WCD(>;IR[Q0R/CY0##1: N]X+5#]KR!7LC]35AA@,I%K?:%K&@.Z.=@D
M,!EAUD.U0.1A\;:LZO8X5;R[H'B/94ME]I?[RJGRW8;RM4@F5..B@'+O:0B:
M2>6Z8$ZC5:^T\$BX!#=PZELJO4\@S^C[H9)SW$3!T$,U3^B*VK+%.K:BGTE]
M]R,!7'FJ280AR^;X7+(NPG--+]]#739\&4_\.+K<EP"Z? 351+4'S0ADW@4\
MMG^$=]P3IOA?S\4'+Q(78:(WSCWG-@$=Y:6=Z+NY8^M8&>?]Z/_"$DR%AASN
M*K&%HM E"OJ2&8MT0.G;.*9"DY^\Q 78%]@*34>;(W0^\0^PYY'&[8G34-'[
M/IW!]\SB"M97Q;+P))Q'TKVE&G&#"_Y!,ATV$!'9V>'E>7R UEH!9G3/DAT0
MF$C#\O^5<Q\S@4^$%?+BH8)S@5$+XQ?Z)F! HXVF#P)0V3)TRC_H3IGTU<PA
M>.H3^(8Y/XY#EN^:A%I4-WA#;G(^DG6?H8QHLP6(*T&[PW^Z)BR$67DN!1G0
M$&C8_3*$/E\6?FO"=N!=L">B]T#+T#_R76&4QW>%X1TFF'69.7^FH0G8+L6W
M>I/FA$'2J0<(;B3]EGL$V<P3F9%D1BE\#;55E."H*U9YG= &@N+VG.AR.#*'
M>'SP$*X462<P1R\Z:2+2[;+ G([1G*-[5]DU93#X$0-O)"C7R+H!CF&G[[P^
M%?\-+AC,8\:1>#ZWA3,S2R2XG4MH L;"XZ%V6+4>K+FRYO!&>.@R1PXS5 ZS
M?BTQO014)LR6<Q\>N98NY4BX08[Q?=C=#GD&TNCPJ"Q::QD(:MEHO558"GE4
M%5KWS0(#C+6I8AJ@#6;6"2,SB'SX,^=NBSD:C)(TDO#>_RAK(]EV@J3P- V+
MS^!U.#&']CG6[0PLE 9KZ- H= "IY]C0!L9/!$)+^-^I5Z#$R? 7GMN2_7FJ
M\+7_P'!64\DCU]B>'0"*(HT@_!)\ZIF2C^H/7Y;M+<MIDFM[;[V?J>+*!:NX
ML)U!>(%EI3'\?-8XDR;/#\D46)9"JKCP]0>?;F0-(OR>\+_R8/C1L0-9X>JH
M=C2GN&LWZ;W+O'!3.SMN7'_.<!I?GE_5+GXY--[%!8,[2;-C%C$?:5HLU$F0
M&1^!MD/EB[SW'Q4SSNJ.LLBT.#:"XGAFL+[TX2+Y]U@[%K\\/!J_*\F(9#E$
M))TE''PZAI\RU[*-:;]3S3!51=ZX.&Y<7Y^2MCF2S7&&]3TK^I>^,;@(_QWB
M:$( )+MNE=;:7/+HF'R^6LQ<_/ U%S[6'I4C^,)(Q31K(2?\[_]42^7J1P$Y
M6' X^$R0I((D'I:E?.EU4N:J;^CD0^9=L23^(U2KQ<-*ONP1X]8 3^X4(ML/
MPKM*J?2/4+^J'5:*.>\3I_(S_,W]MEC-YUXGH6AS2.9T=(RCCC'(."10]:[Q
M?P-_>IT4 "MY3N]5,A=4VX,;7[,L _QYQ\?G<U+ ]-ZSF !^78//C2V(9QQR
M78?E(3&1DZ %WEG*@?S4#5W'W"?=?*W;5365(A#8_!A+^&&8FO($88]+,?9=
MH=:$;P.-<74T_&'3 [Z/9$PL[PKU7A>:+\D]S*Y^$7:]]%&X'-+,]0=\#1\-
MY+;A$]\LM#VT#=_I89Q&?&+:AV^3TNK&+4ZG&9?[IP1A?U'7>P2NWJ^N;DGG
M12*L??Y+:IADS@I?B/9(4'/!XV7=.@Q[1Z@B2QJY'0+2QO2M']"]G'*[LZGU
M$-N[LP]Y,)2S&3?ML3<+WZ.E1E$+XCH+WHQ!C 1YCV(0UM_7TEJGW2'=1V ?
MA,@=<C_T@W"8.\KO GB=$9'#"Z5L9AI-/A_%OBGHNA" KF=>"+HNS$+7,W&@
MZU/TC85?1P)R@1*2X\C96O8GUG@ BQBFCLH1YXV+PQ0D/_-"D/S=T1Q[:RBF
M(/?;,0G;]]IW:<U)H.ZG /=M1(YI9"E:? I[GV&8[^C8^[Y,H28CJNE-!#92
M.+R#EW=!D-X?>C*=O<X5)Z[%TY?L/A3_#\T['648:+XKTP@CB\ 4!'LA? ;^
MM3*&7HB/H<\,U\'0+Z+G%+Y>6(BOSVP%7[]+LK&G6C0$/Y\ZU[N*>+?FU+=L
M'>,N<(Q[YJ4Q[H*'<<_L"L9]EQAW'[V,%.F^,:2[O1KN>YMH]^PKA+OODE3M
MHR9(0>\IZ#T"Z%U)!O2^2YR_C](:AH<_G8.'GYEI\N7D7BH=7PYO[I4HX-ME
M,TTJ<]'P=9!N<RP<DP<9(DWA[.PJ-NIVEXB_CPP#CEXT^#E-%^!9HV*E70KV
M:Z/[>#C3DBPN@-+/2/-3W<SG;Z5Q];B?A#17%P+IIR^37X$TG\MFIY_)5UE/
MCCW%\:W<@[:<0O:2A.SEWR!D;Z^QM$%HF-N@-._!3I+<VQ(LT4ML.8F+7_IT
MVP35C4':!V$TA'BM(^.0T>/:6>VBWLC<?&DT<(QK"BF,0<3_J*Y43*/HHZE:
MQZ4 IZ$EBN L#+6KKR-%NAT/\J"(1P/8\9A^Y(.'^1$.A>!HM1BS:*,I]^E9
MM.&=^KTN_'&I'CI2(-@1__")8,H=WZF!>>-$=>V;.-,H:;VWNTWY@2[XV_\>
MY+W3*E3KOE+)J]MNORVV;]11USV(D.5QS@IN(T'./?CDH&#HVB4Q.X>:T=:6
M*#5W^BQ+/E_]1V/RZ_-WX^JT_2<]RSEG.3OJXXVKA8@>^:99)A =O3R;I.<T
M_YRD'3HGGSB[.A%;=XRLPYXL#P\/:Y8%/D:M;8$/U+%;ZG%KTIP,I5.S)"HG
MVL%B)1!_BD]26Z[=W/@=7$;PC?!:2 2[%HY]B5@E-_UGA1=M8D/I8>S,880J
M@],995!'Z*!N>SHA)X)6L.[)_;%Z3(R_G1A:8<X@M@3WRU=-;T=MZT/*A;O*
MA>EA[-!AA*J$HD\EX%Q*T #Y9FL@U^J3_*]N:](=C;_K4J-_>5[:B(/@.$JL
MF0#+T_"\10G3%O%U!&QF#IGY\_/K/'XY=SK9EW\G6!!W\.E?B_<DEJ9>MRZ_
M\FNN4[0.B&E@-U:<93X@D0\"=U\UZ[([KW54J7R  (:!;/_W0'VV/^BC@6+8
M"NFH QG<3_Z#1?-I(UUE#[R[.3GX)&;SI5)6E$3G'LQ9SZ<EY$B6^ N%-^6J
MC7-5Z#UJJ;(&5^T@1RWUW$YX:=]E%_X7=&?=L&QK6F^?_+GYKM=OQI\OE.1<
MN#!EG2 QG(T)!M\9\(#EFP65>A2ALN3_XJ%%.H?J\V%?510"#P?NR:O/;5/+
MY<JY@T^'T[B!U!E\T:-;J 9#Y3RZ7BR+<?6BE).R^4IDS?@"ZO#8IPZOL!Q/
M51K/0Z);A(>&T^KPNU4Z^9+_T_SSM[ U-S9!NO ](F@;-YFJQ'7D*I1AHGNQ
M92FN7!7+V4JYL!MBE3+-II@F7!D7XC)-691V@V-"%7'=IX@OL<3@FG2(^HB0
M">N"V'.T<:?75NN-[\KD0=ZN<YKT?=7)B-!E4"BOTXX#JXO4&1V]X&9HHP'C
MLDNR;8GJ*NO8FDM<6NH2AU[D;8MF*:]L@5<6JOWY.FT%W1\_[27ELO" J/K_
M!7@UU"B4YUTSH1VX!4-@<T, %F'R.)!:DZ?3:N>7,I@\/W>WX)[GDW;/;PT;
M:S #MU*IM[6&V 6X9@77O!H_%2CE"R!KQ=WPM5)^29I?0C5S)1>77PI2,9O/
M[PBW1,7Q17"F4RY^K;>_Z6'LT&$LA>HYN5_G;D=L>L[2[=^KBZ]BZ<OQ4-JH
MLQ1P([=U]<.+Y>?<_:2!T>X%T95\&D2_>5Z)=)&UX@56)7:BO9"50+L5"Y$S
MIR\;.2>= =T4I[^@4.V:!DE6?-9[^VM2GKNVV==]SJ%N:&DF>X?^)TO;,0?T
M^]>[/Q/QX6>C)FXM6[>DEB?\<B=_5%R+7VE>CZXN-*<7>.3BLJAU5Q+3[:"O
MI7UY-1*)AAO $*Z_L&WDCJ(G&2O%K2490[EHT^>X;@5@RNK[R.KA'G@IO@=>
M+DO9<JFR;ZR>YE+3]%UZ&/MT&*%.K.1S8L]4-GA )59-5_PSTAIT[DZ@(-I2
M2W^O3FY4LU[93D%TH@KMK%D[;IXU;YN-&Z%V<2+<W%[6OWVY/#MI7-_P_H-T
M08WO=\W;7RE/[RI/IX>Q0X>Q%('N4S#A]=0WM;]_QI?CF^^-. 'S]NJI-6\C
M:5'USO)C>A@[=!BARJ'A3Z&QYN/6E3Q&!"%X(/ ;<T246:WAP*3/ZI/!Q4EK
M\GSZMWJO=;K/9W_VL6CEUL06ZKSY.@Y=H 1@Z30<H<+(X%<Z^\GF\[(!6XSK
MH_-8]#Q7-7;)0K%2SA:ETFZ HU(VVAH;A>:0JK'3I>5<.2M6RKO!1DNC3(H4
M7Z[3K]3JN"@^?S.^[5%=-IL:LKB^94^D;$< JW.X907M'+NHH"IE"U)^-Z0J
M99O-L4VX-H[=+*.8+V>E\BYKXV(@)-<)D*%N$D6=KD)T5/%=_UYIZKGQP[=M
M%)ULIR#QFNEHNA34TV-PKW4Z;*Q#2;$C,(\WB9'S?W$^GE+,+>_3L6LHF917
MMGJ-&Z;<(IL ,1>[+PA\=1_+$1>G:MV:1&X6P#Y,3M5N:]*^'IS^+&OUZU]Q
M;H(B>>H;+D3<^\S*CGA=:_CI8BXVB+E4R66KT0$4J:.^ARP3KJ!C)][$K"05
ML\72CO2860=+,]^]3OGZM=ZEI(>Q0X>QBBOE L29ZP0N5.VF,1E\OFY-Q-[M
M[[^*>&W+_3WSHE+O*7%3N(+;%!MYFKI-KYA7POVE-=I*I_Y2RM![:Z+3P]BA
MPPCUET2?O[0(>$Q1@B5E,#;'O4Z[$><^8O,H0?\&.)A88!M)N7)7N3(]C!TZ
MC*6=_:],WBF!BAJ=&NY<6D(\]>V+U)K<=1YRRF];_J*3?<0$NCL4Z!:S GN2
M0X[J=&=O'SFN9//2I*-S%4J9*V+>]&43*-1L#56EI1BMCC?+M=T9-_5'\K4L
M@3*U51L7ZKW<8B\?RJ;PB,]R=N2MH[SN.O@<TE\_KS]+]W?$$CO1UK&L"W&$
ME40/L\0@. MO)=%]?C),Q2*ZWW=N7IP&O><K^BIK@RL.=?;%\OHKUHT0?W]>
M $#_!T^(2@H]I5FN+<[E%O;.VLCN&Z8Z(8K#)3Y6[1T/3HZ/GT[(B3R?12SZ
M'$%V'S3+LK58B^!\^FQ4?MG]7S\>OU566\0*IS^]C!7X-&ICQ^"AQV'12(L,
M9<U\U(O5\$6*.=KL=<X-ZV+VG#D8BK">9I#J$@9I6M;(8PY%]S/I927_=&)W
M[Q]_%I?RATJ?,\N@E27OOQS9E@T+!_L3O@A9ZUP\W=W??-;4I8LPO(?-KJ0>
MAQ)<4AJYL3BZ['Z6;A=8EB64:,2F!%^$5BNI1KZ3DYKM%2FQLB@P6D27U;P4
M3T/'%U8?M5989DS3%W^9"P@9KD]BFKK-$3)\F=7UE@E+)%$4WFHJ<4I!,D$4
M#-,O#4=IJ)0(8DU<W@$PC7)W].BD%SZZI5-%ZL9@8.CS ^+OCX_CWG?ET7S<
M\BR1=>IMZ9ZBA,"^W:\6_W[]-7RL]S]_GF"/+NX@\->N%ORNO@+NHNB][G/[
MASBV\R3""A8/A%R^ANB&7RIL.N:-N]Q0\RJ57BK@96?#&D9,<T@^G$,B1+O7
MW=/AXZ]?>=+6YK!%A%!WCH*($.=>#8X?FQ=U==0LK?#ZJ,<=/\*5HA9FQ/'U
M5EUA*",6HC;+#U^AE&1X.ZLT*XLX(AC.^9CQUC8*I-N^_5U>PHSS KF31:\-
MB>)\[[XJ%)Z4T;U8JW<6OWN%^&W.SJ.S82&_33:,%;@5HL(CPY>8KV;+I7RV
M5 Z;;[F8#<-R*@L5X2S?<2TT:HZ?NV<//R?7#_'XKA&#[_B[NY+]<WA</?_<
M6?+N#?%=N'*)BO?9"M^%+W$]#9VO9$NY:K8BAH%-(JD_'L,B%_J.1I!MX81T
MR*!-3$$2LP+*#?W0]&^E+#7E\*@A@?<\$FV<1L#)A%' *VD$O*=']]+)BZ6=
M!6H0BZ):D+4K656:>ET>JK:L30?"YA_ER^D?]?+RZV;'@FPH)O9V*>"@U4-5
M%SILHRFCKX&HG,,\T=VM8NP966!V\A)8O.J.C,E*66=SK!/J,17C5YJ6L\5<
M/BL5=J2)T%+DSC6Q954G2D,V=5"25JW3&0U&M!;_A'35CFI/J^N3]GTW;_Q]
MJA>U_9Z![-LJ78["]IM6C[]8]?B[Q7*]G%=7L XKE+=:L#EPQ6;,1"Y;K):R
ME6+L7N%)%Y;_D_+N*^/=</.T0IWM'-X5"]E<J9 5"Y'[*6V7=Y?>KLV"TMU^
M"-Q0^8OY+KX\FN/G\=?"E_:+C6E.VGQY,UZL$'P["<.WI_I@5SJAS++O"J8K
M?HEA0<KFI,BML-)N/2F/+N?1<!,5N[01F_R!FLU%+FW<E6X]A14F-WB]>UP3
M13Z/;HVOPZIY6=QLO3G=^\L-)/-5I]-D_\K&*V3]Z22G!!>VM4+I4,E8P0Q&
MA=:GX\Q2(7@%0A!J9TNQD]Q[/^CLO8V]OC]E,O\9^I_,LH>+G_M1&,AF3X7E
MX4?=_P97_F=DV6IW#(M_/]S<6SH$#MJ,32%.?TN=D$#:U#9EW4+&^"",AD-B
M=F2+@A5=@JK>,>_1[L"1Z),,3F88P /'B"+0#1L>8!N"W2="5]5EO:/*&KQ+
MMLF X/P&V20"8E!@*3V3WM*9-C:6A2]8Q/?!H_VDR)2(X-HS__D_AX?"J4HT
MY8-P)?= W]V 3T7T#GRK7/DH4$@G/$ X/.1:75$?HT8@;)?NWTO4RE!AA-UI
M&M<35.7@OV%='>??P3> [ZK)0PL6XOST47A2%;N/6\O].V2O"SJ,V,8P5/.$
MW[2P8PB\[N#3Z:&?;@[%/@JWXR&LH&:"TNY\%"Y E3.J7AA(/\G_I??.M_ O
MGKYRE-5_W@.=0RAN$OGAL$U 8.'10WI@G,JP+8?$+D/ZV,P[_F'@X?XEX5+I
M02?'TTGR[W_:[A[:>ZJ48 L>SNWW12N7DPZ<K=P2S1BH9N:J+X.9[I 1Y5IX
M6%/O'.WKEA=:F9O;VFWCO'%Q>Y.Y/!4NKQK7M=OFY<7--C;J&>U-ZM<DY8@]
M,)KZ=)(-4NZX)8I2:S*J5;XW1C]+W2K>Q8X&\)(Q_0BH+\>N"8?>SQ;:O4LX
M*1D]/>M@]6U$4]T'4^V@%-4::C(0'VOF/@KA>8V-=7Y:(6C:6)81R(2__>]!
MWCO&0K74PN@66UNW6A[ ^G%\-S[^)MW\^BY.F\RY1GF)&[ZF CCXA*M;)0$W
MLYX7C(2W?*AU/$K)/52.7OXS'G<>!O)%I]G9I4.5=NA0:62WM(G<VU 3I9UA
MDE^$MQ!IZ H)@K-WC7<BM"!\&]R3WQGN2>W&WIS3SIF"14T)K\DCT4?DU#0&
M=7@5YBY_J':_#OZ_,2!FX[FCC7#5-<LB\!_E5GYN#:S+QJ1!]-;$4D;J1*[?
M%BYZB>)!XM. [V=/.S9O902D_XL+ZB)*+UT7D9Y:G%/;H7X.Z]Z^OTUN>@N-
M,-/#V*'#6#I+D2>Z]%[C>4AT\ .\OL7'K4E.4GKZV<7@6-S,%,4$-^]N!#Q'
MR[8^I#RYJSR9'L8.'<92$/EGHH-@:3@O7!FHNHK: >O+N;[ ]N:M@>P&#<VK
MW-_.G\\Y:6-S]=C="D^DE_ *-$$*\=TBZHZN0@[L62!<2<XY*KZH_+\W"BER
M[A"2W?E"'G1>6?KW-B% 2U@OB #"*)?"X'(B_,<VYD'B2K&')%>S):F4E20I
M*AKHY0XJY<"7XT")<>!<-%IL2&8IE\N*U<C%2%L[I% 3XF_9=&O*CP2)V, $
M'-9XX3UKN $97$U^*[]O?YWUQ7UL=,!'=//QW#;=.'-(4Q=H#3E<R$'Q[$ Y
M=OVZ5,YEB]$G):?.]'YSTA)]7H[:5"T$8E\NE;/%XHYP4J@:;P2N$RPBFYT^
M$.^$ !&-X7PUKHU(7OJN#:^_E?>[ 8*S:18-Z H<J+OU9>% 6I[WTN5Y"UDV
MIMV(/< Y#VY),2L5PGH31K]43&M+4^:-:ZJ*\4U5L5S(2KG('7MVI>"TOBC5
M32<;MP8V-UH#ZZ)Y-BD4>V"^Y.+97;.9RU]57V$O!".8*D\5P(XJ@!F&C6FQ
MXH_0!9-5R&?!YNVPW*<<NV\<N\Q,Q<[02MDJL&NNL#/-IE(,Q1XG$M(KTO0P
MYCJ6_GF,34PE$<MNZAUC0"[M/C%; ]EU)LF?T5GM:_/\_FN<(39;!5$X.Q%4
MNI64)]>PA2%<$<]_J\3O7U"9,Y$C56F[P#[^+RZ ?59>NO_\T@L^A]6YUW=A
MZ&Z(V5(O6HKJCZVMYZ]2[O;/C6PGV!MW$SJ09W=3+E[XHB4]/1>P1DQMN$)3
MVNEN+A+8T&+T=IX;[#J;<M%&N6A)A%F)G<,7L[0_9*'ZXCRT=++$9UG5K3,#
M:WLN]<8STFJD6GW,(5]V3TC;]ONH[;^R-OGY_;)RWW\QV$72"4_<.\MWZJ#+
M_?O'"G\%*)#FD5XNCQ35^2DM=7[2G.,KYY4EQF&IHHME(E9(FL_I'U[.%BHE
MQ'CL2C8R@@'QXSTN"(]=D;8M%6_*7'M1['[[(A;.U=&$O,).K+!SUH<5-AZ_
M-#IM+OF"S267Z(P ;\<,1%8 \LZ;,%#*%J5\MBS&OE??2H/)>2,S7I4,_.L5
M\O 2&U==(;$XCX,A&"J+V4HI]@WQ"W#P.E=PFPIUUA648]E2.QY(4=5&"$-'
M R9 I,RFC*9B_#)]CND7O?&^_A8=SJ@;9W0\/48V2'JZX]GOLG3\1;6>/]O>
M2&GZ\:E3!DV@R9;%WC;LZW;K3KKN*Y_O[=\_BKEF/=?S_[LS/G[\K1Y?=3[?
MCW_]O!ZV\\5)K=9JS2[[>,&R3QB_A2^\\+M6D*Z?+R=_O(6?A#)H8DM?J#=#
M:1[/!ZC&FZ@-JO,JVG3C.82.N=IXP[7]J\T=%<-\E84CCG?)$+R=AO%[H CS
MD13A3)? X<7%]46W\\O^47X115B.J AG%CZY5[7OUV+_S].?/5.$RQS)> />
M-Z,&EZTUWJ3WH!(,19CMLQ),$)4VWP]>U[T5&$5 6F18'7;LANAG8. ##=!E
M5')XQG]D6S8XPO#^].)M)9WL!\S_X.2N,6I?C+"GY667B<&E1^(%3JMM2M7G
MYZ_5JZN^J_)^1#A%_PD"RS&]M!%M+B[?,-<V,_L.W[)\(7VY$96A>-.+OV7%
M57!;L ,KG7,LUS.?BYIJ"&K=:-9AQ6.+N8-XKKZS@WPU6Y2JV;P8=G,<QW*D
M:*V7592-M13EC&]H:P_UL7%>*#UV=U11%M=4E#-;_O;P_:G[>/*U]YN\&46Y
MV#G-Y^)%Z-M3D\O6'R\0<)5D.2OE"MER/BR;O'M*,IVR%7@'_>RVIH*D,[1V
MX#07S]"JIC.TDIRA54AG:*W%OZ]AAI;KDM$!6H4#=Q_M-SA#*_"2!9\+3G:J
M]V6]!TM0N5,9'*N<:7R_:][^$MZ=-$Z;]>8M)]H_VR#>EN9RK3I&J]82Q4)K
M,AG98H/\^5PI%*./T?(1VS_!]?\1V Q7(#/IJAW5_F=7IVS-U^D><>>[G([V
MCW"Q)/J/R][*' SF=4=9?]3I%MNGB(M</"ZTW.C4Y4'&975PXN"P@25KSZKE
M?:Q.0TO*E^=T7$]K<F^7[G]:ZD/I3S4RM2-M[^!3;6",=/NU4/MD96K7X'T8
MN,G:E:PJ3;TN#U5;UAS*?SEI#*I?\O5J_R%IR@O\5:^%]HV5:7]-L-$=49QK
M-(?HU^8Y>5 [)7.H)JU<N&)_+30_;4W._MPWOW][^DDPVY0LL3P[N"EZK3[Z
M:X<L7^)SWICF9R[)?G/HHLJ!B,28CO=8*)B;B;\A&/-T./4EA83_WPHK01MR
MV-19./K&#[#6Z8P&(]IW^,W38@46HOW0 F$)CP%?FK>9+=\D:^^U-4CCH/@4
M>4.Q2AI#;%IN7H6+__H=^2FB+J/(@H^_V6^'E<I*]5!4 _'%YIYGP4QZ2[UI
M34ZD4??^^=O?F]LX[6^6EQ_QW*=4_'<H+QW+FJQW,(WZ5=9'LCD6Q*S !ML&
M&=:=)+.,)1<,AXD$8YV2>1=P4O$C;&8A)4#+H1H.M(Z:'UF8"CS.V>6B=G/_
M?*GZ4.:4>%D.1#F8VG)U^98=%-)"H,82*$;-NNS"7O,,@.%LHC6SAR T0XS:
M-V<.-*.4K>2KV7PI#+\6RCEQ&6":_Z(R6X02"-\YA1P*>TVR_S=BFXM\KN)O
M<S&7GBL3;]/"NXC$B8C"C!*-) L+D\U3D*78\YB*Q3G=]38J#KM_HDO*EF,>
M:7@.>TK'K5_07*WFL_ER6'G'>J<ZXQ"^U0.=.K$5IC#-.S&IO,D3"VV3DIOV
M\YJ6-2+*R<@$UKPBIFHH%/IT09[H7ZS6Y/Q;H_BK]F6L?HO3!39RVT-\'?HH
M>/ONQ\YF!9W8"WWAN8^<ZZ!5EE.!N0\>&3;FKOTU[NI=HV1<_7QPW;6%M)AQ
MXN+9IJ5;C@:CC>K%Y=>KH\B7*ME<OKA45J):I=4TUQKF+T9EZ@)O2RS.][9B
M+'(M<4J8^X)J9T7F6\%M$J,BO6?'J(JY2'[32U$]*@^5Y_/0:V>8*5:(/U$W
M$58(M=#EB!:Z;NA@A2UXZV67_6RK;8W<D Y\TE;1<G=^D-MJJ3P:'V]F&-#L
M[K!I'1X$7QFBSOWVZZ7,^'):;<R\_\G7&Q?E^JA1U[S2^<54VK"!7TJ,A U_
MU'Z$X89?S!;%?+80P4U^Y:8_GW_=IC]IMES!)<C'[LP-9J!8*6>E0EAOF=TP
MK5'9J_"*O(*$>&F*2^(/(4R*2^:%])T1&([!8G_AFB!)"/W(S5!3;7 0>B/U
MKU:^_7VEQ'$0(H?V3)<+,C"=@B04NGS[6(;&_C8<F1CRVF@+3;92@9?.XEH3
M=AQJ41V'$*)MS%.H?[OY.AZ3FOFCZGH*ZU-NP\[$+(&2]1ZD]>J*0T<FO"VW
MH;H7;D/$W4BYW;-249<N[N_2%[B>,0S6J4_[UA0L'J-E5[?&')?MAVR:H."8
M"FI-)G>Y'VKS+_G>C-/!>WY4&\A \W?.@.MV3 L<)B#2.[JUR,Q9V@L%M]#$
MKBP%FXN%I-@S=XO9:O%5)$BE!9"&M\0^4XP1'VZ0$&.$&I/"W+D/D[:1MQ]^
M_AQ.!NKFHILYZ$U8"A_"$-QA9*AG#!3P(IZ*,?5DQK9$G/(1OH ]VGA4/5%8
MX-&EM)JBU0(7\JW0*OFI""MAC HK9#GC#$V(=:@SZ*(W?9Y3![;"L+]M'U@H
ML%P,[2NZ%%C^H)+FT*H-GO.=C5Q3+@23GY .E15!F@,GWWQ8Y.4EI:C \6D:
M)Y* K'0?C^VST??GA_92X/CVT.(K)@R+47%Y<W!&E6PI5\U6Q.4"\_9"[4*R
MH?:N4B,)S.@:$7@A=@0NEK/%7#[2/=/K.:YD,+ZQ'*H5X$/S[',AFRL5LF*$
M>XIX8.T=.ZPDSVKJ,&*G)Z1L 5V'W 8T?JB75(CG)4W,8?['=_VYT/9@V)%Z
M@B7N-+VDAU1X40_I6&]7"N/^^4GUSQY[2/'FB*0>4@0/J2BE'M+F/:3B"H%Q
MZB&]H(=47 $RE7I(&_:0BK$+'S;M(05O=&9\H>4E:E+MX:E9.;OO?W\M%6J1
M$6K!"K6->#U?&U+7,G/YAB;M085:P4VJ%E;SBTI1E=4\H#KHJ&RE6'[KB+/2
M HS6O@ RXI<<S6>_%1R<T@K%Q4%57<I6I'RV6I;V'811BHTYVU>6F3_!JQ2[
M/B$I=@B%7M2B <\=*%WCF9@=U4((W^#\XN;7H_6KTN@E"^%SWA$&X4O(,DM+
M=\TLPNRV-V:@B\V;BEPPZ^W/7L>?,$K$M\NWC;/+Q49Y9KO)&N?R>D/L$JK<
MW7?+O*#R=]<M\R(.#%<S&S3/L>N&)9P3MO< R=*"FH)7S#3S#71YA?8]&V"(
MI<#(* !1JBK;,M  30_1+1D_=$W &ED0(-\0\U'M$$:[:](Q>CI]"B5C:W+<
M[UV?M7_>_[B1-EI)1@N;.KX%;IBOEG]P!^6SO&^UG)OFS\V9@G+LHE!PS4O8
M_VGO*X?+"U A*;=%MR&Q81])<=+28JTI?+U(&L;?WOWSA;Z5[B(ITO[5(:(C
MJY@%#F=*JR"M*@O2KV^%5FLCL^?[!E&N/2OK]X842]FBE,^6Q>5*/47:1S[/
M^=:W$C6_] )'%HHB*\9 D35:D^H/NU#[K([JO00[?D08:9 _*B)[S<?=%R(D
MI.8\=%6>I5\3%&/4ULBZK=[%Q7BTQF;Q:%^[DYNGJ^'%H[@<C[8^*1*$K*V8
M_:U$!7?.@:Q5L^52/ELJBRM+)B706OVO=XJ/9UHJ)\<54=V3!;F)E/B;$<EH
MH*$ULB"5V%D0T/YYJ9JM5)>W]DVY(R9W)(/_B^4(KP YF^-52;ELL5K*5HK+
M&T"NPR#+88&ODS>29(VILX^?SRI(V9RT'$>5E$)(K$H#_.N_D^'?Y@ U967]
M*HW$W.V=9NZYOO7IB_K6QT_YW*7T]]>WI\*K]JVK475TZEOONF]=7:$A24K\
M/?&MJRMDIE+?^NWXUM7UV[FDOO7>:(ZILX]= /<BOC7\7QGH]BF3\8:)XY,^
M"&(.J'JK#H@E7) GX=H8R'J6_2(KW!!3[3ISQC\(^%'WOU-&D:ZK*P]4#=SL
M)<^CG[74"6&OAR<Y%G.8Y K#Y^PFMVJ'RONX]ML^R<@=A'')^AC8#"(C&QY@
M&X+=)T)7U<'+5K'%M>.^6P)XFP*\786E]$SXTU V;<0VPQ=HPVOG@T?;H CB
M1]3N>,/'F?G/_SD\%$Y5HBD?A"NY!XKGAOP=$8A /@@56!)%F\ #A,-#KAX5
M]3'J-1O;IOOW$I4$*J=PX)K&%0!5(?AO6%?'^7?P#1"L:O+0@H4X/WT4G)%U
MN=R_PP1N_@QHVQB&J90YL!!G'K7O=0>?3@_]=',H]E&X'0]A!353;JN=C\(%
M*&-&U0L#Z5?T?^F]\RW\BZ?('#WVG_= YQ"*FT1^.&P3T,SPZ"$],$YEV)9#
M8I<C?7SF'?\P\'#_DG"I]*!W5(FVW3VT]U2CLB>AG?U]T<KEBIYE:'^Z)9HQ
M4,W,%82] [E#1I1KX6%-O7.TKUOF3[=-6;?0G?@@C(9#8G9DBQQ\\E1J!FL\
M9:LO=#7CR7H]^C6BMG,24E*NW!+%?&LBUH?W/_(7M_8#WJ&/!K"A,?T(:!N'
M:,*A][.%=JJ.!#Q% AZL3K)HFO; R6*NDG?T%4_%)/8,;5=V]L7A=))CO;>[
MH0*0"7_[WX.\=XR%:J,5DC.</'5N<UW1U*7[TN*\GL^&+G&'UY37@T\,%Q$=
MRA52E_2F#G5Z+LNDUC"5JUQM/+ZH[M*A2CMTJ&X'AH5HH+>A)G9'\G\1V:3K
M:^@X^L>/EMHUW@G8G+?,/?F=X9[4;NS-.>V<*9@N #D)%H"@'WME&H\JJ*7C
M\9U%E*9^"4&#;,-J:QU;?:0#]FIMR\;<8DL]WDY/Y]"L05S:U-UH1^B:QD!P
M-TB7(;N[G#J[C;!M2-ICS=TME-!EUX\;>=$F-I0>QLX<1JA>J<PM+%/!AQ\.
M<\-<:R!?U*^.[R9?U<?6Y/GR_/[IO*C7_G:3@ZX[:A8W[21%>$A=PMQE@H3Q
M"M5"CX"_-?_OS5B_X%O$9+?VK\5[$DO_7HYK6.5]&Z\'@4!RA=M58$ 2NS)D
M(>&2/:9_4M9[>=9;//1#RJU2B+24\1:-_W@QQ@LU!\7P=A47AHZIYZ9-!M:M
M@976>D?52(#,M\;*3FE.W(Q;&F9.$J2CCS!LW"\G!UV&SNT+_@5_9BE[=%\-
M1@I#3QW6G?61TL/8H<-8ZK!2].OQ='L(T"OY,,^U?*8,[@SS2[[X9U.>JY2T
MJJ'PI$/: 2/0;X<N@SSCOTG*P M?% ',/<-",;W5%6HM/*<A>A>15!_N COY
MOS@?!2[E N-K=T5[YGW:D[IJ%K#6J6%>VGUBUDVBJ#;Z<L2:IT2K]OEEY?9>
MJFUH2MR&]2G;(G/0N/H\A'_)3*$J(\)<-9-HL@TJ%^%MXU0@UM"O"YDLGIH5
M5VCS-T_-BM*\5J2IDMT%GHJH9$5Q%Y5LPZ=D/\NJ;C%NO]0;SQ@)CU2KC\'C
M9?>$M#$*SE^T%+4UL/QJMBY5NU=_3W\^:7OCJ^(N!5  )+!+N@BC"V+9ME.N
M3X;KI1?F^O3H5C."2Y5 G!2EN/Y<XG*V4"EERZ6P0I1=4:9U?T9R8( *G- 0
M[;)[R@H4]%[=L.RY#FM=-\_NVG_T.WDO'5;_EATU*JA\[ M=2P=WGXKG&N*Y
MB*UBNJBK=-R8XZ(6LA(P7;$0-C0BU?FOCZF6J?L$DDMBMB2*V4)HH>FNZ'N_
M\]S4.R:1+7)"V/_ZKI-XJ7;@+JDUN7GJBI-.M?#E/K]9<$*2*8F^K/>(H.K.
M!9'>$V1P%6R+P9QT1=!4N:UJ]/+L0RJ4NWI=D1[&#AU&J&XI+=0MM4X'M(%M
M7<ECK$BJZ0K\QAP1Y<P3/^IE!OS+SH_?DZ=?S<K]J+^/_N6M*2M$D/G6A2';
MNZMY9$8!)U>:^IGKN 3Q6"Z>!YJ/W:]$K$C94KZZ&RY"RF(OQF)+_-%\[&EX
MHEC(%HL[<L&Y% 4U2]$KDPQE56DPE1B>OVV/*[=_E?.+BKYEK$'2E1Q\LWZ\
MP3SH[-9*2/C35N^$OAGI7G>*0(*XQV7,&M.6Q.XK6RQG@7!1)3UB/_;$@;<I
MX^XGXRZS4+$GK9?%R$FW[?)LJ+6JQBH-PXS);6M@>T9K(-?KC>OZY%IMMB:-
M\YOO^7NM^" G.QLVW);EMV++@#@L8XZ0W!%"ZH))EWD%96] 3\S#[^^0BHC.
MVC&MW KC1.?<IQ6SN7(N6\A'SJ^F%B_EY)4Y>9G9BSJE8T%'RFRE6,V6JY%C
MM!>S@NN&5FFRXK4F@-/#V*'#B.NWNM>FH2T-6I.1>?OSQ^/O7X]7Q7WM;W#J
M]3=P=YOV-]@3ODX/8X<.(U3)2/Z"!WE,BS89YJ[)050.>DP,9G$G=Z!>3KI?
MR4GIZ:9?V1LX =\DPXIUB6E"F&MTX0='KZ1XL>20N%(A1>+NV-$MB;T6Z( X
MP984.S4.#D>V6GZ)"I054XK79.C2[$S5"?P/J^$)UYFEAW/IZJ]V?3Z6][&V
MW^$/."V%F$XA&%T$+083-" !*M<.I4$JC.L(XUS6BI?!DV+/.A-SX@N5@TUG
MZ%(.BFF)=[+<MA8LM^T0HEC(S7[&OV8JY@JU"R\($SV(&:K4ZY/ZS\GD]'K2
MCG,7\T)N*-\MBVS?.=NEJ["-?VBIK6V\3ZMM$W9O(C)9/ 5;6*7R-CRU7)"D
M;+40-@HKU;2[#"Q;B[&6.-&%%;J\S10TE*2L&+VQUDMG('Q4G/&E@TJ_VSEM
MB_7\=?UG81_]Z&/#-(TGG)J6>M+;](,*:6WPSAU=9,6Z/ 9:IDEC3Z3#LK!\
MMB#NLB;-S=&D/V33E'6[\4S,CLIZUTPIT^\_"V+CV[>SVX>-M5/8L ?]Q/8H
M$&>3J= E)'33W!/3-8X--I3*62GM1+.S?!35[I9W,?]0GJ,QG;PWV!IO+/FL
MVGS\\;64.[W[6[ W<[T>18,F7]# R$#70E6K)6O,#Z6D@&<"+=X>;FYGD.+1
M-7<H%\=4WRN YF8:-DKY;+6\,XCQA0>9,O!^,O 2O[^X0F)NVN^'[Z]R]_$"
M[+LT&(B.'F-5#TZ;(*_>P:V#0+/W\^3L^+=5_G(IM3<5+807/*Q7V\#J&H:<
M"/3][;$SQGE1?4/J\ZTBP-&9+9XI*L8:/3!ME"2IF)6B%R*D8<4K8K%EQF*%
MRNUY#,8J!$JY'6&P=2H"YH<IJ0R\5JAH>A@[=!A+VX"A+L3_-OZ.U$?01[IM
M71/+-M6.313\0TU7@K_P??(*WFLHL_7%'6V$_ECCN4/[;UW+-FETNP0+"UP'
MT?85Q)[DGBK];_VR<:HFYQ0F[ "J?)?".X7O\Q\L<46_,&7_->SQ=ADPIMNX
M A)U?G_ ?*F0K:;9Z%UETR7HGQW@TV6^9ZS&J//FJE5>POV, )\N)66\7.J?
MJ-;0L&3M,UB5(7P#_HW$5_4142[=N6(M]8:;KDFS1XS[DGW_;2"]5&5<TIE[
MI$V6I35(3]5US&D876%,9#/-=NYHMG.;W!_41S7KLCM7"ZW2ZF&^K93$'4Z:
MIE*02H$K!?E0*5BE4<1<*2B(D5M%[LK5@?ABYKGAF&<BM^6RKIK?[Q^2BR9C
MV>3\43$AJTQT98D]#EE@TLN)J9[H:P7%&+4U\E'8;-G_2AUJ5EK8*]=BH7%O
M*=:(\-FXMY05X]MS>DJ;YIN%QBX5K52TDG:32PG<1*[E)K^46*7727N8&TNO
MD]+#F.OR^^?>WHR&0XU@_9JLH2K%#DQ-G2DZ4$Z!!E/'1+8[OWY;W7:<-%I\
M/WT-DOBW)RA@ C3#&IG$F</H-IT2?'M.N7E7N3D]C!TZC*4U_DUPK$SPTZYD
M5:%P^LFEK)+1Z.'/^"[.1*KE>?AM)-T%;,2-GJ"@\OV]\4SCOUXTU>C_XH**
ME-+RBI0T+9TR"V>6Y>U3=B5[FP\.9S$&Y%9^)A:JW O""NDGN894_GUR^6?P
M,T[A4D2PSJ95+6Y-L'%OJ03MO@25<[LH02FS[":SB+O(+$M+2"\,';&$3?T1
M?$#$H>N*BTEOVF00;,[\: W/?GV9?.G'BIU?NCES((RV.GVBC&B9*%V%;NB'
MM-HFK+HF'=&ZLP%<>A@[=!CSHNG.R *= ,Z=6QW)6S18E[J_W11V2PGT3YH\
MY@O:%Z5,?AGEG<1H.SO"/!QOZ&$)AAYL@$?[(CG9NE?3&VG&++^(V2VES9'6
MNTC=_)7H;>/L\L,JHA\'AER.W2FVF*T65ZJ7?IG:&4>'\EFOE[P!O#>S%+1E
MJ2Y^OOWZ5#DU-N.?);ASO@VWD;TSBG0_A6L'%6,U58P[=W;SU6.X5,=1A)78
MC2.JNZX%RYX6Q,:D=0.B5M."-=X:TTV/)H^W)_?UAXN_O\_CW-)LWG'$#>#I
M\AT(MK&H6U$J2C'58"6?JL&=.[OY:G"!6,?2A;$GVDM9,9?+%LN1D? OH Y/
M?$ZA\HC.M75KU+I=55/!K68],R?WRB!7.ATI][&*G+?K$O)-H"Z4W6VDTI20
M)BRFFG#GSFZ!0Q@BT;%48.PNIJ*TZ_Y@W>\/LL%HC@--QS_5^[+9(PJ04%%4
M7+NLX9VRJM?EH6K+&M.0M>?O-[\*Y5_%TTTZBB?3D]O8U#:AP]9(=9Z[2GIG
M?$C[/-"%N@+D4":2 $1BW:'_@%C'SL7'\U$8P(I5>$1NB2F/<2+Q&B545BC^
MG#+S.2F;KX2AV8<1&-QW&ILYG(W;A#A) O^N';%\;\MMC7S*9-;B)_BH^]_@
MS=\?$'.U.XY-$EYQ8*D3PM8THV2&FUM\AR#&+LFUW_9)1NY O @/'*,NT0V;
M^4UVGS@WF'C):8/98,//9),(\':$^_5,JF%,.E$2OF 1WP>/MD&1#1SG?]KN
MB;8_!?:0^<__.3P43E6B*1^$*[E'/L)#_HX(6-</0D7\*-S+V@B?(QP><L%5
MU,>H6 .V6_?O);H6*@UP[IK&[_RIZL%_P[HZSK^#;P"#HLE#"Q;B_/11>%(5
MNX\[S/T[;,OSBUEL8QAZ=1XNUXQ! Z\[^'1ZZ*>;0[&/PNUX""NHF7);[7P4
M+D#A,ZI>&$B_DO]+[YUOX5\\A>%HB_^\!SJ'4-PD\L-AFX!&AT</Z8%Q*L.V
M'!*[C.EC-T^HAX&'^Y>$2Z4'G1QO;X>-MZ*<T*K^OFCE<J4#]^U)[NV6:,9
M-3-7X <,Y X94:Z%[S3USM'+;'G]G?&GVZ:L6^B&?!!&PR$Q.[)%T$/Z='-W
M=776.&]<W-;.,O7:S1?A].SRA]"\.+V\/J_=-B\OP/_8RYUOTXIRFQ'FA#\Q
M)SQ!3G6% 0.-:G"N_2J(J0Z&93D1PHP6_B3"?UJ3RK?FV?BN)MW)ZH%@JS8N
M]\*!'_&J3KV7]8;'@^%6!/>%@J]7Z"?G>YF5OL?/Z\/V>&XKQ_8ZF1&=O3IS
M]023=-!;4)B?)ZNF\(C."SIR,AA]!+;!C]/L>^SOCJ')EN5>PE^:UQAJ7(P&
M;6)>=F\@GC8IA]1E3<,VM>YE/?N@U5*;K:&J,,:F[-Q2B'IX>$9ZLM;0@9O'
MM6?5:K6<P/Q8'M_TP9+?FO"+<X+O:4U(_4_UOM<_ZPZ+K@2<!G;#]N(B:E3+
M&A$%7"A</=O6L*_;K3OINJ]\OK=__RCFFO5<S__OSOCX\;=Z?/+KYX71;/RV
MVI(R:=;[WW_]_*JU]6OC]\_KX:_\J?7M>ZVUM)I[/:HM*M#FE&J%$"H8Y5:C
M)K/!L/CBW!LPM:@I\MF"5,WF\G,'-4Y3&\,)6)1 5R7090G*B*8ND/NP*0@V
M"($/GI .7:\@B5D!=\:.#\?3R\.A:3S#PFRBC85_37.F.)O!8=J+S>]N#?6"
M7@K5HG'8SO[Q[<]9Y7NN\JWOLIV;EV%1$V%IF>US6B!GXJ=!M*1?="Z*VE3R
ML."V "C-0&:.JO/9"+2<QF\TE5#B;C/$3.U.(G9'YF@=V1'AC8F'3SG4_:..
M^'C24\,\)6218I@<__A]4CS_TO[Q6UJFUJ>>&B>_7HV:7U\D3[FCW.Q%8V8J
M,9?8P3H".M0@ L/]"UU"7,0J)J*W><JYA:=<G*?^?;7_;4M55-D<WP!QP1KC
M93$S!KY!6>HC;.[*V;!C$'YT"N>]ZH,]&:@;815G!:WP!4QQ4E0$XV%Q/B>)
M1[,7-IMG)+8['T.YEQR>PY!9Y#!D07T1D[3'PLNH%Q_.@/E+3>H"H;?;29CG
MSL7?5Z?WY4[S<]YU0M@[IR>6.5[O,M\T?.T+?<Z5^#)J4\$Y?F>I$NIU;HPK
MK7!BOI.[$(<*/0B!$6U*^QV#LLL8(W,F8/(/>*:$[1N:0DP+6S39XVN"^!3"
M*#[45-OA$='54/#39/AS7*OF?AT_#*M;<"<A& %Z=,+5$ARZ*'H_!<ZWD,L=
M3'%4A"V#ICD$ICC,'^6*8#KH7SFA+?R[<]Q\69^"ARTD=]IV7P9UTX$(C%ZN
MZJYNR8A<M_PC/(%JX<)T! \BPH4!VJI$BW*=*:PJQZ=;M+V^H>N$R=J3:O=I
MO..HM'V](-FZD[HI7Y2!)L%5R0K#D8FG9C.GQ8>FE'LFH0HMRS(EAJ;1T>53
M=3D*@C!!4<S$I?DY4S:OR9#[ 9==?_4"XM;\WHHH2CFN"_"GR7/)F-P]J$H3
MA\IRI7\]LY27RV]$W>,<MT<4#Z6<]].4?HG:<VZ17R,=S6TYYP\XYVO\C*OQ
MA3"-+R:A\2<_3H_[I<+@SUCTG?*,;MQM:U#8GC40YBIOP5/>\-L+XY&[BSGV
M6U @(-5><@J+AV@G+%H^)/SO_U3@/#YF+%#U>#,N%+(0,&M.G=Z,M)\&/$%'
MB3ANW0"B; Y*!5$0%P4E,7)2[>^_RG\,XW;X(+L\XP(A32"'^DA8^PA/O;U@
M'G09=9+-5A5RD:/KA3%18:GN4'50#--\45[$%\R_]?.%DQ9/@"O4N\_ERM/W
M1^VS&)DKL@+S?'>(.Z9IE#1W1,5]A4<FI7(A6Y+*<WG#"R308@1,"UZLH6-Q
MWKRNG5U^_KE0O8C;42_GJBEK1N_Y[*SNL-'5U5?YY$XQ+K%Z^JTIEQEZ!)E'
MC%HGM5BUS&<?KEJ.PG7+\39T2PA+G'5_Y1\O*I7^'^WM:I9EK!'58PW7*Q6I
MG*T4YONKC)B9$+UR1/T:7QS# 'KS/1W40],Z"(_1&FD86D H*PN:8=&6!/@@
M9:KJS.AF9M25?T[?9UG5K3-X +$N]<8SP@A&JM7'Z."R2X.>9+CR>/R@]KYW
M.F?B@^]F+K#6EV.^I41(EOD*<<',Y6RA4LJ62_-5$HKULKO;-+_QPOD-%^,Q
M(YD%GV1>PCF:UU1?(YC2P@'#&$:!7"!$P[L>FTI=^R/Z6T2L,1:QCL?^OTSE
MLOU_<D3VZ:SWLU!N7]_W"IXAH0;;$I01$;H@!H%TB_J2!F0^N2+ER6<),"6T
MR=P"BM+20"4J @-%77;L^D!6",N1!?)?U-Q I.Y^CB9*%<R<*1GX>)N&SQ2/
MC-E0Q#1#O#[]K@*U0KXZ%L,=3/"*=,EB%'D^19$GB2(OIRCR/;&%R2.*_].>
MQJ*772SZVX./T\*>S(+"GE>WXY-&O7%^W+C.!,P+-6JOQYHL3].'%CT2<!V&
MJ';-$9ER0"K3:?OCD06QHF6=P)=,=4CG8.A*K=-!%PV,QQ58G@[X9+?PXF,-
M&RR@.G2<S4J@"?[*SVI-'C^7KJY__B*3;UXKJET_*% ]>#.<$8^FTC65?+TU
ML8Z'A<)W4\S]SF,YKTL)#,?;G$"45ZW1 -8_QM_CF&.U"TI*MQ%#Q\DE##F]
M7)[8CN9*HZY94Z-^N@2WYU$E3ZP()SV)%XE_%QEVX1U>Z.5S'_FGZ+_$CP)/
M9O _\O"9__$?X4FV:$C&TF"U40_QZZ!,12JC*H@JSLPQ546FC=G-H6&RR,@D
MAQU-U7$!&;"SX.BU56,86)C 2V_9!28\2R&/L+8ARK8*\2](-[;OPH<9RJ@#
M(12\$]YD$Z $V\0A6#<9PBOXGF!!;*@) P.B+.Q(K!!4&RR6THC>@TWJ&=SI
MR46-7FV6/UKX9!N#LD<([/")&+F!<; 02:=V^K3>MV..J+>@LN2?W*.Z!Z_Z
M+8NE&GU$HT_M&?AQ6DE,GH<:9ASQFT-X%V@N( CH-'<#Z(685)]1D(RA]PP&
ML; @,(4E8/91IW&O<U^"]VQ"?P0<\9I"P_U9_"WG%"LC.R?KL1$.>T4.8L5$
MG3[X(8:% PMH]F TQ-\#!PH6#\?8J=('J'">0LWB1PN,!GSN<*4E6'W#!/[)
M,C89$*SL@>B,5:.-L9"=:+QXS5D3<JC#R4-D*,PJ.4_'MQ+;Y2WZ5%K:WH&G
MHM1U^LY='#I6-)."Q7""3@MV\/<*Z1&=OO,1R^*5#"SYT,F-**J%ST$1\13.
MM'APB:>KZ<DJ=OSMC>#[!AA^6O3R"!_%)(Q/WN&W0\-B@MT&.:<_@]K1M#$C
M#I7RMFD P4U!5@>XU"&> ]V !A)&D&3TI43O\RH_T"'X#.'O"#C'IGZ'IG9)
M*F$OL'A$!MO@[0%?9;P\&)QVCW*H@!R&5BCO7B%/JV"P/*AIG;K-'N-17,&)
M.>JYMK!Y<>*:.N WL#CT5=2PP>L[ZI"C^3-M#!PU^-F%,MX=W1P)IX:AT$70
MQ]:4 ;P8"U?I4YRWG)[4W+? ZBT" J4(?5GK(I?!/HI'PH7L-*WI@]3@NX I
M6<,)[.G:\99!%8DO@=E53;#)P+:FS<02'EA*V?8%%E^S,FS](U1)",57]6PH
M>_JO*[/@OV FF9=M KNSN\TL<J'IU'YAWMF:\M3P$?0>U_'EN#1DIE\W=!^S
MSANOW#_Y7_J:."WI?$+>!873PL09Q!^-^,=S<@<%7UGGLF^V)@\/P[NGZS\_
MVDI_?S(%B7'.O*72T-0!CU+J"3<<2LFCU$V]VLM^;^;Y#0K$1:,V@_8,J!P:
M9&D$S$=&#@.5HL' 8,L8V6AR%=93S0?2&@TYZH&9) =,,:UB;IA1JPW851IJ
M(AS,3<UG#2]$- 8":[I1(IB[C&M,G2 2'F.":\OR/C?X=3"-AM#E%WF8M&5X
M,GK)AI4'*OAL;:<P85[90<C&LW2-Z/%9HTX_,_L&AO_ +=-+V#F/80O!1SDK
MH?6DL!3P]7G&62?X0/AH'X)3[C^SR)&_BI9-M#62<8E-GHG9 0_:P<WYC\>I
M,,^ZWH_[Z2'H+?H=W)/O@WT9&*5-('24%60AIMY!GVL4S3V]M0S=VI%PIVN8
MCC/PVO<)GX^)="7+J-:7^<9=^P'4=R?GLG 9[,DU@=.VX?FV:5A#QK/:V'FW
M-8^N1\*[&T(RO,9DOLW[YXC*V/[8G5=D+J?QZ(F;SWS ?#:93W\U:H/M<QHB
M+C:AI[ZI.1&^W9K\M,O5D79^?_ZSLC=FE!\-M753&?=2M34I%^7^#[OZ^.52
M/OC$J9 94C*XY5CNN:;)VY=:_*6>.25M<X2V3Y38I=V4)==HJ@.MM1/>3AVC
M\,[GKC>O+MVH$V314EG_HI#.-L7ILAU6^WI"8\PK>+*A,%0F[(;^R7*AM(5<
M7I0H:)'_M%)U+RS1 4+]K96O?N5_3_Y@@Q8.A((_4W"/Y4)GE^"3HBU^7GO4
M_*$H>3^YJ"5WD5/**2K",!S>*F)7X$6=@7W >;_9R\BV('MV?@;=YF^R1=]U
MA1_U-QQ:\Z!ZN3_'WWMWM6+5@SXWY[!CQ%-SEQF*(HMZ'E'!8\'SN+LYN7+.
MI'RTX#@\+X>"PA9WY*G,J7QTYC>%&B-?T4)B8G5[-?IS?-'\T9 ]L?IL(I9Y
MR)>U2E'CPN4G)%91JU$6%1240_HWS-8J";T (8Z$&JUT!-]]U''3Z.C+FT_8
MF(H'1N"KT]I8<'RI7YR9GKUDN7V;9OFB-(T]O?,]WAE"M0$V>&I_^Z9_O<\7
M'JHN&]PMV]G,5*FEO#)O2\FPAI1,K4E^&6MD>=!FNZSA!'*.):8QW\SA'GO.
M9D!HPH3E@MC.9S9QWJ16O:I_TW)-K;)42?LWNK"OUBJ;2NC$DRAZ+AY5EE<7
M\6M<U\SRNP;;E&G(#;_&3US(EB+_S? VZ\*Y;#X \>"/KN=6Y6@KJC8HSUCC
M0=O0'*<,">ED:]_YFB@L#G#WTJ%]B8A1FJF[QN2?/B+7I&/T=-HL?W'$Z.]G
ML_2[K<GE]Y-A[THY_CR0]R9>#(\42ZV)<=?[>E,\^9I[.OC$]YXQO<V_CB"1
M[=YASKW>2J"?!ZO# &>T+UMXOV,9(Y/%""8[RB/A7+40]R[KQ!A9%*\SP#L?
MO:.-J);#MO:8J.3W0/3@)WCEB9@3(IN(IFF/_99P3PGW(JJI-*V:FO0 ;N7G
MQ1K)#R&=]Y76I/-D_6A<_GR\);T]5T12:U)0?E8;I\>R^%C%E!7N.6/+SR[4
M4]ASP=WK1-541TM6JX8Q,5,H CVH0%,A#D=Z5)UJ7 _SC'<\NB*;X&/7#86"
M? /0B=I-W4UBE0NY0S&7=7PE[R$9?#MC$^$6W^YZ6-Y3^+>=ASFP*)/\':DF
M;E<&QZO' Q^[C^ +O%\19,LBK$)84^6V2J%!-/B7X=O8*T?6.HA8PF6XC5K]
ME&"^Y<+'.(O@=R&NP648*^<Z7GYF3[$"CU&)Y1:D.D"13'=DCTSZ?IKY<Z%F
M>'='!GC[!JXJ4!L>S?[0)O83W@[A4SJR:=)Q*#*O0W1NF?!Q;81T46Q;Z%(@
MAJ:@ G:[)V._* HB4RW&  JO;>MV&3G&-/H(VR/M*D:/"'A2[K&&B&VBJ6#,
MP'91O.@ D96:^H I&+L/AX5U=A1,Z@1PSI,SC/[TB@X_A-=T!$0$K-MK<J_W
M9O%;7;8/HLM[F%DS*HE1$_1$QM$3^&]?-U>?RD+6O .N-FU$+'IZ1[@R+)55
M; H_T&5"=C8)B*+.@%P40$:S"R;"N,;(AB/G0:@0VL:(\FX&G0Z;RMG0>28\
M[0&>R46=R:9S&>]\B#'_DS'2%/ILS78RE!80 UZ"K?N:.E7;ID(ET[TB[XU4
MA0,^IXG!$B)MHI,N PS(=&ON6X/>(L=)H^+!LDQ*P-!A2OR#0YJC=Q!M5.:S
M5,_07E:@0S+RHZQJM(R3H J!169C:P5WT<YUO4L9AG0@S\#2.M5??M<8#P4T
MM*&-',4,VIL@<!8.!'5?C]DMCKI%3E6[J.".*&=,GR)R RZ+*T),*/=Z)NE1
M8C$<.#5$0X^C H_)T/T,"&&;"MVRWY#8?5@\=A^C;QX0V1JAON4TT;#HV++]
M3(6JGI^W@\X?,!R[K#/V*'(9P9(S.(4,?SV6\1 &8&?ZE9$5=FEK[+A<CN.
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MC-?H/3!XQS_RQ?& L2A.8!-VPE%(T[^5 G4JWIM\X(0,'YU#<7:^=W( ,T6
ML,N?+%6I[E8$9RNT"I%YH>W 9H69S0KAF\WX7\Q3W\$I:7Z$GEM/PPDU]*IG
MO)$W<,PX!5;5Z#DN75%@!9QF_$7SWT+;G^! SYFS8#V>:)_H:912P:<;:^ A
MT26"Z;\A'8Y@;# "**B[ZY03&;R@.ZU*.:Z)M8X6<R)K'4V!3:VDWG$\#G_
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M/U9,XS#_Y7 X-DU#.\P?CK5_!/B'JF"W0*2R, S$5N[T$9H"L8 ]:!,2O,?
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M .O3^@)L8P>:#^Z!Q8;3CJG!Z(,78/X.)_VF6-\A I/ /;.\UW18YCU@!9E
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M1VQKHV.M0[N1T;'UU3\^,TVIJSZ2(_X(K(T-+WH[QS2LL8'O&5@<,<M) =:
M*2&0(<'/Q@*0 ZL,RE#1<';'6Q2&3?4#O*-92:^[Q94EJ.O/WR?B/)453N4E
MS]ULD9CN"Q,^AL++0;%GIJ\! ]"RN !?#> S+[$#V6<$A9C =B53@5CICRD/
MK@E8@8 @H"6((]+XR_A1NFJ)=]C%=''/#F41\#=\'-9)(YGC161#BOP$_)0D
M!&D,MD"@MB[X2, '^@CW<Z% .* .GH6OF\@B>(8([C)N_Q+Y!+S$J8[?V0E
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MAE9A96?9!0PM&;4G!]!@T;M-;C2&3:J./E_QF1<!5V;U4CWJ;_5B3QLELXY
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M:2S)'B[OP<<5E-N:XS0CP>K \$1 JOT^6!9AL ;J>+(&JL2<L@2.:AA(*(H
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M**E4A(#@!T<Q"]=[DGY=C!^+U!7U=-]5MD%J_[I5LJE,F#&P 56M*N0_S,:
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MWC$^4:?><ON2NY"**H"(J@8-0<$40MR6LVVE?5U+DU4;BBF ( \J:?VVLZ6
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M"CQXJ001E@0)SE&AX@3X@6%9P$TP]DQ,!6U(5"$ H\2(1)N?\)(.YPIP/.$
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M]H%S;D:HCHGWOU&44UCX>"&((H5 '%*JJ7:4_X&Q6PH,G9X+V?YE^DCXCP5
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M%*[D_2;Z&"I^N9V'/G&D 7Q=A/:??0?YN,7E\\53KT.44&1; FL;C'Q#U2<
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M=A?XMJ?_'J:?Z]C;VY[L:FWWRQ:U"G-U.A%/JSG%*/PJ(JU"Z"-@5_/GHU!
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M68\EC^WIVGZ?L_#.+.B_</<>4$UV6[MH_% 1I4CO1 6D]UXDHM(%I'<B(D)
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MAJS#^42(H79]I9B\C8B-RXR@]@/).Y5\3R6OV-.)FS^27GDE@/&(LQ< X"7
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MECM%Y@Q7IC$0F(8O]TZ[][P^->'XVJJZMSN?]WV^APGWM81EQPTX097W1EM
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M(C^UE#!8BNI#GV/5=!.][IDV),!:DXL53:=G:@RB.?0RG%M0?Q8A-T>EVY=
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M%J0MZ:,N-E*I:/Z5^CI-M4126LK^R[.^5 '5BF.^T(W+FD$ON@0ZO/3A;D[
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M&'^AW?P<]-$]Y""A\!R4R7$.ZO7&U<)'=,A].TU@Z3E(&*(9=BNL_QS4H-F
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M%$[@<>TB'UUCRP 3*.[A;(J534DI952(4<F"RPDIUJ&BCV-3V;>ZL'AAP<I
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MH:5A,=BE_[/1__^! /V_1,2]?XCHWS=*2T>T/=.+2,"2U(E<?H=_+U9RA_7
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M$ P0PL=[[CWW.V.<,[[[\_ZX/S+V'AE[9.VUUGSF,V?V7L]:E&)6\D.8Q.*
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M#*%R6F2A,LP*;QFOGT(&I8!N7JO70Z)H3GA,XC:0&"N;?J0WWY+*@C5&*S?
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M"MK,M"E\NQVYG[NZ"[.U\R>K'+J[BK3CK=;Z)4@KB8>_X)/Z9?Q(66%\7/2
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MNO:<VISFS8,<"N[L"H*A-)9)%IPEOSC'#5U_RYR+-7W_; M(9)3,SOVJ<-V
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M6#4VTE'C=1+1U76\P9D8K&D1FTL]7/@+)9AD=)^S/L#T2-1Z,*&&7S589[T
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M;3&XJ3"KJ.E4XV*>]"[WN*2S<:ZA9<KXP2ZI7<_\"7>,LSD_1;;-ZS]W1I'
MX Y.P92W %X=%.:<T0)"\_K#"UE.E7/\1Q3XE LFEV4&[S%ST9K?ZX9Z5)A:
MG 2,.+6YI@0-D@[&A[0*S<'$+8>#LM>M3XS+'7M_3FNNWP)>'/CT$QI7Z+8J
M"W[M+33WKB$RD9OD6]RMHI4ZYC<:G:O2@O:?&!3*ZI*C,PTT?IKD ;L@G+>
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MI:3Y.'%$;%V]\>#L6F:@&[A68Q [ZH6> !&#/:3> E_.^X>^97Z%.K3&A'B
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MQYEP&MY-;0ID\*E4KX76<BLD]19 >*[D]6R1WG*VU>T&S[1K07+*4X']U]>
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MRCP8 3S9[>@@G;2TR2\9[SA=;[P7(=NU-BB0%5"GIQ>T:C?8E6@Q*!3O4'[
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M\CMHUH"P>!Y["/E&.\3,()'KWQK![/"MH9/HBQ=S;],I",$"F]=&T<;J26K
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MV.Z!<A#RNP"2>  DY "9BHCO,>QD0) [Y.RGW+$$&1#/35I"[LLBF"C47#,
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M R.13+ORVH.[I,C+_>R+%NDY$NUT[H#+&1>I+^E,?[N_EYO['GF!X#_1IR&
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M!/\D9HL,8.CR4'S;84"HQWF$I7S8)O&^;<HT:<>SU_+6'MBQ:A2MW]',73E
M8NFVQW 0;-G8VL0 %/!+]2CA-Y&_@1).#OK0RR00U8H)&7TG0S:!G;-!7H:C
M3FW?OGF$-##F*"I)3BV,7F9Q.^ZEQ+'V"!&"!"[FL X/C8J0B9A\'C&CJ%J>
M@P4MI!WZ/0E'DZ(XHUO'@+V+WS^3I*<54E376E6$9EWR](NT$C'AROL^CC]'
M;=ZW9+W^H)<LS'7;QSQ?A1.E,B9N8NJI*MH@YY]HV3%;FH>H;9JMW,STJ;,S
M6!3;%3EJZISVX3X8)K*4D.@%3SGAL$/M-H)#"3Q3$R?ZE 2 4UQ+ & D &3=
M#(L?UIZ5/P6Q;I"D" %HNM8YA%>]EVT9Z4-X.;Q?;[H4?X='I*%BV5-)M2XN
MRP^4?N*#PQX>G^5'R,#) &U"$*Y_2(XP.L S1IR[\=6CD!L?:&6YZT+]9\N*
M)VGE%T>PK60$3R%5!2&:Z<'AR)^A'71;]-SN9Q:9H16<)2H:V11Y%J-@!V+[
M,-P+92;2$V)7C;S0CA6G$#NX"R42ZF](C)">RT3/Q]=>G=Z6\MD?D^N/$,H<
M;K:&ST/?I4ZI%8C@#^19/#DXI'-1.!T*WR/.MY_E@75Q=JO?#_:/4.?!)@$P
MO.% V$I"+=%(-)$(Q8R:8=0FN)2> =I=G"NK/Q9:S'#T]?%>R>"FW;!](:YI
M:[Y96N<Q4J!7I=1D_+@B>#9W+?G%&ZS0L>M%<_WRS.XS7GTB-KSBN^VOL^="
M8D+[5/*3QU=\G///5FDO[$3[KY@SJNLU*+XCM.-^,FE,6'S M\?*[]!9Y7H]
M81@(61;\LKW/%!9N=J,C7G^V7H9E9%/O8=LKQ83;WR1-/WE.:_/J@2E1.7('
MB$:F=A0E7<5E%V'D*N"6OQ:^>_$TQ 7YL.J^0RG)+7WHCJ_VO*?EA5'SS\:L
M!:D+_Y8LY+Y76LO%<K ]GV<)+6G>>I0;+K_O(5N8B3<;G@,Q("YB9)[Q5,1W
MA6)&@8S6ZF?#\1I<!-:!%59P2'7]?MHVB1\G$U/;*L,"SS@*J"VZ/Q5XFE?"
M8BA>72TG,[B",T8MO24MK5QL0'A4$P4)H[C. 56-F@;;32=<$8*:T(I+Z\T=
M+&A( 9NAQX0(( =">OF@"^9T2PT$'"0#+F:UQ5:O?$(7^-L5J)G'#5G?-3P!
M23XR>N?MHO)1Z%)/-/.%,W_UFFQ<111"8M6!>;Y?@W$R$,4 #QL*/ZU1Y[S3
MG#ALU/Y^5N%BJX..>UVQ18KPAQE?7QE?>\;1 #_Y>JZ/"X!-;/I#1BM!KR;^
M?CKQQQ%F>^>^^0+2XZ@\3)U,!@IM8\<I<=(JZZB+4#['J'_XS(MS3G1,F9F=
MW()74I\,/1D>/?F)2D41Q*V(E^T.N_'M.U \Z/#IV8LNP6)B$$YWV @!1PTX
MTD,N=7'BCC R_0T\8\XPMWIV$(L"$ B7&72DGW-<ECC3^#,ZV-9];>I1QKI.
M47^[90)S+;+1$H)P.R4<?/SAMS5=B"TS<;VG?Y5.FU%G%G#I%N,-!M9Q &_"
M9IC5E\<Y7.L(IKS:K6L-\<5I5?%U\55VEPT4'D^7F>;%1%>8E)9GY;MQ#U:)
M'#AN_%KC;G/)>(!]Z3KK?+M5:$-WL7\QO+FIL&-YXT0X*"()#R1=R*-0P RA
MZ)0&SH#E3"%I>$9P07B0[@Y:O5+5!-Y>U=F)!*(*#M4+ 7H?X-%(1GMX?;B4
MM P;8>3H'A[Y+ C*Y;D87!AH:)-G-!GHH&7[=LIEKE6F%+E:1P:T.:4BG=.^
M3@\X<6IP;.1J'U'H@870WU=$#SY720EJ&KJ4T/S(H:D5\++<W#Y6H<DS'0[3
MG@KR^BYA^/Y=8K\I'GBH7EC:[)'AL&1TXECR4[*BQ(UKZ-SW>?#.KQO,  !.
ME1"R(W>J1+Q^5M?-2)A8E1DJN$"(Z=%0:HR3^%I7+]!O\^7 D*$2M@]E(< L
M$NZ>Z#YK83)89M(RG)$:_U6>-)+EVIH+?UC]35MR+ZG*3XG#-,[-D#WO?@#?
M$I.VN 1G?)]EL?A7SV!/OM;'^V5&VM#EI"+YO/S2IFQ5>#)"CF_PB8_EL%E=
M4H5^A\;B4Z_;UHFR'DK&0>Y#K<K&8V;Y:)'WYKFD2QH7R(#>A\C5URMT&F+N
M*Y?!%J>W"=-89)R5TS1=*HF7J-TZ=0!BA.?=^C#CO7/0^>3\J%%3LP;#C$O<
MZEBQ(]Q_1TI*>DIY+?74J#-*B RX#;SHI4@2Q(W'8-3T?*5V$)HE'F%K'UH7
M8]^WQ5B];4<E+@?1OS:BM[]0QH>>V7.:D.DA PA*G(>!! ^\FS;^:, I&7))
M0XZ@U1>V4_0,K(Y;=YJ2E^(TFI&1KTD/*@7R>/(\N-AZ:G?=N3TW7-FYL;V[
M4"345#E_ /)FR2)Q4;@]3OE-W!46KC?GE=^D .ZDR@/$KXG'IG ^U:97M?H*
MKQO@.U?T2,7(D6J$P\D@F[Y+3G7FQN4>9Z^9PJOS_28I%\PKOR/X53/ZYQH4
MH$OO1&F$\M13108?PC\[LI1K1M5$%S,RBCW *E>*?\VR+;.UN&I\LRK4K'^\
MD*?52BS<L\750K.J?-=<YR%US+O[Z045W'34  V7Y+0\7HW[2@\Q<2\B]>RQ
M*],-98CU4V.B$N$,+X-^B5O?7L)O#A\&$%(1VF\\13%_/]M3 ,(\A7SE,((O
M#D6#%>H=K6TN!KGF+M!6K3]YL^#SS!QV(_W8*3NG=>>)ST:'AH]:3?V.5TG'
MGS 2W1=3U295Y_>\T(]ZO<J"U(@%ZI021C(@2.]!>3=H'N)#!IQ#@,]:$5*G
MW AK'#*)Q.T%XB0R@VTHUNJ(Y^O@)8H2SC!2@A.9&+J^!H8M#JMIQU\0=B+K
MPSF>-W##@;8YSF[IR8KWLX$B'1S9^&7BFY7&(R+[!TT([A#"B)\FW9A&3_O#
M06)X:;O,'OXP*^PZD;UB568'CT%=0 B>)1^D+5%ND QH6=\Q.M5":.(J*('/
MHX:8"*ZSEV!.W.E0!&!6@V\K^V2HYA3JA+B'(P.>B>+I>F'41.$6P_>M,GR#
M;"[6N;^A%VP&*S\]"?7AHCL49MNX?K\X;DKS>ZSO^74QZ,MW4LFJUS^*\AID
MYW8UK$[$=R%75V)!C%W7\69#.*(A(0>]<HY@IHDG P;T @<F=X@^F#,)O:8F
M/##QZI3+(T.VN0/Y]ZC4[WJ77[V\P;RD6Z8PX_ZE-(5'/O*%UK4$OOH027?C
M===A\=?Y/YB?1M)T=$2/7_SMFZ_M V/,G)![<7F046QJ3#"C)S95V(,O/:5F
M",K^HZ-A6.9I+G-, [S&D9""EF&&P_H7'7/JO'B66^LW+,.>9&?6VT-]WBP;
M^<]/\($6<^Z->E0L?K\C4^^;Y6QXW18NF#/C=CXH6Z5$_UJV8JI>XD67;)5S
M^FQ5H!OI-U-X[]^D8R**H)@H)%P%>@OIYW5:2#W%A/04<<"5#JWP1[UI";E.
M0Z,P[BV>B(9:@LM@1U6,"6ZV**KUB=BR@_%\[OPSA1U>TB6:M^VYZIR#7SP,
M*SQ^M;=[3V8W37G^/C*U#-M]M$_4N!41ANSU EM0X)D,0"XB#YT)2YAC,'<M
M?!,$<()OK@PG-3AZ%0'_ @KP8,O!L+<0,.\-YJT>])-N8'[O(Y]=*)3_B2/&
M66JL;C!K4>X6Q#>"&]EK0@8\!'$0^0A:>"7*Z)3#-78QT'YU"$:@8M60X4G
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M8O2HMJ0=:^:5.&IY1$(ZTV.KK1UQVY^G%[H0%6FP7TLX+7=ZTM(EH/H*6YU
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MBZB<V)7PU3XOX3;3KVD*TA1(6):( E?5$UG.-0G.&" W8;WCR@W$Y1(0OPJ
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M#^]*=Y><Y[(I")*EB$0(-X\S^=U)%+QIZO%PA%*2X?=(BN0.93W/NZ60M-
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M7 +,:\+D\_#,"D[>I@A=\PB#9@<#4Q-)XP %8R[>9RFR<II:R<A+@.7#4=^
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MB2W31JL \3F[*;B2Y>.$8CW\4C>'.U$8%0RFA[^SH<6"8I1,,/T+%%VW?&V
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MI?Z<0T+&J^60@/]%"3[_$U!+ P04    " "SA41::["[W^==  !D>P  $
M &9O<FTQ,"UK7S P,BYJ<&?LO =4E,NR,/HA @*2<Q8!):-$"3*$#8B(!"4G
M)4@2D)P9#(!D! $E2Y#D,(+D-))!!"0..><X0QQ@PAOW/6=O][GGWG?/_>]=
M;[VU_H_IM::GJZNKJJNKJ^KK!C>.FP>H[ZIKJ@,$! 3 (_P?@)L"5 '""Q=^
M?O#/1?R'Z!(1T<6+1&0D),27+I-=ODQ.1DY.04E+34%)0TE.3LU(34-'S\#
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MS:;65#["'2E*D5+H=#PL*7)B:_",7$#!UDN!%0FE1G,T(PM?-EIX%CABN;_
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M"D@//&?@9HT#O$(>/OU)::@@^.G/Y3)B=3+*-24-.CABPAP9_G,4!E*C3W%
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M[[9TT3#I?1RJ;TK! 8BI]3Y..NKB^K+TE3V;LMS&,M"D4,N0WRB:7VJ*:J?
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MS1O?-$+ABSK].S,N=G43@N^]'#0FAEU]Q_:T@F!: >^S79$A'["%.N7#U#B
MH?VC!E?H8CQ*S7L*ZX;6$B<<%;8V[EKK@>Q)X /^+.FY$WQP$L;Y!!_2*KC
M]A;P4?T1?OENC."  *A^X:=IHQE*-11[ML5;<,2EKA5PI]$381!%I>Y465ZV
M;LCJ[A/W4WN&&KM<QS./L*J*%X#<TQC"TR'_M%0TLAH'P"+0_ =28J=++C@
M3(4R\F$3Z$6XI5.IW P>,<!BOCM9EXX:%DO#BT/^<H#O+^1\A((QG]:^U1PH
MA"WY=\IP.1W%/7"-^K#J9'70.87%<B'ROH_ UF)K,/CUH\2T7O*7S@I]6EB_
M*?!<&Y:>(.2_T0EPQ '(TR(P7.]G<AEFG*(3(@JM[G#5>2=C-V"1-UGV*Z<7
M, RJ?Z+5>%\,'F!S.T>!6T/%!A_^@O2_V.=7S^L7<A]N<Z*U JN%/(*6&D0#
MY@-UB6?^1X?]#_L @Z!E-JY1V"&/T1:=9B#R,6<WY-M*G2BX,;AD[;\X*@^_
MM^!7!IZ+G$=)8.]/4Y-?IHS-+.Y=:K?TOX?E-52H7XM.N<[3YC,?>J=C,WN8
M'?XF^OOZ?&&//ITK_,2Q7VLOQA26W%]B[#AF%*TUIAGR= 2OO2\J=<C-S0<*
M-I FO1Z>/%>63[H^'T/J]\4NHF =<#B\^%BBA*"7=YN;AOV8-R1YXEK58K4W
MQ4*OM[Z2R/'*+<XFH9;>6U"2]PM+KPO52[2KT )-F351SLCAXIG7WS87/BX(
M=.GL\:&DWZNV@\B\M#4>CDCY)&()O=*A3R&[D_)FK44/66S8;W9Q?'F>]NTS
MBG2A"K%;4(@I-7&H,KOU=#6YBDD\GR:QAU7&0"_QAKR[>7A5J13\-=H-7(H*
MUY8W&;07*' L#D(4OKUR.:)GX\:;:,*$@$<V# &]BV/9B\%L>M$F8SN5.Y3#
M;<=RL4>[Z>XK/9<3)4CB_4"B/F% T/01M$K!<[C2BM#8D=6@X-47B\W!B7Y1
ME^61CP?YD2./?3(N$W&0.-ERTF7M#[0;IO7GB18XEFI=N4/278T0WZ&!AKSG
M/4O;AY!WS@HA?%^B%>M=8ST7B\2.U']SV[FTEC@V,?YN/E%E0IRH95J3\(/4
M5LB]YFO#1_(<=_@:Q5Z1V_GTR@GHWO$QIW\$K@>S NV-*)$%+8RZV<:V;6"D
M5]B/93?9T$"[*T4\YU^?AV]U./AY+C0G+?1=UR\W:A@!5U:(B5:QO50XB&T
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MG?N(V1>PL2M!W,\S]Z^9;0Z 5S.4ALX0]"4?#P10  6'TKT+A_.1TL\>;#*
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MOA#K!^FKT\C6R%FHC!LS^ C$'U>4?]N*9MME)-HDK*1C'L/# 7I#'4V&.8_
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M'-#/2FUM-.>4XY1;9>Y"P&% X*^Q)O[+?P%02P,$%     @ LX5$6KKY+:S
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M1-(S+Z'(-6U (('/^*B@K3PY*2,#R/R)T?FQSEG8T4OX@2E_1'H0%8+M._Q
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MG/XEC .3BIF@^]5A FT5V,"7FD8B23D@$24:*P4YT"][RO&T",E1Y279P..
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M3V.]Q!+GPU>[#]<4*I[Y:HK\UK*QP;Q'(#U&5)JU!4"JNDV?B3PWW'BA!%I
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M([CB7(',&/LEC-Q/B=0@NE"'WN(/V3NQ?6_G+.9"[(4@^>4%,<EFAN) HPQ
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M2Y(PEO]8H/<R2(#HE&1V.ZIL4-#[=K1%Z,5!_GQ/KI?OKUC8!7K7+%=8[OL
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MV@#7EPM1O)ABD^J,P.M9'DHN:I>5M_ISW_%[6' /O^0G"3G7GLEH^ 1@)P-
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MJZ1\9PY^X/I4.5_=;K"[+9,>_,#]PSY('P)<L*6?E-^)8U23#RK& %LRG"Z
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M=XWO#H9P8Q0\A9HA2:\HN"?;8,[5T>4=AXJX)GZ[U1E[X<>R575EES2'1X;
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M8?;&G,?1SMY'<\D^8.,FYGCT+7Q-XN]O+6G0J_\..5^+<R,7$=*.N?TP?KD
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M%=T3FFD^Q2U)_4.,OIB:T2.W%M>"W]O(RWIIT#$KN@\2-)3 :<KW0SADI*R
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MNT"6S15L)(A ;J/HF2MWM*7%#C6%Z9YC4^+D-T>>I6O<_+[$ OD3Z8F&*A3
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M6Y;5?!/BS*2A&G/@*+)G'\36Y8ZB5-\ WA9 6AFX:FHF>6V2*8SR]9E4)E?
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M^]$ISTSU4[A8>/3'38S'/@C0-MOE0.^Z =)+K8.]@9)F- MH].^7P'A .3V
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M[_5%**$]C\$Q6A(EE_K#^&A1PB,7?</X)@]5'EIG$DY_:#>_<27W^UN%OQ=
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M7A$8L3:0-AN@Y:2353]D,Z?*8J+*HM\LQ QL]-3%,<RRB3=\V8 0/@*[64[
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M%R9E)<=8V04TF5G_2Q0A%ZA].7@#2SO:KBZ)S"Y@6-U+4WOBQU^\UD9&2]B
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M/; _EW#@[-,NWA&L$3PWSAH>)[XL#I$W$%9<.*^OKW\%("D[19YOG'YZ[XW
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MADC(ZBARLPTK">MR3M$,6TI5GO_SRH_6TS$%]=I5<.BB<+TZ%-HOC0Y^"*]
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M'+*:MD21^T%_.$_+:>'D2?^%]G\B^_\&+.[_%[+_!>S_QC4%<+,P,1:/10"
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MIVO[1UFU:.3+7XK0EY_:LY_K1TW\WRUZT@$!4"IRI0S/1]&#$1OIP)@*%T,
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MY.2R=^&Z#5H7+06K1X9.M/HG__F_Y[_@PJ+#9DD$&2<\Y69J_@C^(GAMC>M
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M3@IN*Z=;'S1%C*+OK@UM#9T[!M$[=:A-68Y*91P^U;T1G92]]GI7,&D-6CW
M_8=;^.+T[N]/HR(_[;+T2N[6##_^='?\^C[B\),;7-3C['7+%WS\/[[U@2^9
M_J(3&5^_8(2IA/L\2.M(=_;73YMDHGC786&,%3/6YPMW5RA1LODG^M#G"@"Q
M&LN "J%S242H'MPJ^FC'!&:O_UW:F@28-1\:7[61>6+NR%M$%1%PPJ7C!:UU
ML8,PX5EJXI)J;^D>8#*;:N7L-(ZY6\.Y6F#+M$ZL[&Z?S^!!%)L55\-'&,JK
M[];KK*;(C@+D+O6&R;7*OUXNH64FG2IG^#SCM5/6:<=&<*2 _1CC!C"2*<B
M96./72]5 (,!6;K;O76<\B),<>-L;;,VFR X%%D/+G<KH$CQZBW-H1W$=(6N
MNL@R\+2)QUH3>Z(]2Q@NT@\#+F3/J.%ZCL/CV6>_<D2!@94!IFK/_#'P*O5H
MYZF7Z+)>8M/(RE]^3MJ-'ACP%0!:'_[7(Y9LK0U&;?MF\WDWA2_(Q-%XSPG]
MND<#M@JW*VF9;N>)LC(*MPI:901_G[]1?+,6?U0>DK5+;??)Q;;$Q Q#0>FM
M03;J7URH/J@1N>< UA+CU[/GRD^J9J;<E3_B=JKU=O TS@_POPZ3T^#'(,"9
M*SSU"AW-CX@>XF[L%QB,>P0=U(.2Z))$U] J&D_D,C3&-3YO*+Z+0#%=RVK<
M9SB[  DP6'>*C&B>]PB=UV;*M-)1NT&['I8L(IBHS9_V56&F+,,M%4%]QF>$
M@D1. -MTB0*UE@<C&&O]: Z?;);I!%*$Y%>.;1KTOLJQK!GZ;+>%V,)()MR@
M_3$RTEC3M_7^RNC'1^ IW8FF:P+,GRQ*)I(C16#1 R\E<@W?>9[:WVB!3YBT
M][]P^.,GIGZ>>B<^Q,@NDG6VS%U_K=:$4(ZC9JP,L#@[+VUM=K&/<&"'MI*=
MH'UXQ8.7F\:$\O##.3DR<P%W%("7C^;.Q4?_1:Z^.8( +E%F[]U[<0W1>/6:
M869&#>"%G"\OA):^,+1X8?&J(3#)Y=+2)<IY7(_"*43KSU7--@X%>$\1?)RP
M\,F-/I(E_58+HA)(O_GG3D;_Z5/^.I3YIWYUZWJT4-U%(.+=72_N3!\AI;PN
M?,3'-&)A$3=X+LTWIHD'>6N!F(K^C B@Y.O/9"<\X\[AF]?3A+[V(<EF_< )
MLGW+Y.Z(PL%+8LMOM&?O!O @>U9_,E <J5:E;!")%13?7?)UI\38Y= QGQ2Q
MG%:__C:)6IDO+V9._8E8Z?YP:*>JZP:#M;K3(-<@F(R0^+QR0T?SYI83UL])
M</;E%;76[2&N\-<3G!!^E.8EWK/+QNY3+A.5@DX/_7,A;=^$UO.SIYZ,/_-Y
M[5D_ZX[HQXD3OV]%4HKIR!T/F^VM;]PZ!F'KN+<B5Z=LA!LPG1W$@PC: !36
MB4 >)/DJ*/EWWT@B36](K?RLPN_7;0:/[((AD+_';CYW[WOCONH)_:P_O<:]
MX,".Q4W!P*.(*X@?@4S*20@D#@)1OB>]Q8.P%?9%3*=0KZA5J4C<:]#SJ9
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M:L>:S/*D]?X6("BSZ] O[*')_IRJ7S/+BB/IUN_9_I=W.H@!.S!:;#<TPZ*
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MW8&;BI;MC]5OGY6Y-* R6O(D%R@4?_ 29.:R4;CY[+%" [E#LHT*6JX-]2\
M?<V]MV"?_M'R4A)\YJ26S=7WM^V5@0_%GMHE5A@**'E(/%&TZ/^6EPDM'7U'
MRR.@-RII:E2I#DH*U;P KD6^C^W$3,[@1=K!*?;GJ;5%].MDGE\8R2<L10>$
MD><C LRY;8_Y5W"NVLL,[_%\X^GXBHF5]["]U>2ZC9@TC7N-C,)XI+S(%:"*
MT<S@MZD^>.4Z WR8/&D9LW#KPM7EL)E-F9MD9.RE0\#QMKQ',+M'=G.P3SD3
M:5>SZJT$[6Y'WBZU]CI?BIA$@N&/2=N&5'6R .%H"<$\6E,U6,:0;!9?^"M7
M>(CN3,#$YAX;/9-M3D+&Z9]S/>! J(Q=VE3L<JH?0G>*EW\\F;F2'HYD?'K\
M.W\!Z9J25(^I\>H^!$C1G9I_G"&U!]>MFR6:D4;5L[N&_/F$KE<.[=I=V%81
M7'.WE1"=MGTCD\#EE/G"YY_D2POPK/C?WW_F["@-:L?8,;(?OK>Y^[U2=$U9
M<!6?%UMD <GA/U7&^_2,O_N3-0?II9A>5R.:9E+H6JG"2++,0+"?2K]3U?>O
MG]C%]GX-GNAT'OT2,*;L;C/Q4OON=U6?LA<=(YE*<DJ/5MM;7+7#_8[G/13,
MH LN=(^S'0<=O,]+X]>)_)VKXGMS,_5>][;:$%O*+DU.FS)*>+Y/S-6/_5(B
MI' WO2]Y .?1O*<MAD_6\PX=<948J);V812XI(Y$%LU$XQ!<6"EF[<%)Y#Y+
M)% $4$@J/[L$2R<L_C ?> :/.0&9^&>>SFPW\DC_[GVA0JL:8\@X-[H4MRO_
MNQ])-MPK"% "2+XUXVJ%:+=!GK,/T0ME9*)\Q?G!4@6Q.]#AW($:%X[? /91
MVBXXQ;)U,0+YO29MI@QS%OD10X+*D&R9/"])EBQ]GT _39(@I'0E.7:*0R-T
M9<A2(^U?5U(NM C Y:AE"^B(4&1\S<!34R.B0+P2W(\43:B/?SKBN5(YK'M"
M/[7@85?!W$#YU$"1[IECR^"/2))99>DZ^(O71M5/9=*I>A+M?@OUPH+UWCR
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M#L9MHNS)A:*[>X32?*40>\ @BQ[O&+<- EK%5@#XW>?I2M<\;]?;)7;/^NV
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M:I\ _X&QTM688KX(#B]D]X[Z5<4+9+Y]2_U[U'R;O!T'UZ*)"["DU&6J*WY
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M-EQGZ>MHMD/ IV)DUM[CT=ER\_,Y$2%B_8[/]%=0_/0GF?'<G=Y79%T^7:E
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M:N>!1L"J6*/0I*J2!3H0VNEVWQB%NG<KL!5)P-9I3+3," +K0@H<M[4YF_)
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MV#S?0>YW+H#!5JT.DHOR@O?M2-ADW0LB\?[?Y *VC]W"B\'O$R]PL(_30UC
M$LYX3U>G(>':C/0-N&R+ID@0] 1"F+I.R(V57*!&DG2(]HE(?-F-^;^M1O1%
MUI@B7\B(CR1B-U-XK)3.(E0AW1-%ZZ'":L^*)[["#P+3B]:FC=8*NPX!B;D
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M,9WLZW<[/&'-ED[J> ZAXSIA^[B&[(G45#WQ\4]YSIWS!9;99>CB&RT$WZF
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MKK5(&.X %+Z9H] %\#U'A':.W]L$IC!QT+FG]P<6)5Z*57S1:]\Z*2:>?9\
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MU?8:OWTW7##_8?YI5\+IV+U;<52.>#8^-LI;=4;HL%&1CKQ6##!GE#FDHF8
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MAY!M![2# [O+'?EA>-WE>^6[,%QRB(]<<W_>Z\G[XX3G551^6KE]@+!M/[<
MO+H#B"RZ@C#K:)@L?^R4VHG1 ,MC/CC9NIAH%"CF^4+U\LTAW-T=X GN0[;N
ML!*Q6T_>K2_BK0]L/Y/37UU6]48EH,HG0LGI^>V2>;-'8F]B<6=P@OQC<SA5
MK 3W!#C*>(Z\.MAJS@EA_+?^0O-^U+VF _M]3910> RR=+$@AO NMT$^O+QL
MPMG]K,1,^*;1696YA2R[EW=QUZH5><_;I#-BB8*6DIC]*"E'9B-_/\: C>R\
MRS'NCO<Q0L>B]3I'S( 1KT%6T\<,5-XE%]F6K'[SB=H&PS]BB%=($]2]%X)/
MCOQOT_G<=IC[?QA[\W HO_A_^!899$DD,HQ"2HLM^S+4)VN,)21K(4GV9++,
M6$++((22I2)+8E+V;>QC*43(.F.&9)^QC&&VW_3]_9[K>:[K>?YX_ICKGIGK
MOLZYS_N\E]?KW.>\WP^H)J2[4/X!LC/!)*Y5J@1%OW9['L*+0=%-BJD1T*/P
MMW9W:D]J9!V@AE^4-_3G?C9Z8ECVZEV8'.>O>^C718QJI-?OB@"T-Z/0@!_K
MXTW6P>%;Q@;H5TG#B4+/Z\)5G*;ATHXG%NV<<U;@^)N\;1GPB[6:MY?=!1&:
M]%-4C.:+BE:Q*#,2K.L<_3#A'%V!>+;Y%$%?TPTI0$V9$M\X,Q(6-EJ<.^G*
M4S039WW,MC)-]ZN6M9!=Z<(BC'AP3EW^__T61])Y''IP _9'B"EH'=)Z@I&J
M@NO&G43"^*DGZ-%^^S8AIK+H[Q@7?GYB;'(GV(<S5_#\P2?V9+RBDC!KC\S:
MI"]1QPJPG0:'L?OMZ$7#A2501KHDNM^Y^.=&"0:15$<IB.]3$OKJ3N/]5]W[
MJ<\6\KD04\UE##F**O]'X^[P+WP+>BPA0]Z.*D_A#D:!B;G$RS&<!=G@M%XP
M$3-,&7*K7O.?:3'I51NFUP?D[V-M8E?NGWFY)<J!2N[:P7(1I1IZ8,L3.\1M
M\B3Q\$UR/!945;P.V_^#5&*V*.0@&[5EA%XSM?>UL$B/^\,Q+X5RXV6UVHGZ
MI0KI!LC'>WYGKZ@,QT^_ES)K6X[_M=-]0[''V$TEKW/ZCT!Z-(@KE1(S9&?W
MK1>C&(='@?$QVA 71$EM4+">\N/7H3$\7(DK<([P")HP3@:/<OP%>9VFJ#%S
M5CX(II#.N[HF"%= 6S6/_9;-D,E-!X#MH>#\9C!GNK'1 T'CBZ?_*TP7S26I
M"LF%;>9#+X08"YA+W#@F:,*9L:N0W\:?'RU$."Z^?;DFO'7.U/.L#=U)(<84
M:PT#MGLBEBKU54QEMCG Z<[Q@VLI6ALZJ'!\6-G'7&2D!&7A(0# )/2VXQ#Q
MISRF-NL!FY#@OS"I T'5:%Z!G<&B!MNQ\B;?Y="(A^"W#NF/?M9\PZ #MY42
MI)UD97TO*$=DR@&AN:3R?,9VAK683$*//2_@^4<WQG-H @UY"";;[K_XLBX^
M_S7I4Z5D,&?JV_C8C U>0EE_5QV(K]U,2E*6,_;7(X5ZB<_[#8UU 4M71WY&
M=IJLJ+P6FX]]$*+,A]JZR;^K(-4HK=7M$,://64E" *A8N 2V"C^.&51SY1;
M(X<?Y";O\XGR[XCK<?[V6H@=_5*\GROR,C2]1%L+[-WH"0YF 1.7!34R%D8.
M(E;K<%6"5U#K7!IJ[7=XI9IV@-#\F-S</V(<AAR=N1ZE^/CX&(,BX2%DB1JQ
MY I/1R[%]DG!<,ILM)K-:8T;6T(@3C0I)30&9!B9TK!R[]RH;TW80V:$X#49
MKQCQ.FF,)B"2ZSDM(3YHZ9X0<0;A\C*XO=<H(W\6 UZJ5&RVJ(^#SKIIKS<D
M1H. @X6(NW3>;> W5 7K$E*4-J'?KM] ?-]E6>.G44=_7IQ9ZVP6X:2KE)GF
M#_ 4%C^&V%IP[ L]B D>^:IN)KA@DYHF3&,L>5A%MUH#JZCM'P_R"M.#5'7R
M-3U*H6FRP_P%$4N!OVM&.?=,GWKL<0SJ[*S =U9_>.TF&^_6*%:XN[X_4_%W
MESO=\J-/"?$L9+R$+GS=DR)7:S,<=8N:!6(>]O4YF%C]&OV3&9E#?\H"XL[F
M,KL<BG:A8@CY=.3ZZG7(",9U=",5NY_# @R:C5E 1FS/7)3E&PS]+3\R"OX8
MN7OBB5(YLZW-=8\Q:XULQ&T4+/@1E:99 !LV2.GYT$[3[Y!P:\O!A-<&BO>S
M\D^D]$^W(112VR%'U0-!T_"E3DUWD69]TEY/J*N3R;R[%#QC'B5]?CCJ%$$X
MNL0@FR!EWK,A97&](47 >'2-V>+[\2C)WE2\3>:HQHZL=KO44S3*H)<9'N6'
M5Z*>KZTAG:?PD" Q.YBCRXY(;K9WE"&GKMM]@K\E/LHHBK*FOB?A8-2,XOLY
MD!BE*']?Z6\L@-<DL?DX:8ZV5B"U68(9I=L1D<>I#CT"&C37T<0:C9H#":5N
MW!1Z?G.]@83$8[J2G?&:SYE\S.%;FNM"%7 ]N&:[M#8)US7$[1PE_85D]6V>
MYH]T&M<+1,/#NP20_H3]SS4^U<,[7[(?D7[X@,TN?$'_K;+7-XX ;^?SR.8W
M"V-9@,O$$A+[>Y0I+<%FTJL<QD(Q+,!_!I4;BL>Q_8N/I!7A$6,F_?=,J"%8
M<_T-C8.Z37E#_49 _TO+-%%(OS11X_[;A,@"UI+>7:H@[5VGQ@JF$H10S%.D
MUA8_XC1#I.N8V?M5'>,,P;@IMY+Y/ OSAA.U>W_@<HEP&=!6R?P>7;*/N,EW
M;TZNZA?&%PFZQA8+Y.GES:,5B4EXM+AET=]1]+HG[3)S=*HFH?8]&MZS;=]:
MUP ! NFR4HR%]3 UZI?[FFF-4Y)GF"4YEZ,"K*>M%H=T);FXKS-Z@)<2089R
MA]0,DT]LE+J)WC;^F=!F?85XRA#@;'-!7S$"@K0!/"HF* )%,2"V7!2UYKCV
M/Y\W$EAH&A/>#5P\OJVT_CB:9NN$&"HXZL- [6"2;J'792GZ^@8GEW%BEY:^
MD(YWKS7V%' 73>TRRI-JCM[;<G>9$CUA>;$KN.?"T@5[J $]$,V&C"&G U%+
M;0AN1G*@P0_-M6V%=M&QL/607RM!,*D&1N$\V2&,/07?(%:O9E*Y6@.YR\&^
M2:-'#@%0GU(T"NGC>I4RUT =I9D[(T8.3-IID-AQICSI+R-K%Y)4IYE*8#AV
M#'SH/O&LF)IP.RP\E/$F*NQW2?V7)Y>_C]?QI)L](+VUHX0!5_[O*L!C)K13
M&/!IYDV&[^;_E78&.6X<<>P&0C(TM=CPAX\^A@1A0#F@SR%0AIHUFVD+W*:L
MNLG(ID>9$%0C_YU0N#^#R$5(A=X4G-XRL!;D\-"'M\EMH_A%,M*P47]7E9J<
MR8*A">1+K0U2G7Y3<2^U5I,0T*D#3ZEVOL_H3!EO\?FVWD$R"K4$2LG=Z486
MPRV5;\(NB(FP &M2TO[8\XR#/^<=F?O/_Z7VMW%SW(_;@G.FFZVFJ_28*=[(
MF%@$*6@;)L7-*+V3 (,]<CTE\"0=HO[]F[]4%!&A]:J>7T!:H!B5E(8E+7:0
M:%W<!RARH;$);1*[@]H'.\6[8RMFMZ[=;0-[H3)[90&.^'23?D&8 NF'X)5#
MO]TBPW5-N8Z:_8T  'U]CM?^R9Q?.OE?6H7VZ2)EM,'Y*BC\2=01X&8Z7$MK
M86^]O<=$.GXD[L-(^'T6D+DYT6L_@'EM.J4]Q0%XB:"\7K:D(EH3*[[AQ>Z(
MHM)2#N47_O:4T**'A-Z(Z>36MDE1U=D>,IRK5^#4QEHIMG1]7^)(F1%Z';LM
M&*3-6:85\%I?WSPX9$PC?6X.F?^,&9%WOTA6TND,Y:>K;GAKW6A@XP+*UO"[
MM8J@Q2[72ROQ"-6T?'WJY\D8Q(LOP8GZ?:!X9I]$&SXX-I]"C&[KXM%7J19&
MY6K"'BPL->@;7[WK^OQ&D(ZRF]F@X WIZ-1:P[]J-K>*=G%;RAF/_&MQ)F,7
M+].9VX+6[2E"LPN9;7IB8-118[6"0#< +0N\?S9HUK& C,P-[Z--@N*X5=+R
M>/GXJXSESLEJ'8XH>"T8+I(N&!P'.IQP5ZI!WKQIHP\?4YC\'A3RR=C$!1_>
M+N]]IIE"0S5\G'TJ&3!SSEY*<M,GO5,6E<*.J,47Y6B>ULZ)WO+&CQ_@Q< +
M<8XO;_BD\R[\O!/#V&QY:89?TM:'[X!0H1,5QEXST]_R/O-(J5[U>@F= CCR
MX=VRG]X&/L(U8JXZ/O:^8&42% &9!WM'"#?%Q@29ZH^;B=\YX]]>/Z-SQJ@S
M2,=31C"RX./Q>M>&"_8-O728)ZYL/W)WX.C')8E4(*;?:-"HCR^T3S:?6]]*
M6\;Z?N;.AJK1-Z[%F$'!X/3?XBY> +>R3H@IWB%TD%9WJEVV)$!("E:G+2.M
MU5=QQ::N9^&<+ _V7=16/T@"[.7EL91R7G_]YC'SI7?R7]2P+@N"N5[@L#;9
M'(DG93_,R?[J8\X!@TQD]+/3]8/AX V7W-V_,/ >2$_P-S%795(N9R:7/D'1
M0WD<Q]39KT7$#^GE&XFWQQ3*+$8(UG-Y -P\VM)8C%O/^Y1K:M-E#D/3:U.R
M*:("YM-<1_4?]_7^57,:'\^\L>N&%7Y()]678EHOEBQ,3B0T=EDW^7]Z[8>A
ME7I +2#+GWDOQK-C::W0PF&#0D@4$S)X"TN^U. WGW?$@2RPHY/7G9)4XGY_
M[\N]*;?W%2O?;BV/9[A9"N85+CM,Y*241:I>\:SY4E67M;'Q*&5N3OM,FC#F
MAWCM*"9[89-:\/?D9(3DI5BJ'#[N<_/1_HCXEZ:]_>D\6@JY^,3JL[0ZKPV]
M+67#OB,HC\H@\[2DMCEQ+\CW@D0(R5; F:"0&J4VWW*5(LFHT0/AH> 9W]5Y
MH1<G-Q,0PM0"BVRS,;2SY4BS,P&=A.%'*,&7B*#8J..E;M?D_ AH$?BAZ>NC
M\MY)7:I_ZXX$^_L?^ O?J6BHD]K@V(_@C%'^W.:Y\=(JA%?&YU"BM'F87BTP
M<V4#".CE.KO:LCW#"[XTI@5Y^^\ X$MN# U4^A=35]+^^1 '1"FI^1ZHWWB.
M$8-]X#6Q?!'ASW;Y5Y +'HPGR#6&@0 +6-$GZ@",TV>%7/(Q3_79,R:^_Y@K
M-A><.R+*UF,>3K[@_'IYLZ5B7EDI$*?0AYB3I66Y_ C @Q_/S]'6UQ/R6&^T
M]/_LP?!"61]2F0#I>7BDAZ+X/:$:'#T<,X9*E4*$E Q"2^0\-J7:_1#\HYX0
MT=^QPTUFE"Y+/'?APZ_WI+IGEW;*ZQ_Z(R)Y\0V)6P)G&/B6G*F;KG=3Q R/
M]W^->013>W?!,897ENNED81D_170U4%B'Z?X4)L[R2:0DSG06+*V2H"F8FH"
MVW7=4Z1/,%+6=Y6F?#K<))T"1IU&HFZ3IBTS7$?#4@5>A[F>&7&]+W)?MCK5
M(<?U]%T9=V?+HT"4):D3[TX7%>EH3%IC >RF\)\+^*-\ DF;^*3NU$-TMR])
MUTC>Z5$P*IHP@6$!":%D;B&#<S^2ZV);L?-4GV^_>MZ7NNE%+%<WUEA,VD86
M5"MT;K*]!3\2GUA0DQW' GQA4T?,&&4&%Y:17Y?6#S-:R.C_?JX_C);LSO&B
MW%I@@E-&.G#?DS%?JQ6^C2J=R?)K4&BM;51UT7EP8_!K&5_8_:M6M]1R7?_[
MI=^BH/@\<RIYS#PX5?.\O['EI+YYT7N=7Z5]?1W5\[S]F7GFCA7&EP9NY)FK
M*](DB_-NF?E]I9L7,/F.LZ$4NIFT\<T_E/TMFOKFS MT5!BDIK+.^U\MW;A"
M34RUJ/7LRD6R^7^PIV47$')/7&"GJA(*AT<<?^=8W4:E+F\S>8GXU,F'=.%:
M1@G4>S.6@N'ZC/2_7<S\67!TY\W=QFR7B68?0N3C2\Z.Y%,9#F,/_]9X.2V9
MI%[U<Y7T/3,R?OEL)Y6GMHU4_=35"3DOE9FFL15/T_">$B=7'^L%VJ9CA^]@
M6C!4N=##;.CMP^RZRF&#\4$#:OXW7-26O_-VQ(CF%>4#((5*2X0".]0_;=B3
M)L"S\D,3VWY^S!AOTQ/]2MMVM"_W]'1(]NN?>/Z1QTH#E@,YUA3($#YX''U<
M[_+!Y46F"(%NT!-\]Q(:K+=2>9^:K?8^]:-5BE-6T* !*NC&O47MJ-+!CP\(
M+2=?+3WM,L])_?9JZ:PV9B3G_YF%XO\L#R!P_^<X^M!VQ<YN*C-39!_YC_3W
M1"G1I/@+]B5;U1^R@"J?MDQZ21;/$>G'6E('^:"5Q\M#]YF?H?A%/38M4*%)
MA<;HN9+1^M"_3B2%T-'C]!*-84&"!"+ 5$]CS8>SDD.ZJ^Z=%O,7*9)IN6'!
M FX[89F?R:"MI.>0+>>[&(I0)G+E&_]_SEQ)\_6#'%@C5+0Q%$PI56YZAN F
M..I+_O&DIMQ@ ;O?WE['9G(M:<L)QN<"L""-E#SHR<^3(5="'(,>D >D6[;[
MTR/"I*F,RW2Z:$SWVX3]IPKO+TQR(=M"J7=C1@'MC!*/>KK6LOGINQ*.AT&G
MS"1DN?PY*PDZX9RE,X;EI[3 ^?&E2^0E= 40/1F#'-K>I=\WG2GD^!7:@TR"
M*/>8E RDJ,*L%/5BA_:AL%LY6DY?9I8D5H!VB(;*$% U.#\ZWOJ.WOJ]6GXF
MY#40V[>4;[:SFFZT<X"W?[PP8PB.:CZ&M(I/GC5YOWOH\V=C VZGX.$0CKTA
MJ!6LY'["!SO4\;:AN?4U'6E]0=-W<SFVBZZN%)Q%U5/^>+D08]@[3AF$ O@8
M?'/T;2F7^4WI0BVLYTNUW8OYT2I3'Y(/Q10"&;\B\^?JI10?+'SV"KIQ+#3W
M+/0<L1)T1;OO>+>M^;+V19&?K6P4M5/:F:GI\_76P=X*K76/UR6=9S\Z/@Q[
M![[X->) *.*CW.!G8PX]G_S'\H:#.DNYY!C3MI(&<:,4BW,R'L>4C8UU0H)T
MCL+N/XO+?5DI_E!N@2.O*[A]2$MN2<YKJ1CQT^2_O8G_WGQ^5U13,_["/["R
MU2T:>DA^BG>F+:^$4V(F!'-.]ZG+ 66)4_\T_^+@, !Z-71D$$'1'@K0.<2C
M+FUT!P %!\ W9C@''P\AZ#=*-39F #8SUQ4<*[KO^REC;/4#71#I<[:IM'9\
M('-U+_I 2#9XOXEC5"9<2I^D>./:E#*W,T@!=4QM8EAH2+KF:(^5C@=2HZ1<
M@R__!N>@LB,D7/\IGHC:*PM8;PF+9@%]OY=3.R7+=<\7U[0VS;IO*EAK"O_]
MK+4GP^_Y"YQ*/HXXPY.+5KB@;T6 4V0\F(C,0V=43?5">/&Y(8)P,)*/R+60
MEI%3_8+^7[XX\270MAD[L_AX+3K(5^*3_QIAMS8[@MZX+VRI\RG 6YM+E"M&
MHD4MOD<U=#1EO_U/<>;'EPWN;Y+.JII[8VV%M%?;]H."0-')ADU?%>.K@@0U
M4E_[Y$>$"*T8--B>Z0@_]/%5D %Y?T*/,0;2(_?I'XQD5"NJHS<^34TQG@E-
M:A;ZP7$/USZ")@YVH16;U-,% [1C3BA/YJ6AKF\3^DJ7OS,1>8V1$ZN?HG]2
M68":>QJ2=,T:1^K*>@Q J,[08VV<*0)_7C\>NJ)-++B>DGFPT@(5H?] %B!.
MHZE#U)\M+&#<9<@*(WV2!:1#6^ <(20HS\>[F"]!.I4K>=<8X=]\NG$U)>LG
MR&KXASB^* 52Y'Q=)_(9[AA3#9[4Y08FY6>3?8CCJ22%CJP,JD]G'4)Q3"'#
M5EJ4&D\4$IGI+'3"S56FX3<Y5_:LG6_"@C_AEG^:/?"JH<DR1Z25J/LD/Z88
M"^@:.ARE20U]KU\_M@,%1ZE1R?.;*1"N*.0\3X677X$D58D O@6*58\4.-W_
MIV-KX.8(/1@_Q'=_2FJVI4O3>N9QB$MJ/)N:55F@X1&0R5 "MM,]&<?+ OXE
MT6$!@LU^Y-.X>6R/^W/W:G0[+*:VT3B;".7Y[6N@19I[.X]+10HA3L./$'Z4
M/+\\X&\@Y6A^\EI6TWSVZ,-9/ZM?\TX;^,9M%C!9B,]/IKDCVX6;U4@%E,C:
M9M(;\D+KV?$J<D97'W']"&$B-4J2!EM%:%"KPHD02:JL*>E/*A'R!%==ETS7
M)-!>D1T[USFOD=C/U(EYJK'GQD\:0R?=&=T))2=-%#2&PC$=CP;FZ^K))DG^
MHSUJUT!/<J(#+9["BR/+C7_YXTGSD1]=0YS6C%H3]2_,-M?>"Y!U2+ID(,IX
M)^'(Y/NW_7>-*P8ZS\6H:YLQI+4*4"^8NNP"AYPKE4-1CAW,?R5C[R)&F&>H
M0C01.E]] ^.M=.!D*%&I<^B9 ^[XAA=Y%ONB^<2_A&5/=92Z70,[,4+5:45&
MWF5P*:^OOPR.7<,G7[4A[8_KG?*;EXKP#[>,%MOKS&:2B;#X1O:(6 !546G-
MDR@ (^)Z-I\=(%/I\K0@]V6<$%-N!0$TDS0[X2Q@7HIZ+2++ *@FU<7HG4??
MFOXO&S/9JV=222W&+[]T[@D\=N]/S@ZS%0_UX "]!TD%3\<@TT!_C3Z\2RY,
M5A9?DWR4T3M=<T.J[9B1WL9=S_3'4P"O^F)%M>U0</#QYJ/7Y+:'=#];MW.I
M5'^SO/SU>,K9.\D2"UG&-ZYQ?>,S*_G@V]I7?%"1$?AP?):SHG&*LAK S/?J
M?N4EQAF?'V0B8;#/65"B3E9:5R"'4YJID61W"H*$7=NEJ<'#B>&=,*G[;JIU
MU'DB(Y+@1Y4FSLLG9KQ7WTLHKANQZSSH:FR$)SDH_U8?^[22WG;U0J-K]:6I
M#U'D,)KO?5G*U-=T'*69/0>1)6NB!2#T>HV%$T*3RD,/A:4\^US>&7R\$_[;
M]_S\JR\ID=HO3%YYWX-8:"JJR[-M]+ 9%4?8%&1VU+D+_X]2HR:80AAR:A<Z
MA@D>-E"BRV)(=4\#[3KR=:D?YY%"JSE)\;L5)M?)/@F;W.\_S,VU<Y?FW"WC
M]SW?TKA/ENL3*>>[L3*6L7?OBKVB4S%1_)S9K.LD+=WL,EIN[*WEI6:Q0ZT^
MR6V+]?!V@IJ>VPF.!/M/T6ZH56*PJ'+UX]7^O&OF&65/2];/*X;9*_K_"LIY
MCF*/:SYIW97]J*YD8:H.0A;9KA7%BR]M=B;5$2>>,A4O0*N/N/W 0Y[F@UZX
M-E!5\"\O-BN55O1'W4BR&EE3:!R==JH9V=@MJ'&]K\$]03,(Q""]E)Y"(,RS
M40 )Q#:8^TKQ.CYK-/*0\VAQ-A;)>SGU.);H+,0[UXT,/URM3$T4/3H;_;5?
M2RGG;$FS<Z#>E8 _7EI,9X1:E!,#W2I"!75AA/6T:1',WR>FL$_"(+SWQ4[Z
M/(MR)F7?),V.6))!'0=A/=D5OE5TR:I\%F#9^%/]R \=R\;,FNZ^5ZX60:.G
M72P8J5W]R6=@H( 1#O\V:9>8HKCP8N-'@*'UNZ-:(6NC1W)LR^R.V-[7BOB:
M$'BOX481\8?/.7FITT0[XYRD"WF%<D/59*%. P52IVJ;MYX=N/9F\\1A1E5"
MENMK$^42F "_?11FLC&M),'<)E.KX=IP5N;I1=_9=',SK?78@FP9QD;#^4Q
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MP'"_IA;8*G1J%[GF7A@]BQNC#FXV,;OP+S!OFS;#<78[*879&Q#L_LET]K6
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MU(O<O;B9^#"RQ<1Z:UVHI\ -D?E24.WW0O1C].#0% A"(@U1%6PNB"K%( -
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M_+(G78IR,^)AB:/V?-]X!=A .CXWZWS225N*L&U&YN8GO[M3XS@(<P*Z=<5
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M26[\33IW,RGZ1V+$'<F$A!':/#'Z@B[EI)/"ZOCZ)Y=L;!>.B@ 7;*^#U-C
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MA=@]X[G*.7#/B/J*<]@EWXY2-3/-!B2.D"1J<&@,C0VT#_RS1?^_;.F;6ZS
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MXC/B(F,B'.C7[@HA)?"_&;YZW<4# *+XNGA1'J$NG\$Y;=G@R)[^R;PCR0?
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M8R,:C>=. ',"&OYB (YG^OP]&Z*9(UAL.49J#60& O-36L2T<K4>*E:,LH$
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MU=D6H[VC"FGX1"C9;K2<3_O7P1A9S[/'C/@R+*V:+$\S9R/4!;#2JE.L0J_
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M6-.O)>Z$8=X=N#T5^%A(UC03XP4I9.YZ\C[_3ZW&F%"'3^3B<+YK,1>B]Z7
MU!JR/Y<6?5J@L'!?%^52<&S@\(L,HVG?DM/O#(#@KB\T/^9OY55F8<;]*P\O
MLV(5LCOJXP9D*!,TOH%8<KHH>,+UWK=337N,^&H]\$]Y6K076FUU(J.\W*_!
M[7.W:O5$[>U:WU'YLW=\7=;];5?_DX\*M:[9<J[IMR6,&++WV:BLJWQ2(AQL
M4A/98"S;MK ;1A;>1OT ><B S$( YX]>V9:\$7M:C4%I'X2P\J3S[S_92A"
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MWBR>%H;=_P.C%@PT7*KK>\^%W!FO2*C-)Z2H##8= ;',3JS2$,<,;<\$&NL
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M5Y>!(6**GO5[,_MU_9WT:N088?TAZ$D&+J=#;7=>56D)11%X.F0Y%7YX#GD
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M.><N]:D16$\/88RO-?17(1,G!1MSVASESC\9^;=;]N^,LE@,IY<+ >QX!MS
M51,IW<+TWE9JNA-9N&JA-]UEJ17$60+0UJ&"RY]88A^)LY?GLL;N&5REHE_)
MNP7YF!X=].@CH<K!Q#.@/\Z'/N$@:C!/Z*2.SW3@]I'O3]BL!^P\K<:)8J[U
MB\6_1)_JK(<F8X60Z$0'4);E,LV%V+*.QK'&6[Z5+< 5/H)++]"G+H[H!;)\
M:.P<M&L'%R)>[M2&W(_1*O/9NDY.6D7;%#?PK^9=9(4U(\93UX,&](4U#"^
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M-N+F7%&Y#5#4?I LRKC.A<QKG>1"9I*X$,910)^'XS>TUUW);Z?-<7].[\P
MJ#BV#K#1BE4$#./T4A'B:)M6%SB!9QVQ>[FF'25/BKP=/SI[KVO+OLX/LXF\
MYY79_3G?)_G9I<J+?TWEYCZ96TVK;_[%@5K4MO\4.-U(B38O4U>*NZ+ 2N86
M5.E49^3CTP>O\"*/YI^XYX+_: %#TZ*9"TE9;BL$Q"P?_J @$B-P+"'2F>H1
M44_D3O=O ILER3*-@;$'C7#L(_\_Y!)T>0\YWD!YN8/H).-5N!"H(,9 M)8C
MF\<X9A;"FDG8VL)],4P++F2.%%] T&B$A'8F1[:(P>.O=1MM.'9Y*6_-KS"D
MR*QTSX?4G0KU?]:@)I.$Y9%)VO/;N$_3YH;C$-Q9BY;U+1K.Y6;FE<T4#EJ>
M(R8"!KR @7>12>^"8XLH>(63YHAIV<R11CU<2PM9+#0!42G=[B&&FXX")D]#
M)-$#411ZMSX=D81<M64X\>:"8_]5XQS&[<+].)O(\[^;%"[DJ?CL7:?VF."_
MG_8WJ]X1L[L@;ZF[YY=EY.T4UG(&%R)-,@6DZ=!V1&K325+L@!4 BZ\V]\W_
M/2I]>?!%-!?B.3M,QX7K#Y>]-2].)UT6S+;V.WC:2!FK2.6!7XN[H$&8: GG
M.];(L/-PS<(;<.6,ZV'V)_GD\JKP_]>RF<=#V;9O_-:(M%A"J!FC*%NV0F,9
M0S*V&+(EKZ60*-M09)N0-K(^$L:>:)%D9RS9ALC8LF]C1F.291@,QLQOGO?W
M_G7_=U_G?=['>1W']_.Y+D_;7H_=QP\EI-QB,&#$@R2&W!6\ZQ3*NO8K#5?C
MPL_P>N<C:SW0+!YZ:Y5&=ZW%BZ7?_\QXM>&52.K(^MF\_$'),T>J<O@T>MN^
M< $!;VJ&K'O%5TS4G);H/^PI87>4\0!YZ<NYYI-EU^T4'KHKU/U'/6 <>WVW
MA'MA^A?,R R5V6P;FKD3#U9[UKN,DNO$#:M^,!1]UGZC?;ACL/CJ0WG3&YUW
M)&4%GL6;%<57@2FAQM>J]82]W]6EWN])6BM7OMM4AW0SLXA\K+32]@;_LWK1
M4Z++TA)M<27\Q$<T("T.T=?J@9A2N[R'(MY%=G*#4@L,_7KF00EARB;B7:$E
M4N08E.+W56"K"XTV@"W70I;W)=6)X@K6KPLLU4I,KWPL^??A_-"6.AR/LM"&
M_OB#6Y3O+ZZGR%L^:FIZMRC_\Y/O?D__S.G:TM]'K<@U0R4Z#8!V8&+3$38@
MM;EC%+\8_D4LU11T+ TO(2%=@W'NNNN?\04-0X1+2"6&D^#?5+6%;3UJKK8'
M^1Y5Y3'1ZC\#T\NG=Q.(.:2'(4J:<RP@2#LI+7/6V64R?$9I'/_@[:YT  !U
MQ6EO4F/0,"W=1RF:];P2_7]!_0$F9*_W7#!(JT39^9IX&3 X%6W@1P[Y&X@G
MX</<G;ZG;0;F-0Z+PV3]72:H,?PH[E\7<E_^N;LHI^>@N.,0Y;"QOT=O+I8H
M<OTG7^I)Z!+X^"&4FZ4!I<5Z^NIG?=@\&*O:)8 60%TUEJ9F#8220,D!7,";
M+GUJ(MH I!.^O?5>7;5B^F?=?%"]"5?DRYXM&'A8I#[8N\P_DHEKD5;V=M;_
MWBT5XQ [$#N<+\$K21$'B<K< (GU$/HX5A<*J(U(ZC](W!5?MI^$'0,*+,.B
M$P2Y"*6\W//8,/3EZQM#JF; )^S\_'PN@QL-Z))@A&(O]9F_S;W,S.)313)3
MIE=&#W!IJ[8YT3H9T@KHL."I6((G+R+',_71FS]74WGSH>V,8#@A[-=#95/Q
M[]PK6JQSIM D@#+T[3V7 5X"!O\&DNMA X\M35<%-+K"Y-]_J0F7J%R=J4O6
M@A^AY@KHLH'(BMRFH&B[:34IM!@O3#<W$[:]LF;_SACF'G,YE=<2"1 *>B@%
M>N2[D(1\X7YCL&9@ FUY2LJK/)\4=6]J@;GV;4-+<0A=^CY]-(O:XAGN1-@\
MI5:?SF_03ZS%8M]0EO0!^G=$C-3Y8JGC7PZ1="[7::(?]W-Q4Y+54FRF$D[Y
M/?\-J=@\5$>(  1X&8TVN&1A-_P=M';*<H(PQY#/&?$';J-?;X4KZBUW]]BD
M9?F&-SF/>5%F.^^VI7;$]!^:!Y..]4 V<[5W""Z&0C>O=+<K1$5$;WJDW@S$
MYW=9JA%\JJ2%+M5P40IVDZZ&DJ1+EBTF"6?=-\CN4H)U70!$AP1GW0B<_);P
M.*<9,S;K?5[14>G4!VID]?+RL/7KTV_ZPM/-B YIB5Q+X<!E+*4\@NMV42!?
MZ-7LI\=DG!)%",<N)C]3BJ[LL^5.&WBS)3+_D:^U:P')CQSLD0J :^$-HP>.
M!@242F1(U9VQ>R'[14P*@N,:3\$^";KU RM[I/-#3U"Q!D_A+ZVV8H7$$]7[
MW5U% >GTD$DRTD^XY#%2_9?90UG/_5F?&]O_U)_WE=?J5!AL(F-%<W):!D.V
M[1F[1/])AWEHVUS"K-C(;5PM#?,LN&OT]I-8Y;2%7D4#SX5(_CUXYWR>Y6A1
M8]R=A\A4C=HZ_<%IPY8E<@ ^%GM8-N"[Q)*>VQ$8=S25P--"R-[6.6AIAD=U
M2)X=46D6\]G.&HO%&:K;,!J)(?$G^F:%QE:+!)%9U8539K5ZDC2)FCA?GO+W
MEW;7A7Q+;[G*!.(P-9,"3+#__!)]V9.F\K>,9/3KJ4_&_?R(JP-SUQVC==Y,
ME ??O*M&KDBH[6]=,$CO9L$7,(=#:[FRW:63W8JP'K_NVY7%I"O4F<%>V7ZR
M^V SON#^LN/V7$V)?/5/5!8VO\!+(L@(8Q4P%Q^A\;I7U5^W_&*>>LE5]8K
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MOR9?$DIDR320>[1KK3T+WI2>&.O_Z=KY327E:O'RLK+W^@1/V'D4\@RG>,%
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MB/7PWM^7OO5F!VR@O)L]\7]02P,$%     @ LX5$6EN>!Q3;)   MS,  !
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MO9S;,;C=*_CRT)[AT-N]9<LXDT7:,EHGT_'+8[&'8/GW[K_Z;9?/7_R9& ?
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M*CI9G>0V@^X>7O9PA<)%\RHZ=%K!9"MYP'LK"#K8]]0>RM7N#9.QI/ 4>NK
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MG?%3]3^W-J2K/$R S]XB :%Z/?X^DXLN[&TTKIR:G-21B@FR?&>5<ENRBTA
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ML%2Z6,?M5PM'QIO)1/OJ^+5@"PL5PXR];OB%/B9M*M+0?P!02P,$%     @
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MN*9[R?HD[^6T V6X@&,%$YCT!W0W-6Z6G3?/[7$#()A^8#CY-6KT5#O8J7B
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M"EIO)D)*@Q6,/X!YC[IX^DC$.@:.T1_ >IIBU()&6R 7X61S;HJIM$P72J\
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M):M9X.W0%F55B&-QJ0X^*(8(M*+ >C\69HK$#<=L<4O9BCUBJNN_F>,R8E_
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MW\9'KN*^<.V](W(SLW^N9)/#HVKAOO*3QYE<72N7@>:H_7<>J4!"UWRM[]Y
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M8#/Y5OPWX_;69!@D)*BAY"H#"_5B2\6*$Q%4>CDIN:L6C! Q JD9J%9B?")
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MD^=EY>R#/U.?<!Z'(I')>0?P 05)CW]F[;::C:S(*G8OZD5,O]V63(+Y+/0
M#;D[_S 8YVQ@Z!7 +>_*9BU&3!32@LT0<P!S^FE(%RI#94:A%9+*]N*=#, 3
MPK-YE AGQ[YYJ+CA/BE,*F[V/)3+!J]IKH? D54$E)JZ!,EMB)80^UDAVCA-
M:YKK07)L%1*EIBY!<L/KO9"'<80?DZ5#GF,UXJ*BT0/GE55PFG5V":%4HZ9@
MYDJLJ#%Y-2P.63GWH9I1PJGHT! 6G T'UQ@^\-HAPJ@Y9:MJ:VD^IOL-[!:N
MA?<X(S[_)(R1;Z*.$1/;,[M>L>U9;FX:E\9C$A=,4*PEL.T7M!%K4-DE=*[%
M)N#-])Q[--R<HU2WMITZ:N.B4M8M4#8*:?ENIYQ9K>U?PG2H/T!3!J"JK;4*
M,$U*$I&2%71E_5=N;'O\* XNE4K .E5=&D?G=+&@1 >.<DO;84X;BSHE70+B
MS.>NGJL,@UN(_0DYATL</>_#5N20=02VHYPV+ TJNX3.G=@C(,B_A"'!9,9X
M8ALOXN3LR-99_C)0.K2VUTVT,=,WA$OP23$].4FO'SN;*6U')%W=ZM,<,\0L
M%C,F^C6=,*Y3\_UH6TN>C'_?WVY;]2F<PM;;L7+K#?Q<8/%+WWN%#4]J%21_
MM27Y,RV@4R!1VUD 2/LGL_RHG*+T+S>U%9@>$8G1%9\UYY1$(?2B/W T/X]9
M1!<HO%QY02P>VA5+A8PE)R=4D:H%,]O^KQ:U4N1J;:D*CS&T%LO2YZ<#L;KF
M+S#!+$J/+63JUZ/;2&C;T^LBJ6D!EQ*0+R%\1$+B2Q*A4*10PNLU0M9 9CO3
MUP5,2WN7X+I##'%)YESD"^XV KK4@JN!S':2K^\I-;1W":[/*$K/<UU3I@C:
M6\UL!ZY*J;<7Z&LA<RDD3<2T1BQ3)]E4J$>ALK'MT*.#A4)+ER9#+F8V8CY3
M0O-!U Q*)9'M,&,"CD)KIZ;,)QX$F= 'L1MRN1)RQIC-A:.]F5Z@!\5ZD@:I
M[4BC@YBV!9RKUUN^Y*-0";]65L(95X )D/G^'2XI>P=2]N#GK(.]5OCEUX,4
MU'JC5HL3@Y3:5IX@1$@.XG,;?%R+)SDF9!-DLV=OE+N9)CQ^9$-&+L,0FRU_
M4NUS' K,U0]%*;9M:]H[D"OMAI3:$"Y!)C^RDR1\Z8F,-&JI=JZ59 [D4[L!
MJ&46EW#\O\^V=L-SEU3,7@I]MJ!AA/^;/7MVA0DD7O.#'FHJ/2A?NPNECE%<
MFID\9(?B!0 7*/U_0G1.D:H*V7;\](!_XR[PNQG2[2%1?)S&!/QM2CV8W[XD
MF*N-XY2GKM%ZXYUVJ+LJ>5A*%N$Z*Y)%R)PP%HM=^89PI"1RM"93X+:=*#:;
MQ*F!>L>G4B[QM7P&6[7G4TOB:*&F#U^C.9P"C^OI(>0SL<,O2UY\2Y4JU]?G
MX&@)9S S#8WE4H(@RZXY2Q4DCE9O[:#4G:5.8)>]F^ERA4(/-RVH**@<+=K:
M(5AG%%=!S(-Z\L:Y_)2]'I(UI(Z68NW@5)K')4R%RN*OV%QZA(&(!G>(12'V
M>#@07_#ZL?B!U/(6A9CZY=HD.U)WN?*2#2WQ-J#T'4'U V3?<MC.L>W8O;QW
M8EJ6.GE6W&5CJOR'TSO<ZFL6"MN_;S6W?WL[H][M#0X%Y<;BV/US&_$J+IDM
M$'S!,V, B0]RUD#FW:NJIC<L%#1\M:UASFU+U9Q?'VKU>G]#IN[)R<GA^/6V
MLE(78K0^9)TD0+*T&_$Y>^X(P$U/8+GIJE]#5-[6(*GU9ENMA !L*/J53NO"
M!DG:M]O29@P S#G\ X0I#[!,F?2K@,G]#9(>OV[K<2<+#1XR3LE8B@J\>L:C
M>.6#)/%)R?)9T[[/$M4^EO4LW-'AMG"%4U __7HT?OL.H*T'\/H1N.IF"$G2
M\;:D:7N0$;CL%!7.\>BH'^?(XW[V4^^'UBHODI T+$7SE #\G)+LX5!=PXT2
MDJREN%P_'?8F?_VM$Y+@I1@KSXZ]B=K3=1*2GJ6@V]5TR3H'F]Y[-Y;6]122
MZJ4(7L@W;&C0ZI8*2:-2+&_*26PHN<O%%9*NI2Q ,V^QH7*+NRV>-3TNIQ09
M.S$/O0U#\5L@6 *4\=RH^HN=0\N)@F++M'[-3&IBZ=5I^4*1AK!5;6TOPI7$
MKGL,J]S0H27<;Y#7ZCRB:H!0T=3VVET3!K7:.;=ZUG"CC>242M5#GH3:]*X-
MM]M(XI>J!-FG/J5L ,SX2'[4LBJJA<Q$KU)MH*?7WM^\T?[Z&TG9<G$A*?L=
MK0%\Y@QBSAI$%#P*YKDIF UHU;?E2/J5:A!9/YJFZ#;'J.&E.9)FI:I#UHQP
MM1X3OH )QD!<Q.XGF4[.VH:VK6[2D70NE1L&PY6)+C+(]SEF]>_>D10M52&J
MFM]FN-"YED?2JU1Q% 8MBH"?,0,17 DP460]!2_I]RE4/EI7U][NN\TWTCQG
MLURJ<SYDUE,:<E_NFZBD8F([G5?C5?.>= /SN)3TE\07)\(IK]E9]6L\#"!N
MY&2[9-@-9TU#.0TV_R'_++]L1 KP7*&/B* ICEAU<J$N$OOIS?;1V=T&38<&
M=WU@96\?;QD?ZAC8/FZ[,_P*LSB-:,-K>>K:VSY<NV,L=_4M/25)>1IM $[2
MVKDT2]*A"9@BBBX#(ZK3U*9!0)_$=H@!3E7$SF5-!K#5&Z/A42 ;AQA-;UY]
MKE)?*7>+ECD[P , P.F6=I1N:3M6J';@55YVB?W#)_[PB3]\8E=70LLNLK1W
M);O(L,!=?()R_I+#!.)TM&V?N=$WJ^>R JY^0-<26'M=0H97P>8U4IY%5\@7
M;T\61_-C+LVZ@+>&UMUT8]M/-Z!>?NM"]S9VR</7*)@\OW%&_&O>:5!Q$E9[
MF-0SLNWY.QD(379Z 5"GKYR<D)UB?1>\;:\/=C(@6EBSPS$B@G\"_/CH>)R
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M^.#O__.?_V'1__WQ7X>'UA6"KO/%NL#VX=";X-^M6S"'7ZQOT(,$!)C\;OT
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MBR?[$'U_1DD0.WR"APYBBHKV8\F'"N(S*L@+CFC3HZ3-42F!]OE>?>S0P7.
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MRSF.MQ(WR8F*AUVAZ6/CL.6/=AQ(Q&,#RWDV;G9;.]GN '*&WCE8H(!YW,2
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M2M,:-3*BJ++6VPD9XAP=SL#R888)').0O8GE!#6PIB4MNXX$XIDGEG+9],3
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MD1EPET%J23#T,<(;<J<61JWTT1HC33_T,2515JQ>;F[.];V00LA;'Z0%V/9
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M4\NH HA@+C@U-.NIGHF8%);=K3: F(4@C)LE"?U09?W'39KCMUK_E;)^V66
MV^>40A 0D_3H-/RI)<^:OR"FPXXK 2'-NQ&NO@M/FG>NI'D'FC3OII!F\:4
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M2WS8K1^+3)-]2BGEBP0&B T/%"(@J*#'-63#;8%J421D0V2GZH%5N#-X[HL
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MTMX7!MPHJ!$%0S<S/M5Z0%6 6PVX8:?AY\MS.@5)+6M+:E&_O:@>;+__E.7
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M;7M/03!!"4D:M:Y6!*]8>]%V.P!.9C6PZ6!Z5Z:E\0R#5M3SN$0+=C VD>1
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MYRR3R7<J?XY</V4>//>6N%\%J\W7WWT(:1:L @9@VMO"6J25,A9J*."]E'O
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M0R5U$!35..7$T8$N?)*J 8]E:7TY%U2:-@^OUQLZ$I&WM?O/)]-Y\FM T/[
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MQ5[UU=>[_D'I$WWKX4M>4XU3?Z!C5K?^&\ ,+4[BED/M6MD/RT(^&?)ZDCV
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M(]+I=5_?'>2P]>JN7"_M'@]L>%-GW1- 4 =);P>>RG(TKXW/<O:+$Y!7]Q)
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M,%H%O["&#TK)=,ZSNA927P50^^:*U+7H I61.F/3N0BKI',]<Y"MNS:@DIL
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MEA0$ $(;@)K4&,]Y0TW*$!WTW4CYH@F_S*7RW%9+07D9[N::(<CB1URJ*EO
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MR+!G&P4F$9=".[1("X.![]];: "\1M>QESU1R&2Y8\:P6>C'%GEI,/;]._Z
MBTV=IHC 9Y)4.B,(?V$E, W].^@ZT*#0&V, VHD&'X;D5>"9'H=@ HIR!%4'
MA94\6NVK$Z0Y;&PUO%IGUX5\GA2#L$V]EB;3-L"\#;)K-N>M&T:C'V;45?D:
M9R-P%B*31R8^)-H=A6$;8"('V7:;$]D-(W0B=\^Z&M,GJ@DF;9#]>1^DR?%
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MP?Z?T?->'N!8(ZN#',!@2(-:\[%O<95SC[\B_(R'KQZ^.H&\*R@K((<N (D
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MEU$FSD44JR(]!&6Q(CS46(K/K*6JHB]BOSK4YZ$F !($1=%"+CJ0(-44G0,
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MI,%^\_\!4$L! A0#%     @ LX5$6M'6>"ZHO0  ">,   L
M ( !     &%U9%\P,#$N:G!G4$L! A0#%     @ LX5$6G;GL*)V!P  ?#8
M  H              ( !T;T  &5X,S$M,2YH=&U02P$"% ,4    " "SA41:
M+F&TU8@'   G.   "@              @ %OQ0  97@S,2TR+FAT;5!+ 0(4
M Q0    ( +.%1%H;_R/D9P0  $T:   *              "  1_-  !E>#,R
M+3$N:'1M4$L! A0#%     @ LX5$6O(DJS]W!   P!P   H
M ( !KM$  &5X,S(M,BYH=&U02P$"% ,4    " "SA41:MQ^M4K.0 @ Y%A@
M#               @ %-U@  9F]R;3$P+6LN:'1M4$L! A0#%     @ LX5$
M6CF1L ,&D0$ VZH! !               ( !*F<# &9O<FTQ,"UK7S P,2YJ
M<&=02P$"% ,4    " "SA41::["[W^==  !D>P  $               @ %>
M^ 0 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0    ( +.%1%JZ^2VLP"<! )<S
M 0 0              "  7-6!0!F;W)M,3 M:U\P,#0N:G!G4$L! A0#%
M  @ LX5$6H$_:I\OVP$ ".4! !               ( !87X& &9O<FTQ,"UK
M7S P-2YJ<&=02P$"% ,4    " "SA41:6YX'%-LD  "W,P  $
M    @ &^60@ 9F]R;3$P+6M?,# W+FIP9U!+ 0(4 Q0    ( +.%1%HWJ7H4
MM1X  , H   0              "  <=^" !F;W)M,3 M:U\P,#@N:G!G4$L!
M A0#%     @ LX5$6C^P><;M.@  %$X   \              ( !JIT( &9O
M<FTQ,"UK7S S+FIP9U!+ 0(4 Q0    ( +.%1%H<)09OI L   UN   1
M          "  <38" !T96QO+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( +.%
M1%I6/H!$W0T  *.M   5              "  9?D" !T96QO+3(P,C0Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "SA41::)SGK:<@  #Y&0( %0
M    @ &G\@@ =&5L;RTR,#(T,3(S,5]D968N>&UL4$L! A0#%     @ LX5$
M6D7F!DI-6   318% !4              ( !@1,) '1E;&\M,C R-#$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( +.%1%IOIWU^E$   +(Q!  5
M  "  0%L"0!T96QO+3(P,C0Q,C,Q7W!R92YX;6Q02P4&     !( $@!/!
&R*P)

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:TELO="http://telomirpharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="telo-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-02-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2025-02-04</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-112023-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="From2023-11-302023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-112023-12-11_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="From2024-02-132024-02-13_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-11_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MiralogxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:MiralogxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-15_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2023-12-112023-12-11_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-24_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="From2024-12-092024-12-09_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-09_custom_StarwoodTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:StarwoodTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-09</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TampaFloridaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">TELO:TampaFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:PlacementAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_custom_BayShoreTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">TELO:BayShoreTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2024-02-13_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TELO:TwoThousandTwentyThreeOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TELO:BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember11697890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnderwriterWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember11698062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BayShoreTrustWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:TwoThousandTwentyThreePrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:BayShoreTrustWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnderwriterWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TELO:MeasurementInputFairMarketValueUnderlyingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">TELO:UnderwriterWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">TELO:StockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">TELO:StockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001971532</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001971532</dei:EntityCentralIndexKey>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:IssuanceOfWarrantsOnRelatedPartyLineOfCredit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:AccruedOfferingExpense
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:DebtConversionToCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:AdvancesToAffiliates
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0576"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0578"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0673"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0691"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0707"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0709"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_StockOptionsOneMember"
      id="xdx2ixbrl0744"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0760"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0788"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0811"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0841"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000013">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000017">001-31361</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000018">Telomir Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000019">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">87-2606031</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000021">100     SE 2nd St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000022">Suite     200 #1009</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000023">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000024">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">33131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">786</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000027">396-6723</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000028">Common     stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000029">TELO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000031">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000037">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000039">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000042"
      unitRef="USD">113300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-02-04"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">29762671</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000047">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_006"&gt;&lt;/span&gt;Item
1C. Cybersecurity.&lt;/b&gt;&lt;/span&gt;We
recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is
defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud,
extortion, harm to employees and violation of data privacy or security laws.&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zqebkt8Y6Xvi"&gt;Identifying
and assessing cybersecurity risk is integrated into our overall risk management systems and processes.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zXUoPgJAApkl"&gt;Cybersecurity risks related to
our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including
third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity
incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable
data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement
appropriate changes.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zdsPmK3jxePe"&gt;Our
risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from
third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zL3oPVtJjeWa"&gt;Cybersecurity
risks are evaluated when determining the selection and oversight of applicable third-party service providers and potential fourth-party
risks when handling and/or processing our employee, business or customer data.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000048">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">Cybersecurity risks related to
our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including
third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity
incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable
data, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement
appropriate changes.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000050">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000051">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <TELO:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact000053">true</TELO:NoInsiderTradingFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000054">106</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2023-01-012023-12-31" id="Fact000055">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000056">Salberg &amp; Company, P.A.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000057">Boca Raton, Florida</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2023-01-012023-12-31" id="Fact000058">Cherry Bekaert LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-012023-12-31" id="Fact000059">Tampa, Florida</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">1266131</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">1231</us-gaap:Cash>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">303281</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">57874</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">713</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">130000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">1324005</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">435225</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">4338543</us-gaap:DeferredCosts>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">1324005</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">4773768</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">587536</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">707187</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">93432</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">527377</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">101000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">680968</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1335564</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">680968</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">1335564</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000115"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000134"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000136"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">29762671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">29762671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">28609814</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">28609814</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">31239895</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">17502346</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">-30596858</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">-14064142</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">3438204</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">1324005</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">4773768</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">9636333</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">600192</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">370500</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">1767550</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">2235341</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">1574306</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">12242174</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">3942048</us-gaap:OperatingExpenses>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">48000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">4338542</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">1643049</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-7486767</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-13071864</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">29539219</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">29539219</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">27304724</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">27304724</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">26829269</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000209"
      unitRef="USD">55000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-992278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-937278</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">268025</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000216"
      unitRef="USD">910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">1512478</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000223"
      unitRef="USD">10587346</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">10587346</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">42</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">5950000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">5950000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-13071864</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-13071864</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">28609814</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000247"
      unitRef="USD">17502346</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-14064142</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">3438204</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">28609814</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">17502346</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-14064142</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">3438204</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000265"
      unitRef="Shares">1142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000261"
      unitRef="USD">6832973</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">6832973</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <TELO:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">10000</TELO:StockIssuedDuringPeriodSharesWarrantsExercised>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">37300</TELO:StockIssuedDuringPeriodValueWarrantsExercised>
    <TELO:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">37300</TELO:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">6867276</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000277"
      unitRef="USD">6867276</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">29762671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">31239895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-30596858</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000296"
      unitRef="Shares">29762671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">31239895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">-30596858</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">643037</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-13071864</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">6867276</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">130000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-7486767</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">4338543</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">1611458</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">183629</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">114556</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">57160</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">713</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-5070428</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-3859796</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">255970</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">101000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000340"
      unitRef="USD">-433945</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">1663164</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">1452414</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">37300</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">6832973</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000352"
      unitRef="USD">6335328</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">3859608</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000355"
      unitRef="USD">1264900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-188</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">1231</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">1419</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">1266131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">1231</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <TELO:IssuanceOfWarrantsOnRelatedPartyLineOfCredit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">5950000</TELO:IssuanceOfWarrantsOnRelatedPartyLineOfCredit>
    <TELO:AccruedOfferingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000380"
      unitRef="USD">90000</TELO:AccruedOfferingExpense>
    <TELO:DebtConversionToCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000383"
      unitRef="USD">3100579</TELO:DebtConversionToCommonStock>
    <TELO:AdvancesToAffiliates
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000386"
      unitRef="USD">130000</TELO:AdvancesToAffiliates>
    <TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">303281</TELO:DeferredOfferingCostsChargedToAdditionalPaidinCapital>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <TELO:DeferredFinanceCosts
      contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember"
      decimals="-4"
      id="Fact000395"
      unitRef="USD">5950000</TELO:DeferredFinanceCosts>
    <us-gaap:PaymentsForFees
      contextRef="From2023-01-012023-12-31"
      decimals="-4"
      id="Fact000396"
      unitRef="USD">90000.00</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact000397"
      unitRef="USD">1000000.0</us-gaap:PaymentsForFees>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">268025</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-12-112023-12-11" id="Fact000400">1-for-2.05 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-11-302023-11-30"
      decimals="-5"
      id="Fact000402"
      unitRef="USD">3100000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-12-112023-12-11" id="Fact000404">1-for-2.05 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember"
      decimals="-5"
      id="Fact000406"
      unitRef="USD">1400000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">674637</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000410"
      unitRef="USD">1700000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">837841</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">7486767</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-4"
      id="Fact000416"
      unitRef="USD">130000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000418">&lt;p id="xdx_80A_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zvG6PRXYezK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1. &lt;span id="xdx_82C_zsBp44Qr10Z2"&gt;Description of business and summary of significant accounting policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Overview&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Telomir
Pharmaceuticals, Inc. (&#x201c;Telomir&#x201d; or the &#x201c;Company&#x201d;) was formed in August 2021 and is a Florida incorporated pre-clinical
stage biopharmaceutical company that is developing its licensed product candidate, Telomir-1, a novel small molecule designed to lengthen
the DNA&#x2019;s protective telomere caps, which are crucial in the aging process. The Company&#x2019;s goal is to explore the potential
of Telomir-1 starting with ongoing research in animals and then in humans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Telomeres
are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity
accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and
age-related diseases. Telomir&#x2019;s goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with
the broader aim of promoting longevity and enhancing overall quality of life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Substantive
operations began in late 2022 and the Company&#x2019;s initial Investigative New Drug (&#x201c;IND&#x201d;) application is anticipated to
be filed with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in second half of 2025. National phase filings are expected to
be made during the first quarter of 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
&#160;used herein, the Company&#x2019;s common stock, no par value per share, is referred to as the &#x201c;Common Stock&#x201d; and the
Company&#x2019;s preferred stock, no par value per share, is referred to as the &#x201c;Preferred Stock&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ReverseStockSplitPolicyTextBlock_zkkpUwRjWbdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective December 11, 2023, the Company completed
a reverse stock split of its outstanding common stock upon the filing of the Company&#x2019;s Second Amended and Restated Articles of Incorporation
with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable
upon the exercise of our outstanding warrants, and the exercise price of such warrants, have been adjusted to reflect the reverse stock
split. Unless otherwise noted, all share and per share information in this Report retrospectively reflects the reverse stock split. (See
Note 6 &#x201c;Common Stock&#x201d;).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--InitialPublicOfferingPolicyTextBlock_zXt79ulMVMX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z75ahWt9vHOa"&gt;Initial
public offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2024, the Company closed its initial public offering (the &#x201c;IPO&#x201d;) consisting of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqA7PY2Zzj93" title="IPO units, shares"&gt;1,000,000&lt;/span&gt; shares of Common Stock
at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zg0jBQgUA59l" title="Initial public offering shares"&gt;7.00&lt;/span&gt; per share for approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTPujBNIWEa3" title="Gross proceeds"&gt;7.0&lt;/span&gt; million in gross proceeds. After deducting the underwriting commission and other
offering expenses totaling $&lt;span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwbKKnJV24k9" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt; million, the net proceeds to the Company were $&lt;span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeA9PCKl0Il8" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt; million. The Common Stock began trading on The Nasdaq
Capital Market on February 9, 2024 under the symbol &#x201c;TELO&#x201d; (See Note 6 &#x201c;Common Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zOQDpgPdBGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zoUgJS5DJ0w"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has no source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zcwsWEOXvTeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4dX9EFBa1v9"&gt;Income
taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes pursuant to the provision of Accounting Standards Codification (&#x201c;ASC&#x201d;) 740-10, &#x201c;Accounting
for Income Taxes&#x201d; (&#x201c;ASC 740-10&#x201d;), which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation
allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred
asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has adopted&#160;ASC 740-10-25, &#x201c;Definition of Settlement&#x201d;, which provides guidance on how an entity should determine
whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a
tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished.
For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position
is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations
remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities,
generally for three years after they are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUZxHSB5Cjyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zr5iyJ7pgiwg"&gt;Research
and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zKocMBfqSUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zZBMGwwFLEij"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFsiosMfeV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zAxnAwav3f9c"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased,
to be cash equivalents. The Company maintains cash and cash equivalent balances at two financial institutions that are insured by the
Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company&#x2019;s account at these institutions are insured by the FDIC up
to $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zknBa6WMXQgf" title="Cash insured amount"&gt;250,000&lt;/span&gt;. On December 31, 2024 and 2023, the Company had cash in excess of FDIC limits of approximately $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zdzrHETIHRLj" title="Cash"&gt;1.0&lt;/span&gt; million &#160;and $&lt;span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zCWBxTaWb0Jc" title="Cash"&gt;0.0&lt;/span&gt;
million, respectively. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually
the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could
have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its
cash to other high quality financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvYtSxWf6uSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zFNYU0dot5b"&gt;Stock-based
compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation under the provisions of FASB&#160;ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVnmNYchwC32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zslnRouUK76f"&gt;Fair
Value Measurements and Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z9pZXaDSS82g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zc3o324Lkjg"&gt;Earnings
per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Earnings
(loss) per share is computed in accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d; Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAzY9wDNiCSl" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt;
stock warrants and &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zMjFmzBmjW1i" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,352,670&lt;/span&gt;
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvrsUqp6XMrj" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,774,057&lt;/span&gt;
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <TELO:ReverseStockSplitPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000420">&lt;p id="xdx_841_ecustom--ReverseStockSplitPolicyTextBlock_zkkpUwRjWbdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective December 11, 2023, the Company completed
a reverse stock split of its outstanding common stock upon the filing of the Company&#x2019;s Second Amended and Restated Articles of Incorporation
with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse stock split, and all such
fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable
upon the exercise of our outstanding warrants, and the exercise price of such warrants, have been adjusted to reflect the reverse stock
split. Unless otherwise noted, all share and per share information in this Report retrospectively reflects the reverse stock split. (See
Note 6 &#x201c;Common Stock&#x201d;).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TELO:ReverseStockSplitPolicyTextBlock>
    <TELO:InitialPublicOfferingPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000422">&lt;p id="xdx_84F_ecustom--InitialPublicOfferingPolicyTextBlock_zXt79ulMVMX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z75ahWt9vHOa"&gt;Initial
public offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2024, the Company closed its initial public offering (the &#x201c;IPO&#x201d;) consisting of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqA7PY2Zzj93" title="IPO units, shares"&gt;1,000,000&lt;/span&gt; shares of Common Stock
at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zg0jBQgUA59l" title="Initial public offering shares"&gt;7.00&lt;/span&gt; per share for approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTPujBNIWEa3" title="Gross proceeds"&gt;7.0&lt;/span&gt; million in gross proceeds. After deducting the underwriting commission and other
offering expenses totaling $&lt;span id="xdx_906_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwbKKnJV24k9" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt; million, the net proceeds to the Company were $&lt;span id="xdx_90B_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zeA9PCKl0Il8" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt; million. The Common Stock began trading on The Nasdaq
Capital Market on February 9, 2024 under the symbol &#x201c;TELO&#x201d; (See Note 6 &#x201c;Common Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TELO:InitialPublicOfferingPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000424"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000426"
      unitRef="USDPShares">7.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000428"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:OtherUnderwritingExpense
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000430"
      unitRef="USD">1200000</us-gaap:OtherUnderwritingExpense>
    <TELO:ProceedsFromInitialPublicOfferingNetProceeds
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000432"
      unitRef="USD">5800000</TELO:ProceedsFromInitialPublicOfferingNetProceeds>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000434">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zOQDpgPdBGma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zoUgJS5DJ0w"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently has no source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000436">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zcwsWEOXvTeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z4dX9EFBa1v9"&gt;Income
taxes&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes pursuant to the provision of Accounting Standards Codification (&#x201c;ASC&#x201d;) 740-10, &#x201c;Accounting
for Income Taxes&#x201d; (&#x201c;ASC 740-10&#x201d;), which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation
allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred
asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company follows the provision of&#160;ASC
740-10&#160;related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the
merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of&#160;ASC
740-10, the benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all
available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the
resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions
that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than&#160;50&#160;percent
likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions
taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying
balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The
Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded
a liability for uncertain tax benefits.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has adopted&#160;ASC 740-10-25, &#x201c;Definition of Settlement&#x201d;, which provides guidance on how an entity should determine
whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a
tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished.
For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position
is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations
remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities,
generally for three years after they are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000438">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUZxHSB5Cjyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zr5iyJ7pgiwg"&gt;Research
and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000440">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zKocMBfqSUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zZBMGwwFLEij"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000442">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFsiosMfeV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zAxnAwav3f9c"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased,
to be cash equivalents. The Company maintains cash and cash equivalent balances at two financial institutions that are insured by the
Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company&#x2019;s account at these institutions are insured by the FDIC up
to $&lt;span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zknBa6WMXQgf" title="Cash insured amount"&gt;250,000&lt;/span&gt;. On December 31, 2024 and 2023, the Company had cash in excess of FDIC limits of approximately $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zdzrHETIHRLj" title="Cash"&gt;1.0&lt;/span&gt; million &#160;and $&lt;span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zCWBxTaWb0Jc" title="Cash"&gt;0.0&lt;/span&gt;
million, respectively. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually
the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could
have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its
cash to other high quality financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000446"
      unitRef="USD">1000000.0</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000448"
      unitRef="USD">0.0</us-gaap:CashUninsuredAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000450">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvYtSxWf6uSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zFNYU0dot5b"&gt;Stock-based
compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation under the provisions of FASB&#160;ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;,
which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors and consultants
based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using
the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the
requisite service periods using the straight-line method. The Company has elected to account for forfeiture of stock-based awards as
they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000452">&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVnmNYchwC32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zslnRouUK76f"&gt;Fair
Value Measurements and Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the fair value of financial instruments in accordance with GAAP which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GAAP
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use
of unobservable inputs when measuring fair value. The Company considers the carrying amount of deferred offering costs to approximate
fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000454">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z9pZXaDSS82g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zc3o324Lkjg"&gt;Earnings
per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Earnings
(loss) per share is computed in accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d; Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAzY9wDNiCSl" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,814,057&lt;/span&gt;
stock warrants and &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zMjFmzBmjW1i" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,352,670&lt;/span&gt;
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvrsUqp6XMrj" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,774,057&lt;/span&gt;
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000456"
      unitRef="Shares">2814057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000458"
      unitRef="Shares">2352670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000460"
      unitRef="Shares">2774057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000462">&lt;p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zz2S0BKBUbN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2. &lt;span id="xdx_826_zwpn30GsllAh"&gt;Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared assuming the Company will continue as a going concern which contemplates the realization
of assets and settlement of liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had cash of approximately $&lt;span id="xdx_900_eus-gaap--Cash_iI_pn5n6_c20241231_znS4OfaHuDA8" title="Cash"&gt;1.3&lt;/span&gt;
million. The Company raised approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231_zfYfak5AfCXf" title="Raised amount"&gt;6.9&lt;/span&gt; million in 2024 and used approximately $&lt;span id="xdx_909_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zPC90RPBAgF3" title="Cash in operations"&gt;5.1&lt;/span&gt;
million of cash in operations during the year ended December 31, 2024, had a net loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zFwtebQi8xx3" title="Net Loss"&gt;16.5&lt;/span&gt; million in 2024 and had stockholders&#x2019; equity of approximately $&lt;span id="xdx_909_eus-gaap--StockholdersEquity_iI_pn5n6_c20241231_zbIMkwdbg1H4" title="Stockholders equity"&gt;0.6&lt;/span&gt;
million at December 31, 2024, versus stockholders&#x2019; equity of approximately $&lt;span id="xdx_906_eus-gaap--StockholdersEquity_iI_pn5n6_c20231231_zRqjiHc0Dagf" title="Stockholders equity"&gt;3.4&lt;/span&gt;
million at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company&#x2019;s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company&#x2019;s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4 and an initial public offering &#x2013; see Note 1. Additional sources of financing may be
sought by the Company. However, there can be no assurance that any fundraising will be achieved on commercially reasonable terms, if
at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of filing this Annual Report, the Company will continue to generate losses and have insufficient cash and cash equivalents
on hand to support its operations for at least the 12 months following the date the financial statements are issued. &#160;These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for
a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. The Company is seeking to
raise capital through additional debt and/or equity financings to fund our operations in the future. If the Company is unable to raise
additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations.
These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and 2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000464"
      unitRef="USD">1300000</us-gaap:Cash>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000466"
      unitRef="USD">6900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000468"
      unitRef="USD">-5100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000470"
      unitRef="USD">-16500000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000472"
      unitRef="USD">600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000474"
      unitRef="USD">3400000</us-gaap:StockholdersEquity>
    <TELO:LicenseAgreementRelatedPartyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000476">&lt;p id="xdx_803_ecustom--LicenseAgreementRelatedPartyTextBlock_z2FmDuIvdWXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3. &lt;span id="xdx_823_zIuJuJWzprN7"&gt;License agreement, related party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company licenses the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (&#x201c;MIRALOGX&#x201d;), an
intellectual property development and holding company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 11, 2023, (the &#x201c;Effective Date&#x201d;), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement, under which the Company has the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell &#x201c;Licensed Products&#x201d; in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the &#x201c;MIRALOGX License Agreement&#x201d;). On
November 10, 2023, the Company and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant
to which the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals,
in addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and
commercialization of veterinary, in addition to human, therapeutic treatments and uses (together with the &#x201c;Initial MIRALOGX License
Agreement, the &#x201c;MIRALOGX License Agreement&#x201d;). &#x201c;Licensed Product&#x201d; is defined in the agreement as a drug product
containing as an active agent 2,4,6-tris(3,4-dihydro-2H-pyrrol-2-yl) pyridine or a pharmaceutically acceptable salt, ester, or solvate
thereof. The Company also has the right to grant corresponding sublicenses under the licensed patent rights. The MIRALOGX License Agreement
provides for the payment to MIRALOGX of an &lt;span id="xdx_90C_ecustom--PercentageOfRoyaltyPayable_iI_dp_uPure_c20230811__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVopxE5gbCN1" title="Percentage of royalty payable"&gt;8&lt;/span&gt;% royalty (payable quarterly) on the Company&#x2019;s net sales of Licensed Products by the
Company or its sublicensees and on non-royalty bearing milestone revenue. There are no up-front, execution, or milestone payments in
the license agreement. Further, no payments have been made to date under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
term of the license from MIRALOGX will continue through the date of the expiration of the last-to-expire licensed patent or, if later,
the date of the expiration of the last strategic partnership/sublicensing agreement covering the licensed products. The patent rights
are expected to extend through 2043, and additional patent terms may be awarded, including additional patent terms based on the time
taken for regulatory review of drug products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
agreement also provides that Telomir may bring suit in its own name to enforce patent rights. MIRALOGX will control the prosecution of
the patent applications for Telomir-1. Telomir is required to be kept informed by&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MIRALOGX
of patent prosecution activities and may select identified countries for patent protection. Telomir is to reimburse MIRALOGX for patent
prosecution and maintenance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</TELO:LicenseAgreementRelatedPartyTextBlock>
    <TELO:PercentageOfRoyaltyPayable
      contextRef="AsOf2023-08-11_us-gaap_RelatedPartyMember"
      decimals="INF"
      id="Fact000478"
      unitRef="Pure">0.08</TELO:PercentageOfRoyaltyPayable>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000480">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zC1Gl3PLKyg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4. &lt;span id="xdx_82A_zjVG78OMRSxj"&gt;Related party balances and transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Due
from related parties-&lt;/i&gt; During the year ended December 31, 2023, the Company provided working capital advances to companies under common
control. These advances were due on demand and are non-interest bearing. Amounts due from related parties as of December 31, 2023 were
$&lt;span id="xdx_902_eus-gaap--OtherReceivablesNetCurrent_iI_pn4n6_c20231231_zXmRwWBNEgW6" title="Amounts due from related parties"&gt;0.13&lt;/span&gt; million. In 2024, the company under common control was dissolved and therefore the amount due become uncollectable and was written
off and reflected as credit loss expense, which is included in general and administration expenses. As of December 31, 2024, there was &lt;span id="xdx_909_eus-gaap--OtherReceivablesNetCurrent_iI_pid_dxL_c20241231_zYN7BLzXgjmd" title="Amounts due from related parties::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0484"&gt;no&lt;/span&gt;&lt;/span&gt;
amount due from related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Due
to related parties-&lt;/i&gt; During the years ended December 31, 2024 and December 31, 2023, the Company received working capital
advances from companies under common control. These advances were due on demand and are non-interest bearing. During the year ended
December 31, 2023, advances in the amount of $&lt;span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdwOnBSkqywd"&gt;1.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
were converted into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zIKc0uHF7fpj"&gt;837,841 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of our common stock (after giving effect to our &lt;span class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBDYXNoIEZsb3dzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--MiralogxLLCMember_z2SmVAdsoBP4"&gt;1-for-2.05
reverse stock split&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that occurred on
December 11, 2023) at a conversion rate of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zFTx3V7H9246"&gt;2.05 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share resulting in a loss on the conversion of debt of $&lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zmMYbuxcQxZ2"&gt;4.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.
Following the conversion, $&lt;span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231_zVKrOBu9aY5"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
of advances remained outstanding as of December 31, 2023. During the year ended December 31, 2024, there were advances received by
the Company in the amount of $&lt;span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zL87h1GcDGy6"&gt;0.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
for payments made regarding studies on behalf of Telomir and repayments made to related parties in the amount of $&lt;span id="xdx_909_eus-gaap--OtherLiabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zY8xdMUHvuwa"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.
As of December 31, 2024 $&lt;span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241231_zMiulhJzcYx"&gt;0.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
remained outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Bay
Shore Trust Line of Credit&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2023, the Company entered into a Promissory Note and Loan Agreement with the Bay Shore Trust, a trust established by the Company&#x2019;s
founder, Jonnie R. Williams, Sr., and under which various of his family members are beneficiaries. Under this Promissory Note and Loan
Agreement (the &#x201c;Bay Shore Note&#x201d;), the Company had the right to borrow up to an aggregate of $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zi7lVuBQ1oZ7" title="Line of credit, maximum borrowing capacity"&gt;5&lt;/span&gt; million from the Bay Shore
Trust at any time up to the second anniversary of the issuance of the Bay Shore Note or, if earlier, upon the completion of the Company&#x2019;s
IPO. As of December 31, 2024, the line of credit is no longer available as the IPO was completed in February 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration of the loan facility provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a Common Stock purchase
warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_z52ibEjCL7k8" title="Shares of common stock"&gt;2,439,025&lt;/span&gt; shares of Common Stock at an exercise price
of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zEduPDIyP3x8" title="Exercise price"&gt;3.73&lt;/span&gt; per share (See Note 6).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0A8JOQexfca"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in advances from a line of credit from
Bay Shore Trust. On November 30, 2023, $&lt;span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn5n6_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsQTH0c899id"&gt;1.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million was converted into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20231130__20231130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zPNZnfjyYOCj"&gt;674,637
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our Common Stock (after giving effect
to our &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20231211__20231211__dei--LegalEntityAxis__custom--BayShoreTrustMember_zsC3cVibxcU3"&gt;1-for-2.05
reverse stock split&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;that occurred on December
11, 2023) at a conversion rate of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_zS9IsnJOQtLi"&gt;2.05
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share resulting in a loss on the conversion
of debt of $&lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BayShoreTrustMember_z9oSX84JgDY3"&gt;3.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, with $&lt;span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zKpSLqNLqnmk"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million outstanding as of December 31, 2023.
As of December 31, 2024, the line of credit has been paid in full and is no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Starwood
Trust Line of Credit and Stock Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 24, 2024 the Company entered into an unsecured Promissory Note and Loan Agreement (&#x201c;the Starwood Note&#x201d;) with
the Starwood Trust, a separate related party trust established by the Company&#x2019;s founder, Jonnie R. Williams, Sr. who is the
sole owner of Bay Shore Trust as well as our largest shareholder, and under which various of his family members are beneficiaries.
Under the Starwood Note, the Company has the right to borrow up to an aggregate of $&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzEETtdviqa2" title="Unused line of credit"&gt;5&lt;/span&gt;&#160;million
from the Starwood Trust at any time up until September 24, 2026, the second anniversary of the note. The Company&#x2019;s right to
borrow funds under the Starwood Note is subject to the absence of a material adverse change in its assets, operations, or prospects
The Starwood Note contains default provisions in which in the event of the Company misses payment, makes false representations,
fails to comply in any material respect to covenants, files for bankruptcy, or experiences a material adverse change in is assets or operations
than the Company is considered in default and the entire unpaid principal and accrued interest is due immediately. The Starwood Note, together with accrued interest, is to become due and payable on the second anniversary of the issuance of the
note, provides for prepayment at any time without penalty, and accrues simple interest at a rate equal&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240924__dei--LegalEntityAxis__custom--StarwoodTrustMember_zzXwWsW9LIMj" title="Accrue interest at a rate"&gt;7&lt;/span&gt;%
per annum. As of December 31, 2024, the Company has not borrowed any amounts under the Starwood Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
on December 9, 2024, Starwood Trust entered into a stock purchase agreement with the Company to purchase &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zBZtnPjOZrTk" title="Purchase of shares"&gt;142,857&lt;/span&gt; shares of unregistered
common stock at $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z4w9gMo6zopf" title="Share price"&gt;7&lt;/span&gt; a share for a total of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zDQzQpaPItV9" title="Proceeds from issuance of common stock"&gt;1.0&lt;/span&gt; million in proceeds to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
agreement - See Note 3.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Related
Party Travel Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2023 the Company entered into an Agreement For Shared Lease Costs (the &#x201c;Shared Agreement&#x201d;) with MIRALOGX, LLC, a
related party under which we have agreed to pay our pro rata share of the operating usage costs owing by MIRALOGX under an aircraft lease
agreement between MIRALOGX and Supera Aviation I LLC (&#x201c;Supera Aviation&#x201d;) based on our usage of the leased aircraft each month.
No amounts are payable by the Company under this agreement unless and to the extent the Company chooses to utilize the leased aircraft,
and the Company may discontinue the use of the aircraft and terminate this agreement at any time. Supera Aviation is a company owned
by Starwood Trust, a trust established by Mr. Williams, the Company&#x2019;s founder and largest shareholder. For the year ended December 31, 2024 and December 31, 2023, the Company incurred
$&lt;span id="xdx_902_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zq75LHaJznV2" title="Travel-related expenses"&gt;0.37&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--TravelAndEntertainmentExpense_pn4n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHklkWLzuRij" title="Travel-related expenses"&gt;1.77&lt;/span&gt; million, respectively, in expenses under the aircraft lease agreement. The aircraft lease was terminated in April
2024 and no other costs will be incurred under this agreement (See Note 5 Variable lease costs).&lt;/span&gt; &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Related
Party Rental Agreement&lt;/b&gt;&lt;i&gt;-&lt;/i&gt; see Note 5 for Variable lease costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-4"
      id="Fact000482"
      unitRef="USD">130000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000485"
      unitRef="USD">1700000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Shares">837841</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-12-112023-12-11_custom_MiralogxLLCMember"
      id="Fact000487">1-for-2.05
reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-31_custom_MiralogxLLCMember"
      decimals="INF"
      id="Fact000488"
      unitRef="USDPShares">2.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000489"
      unitRef="USD">4100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000490"
      unitRef="USD">500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000491"
      unitRef="USD">100000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000492"
      unitRef="USD">500000</us-gaap:OtherLiabilities>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000493"
      unitRef="USD">100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="-6"
      id="Fact000495"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000497"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000499"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-01-012023-12-31_custom_BayShoreTrustMember"
      decimals="-5"
      id="Fact000500"
      unitRef="USD">1500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember"
      decimals="-5"
      id="Fact000501"
      unitRef="USD">1400000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-11-302023-11-30_us-gaap_CommonStockMember_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000502"
      unitRef="Shares">674637</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-12-112023-12-11_custom_BayShoreTrustMember"
      id="Fact000503">1-for-2.05
reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000504"
      unitRef="USDPShares">2.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_BayShoreTrustMember"
      decimals="-5"
      id="Fact000505"
      unitRef="USD">3300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_BayShoreTrustMember"
      decimals="-5"
      id="Fact000506"
      unitRef="USD">100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-09-24_custom_StarwoodTrustMember"
      decimals="-6"
      id="Fact000508"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-09-24_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000510"
      unitRef="Pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000512"
      unitRef="Shares">142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000514"
      unitRef="USDPShares">7</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="-5"
      id="Fact000516"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="-4"
      id="Fact000518"
      unitRef="USD">370000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="-4"
      id="Fact000520"
      unitRef="USD">1770000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000522">&lt;p id="xdx_806_eus-gaap--LesseeOperatingLeasesTextBlock_zO8tcZhDNcE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5. &lt;span id="xdx_826_z4EN3TdXV7W7"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease
began in November 2022 and expired in April 2024. The lease was not renewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
align with the accounting and administrative staff detailed below, the Company moved all remaining corporate
activities in April 2024 to the shared space in Tampa, Florida referenced below within variable lease costs. In September 2024, the
Company decided to no longer utilize the shared space and moved to a virtual office model and does not have a physical office space
as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Variable
lease costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Variable
lease costs primarily include utilities, property taxes, and other operating costs that are passed on from the lessor for the former
corporate headquarters in Baltimore, Maryland. Variable lease costs related to the usage of the MIRALOGX airplane include usage expenses,
which includes pilot expenses, jet fuel and general flight expenses that totaled to $&lt;span id="xdx_90A_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__dei--LegalEntityAxis__custom--MiralogxLLCMember_z1yU3aMLGIkc" title="Variable lease, cost"&gt;0.32&lt;/span&gt; million in 2024 and $&lt;span id="xdx_902_eus-gaap--VariableLeaseCost_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--MiralogxLLCMember_zdvd3AT3aK28" title="Variable lease, cost"&gt;1.3&lt;/span&gt; million in 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
August 1, 2023, the Company&#x2019;s accounting and administrative staff began sharing office space with a related party in Tampa, Florida.
During the year ended December 31, 2024, this variable least cost related to the Tampa, Florida space totaled $&lt;span id="xdx_90E_eus-gaap--VariableLeaseCost_pn4n6_c20240101__20241231__srt--StatementGeographicalAxis__custom--TampaFloridaMember_zccJvG7iXKJj" title="Variable lease, cost"&gt;0.02&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_ziOomy0j7Hm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zGf0E7G4Oul5" style="display: none"&gt;Schedule
of components of lease expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zwrYw4eRiC66" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zEvQZoq869vl" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zCwbOHzFsha2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,667&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zo8jRWbaGwHg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Variable
    lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336,656&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,778,884&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_z9C4YbTNQNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;392,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,793,753&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zvyZhb8zymTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31_custom_MiralogxLLCMember"
      decimals="-4"
      id="Fact000524"
      unitRef="USD">320000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31_custom_MiralogxLLCMember"
      decimals="-5"
      id="Fact000526"
      unitRef="USD">1300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31_custom_TampaFloridaMember"
      decimals="-4"
      id="Fact000528"
      unitRef="USD">20000.00</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000530">&lt;p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_ziOomy0j7Hm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zGf0E7G4Oul5" style="display: none"&gt;Schedule
of components of lease expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zwrYw4eRiC66" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zEvQZoq869vl" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzhnC_zCwbOHzFsha2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,667&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--VariableLeaseCost_maLCzhnC_zo8jRWbaGwHg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Variable
    lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336,656&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,778,884&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_mtLCzhnC_z9C4YbTNQNW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;392,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,793,753&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000532"
      unitRef="USD">55667</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">14869</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">336656</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">1778884</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">392323</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">1793753</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000541">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFb4r2EpOdTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6. &lt;span id="xdx_827_zOhRK89b3Yb"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Capital
stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the authority to issue &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20241231_zPIRkHhhA5O6" title="Issue of shares of capital stock"&gt;400,000,000&lt;/span&gt; shares of capital stock, consisting of &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zQXKDQtbJBZ" title="Common stock, shares authorized"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zirdADbPCoA2" title="Common stock, shares authorized"&gt;300,000,000&lt;/span&gt;&lt;/span&gt; shares of Common Stock and &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zfR5eAAbGPr9" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zvUY1Hc0Qrfi" title="Preferred stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt;
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
December 11, 2023, the Company completed a reverse stock split of its outstanding common stock upon the filing of the Company&#x2019;s
Second Amended and Restated Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued
in connection with the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded
up to the nearest whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise price of such warrants,
have been adjusted to reflect the reverse stock split. Unless otherwise noted, all share and per share information in this Report retrospectively
reflects the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;During the year ended December 31, 2023, the Company conducted a private
placement offering in which &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMQYtLCIsPW3" title="Number of shares issued"&gt;268,025&lt;/span&gt; shares were issued for a total of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIuPelYnM3R4" title="Net proceeds"&gt;0.9&lt;/span&gt; million in net proceeds to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2024, the Company closed its initial public offering consisting of&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFyphSDXvbb2" title="Initial public offering shares"&gt;1,000,000&lt;/span&gt;&#160;shares at a price of $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrVnWyR6tVKa" title="Initial public offering shares"&gt;7.00&lt;/span&gt;&#160;per
share for approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGLDcxtrJlfh" title="Gross proceeds"&gt;7.0&lt;/span&gt;&#160;million in gross proceeds. After deducting the underwriting commission and other offering expenses
totaling $&lt;span id="xdx_90E_eus-gaap--OtherUnderwritingExpense_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaGcOftAxbpl" title="Underwriting commission and other offering expenses"&gt;1.2&lt;/span&gt;&#160;million, the net proceeds to the Company were $&lt;span id="xdx_903_ecustom--ProceedsFromInitialPublicOfferingNetProceeds_pn5n6_c20240213__20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEwddJ2ePlxf" title="Initial public offering net proceeds"&gt;5.8&lt;/span&gt;&#160;million (the &#x201c;IPO&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2024, Starwood Trust, a related party, entered into a stock purchase agreement with the Company to purchase &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_zLRrNQWydoo6"&gt;142,857
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of unregistered common stock at $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_ziwOXpZKHAW8"&gt;7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a share for a total of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241209__20241209__dei--LegalEntityAxis__custom--StarwoodTrustMember_z71nKKdnMyQa"&gt;1.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in proceeds to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_c20231231_pp0p0" title="Deferred offering costs"&gt;303,281&lt;/span&gt; and offering costs of $&lt;span id="xdx_90D_ecustom--OfferingCosts_iI_pp0p0_c20241231_zYFt6IiE7Z9j" title="Offering costs"&gt;863,744&lt;/span&gt; incurred in 2024 were charged against additional paid
in capital.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with various transactions and the IPO summarized below, the Company issue stock warrants. Warrant activity for the year ended
December 31, 2024 is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkcpQeEIDEme" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zeRTAB7YUAc2"&gt;Schedule
of warrant activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt; Average&lt;br/&gt;
 Exercise&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Remaining&lt;br/&gt;
 Contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Aggregate&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt; Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Term (Years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Intrinsic Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; padding-bottom: 1pt"&gt;Balance Outstanding as January 1, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrQFLfy8V1h" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0576"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmvO2LtO8dk6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0578"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;sup&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDgGQS7xn89" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmc8OFiFOIf" style="text-align: right" title="Number of Warrants, Granted"&gt;2,774,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3vuNhLnssra" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;4.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zN1bwplKmhrd" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;sup id="xdx_F28_zYDCwQPy7Fri"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance Outstanding as December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvOEQEB9KK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;2,774,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3ASIi8k3T8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;4.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zfhLVu5dRok2" title="Weighted Average Remaining Contractual Term (Years)"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F2F_z3fvAQq91oy3"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzNlIHiuPI" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0594"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDmHdqODkvl" style="text-align: right" title="Number of Warrants, Granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS5iXwbEsrG" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYFQe0cyo58d" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xJBKBuDLUd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOIcRigM2Kah" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance Outstanding as December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVl15ciPfzB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlRY6O7he8Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;4.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zJFlCq5eWEve" title="Weighted Average Remaining Contractual Term (Years)"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F2C_zVbcXrLIUZfk"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhVghFxQ1jYb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztNklRWWLJ86" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSff51VEGAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;4.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zGRodkzsqN91" title="Weighted Average Remaining Contractual Term (Years), Exercisable"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F22_zbnDra7E6ho5"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH3HnfC50CQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F09_zCpFSYfkBMLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z2p4qKvqXJFg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants herein consist of various contractual terms. The warrants herein consist of &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zeu5UwoVUKck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,439,025
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued to Bay Shore
Trust that have a remaining contractual term of &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_z2mJjlntxaqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.5
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years as of December 31, 2023,
and &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zD8zlhPuV63h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335,032
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued to investors
associated with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
on these warrants&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F08_zbCtIAN0zB32" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zLGI4xf8sBy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The warrants herein
consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued"&gt;2,429,025&lt;/span&gt; warrants issued to Bay Shore Trust that have a remaining
contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term"&gt;3.5&lt;/span&gt; years as of December 31, 2024, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued"&gt;335,032&lt;/span&gt; warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued"&gt;50,000&lt;/span&gt; warrants issued to underwriters as part of the IPO with a remaining
contractual life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term"&gt;3.2&lt;/span&gt; years. See disclosures below for more information on these warrants&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zr08WOXblbtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Private
placement Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase
up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zryETalShkr7" title="Purchase of common stock"&gt;268,025&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFeyvmgLQBy8" title="Exercise price"&gt;15.42&lt;/span&gt; per share. The Company also issued to the placement agent a Common
Stock warrant the right to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zSA8SWVmB5C8" title="Purchase of common stock"&gt;67,007&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_z7yjSJuIgty8" title="Exercise price"&gt;3.73&lt;/span&gt; per share. Both issuances of warrants
are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an IND filing is
made with the FDA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Bay
Shore Trust Warrants (Note 4)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration of the line of credit provided by the Bay Shore Trust, the Company issued to the Bay Shore Trust a common stock
purchase warrant on June 15, 2023 giving the Bay Shore Trust the right to purchase up to&#160;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zBqQLORtid59" title="Shares of common stock"&gt;2,439,025&lt;/span&gt;&#160;shares
of common stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zVXaPnYsV1me" title="Exercise price"&gt;3.73&lt;/span&gt;&#160;per
share. This warrant will expire &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zihPsqtsAPF5" title="Exercise price"&gt;five
years&lt;/span&gt; after the date of grant.. The fair value of the warrants were estimated on the grant date using the Black-Scholes
valuation model and level 3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the
risk-free interest rate, which resulted in $&lt;span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20230615__dei--LegalEntityAxis__custom--BayShoreTrustMember_zcq3pca5Ye2c" title="Deferred financing costs"&gt;5.95&lt;/span&gt;&#160;million
of deferred financing costs. This cost was recorded as deferred financing costs and additional paid in capital on the accompanying
balance sheet and is amortized straight-line over the term of the line of credit (which is 24 months). Associated amortization of
deferred finance costs is recorded to interest expense on the income statement of operations. The line of credit expired upon the
IPO occurring in February 2024, and as such the remaining deferred financing costs associated with the warrant was fully amortized
to interest expense.  As of December 31, 2024, the warrant is fully amortized. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 22, 2024, Bay Shore Trust transferred &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0ujnrZcbGP3" title="Shares of common stock"&gt;100,000&lt;/span&gt; warrants to an unaffiliated party as part of a gift transfer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2024,&#160;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zqU6tShKMJM" title="Shares of common stock"&gt;10,000&lt;/span&gt; Common Stock warrants were exercised at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_z0xgQgSNENc1" title="Exercise price"&gt;3.73&lt;/span&gt; per share and the Company issued&#160;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zT6h0BGplEYa" title="Issuance of common stock"&gt;10,000&lt;/span&gt;&#160;shares
of Common Stock upon such exercise in exchange for $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20241201__20241231__dei--LegalEntityAxis__custom--BayShoreTrustMember_zgOxY4g8OnH" title="Issuance of common stock, value"&gt;37,300&lt;/span&gt; delivered to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYEdrUFFkl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value warrants during the year ended December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zNQlbODRAkQe"&gt;Schedule of key assumptions used to value warrants&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoRls3dblQQc" title="Warrant measurement input"&gt;78.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdUXXGqpSvv1" title="Warrant measurement input"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zvd22Xkgpc62" title="Warrant measurement input"&gt;1.190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zrVujNCbtm37" title="Expected term in years"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlY7EnTuoCnb" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zFt9jbgoXUx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Underwriter
warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the IPO in February 2024, the Company issued&#160;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4SnU6Fj1PPa" title="Warrants to purchase common stock"&gt;50,000&lt;/span&gt;&#160;warrants
to purchase Common Stock to the IPO underwriter (or its designees) at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240213__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zexPGknPjwB9" title="Exercise price"&gt;7.00&lt;/span&gt;&#160;which
are exercisable immediately and  expire in the four-and-a-half-year period commencing six months after the commencement of
sales in the IPO. The warrants provide for registration
rights (including a one-time demand registration right and piggyback registration rights that expire 5 years from the commencement
of sales of the offering) and customary anti-dilution provisions as permitted under FINRA Rule 5110(g)(8). The fair value of the warrants were estimated on the grant date using the Black-Scholes valuation model and level
3 inputs based on assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, which resulted
in $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUrq87iaGtr1" title="Equity issuance cost"&gt;0.2&lt;/span&gt; million of equity issuance costs. The warrants were
considered equity issuance costs and therefore there was no financial statement impact during the year ended December 31,
2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zN6ZMsXXafga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value underwriter warrants in February 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zFnVrF34jyda"&gt;Schedule
of key assumptions used to value warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZSWEQ3GIced" title="Warrant measurement input"&gt;84.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z00A4ZY80Rnb" title="Warrant measurement input"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zYfMJ61WOx1l" title="Warrant measurement input"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuyxtAiURn4a" title="Expected term in years"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zBmlNDvopdSk" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zzYUDaoW94bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2023
Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2023 Omnibus Incentive Plan, (&#x201c;2023 Omnibus Plan&#x201d;).
The 2023 Omnibus Plan authorizes the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code,
to the Company&#x2019;s employees and any of its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory
stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company&#x2019;s
employees, directors, and consultants and any of its future subsidiary corporations&#x2019; employees and consultants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Omnibus Plan provides that &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusIncentivePlanMember_zl2biEgEf051" title="Common stock are reserved for issuance"&gt;6,500,000&lt;/span&gt; shares of the Company&#x2019;s Common Stock are reserved for issuance under the 2023
Omnibus Plan, all of which may be issued pursuant to the exercise of incentive stock options.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-based
compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected
volatility, expected dividends, expected term, and the risk-free interest rate. Expected price volatility is based on the historical
volatilities of a peer group as the Company does not have a multi-year trading history for its shares. Industry peers consist of several
public companies in the biotech industry similar to the Company in size, stage of life cycle and product indications. The Company intends
to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information
regarding the volatility of the Company&#x2019;s own stock price becomes available, or unless circumstances change such that the identified
companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would
be utilized in the calculation.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of
the vesting term plus contract term. The risk-free rate is based on the 5-year U.S. Treasury yield curve in effect at the time of grant.
The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, a total of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zigEyQcetU3a" title="Number of options, outstanding"&gt;2,370,170&lt;/span&gt;
options to purchase Common Stock, with an aggregate fair market value of approximately $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zX5HFAiAoauj" title="Share based compensation fair market value"&gt;9.1&lt;/span&gt;
million with a weighted average fair value per share of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_ztwf8n7htUtj" title="Weighted average fair value per share"&gt;3.83&lt;/span&gt; were granted to the members of the Company&#x2019;s Board of Directors,
executive officers, employees and consultants of the Company. The options have an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zG875OTjM3Nc" title="Weighted average exercise price, outstanding"&gt;5.02&lt;/span&gt;,
a term of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember_zsCjnkPio6z5" title="Share based compensation term of years"&gt;10&lt;/span&gt;
years from the grant date, and vest over various terms ranging from immediate vesting upon grant to the second anniversary of the
grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuXwA47tIZf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is option activity during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zA7c3o28gNUh"&gt;Schedule
of option activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise
                                            price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per
                                            share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;intrinsic
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zg4kJyNCzu23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zNQgxC8r07mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zKOJTfTGOoik" title="Outstanding aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231_zbZUaKJE1W7d" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,370,170&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zRbzBnnWtpS4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zehM2nvOhXgf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeitures"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zqbtoX3hMtjc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeitures"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zMvJeG98gjha" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,352,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zsdknw8ThdZi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zlT0m5Mjcd83" title="Outstanding aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z21L7Ivre32h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, options exercisable totaled &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zYmhPm05Yjrb" title="Number of options, exercisable"&gt;2,352,670&lt;/span&gt;. The Company recognized approximately $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_zCTuHnz2R2Dg" title="Stock-based compensation"&gt;6.9&lt;/span&gt; million in stock-based compensation
in 2024. There are approximately $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_z0V0pziN2gnc" title="Unrecognized compensation costs"&gt;2.2&lt;/span&gt; million of unrecognized compensation cost
related to non-vested share-based compensation awards, which will be expensed through 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_zWaUpSlV4fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zHm6i420hSc" style="display: none"&gt;Schedule of non vested share based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    Intrinsic Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zk8VeZrBbKKd"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_z1GdTVbN5gVb" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Options outstanding, outstanding number of options, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,352,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zcif95o0vXc9" title="Weighted Average Remaining Contractual Life (Years)"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zA06CWkEzgMf" title="Weighted Average Exercise Price"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zW3b38D0bwIl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,046,335&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zJhWQvF8tu7" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Aggregate Intrinsic Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zpVC2G2WSYrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSoiUYsJyBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zqCjHrG9Q6rc"&gt;&#160;Schedule
of key assumptions used to value stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z6JahreGSgk1" title="Expected volatility, minimum"&gt;88.8&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_z8EJUkRgPZe6" title="Expected volatility, maximum"&gt;90.4&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zE7RrRHL51Ii" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_z3b8J3NbvAIg" title="Exercise price"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4TXimg70jz9" title="Expected term"&gt;5.1&lt;/span&gt;
                                            to &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z2KJLt1HfmH8" title="Expected term"&gt;5.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zk269eBnw8P4" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zvLeL9dCE1y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Telomir
                                            Pharmaceuticals, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;notes
to the financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;DECEMBER
31, 2024 and  2023&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000543"
      unitRef="Shares">400000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000551"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">268025</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact000555"
      unitRef="USD">900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-13_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000559"
      unitRef="USDPShares">7.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000561"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:OtherUnderwritingExpense
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000563"
      unitRef="USD">1200000</us-gaap:OtherUnderwritingExpense>
    <TELO:ProceedsFromInitialPublicOfferingNetProceeds
      contextRef="From2024-02-132024-02-13_us-gaap_IPOMember"
      decimals="-5"
      id="Fact000565"
      unitRef="USD">5800000</TELO:ProceedsFromInitialPublicOfferingNetProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000566"
      unitRef="Shares">142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-09_custom_StarwoodTrustMember"
      decimals="INF"
      id="Fact000567"
      unitRef="USDPShares">7</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-092024-12-09_custom_StarwoodTrustMember"
      decimals="-5"
      id="Fact000568"
      unitRef="USD">1000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">303281</us-gaap:DeferredOfferingCosts>
    <TELO:OfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">863744</TELO:OfferingCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000574">&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkcpQeEIDEme" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zeRTAB7YUAc2"&gt;Schedule
of warrant activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt; Average&lt;br/&gt;
 Exercise&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Remaining&lt;br/&gt;
 Contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Aggregate&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt; Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Term (Years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Intrinsic Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; padding-bottom: 1pt"&gt;Balance Outstanding as January 1, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRrQFLfy8V1h" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0576"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmvO2LtO8dk6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0578"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;sup&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDgGQS7xn89" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmc8OFiFOIf" style="text-align: right" title="Number of Warrants, Granted"&gt;2,774,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3vuNhLnssra" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;4.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zN1bwplKmhrd" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;sup id="xdx_F28_zYDCwQPy7Fri"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance Outstanding as December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFvOEQEB9KK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;2,774,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3ASIi8k3T8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;4.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zfhLVu5dRok2" title="Weighted Average Remaining Contractual Term (Years)"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F2F_z3fvAQq91oy3"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzNlIHiuPI" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0594"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFDmHdqODkvl" style="text-align: right" title="Number of Warrants, Granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS5iXwbEsrG" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYFQe0cyo58d" title="Weighted Average Remaining Contractual Term (Years), Granted"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8xJBKBuDLUd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOIcRigM2Kah" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance Outstanding as December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVl15ciPfzB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlRY6O7he8Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Balance"&gt;4.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zJFlCq5eWEve" title="Weighted Average Remaining Contractual Term (Years)"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F2C_zVbcXrLIUZfk"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhVghFxQ1jYb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztNklRWWLJ86" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Balance"&gt;2,814,057&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSff51VEGAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;4.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDIp_zGRodkzsqN91" title="Weighted Average Remaining Contractual Term (Years), Exercisable"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;sup id="xdx_F22_zbnDra7E6ho5"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH3HnfC50CQ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F09_zCpFSYfkBMLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z2p4qKvqXJFg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants herein consist of various contractual terms. The warrants herein consist of &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_zeu5UwoVUKck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,439,025
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued to Bay Shore
Trust that have a remaining contractual term of &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember_z2mJjlntxaqc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.5
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years as of December 31, 2023,
and &lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zD8zlhPuV63h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335,032
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants issued to investors
associated with the 2023 Private Placement that currently have an indeterminable contractual term. See disclosures below for more information
on these warrants&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F08_zbCtIAN0zB32" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_zLGI4xf8sBy7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The warrants herein
consist of various contractual terms. The warrants herein consist of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26" title="Warrants issued"&gt;2,429,025&lt;/span&gt; warrants issued to Bay Shore Trust that have a remaining
contractual term of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta" title="Warrants remaining contractual term"&gt;3.5&lt;/span&gt; years as of December 31, 2024, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4" title="Warrants issued"&gt;335,032&lt;/span&gt; warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza" title="Warrants issued"&gt;50,000&lt;/span&gt; warrants issued to underwriters as part of the IPO with a remaining
contractual life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl" title="Warrants remaining contractual term"&gt;3.2&lt;/span&gt; years. See disclosures below for more information on these warrants&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062"
      decimals="INF"
      id="Fact000582"
      unitRef="Shares">2774057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062"
      decimals="INF"
      id="Fact000584"
      unitRef="USDPShares">4.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember11698062"
      id="Fact000586">P5Y</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000588"
      unitRef="Shares">2774057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000590"
      unitRef="USDPShares">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      id="Fact000592">P4Y6M</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      decimals="INF"
      id="Fact000596"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      decimals="INF"
      id="Fact000598"
      unitRef="USDPShares">7.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      id="Fact000600">P3Y2M12D</TELO:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">-10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      decimals="INF"
      id="Fact000604"
      unitRef="USDPShares">3.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Shares">2814057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000608"
      unitRef="USDPShares">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      id="Fact000610">P3Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">2814057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000616"
      unitRef="USDPShares">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      id="Fact000618">P3Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_BayShoreTrustWarrantsMember"
      id="Fact000623">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">335032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">2429025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_BayShoreTrustWarrantsMember_us-gaap_WarrantMember"
      id="Fact000629">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePrivatePlacementWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">335032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_UnderwriterWarrantMember"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_UnderwriterWarrantMember"
      id="Fact000635">P3Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">268025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000639"
      unitRef="USDPShares">15.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">67007</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000643"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">2439025</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000647"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      id="Fact000649">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2023-06-15_custom_BayShoreTrustMember"
      decimals="-4"
      id="Fact000651"
      unitRef="USD">5950000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-22_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000657"
      unitRef="USDPShares">3.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000659"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-12-012024-12-31_custom_BayShoreTrustMember"
      decimals="INF"
      id="Fact000661"
      unitRef="USD">37300</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11697890"
      id="Fact000663">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmYEdrUFFkl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value warrants during the year ended December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zNQlbODRAkQe"&gt;Schedule of key assumptions used to value warrants&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoRls3dblQQc" title="Warrant measurement input"&gt;78.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdUXXGqpSvv1" title="Warrant measurement input"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zvd22Xkgpc62" title="Warrant measurement input"&gt;1.190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zrVujNCbtm37" title="Expected term in years"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlY7EnTuoCnb" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Pure">78.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Pure">3.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Pure">1.190</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000671">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-13_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000677"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-02-13_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000679"
      unitRef="USD">200000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_UnderwriterWarrantMember"
      id="Fact000681">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember_zN6ZMsXXafga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value underwriter warrants in February 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zFnVrF34jyda"&gt;Schedule
of key assumptions used to value warrants&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Expected price volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zZSWEQ3GIced" title="Warrant measurement input"&gt;84.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z00A4ZY80Rnb" title="Warrant measurement input"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Market Value of underlying Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairMarketValueUnderlyingCommonStockMember_zYfMJ61WOx1l" title="Warrant measurement input"&gt;7.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuyxtAiURn4a" title="Expected term in years"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240229__us-gaap--StatementEquityComponentsAxis__custom--UnderwriterWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zBmlNDvopdSk" title="Warrant measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000683"
      unitRef="Pure">84.78</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Pure">4.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_custom_MeasurementInputFairMarketValueUnderlyingCommonStockMember"
      decimals="INF"
      id="Fact000687"
      unitRef="Pure">7.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-02-29_custom_UnderwriterWarrantMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000689">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeOmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">6500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember"
      decimals="INF"
      id="Fact000695"
      unitRef="Shares">2370170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember"
      decimals="-5"
      id="Fact000697"
      unitRef="USD">9100000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsExecutiveOfficersEmployeesAndConsultantsMember"
      id="Fact000703">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000705">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuXwA47tIZf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is option activity during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zA7c3o28gNUh"&gt;Schedule
of option activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise
                                            price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per
                                            share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;intrinsic
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zg4kJyNCzu23" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zNQgxC8r07mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zKOJTfTGOoik" title="Outstanding aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231_zbZUaKJE1W7d" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,370,170&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zRbzBnnWtpS4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zehM2nvOhXgf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeitures"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zqbtoX3hMtjc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeitures"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zMvJeG98gjha" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,352,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_zsdknw8ThdZi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zlT0m5Mjcd83" title="Outstanding aggregate intrinsic value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000713"
      unitRef="Shares">2370170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000715"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000719"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">2352670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">2352670</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000729"
      unitRef="USD">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000731"
      unitRef="USD">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <TELO:ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000733">&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock_zWaUpSlV4fZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zHm6i420hSc" style="display: none"&gt;Schedule of non vested share based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    Intrinsic Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zk8VeZrBbKKd"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_z1GdTVbN5gVb" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Options outstanding, outstanding number of options, shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,352,670&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zcif95o0vXc9" title="Weighted Average Remaining Contractual Life (Years)"&gt;9.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zA06CWkEzgMf" title="Weighted Average Exercise Price"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zW3b38D0bwIl" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,046,335&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--StockOptionsOneMember_zJhWQvF8tu7" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Aggregate Intrinsic Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TELO:ScheduleOfShareBasedPaymentAwardStockOptionTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_StockOptionsOneMember"
      decimals="INF"
      id="Fact000734"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_StockOptionsOneMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">2352670</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_StockOptionsOneMember"
      id="Fact000738">P9Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2024-12-31_custom_StockOptionsOneMember"
      decimals="INF"
      id="Fact000740"
      unitRef="USDPShares">5.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_StockOptionsOneMember"
      decimals="INF"
      id="Fact000742"
      unitRef="Shares">1046335</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSoiUYsJyBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Key
assumptions used to value stock options during the year ended December 31, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zqCjHrG9Q6rc"&gt;&#160;Schedule
of key assumptions used to value stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_z6JahreGSgk1" title="Expected volatility, minimum"&gt;88.8&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_z8EJUkRgPZe6" title="Expected volatility, maximum"&gt;90.4&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zE7RrRHL51Ii" title="Risk-free interest rate"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_z3b8J3NbvAIg" title="Exercise price"&gt;5.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z4TXimg70jz9" title="Expected term"&gt;5.1&lt;/span&gt;
                                            to &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z2KJLt1HfmH8" title="Expected term"&gt;5.62&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240101__20241231_zk269eBnw8P4" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000748"
      unitRef="Pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000750"
      unitRef="Pure">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000752"
      unitRef="Pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000754"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000756">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000758">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000762">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zU2lOKCZV2lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82E_zRcPGG92Csmb"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zAZQLuKtNXj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of the Company&#x2019;s net deferred tax assets are as follows as of December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zI7bhzV8sYKc" style="display: none"&gt;Schedule of net
deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zMXOCiSazI9b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_z6uRjoUKEGx2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zxkEFecouGw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,427,679&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;288,379&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zSKsopwULW31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Section 174 Qualified Research
    Expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;995,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;526,248&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_zoEnwvDFjWDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,680,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z82B88yW1pFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D Credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,278&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGz55t_zbh2V40LzJM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,724&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_zJfhrPJ5mxMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred tax assets, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_z6E9z0XRz0Xc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_zxl54Vaif8g6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_zPlDZI0C6c86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zC7Xg1Lwaqqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
in 2022, in accordance with Internal Revenue Code Section 174, Qualified Research Expenditures are capitalized for tax purposes and amortized
over a period of five years. Accordingly, for income tax purposes, and as of December 31, 2024 and December 31, 2023, the Company has
recorded a deferred tax asset totaling approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20241231_zfBFohsGHMGf" title="Deferred tax asset"&gt;1.0&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pn5n6_c20231231_zMcmEnox3OZ3" title="Deferred tax asset"&gt;0.5&lt;/span&gt; million, respectively, related to the timing difference between
GAAP and Tax recognition of these expenditures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZu7RjI61vG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the provision for income taxes consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zxki7MCncC9l" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zlPsrak2TOx7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zzjwNL6Q5od5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20241231_zy8iTcXVRNai" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20231231_zTau0HsiBJwl" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20241231_zK8msu1HI4ub" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20231231_zorsiAR1iVZk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20241231_zCPnOxDurBk8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20231231_zyORfGHcChAh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0809"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_z2xwL8fB8NH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z3AQanzghgOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740 requires that a deferred tax amount be reduced by a valuation allowance if, based on the weight of available evidence it is
more likely than not (a likelihood of more than 50%) that some portion or all of the deferred tax assets will not be realized. The valuation
allowance should be sufficient to reduce the deferred tax asset to the amount that is more likely than not to be realized. The Company
has recorded a full valuation allowance against its deferred tax assets generated by net operating loss carryforwards as it has determined
that such amounts may not be recognizable, given the historical losses of the Company to date. As of December 31, 2024, the Company has
a cumulative federal net operating loss carryforward of approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zsiIhHarBsd4" title="Federal net operating loss carryforward"&gt;17.4&lt;/span&gt; million. The net operating loss carryforwards have no expiry
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB2ktK6SmHHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory U.S. federal income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zIu4OOrTJO61"&gt;Schedule
of reconciliation of effective income tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zlosmuMQ4Ca4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin: 0"&gt;Year Ended December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_iN_di_zxUTYeywogbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Book Loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16,532,716&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzNIc_zLHR4QTi3GZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Tax Benefit at U.S. Federal Statutory Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,471,870&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z9RgtXrnfnfl" style="text-align: right" title="Tax Benefit at U.S. Federal Statutory Rate, Percentage"&gt;21.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzNIc_zvsYoTuu9WEa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;State Taxes, Net of Federal Benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(718,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20240101__20241231_zaZKbHJOThq8" style="text-align: right" title="State Taxes, Net of Federal Benefit, Percentage"&gt;4.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzNIc_ztdBygndKvQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,336,132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20240101__20241231_zILioQKfL3Ah" style="text-align: right" title="Change in Valuation Allowance, Percentage"&gt;(38.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationPermanentItems_maITEBzNIc_zD05HJK1IL6e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,182,803&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_uPure_maGOLD_c20240101__20241231_zl7QlZ1ca42i" style="text-align: right" title="Permanent Items, Percentage"&gt;13.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzNIc_zwWpS0uiJEZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt"&gt;State Rate Change&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z6ACJYfNZ1j2" style="border-bottom: Black 1pt solid; text-align: right" title="State Rate Change, Percentage"&gt;(0.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net actual effective rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxExpenseBenefit_iT_dxL_mtITEBzNIc_c20240101__20241231_zAuVQVLODyc8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20240101__20241231_zRn0InWgXbVd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net actual effective rate, Percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z94oue4GCrw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000764">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zAZQLuKtNXj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of the Company&#x2019;s net deferred tax assets are as follows as of December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zI7bhzV8sYKc" style="display: none"&gt;Schedule of net
deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zMXOCiSazI9b" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_z6uRjoUKEGx2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGz55t_zxkEFecouGw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,427,679&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;288,379&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGz55t_zSKsopwULW31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Section 174 Qualified Research
    Expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;995,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;526,248&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGz55t_zoEnwvDFjWDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,680,019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGz55t_z82B88yW1pFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D Credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,278&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGz55t_zbh2V40LzJM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,724&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGz55t_maDTANzg2r_zJfhrPJ5mxMe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred tax assets, gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzg2r_z6E9z0XRz0Xc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzg2r_zxl54Vaif8g6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_zPlDZI0C6c86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">4427679</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000767"
      unitRef="USD">288379</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000769"
      unitRef="USD">995500</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">526248</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">1680019</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000775"
      unitRef="USD">51278</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">28007</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000779"
      unitRef="USD">31724</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000781"
      unitRef="USD">7182483</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">846351</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">7182483</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000785"
      unitRef="USD">846351</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000793"
      unitRef="USD">1000000.0</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000795"
      unitRef="USD">500000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000797">&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZu7RjI61vG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the provision for income taxes consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zxki7MCncC9l" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zlPsrak2TOx7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zzjwNL6Q5od5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20241231_zy8iTcXVRNai" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DeferredTaxAssetsGross_iNTI_di_maDTANzFKv_c20231231_zTau0HsiBJwl" style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Deferred benefit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20241231_zK8msu1HI4ub" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,182,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_msDTANzFKv_c20231231_zorsiAR1iVZk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;846,351&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20241231_zCPnOxDurBk8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsNet_iNTI_di_mtDTANzFKv_c20231231_zyORfGHcChAh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0809"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_z2xwL8fB8NH5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">7182483</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000801"
      unitRef="USD">846351</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">7182483</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">846351</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000814"
      unitRef="USD">17400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000816">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB2ktK6SmHHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory U.S. federal income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zIu4OOrTJO61"&gt;Schedule
of reconciliation of effective income tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zlosmuMQ4Ca4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin: 0"&gt;Year Ended December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_iN_di_zxUTYeywogbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Book Loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16,532,716&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzNIc_zLHR4QTi3GZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Tax Benefit at U.S. Federal Statutory Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,471,870&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z9RgtXrnfnfl" style="text-align: right" title="Tax Benefit at U.S. Federal Statutory Rate, Percentage"&gt;21.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzNIc_zvsYoTuu9WEa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;State Taxes, Net of Federal Benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(718,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maGOLD_c20240101__20241231_zaZKbHJOThq8" style="text-align: right" title="State Taxes, Net of Federal Benefit, Percentage"&gt;4.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzNIc_ztdBygndKvQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,336,132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maGOLD_c20240101__20241231_zILioQKfL3Ah" style="text-align: right" title="Change in Valuation Allowance, Percentage"&gt;(38.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--IncomeTaxRateReconciliationPermanentItems_maITEBzNIc_zD05HJK1IL6e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,182,803&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_uPure_maGOLD_c20240101__20241231_zl7QlZ1ca42i" style="text-align: right" title="Permanent Items, Percentage"&gt;13.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzNIc_zwWpS0uiJEZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt"&gt;State Rate Change&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maGOLD_c20240101__20241231_z6ACJYfNZ1j2" style="border-bottom: Black 1pt solid; text-align: right" title="State Rate Change, Percentage"&gt;(0.22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net actual effective rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IncomeTaxExpenseBenefit_iT_dxL_mtITEBzNIc_c20240101__20241231_zAuVQVLODyc8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtGOLD_c20240101__20241231_zRn0InWgXbVd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Net actual effective rate, Percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">-16532716</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000820"
      unitRef="USD">-3471870</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000822"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000824"
      unitRef="USD">-718347</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.0435</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000828"
      unitRef="USD">6336132</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000830"
      unitRef="Pure">-0.3832</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <TELO:IncomeTaxRateReconciliationPermanentItems
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">-2182803</TELO:IncomeTaxRateReconciliationPermanentItems>
    <TELO:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000834"
      unitRef="Pure">0.1320</TELO:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000836"
      unitRef="USD">36888</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000838"
      unitRef="Pure">-0.0022</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000586"
          xlink:label="Fact000586"
          xlink:type="locator"/>
        <link:footnote id="Footnote000621" xlink:label="Footnote000621" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
warrants herein consist of various contractual terms. The warrants herein consist of </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000586"
          xlink:to="Footnote000621"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000592"
          xlink:label="Fact000592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000592"
          xlink:to="Footnote000621"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000610"
          xlink:label="Fact000610"
          xlink:type="locator"/>
        <link:footnote id="Footnote000625" xlink:label="Footnote000625" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The warrants herein
consist of various contractual terms. The warrants herein consist of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMRCgQkEEv26"
  title="Warrants issued">2,429,025</xhtml:span> warrants issued to Bay Shore Trust that have a remaining
contractual term of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--BayShoreTrustWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqjrVJ1Qsta"
  title="Warrants remaining contractual term">3.5</xhtml:span> years as of December 31, 2024, <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreePrivatePlacementWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4Rkv4rl4DF4"
  title="Warrants issued">335,032</xhtml:span> warrants issued to investors associated with the 2023 Private Placement
that currently have an indeterminable contractual term, and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_zOWQnGluFgza"
  title="Warrants issued">50,000</xhtml:span> warrants issued to underwriters as part of the IPO with a remaining
contractual life of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHdhcnJhbnQgYWN0aXZpdHkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantMember_z3UAfC8JjVcl"
  title="Warrants remaining contractual term">3.2</xhtml:span> years. See disclosures below for more information on these warrants</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000610"
          xlink:to="Footnote000625"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000618"
          xlink:label="Fact000618"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000618"
          xlink:to="Footnote000625"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
